<SEC-DOCUMENT>0001831283-22-000075.txt : 20221110
<SEC-HEADER>0001831283-22-000075.hdr.sgml : 20221110
<ACCEPTANCE-DATETIME>20221110163332
ACCESSION NUMBER:		0001831283-22-000075
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221110
DATE AS OF CHANGE:		20221110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LianBio
		CENTRAL INDEX KEY:			0001831283
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40947
		FILM NUMBER:		221377863

	BUSINESS ADDRESS:	
		STREET 1:		103 CARNEGIE CENTER DRIVE, SUITE 309
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		(609) 486-2308

	MAIL ADDRESS:	
		STREET 1:		103 CARNEGIE CENTER DRIVE, SUITE 309
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>adr-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:10012e6e-b07f-4a8a-83a8-17013968b0f9,g:3852927e-ec92-4d9e-bc45-8785d7c9d0c5,d:7377b691bd58451297fc26cb9421b200--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:adr="http://lian.com/20220930" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>adr-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl8yLTEtMS0xLTQ5MDM4_e01e1975-4709-4727-b82e-d458fb35dfbe">0001831283</ix:nonNumeric><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl8zLTEtMS0xLTQ5MDM4_81228561-1e72-4431-8493-fcb841494a14">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl80LTEtMS0xLTQ5MDM4_8d0daa6d-b783-4e2a-8368-e986784de98c">2022</ix:nonNumeric><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl81LTEtMS0xLTQ5MDM4_62728bb5-3dbe-4c86-8136-d6d3fda678f0">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl82LTEtMS0xLTQ5MDM4_bd523e9a-72cf-4c01-ab6b-3081430fea4a">False</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="adr-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d8ab4f70d646d79d381b547e990263_I20221107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ief76923dc8d8411997af1d7252a67753_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id77363498db642a188305f503a88fef2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96883e148f06434c841b1d92a4923249_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5d825b11064cda8a7136073c98c0d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d073cf810c741b19b080eec0ae65138_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ada05c0bc904557aaf7846916d75d12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8c4f4547c34b3e98e00215a606db47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec729d6293a456680bf668222068517_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e7137c17d549fd820917694b08fc47_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied110c888d57481db184f6175b1e2860_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5656796fbdd145b3849a36669cab8663_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7799072b4d422aab668bcd4244cab6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d221360f31476098a1fd21dbc69534_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9322e8463954303aeee1d8f5e12fc8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9466a2c38fce4a91b583d32e765dc4a2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d25dc71ceec4fb08e8991e050dccdbd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c9cc56d5dd4eccb90e6223bdf350c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6572c181b34370ba0e953f6fa9f119_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib22bfae9e2b24dca8b5d085801249b58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i113de41b7dc04d4690e58ef90231b3a7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922676779aab45b998d8c7c8042fb4b1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf64ccfd7d8f40c18123b97e857d709b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a167087705d44768451e899dfad4ed5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475ba3da26c54ed1b8be00efe29feec9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i770c7a6615c24dab958345dedaeaca2a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0afac83be094d4aa4542e69b5679207_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ff887c265441c69507be611ce503ac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17b5e7664cc4df68c65d8b884872e95_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e238a55eb6949e3bfa3fc5e44d68d66_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b044d6aec8a430b9c9d220877699973_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ad139f307f45f59574c837bac70329_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea7287c095dd4fb394874127ce8b32e2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48907c78fead48129720781ca8df4577_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664446c89c5d42d18ba427b660facc0a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iada45bd66c5c4ac1ad4b3ddabe552196_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7da7e1062844c99aa94c7bbbe052e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i476a15e732a34295adea0c957a427196_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefaabc71b2ab47ae804d1de9bee57351_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6fbb393f9d410283f46ab5e21666d1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib12f0d7ec46545459636f4595ce63971_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i843b9dc93da54466be692b7fe0e517ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf757ee092794a7b907ffc699c87df97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00ba9d6adbc545c784eb291a888dd93d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc809e33c664490faf057840bbfd54f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c747e16a744468928214dcc9e51ae1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd068d3e42c34c279f69aaf1be33f5c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6744690158405abbd221d7a074c791_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81a8e1bb8e14340b40f2c724b9842a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adr:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aae9117d3e343aa9c8b422b360bbf8b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia555d7f1cdbb4263b3e681f74e9864c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094e8e47897d4872a7f705af07fdff66_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d15540792024becacd6f0a5ad4ad608_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2cfe092feb045dbbc9f7ccb340f1d54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f9f534bbe64805a759a975c5e89677_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a7631dd76cf40a4b4fcef577ab42fd2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9065e3e77be445739a59ac03866a9ce3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1e1b4992c34e169c7d86153c6eb2ce_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344b1e6c929d49dbb0309bbb28a88cbf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6c3f36b5eb42d299c7131a79fec1a3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97b84f3425ae4c298fafa57dee035528_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf331c6036a4355a4904f3f4bbb1cd2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7408c111d584b5ab590b62aac211dac_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19cd0b34a996469990768d290687c7ee_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib11048778c5e4d0687735a5893af9693_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8db68d789694f5cb6106efce2a2b3ae_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a99f5ddcd3340849368e824f80c8eb2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f4de76939f4d41bae02354c1c148b7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78c90d28271496cbeedbefdec9b279f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc84f64754e446c292da7857f70711f5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde6fe20c7ce4abcb989cd5740f6517e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id926e92f71c541b1ae612d23291c8593_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b839be2585f4f18bbac068fb248673d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a135bc815214ea891762f3528c47479_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f1e96dce0d4efd8b146ffaad7ccb37_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20f8c40cc106484c8030ad5495b23cfd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be28631775249e1801ff1234f689d4e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3842c85d9f4a828a8135e64dcab877_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b0e96016484b7d974af94c79a8fb0d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89dd2c9150114f349e9c78a6c5a2a70f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15bb3d88e144b8fb0462ca6bc65c410_D20211103-20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9758d92ce7f4beb932f7cfa346c246c_D20211103-20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6621d4b27834cd1a8fdbaa9dae39f18_I20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d453bec4c3b4dceb7ea5525faa7b87e_D20211201-20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1946c96c304391bdd745ff4abb6f90_I20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e6d021cd914175b381a66b8a7cbb8c_D20211201-20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i378fd65bf5a34325aead1a87c2d54e68_I20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeeb6e6bbe6549bc95c5d66955d58c3e_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib952974c6da148e98796252b1f567278_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5eacd74781d44f289c25d5872d43093_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2ea8c3730c405aaaa82862d9f64c8c_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>adr:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i696c50ecd8f14eb6b7b9e1bcbc34acce_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iad897a5006884c3591079e3c6af4ff9b_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6353efb7d3e492abdbd9b5ffce7d251_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b7d9bb22284b6badabc23d684178bd_I20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48477ba30acc44fda8e1ce1e3f7f5558_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">adr:PayableToRelatedPartyCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c392c6026c4ca9864f26feb3f567e3_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id05b0fb48e914379a182a9bec0d03a93_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a57dbf7904a433aa373a461fd34ad40_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3b0a6c246849aa9cca5199dc89a774_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ad44c91d4b4706b2c2bdfbec79da2a_I20211012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f92dc83d35344a29383ddc78d8130f2_D20201029-20201029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:NonRefundableFinancingMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-29</xbrli:startDate><xbrli:endDate>2020-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb5da7838574f67a606a8efb8a5436a_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:NonRefundableFinancingMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie45cfe90a52b41838961759bc21b1b6f_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f085f46e8c4f39a06df0cb33e0529d_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4327ccb2e1d04429bc1d974a2a6127be_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10056a0bfe624fd0bdceedf504ed17c0_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia198b999664b420daab0c08429b7466f_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeba3f0d0ce94801b53b3e5f40d513bd_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f3dfa4fc2174c5aa9f897019cc2c56d_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if317a4c6058f43dc89f8e182c6ba342c_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea5c2f5b96f411b9b2bb59234cd0005_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b66761f9ee4964817884acfbe7e816_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd6484953b02463e9394d252438606b9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63457cea5dad4e09a9dc7c0dc8901912_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5317e2a4b64ef4b0ab307c146b677b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e97b24ff55f44ebbfc3c54fa67ea432_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77f8ab5e29f14552995e67ec5208c971_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieefd544ceaa8467c8b9da24c29b947d0_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f7f825cc684f4eb4def6f2b5dec774_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d52b39d0f33473c9075d48ee2705ecf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0796e693bdf44849a2a5a2478fe283e2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b2cc0741f945b3921b5d42fb85ccf0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39d96e7903c34602be47c9a10fe1600c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859df84b6220412c8216feaef8618ca5_D20211018-20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-18</xbrli:startDate><xbrli:endDate>2021-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife3c16d3aeff45b0a62a122f3ffc24be_I20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:TarsusWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f77cc73d9d490ca49bf061664c20aa_I20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6faf9500eb46d6b9d7bd6521997ed4_D20220606-20220606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-06</xbrli:startDate><xbrli:endDate>2022-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500e758b45e84882b8dc0bafbe78d9c0_I20220606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c7315d139a647a8916844403b35fcc1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:MilestoneStageAxis">adr:MilestoneStageTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0c055d4c454529972b2611f7bf8dde_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901497f9715b416b90b0380aaed8d696_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439b9dc6a4324951a68387b66378f8af_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb3f515f2af46d9a26d73623709d955_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780e8a8772534c3abff5c2590cae6a48_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9846b2679d481c9f25e70face7e95d_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4208c21f9651412684222291161e9b6b_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie240169bdada412780e909f804cd7899_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe5d9ec24324b71b0ae98324e5a1950_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91dd2f17d34d4482a133ebd0c73e8ac8_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc8ffc33df4b44f6aac43fc889c6aab4_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a8f8ab0d9c841ca90cb65c873df8e7a_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82819a00611e420f849e1cfc3bd4f1b7_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica33bd99f1a34aec981651e9aef22732_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id161c6b8aad740d6bf1489f3fa9c21de_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c130a8a3d84f3d9196a9765323af46_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eccd0754c4241649e346fd436f9f289_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c15a8a30aac4770a88597df9720a6f1_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2977a88c5df432e8077c4dacb23d3e2_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a53ee596d2c4c43965805d5c720ab94_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ab1032d3924cd1b2dbf2289e458967_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51c7d53772584519a9e4329929345cab_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85be39f95e554d6a8acaa6fff436b274_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513f6fb095174b909385f721f0d3cf39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c6ba62baae4983b42b842d1aeddb71_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica40e054da6d4740987c1dc1a6a68af4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1827329195bd45ea9e34da5b92c6a744_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1fee8ff40e474fa97619a866abe5ac_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i583601b6fd494097a9a15ee54c69d290_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97fca3542e3e4d248eba0ca3a2c0a2bd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88787dac96ce45a1b690973dc5af39ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a84181a570474294e31e06040ab171_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia40d9c3f368a452aa391f0d7c258b7d6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d9e54db697947818a37b65b4445bf1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77f5c68e566442eaa1bc371b7f5c5e2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79217e78f9c54cbe9bc25876957657bd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dacd15e2cb3482082951305e30bead4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81645e508a424863b1adaf26443dcfe7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e530e77a5746d1a9a908e7d98f902e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1678e1fc3ee4b4c94d479a128462f4e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19f2de6f0d02407e85017a1bd9af1bcd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i146df2fb452d4fe6b51355e29fee9c51_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73431d4fcaa142f5bba2f3bcf88537aa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86a2fcbc7d44e0db98ad39b9b8bdd1c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i089cc9baca7b42b3a27fc68ddcc75811_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a7c6d6dd994b0e8d6e537613ef7302_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i599ef0489ae245fdad40419716223f6c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6992b347ac814ea5a287b5ea80729400_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908a570e002147ee82ad8f4dcc47db40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1ff5fc135e4f3c8cddc485f83622f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47023580772046b381bbc2733f87fab4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c847b99eb014c07aa341a9479de83f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052630a8432947fbab3f9d75efa151ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb632483a8a4bb5ac50c44b07402ce5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9201fc4c854336be93003ee6d57bf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b9bb6127684414952f21a60b0d3628_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfb1e63a5a148ea872a48d503461ff2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib56571b3d91e404288ff07ea7e32d86b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7923c86f54e4a37aa181f8a66eb944f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a9d0cd183640358c221d658d05c903_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26445de729ae4d13b1780d0406629bb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1bd37354b8447fbbdf6d5058cd03cdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a707e5adbc4b99b70f59775be134fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbaad0fc47e54c749c1bb25b94d34c50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ac8403115d4cd3b344dc73c9163e90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b54ba31d4848fc98d64676da86fa94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i006d54f5f1e04251898198b35f13f488_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84c463023764fd7a23b168836df9331_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b91ef85a3c4df0a1c9a6cc175f3af4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8f992a4500455285df2bab55116fb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8842f59d8ef141fcafb8b68fe12e360c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76f313597efa43788e4abcc3748d1537_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52514ae79d6e4407beb955263f7b7dc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c4d4eb4488417fbbe695608850e678_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ea1b268ae24831a9bfec7be1c4c428_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949e844f555744609cfcfdbd4bd385ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17263b03feb4bf599db6d71049821f1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ad1474b304d494cb73a261a3a3b32c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94fe0cda96314d9780ce44c077411b21_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4aa405a5bd447b4a32e03e704b92251_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4396dac7b05e465b80f79cd6478b8a6e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib959c47e99054dfc80bccef6276320e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0bf146cc074bbb926e252ce7e39da9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d076d62c9844f5cbc99d095571fcffa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef4c7d268f5402dae0e1b439efb68f4_I20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f6b78d38b54b2b9954c7b5a6114f41_I20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice923f6c800447bcb1d172a7ed1e741c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a0efa3f6688449aa871fe22f08334a7_D20191201-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc7598a210a4dfeab2ec14ba7e4c6e4_D20211103-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc475a18a1634df89b155ffac5055809_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia858e3c7efff4cc39fbe4c012eb1ec90_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c152c42e3146f894258b2b89a5e956_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia040378a6b2244fa861c27980e968a32_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c27ecbad78a402aa40e15a813e287a6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1340243c4b74132babad381c7136bc2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163994ff7dd148e6a47533a384b804b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37aaf2e75dc4f9c8d8fedc3b1cb29f4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790b35dc63d348a8ad805f2a45e3e6a9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae18a04092e5496faf63315837e7fc8c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385421b8aac749b6b3bb67d39e04d1d2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b0e7ba818d4c4baf09cc8d2c41d451_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a4b2db597d4126ab138b1b321c7166_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d2e669f7ca4fe89612a0a784bcd359_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4875fecaf1f14bb5b5c2ceef28b17b17_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09c463503db4ad7ae3248958a79fe4c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e42e244697487da44b1a88c9ca695c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04ab5e91570453bafa51dfcaedd5a80_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7409e8003154a5392e873de4657fb1e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0e878a4e9940a8ba193c5c8a44bfe7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:RedeemableConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34cd0bfaa564a92bd7ecdce2c826bc7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:RedeemableConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484a69d178e340c093a1bcad9d0db61c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862b94711dca4e4ba65e7ffa96c12b95_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014e8a19793d40bcac2baddf7496bd9d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide326c86d4704627b79b2a501c2b05bf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d0df6c0bc4407982ff2dcc72c8d5f7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOncologyIssuedToQedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42da493784984b80a81dd34f00fb97ed_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOncologyIssuedToQedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd61e8d2ee742ceacc281b00f2bf38e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianCardiovascularIssuedToMyokardiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961337664bec4684bab70b8f50eb6fb4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianCardiovascularIssuedToMyokardiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2547429e3324581bbf6156636e2a767_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOphthalmologyIssuedToTarsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3a509b1bb04448b439c32f4c6b8a98_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOphthalmologyIssuedToTarsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id423453fa6364ca8947d21bf8eeb83d4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dbf76887d084a01a1e484f9fc38af0a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0378cbfd28884eb698663743fe75feda_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831283</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7377b691bd58451297fc26cb9421b200_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk3_a0aab789-0bfc-4b1b-8a95-22c449f4c3ba">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;text-indent:13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YzgzY2NkMGE0ODAyNDg0MzhiMzZhYTdiODBhNzhhNmMvdGFibGVyYW5nZTpjODNjY2QwYTQ4MDI0ODQzOGIzNmFhN2I4MGE3OGE2Y18wLTEtMS0xLTQ5MDM4_9225f0a0-bb37-42b0-b9ad-1a4922e263d2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN181NDk3NTU4MTYwNDA_d9f8d5d4-c255-4329-a0d4-32d02422842c">September 30, 2022</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6NjdlZTg0MWNlMWU5NDllMWFlZGIwMGRiZTMwZDUxNjAvdGFibGVyYW5nZTo2N2VlODQxY2UxZTk0OWUxYWVkYjAwZGJlMzBkNTE2MF8wLTEtMS0xLTQ5MDM4_c623c4dc-1ef5-48c2-b666-69a54fde5fd0">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk4_c4d70b5e-dcb0-48db-a8df-2cc5fe324241">001-40947</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk5_933dbcc2-7906-47c2-830d-26ed130257cd">LianBio</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8wLTAtMS0xLTQ5MDM4_93e744f8-4f80-44f5-8395-fc6692afd78f">Cayman Islands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8wLTEtMS0xLTQ5MDM4_e6eb6f5f-a75a-4c7e-a1a2-a9df4696069c">98-1594670</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfNA_f0ff1629-5aea-4041-a3e6-f7722a93d26d">103 Carnegie Center Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfOA_fb0eecd7-f53d-4dd8-9fb4-37ed8a6b4735">Suite 309</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfMTE_2b1c8631-d2e7-42ff-82c2-6a7010ef9aaa">Princeton</ix:nonNumeric>, <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfMTU_4aa82cfb-d3ae-4776-b97f-0625e825bb99">NJ</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTEtMS0xLTQ5MDM4_33eb5697-e3f0-4e47-9f71-7e935dc84ad1">08540</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDkx_9e387e75-18ea-4683-ba31-f9c5dcc5129b">609</ix:nonNumeric>) <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMTAw_4af4fe6b-08b4-4df8-8f06-f8567079c088">486-2308</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:32.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZTgxNzU3YmYzYTAzNDVlY2FlODQzZjQyYzEyMDcwZWEvdGFibGVyYW5nZTplODE3NTdiZjNhMDM0NWVjYWU4NDNmNDJjMTIwNzBlYV8xLTAtMS0xLTQ5MDM4_c07b5871-19a3-472e-906b-f28bfa6e5035">American Depositary Shares, each representing 1 ordinary share, par value $0.000017100448 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZTgxNzU3YmYzYTAzNDVlY2FlODQzZjQyYzEyMDcwZWEvdGFibGVyYW5nZTplODE3NTdiZjNhMDM0NWVjYWU4NDNmNDJjMTIwNzBlYV8xLTItMS0xLTQ5MDM4_89b7d02e-cdd1-40ea-9cdd-3f4a97fb2180">LIAN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZTgxNzU3YmYzYTAzNDVlY2FlODQzZjQyYzEyMDcwZWEvdGFibGVyYW5nZTplODE3NTdiZjNhMDM0NWVjYWU4NDNmNDJjMTIwNzBlYV8xLTQtMS0xLTQ5MDM4_83d3e585-034c-4e50-8b08-5b9b7a061434">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMTAx_e56d727b-92c7-4f6a-88fd-5c5a444c4001">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:112%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk0_68ea2e28-c5f5-42e9-bd89-a72e045e5d03">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZGI2MGMzYmE5NDU3NGJkNDliZTA1MjQ5OWRkMjI2MDIvdGFibGVyYW5nZTpkYjYwYzNiYTk0NTc0YmQ0OWJlMDUyNDk5ZGQyMjYwMl8yLTAtMS0xLTQ5MDM4_3c81e06d-ba39-4916-8dc1-3c6410e494be">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZGI2MGMzYmE5NDU3NGJkNDliZTA1MjQ5OWRkMjI2MDIvdGFibGVyYW5nZTpkYjYwYzNiYTk0NTc0YmQ0OWJlMDUyNDk5ZGQyMjYwMl8yLTQtMS0xLTQ5MDM4_22a9235a-c7db-4984-aede-fd8a435a91c3">x</ix:nonNumeric></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZGI2MGMzYmE5NDU3NGJkNDliZTA1MjQ5OWRkMjI2MDIvdGFibGVyYW5nZTpkYjYwYzNiYTk0NTc0YmQ0OWJlMDUyNDk5ZGQyMjYwMl80LTEtMS0xLTQ5MDM4_06db575d-c29d-4cb2-a463-d7773b99dd64">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDkz_f4fe57c0-0eea-4fc1-9369-a23aa8998fc3">x</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk1_39a0e226-23f4-436f-b133-a4ba19e2c653">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of November&#160;7, 2022, <ix:nonFraction unitRef="shares" contextRef="i19d8ab4f70d646d79d381b547e990263_I20221107" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18xOTMw_175c98ee-1575-4e3b-bf81-7ddd52339853">108,353,831</ix:nonFraction> ordinary shares of the registrant, par value $0.000017100448 per share, were outstanding, of which 41,031,784</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ordinary shares were held in the form of American Depositary Shares. This total number of ordinary shares and total number of ordinary shares held in the form of American Depositary Shares excludes 2,175,095 ordinary shares that are held by the depositary on reserve to satisfy obligations of the registrant under the registrant's equity plans. </span></div><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_97">ITEM&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_16">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_19">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_22">Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_22">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_25">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_28">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_106">ITEM&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_61">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_106">ITEM&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_88">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_109">ITEM&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART&#160;II</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_94">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_94">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_97">ITEM&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_97">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_100">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_61">ITEM&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_103">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_103">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_106">Defaults </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_106">upon</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_106"> Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_106">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_109">ITEM&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_109">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_109">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_112">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_112">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_115">ITEM&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_115">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_115">37</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_118">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7377b691bd58451297fc26cb9421b200_118">38</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about us and our industry that involve substantial risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, prospects, plans, objectives of management and expected growth, are forward-looking statements. These statements are based on our current beliefs, expectations and assumptions regarding our intentions, beliefs or current expectations concerning, among other things, the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; and other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully develop, gain regulatory approval for and launch commercial products in Greater China and other Asian markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to deliver innovative therapeutic solutions to patients and become a leading biopharmaceutical company in Greater China, including Mainland China, Hong Kong, Taiwan and Macau, and other Asian markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our plans and ability to leverage data generated in our partners&#8217; global registrational trials and clinical development programs to obtain regulatory approval for and bring our current product candidates to market in our licensed territories, and our plans to maximize patient reach for each of our product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners&#8217; announced plans and expectations with respect to the success, cost and timing of their product development activities, preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the timing of expected review from regulatory authorities and the period during which the results of the trials are expected to become available;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to expand our pipeline through the continued strategic in-licensing of innovative and complementary product candidates with the potential to become the new standard of care in Greater China and other Asian markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully establish an international infrastructure, including by building a focused salesforce in China and leveraging the commercial infrastructure we create to benefit our other assets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to establish and maintain relationships and collaborations with investors and our current and any future licensing partners that will contribute to our success in sourcing value and creating partnerships to enable us to build out a broad and clinically validated pipeline;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to design, initiate and complete any clinical trials to advance our current product candidates, including mavacamten, TP-03, NBTXR3, infigratinib, BBP-398, LYR-210, omilancor, NX-13 and sisunatovir, as well as any future product candidates, towards regulatory approval in China and our other licensed territories;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to conduct, and the timing of and costs related to, our product development activities, including any preclinical studies and related clinical trials in Greater China and other Asian markets of our current and any future product candidates, and our ability to obtain, and the timing of and costs related to, potential regulatory approval of such product candidates in Greater China and other Asian markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our plans to pursue the development of certain product candidates for additional treatment indications;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully utilize the data we may generate from any clinical trials we conduct in Greater China or other territories, including in conjunction with data from clinical trials conducted by our partners, to seek regulatory approval in Greater China and other Asian markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our plans and ability to join our current and future partners&#8217; clinical and registrational trials and our plans and ability to initiate and complete our standalone clinical and registrational trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to design and implement the development strategies for our product candidates in each of our licensed territories and, where applicable, our ability to design and implement global development strategies for our product candidates in new indications in connection with our local development strategies;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the potential for certain of our current and future product candidates to have more benign safety profiles or result in differentiated safety profiles than currently available therapeutic options;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the size, composition and growth potential of the patient populations and markets we intend to target with our product candidates and our ability to develop and commercialize product candidates to address those patient populations and markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully procure from our partners or other third parties, as applicable, sufficient supply of our product candidates for any preclinical studies, clinical trials or commercial use, if approved;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates and our general and administrative expenses;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the rate and degree of market acceptance of our product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of laws and regulations and of any legal and regulatory developments in our licensed territories or internationally;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to license intellectual property relating to our product candidates and to comply with our existing license and collaboration agreements;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our reliance on third parties to conduct product development, manufacturing and other services, and any agreements we have or into which we may enter with such parties in connection with the commercialization of our product candidates and any other approved product;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations regarding the time during which we will be an emerging growth company or smaller reporting company;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the direct and indirect impact of the COVID-19 pandemic on our business, operations (including clinical trials) and the markets and communities in which we and our partners, collaborators and vendors operate;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our estimates of our expenses, capital requirements and needs for additional financing; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution investors that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks and uncertainties, investors are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make in this Quarterly Report on Form 10-Q speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data. Investors should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Unless the context requires otherwise, references in this report to the &#8220;Company,&#8221; &#8220;LianBio,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to LianBio and its consolidated subsidiaries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt"><span><br/></span></div><div id="i7377b691bd58451297fc26cb9421b200_16"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I-FINANCIAL INFORMATION</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LianBio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMy0xLTEtMS00OTAzOA_ed555ac4-f075-4e0c-a92b-3143e4182d2d">78,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMy0zLTEtMS00OTAzOA_6bb75d11-9fae-471d-87e5-748874661f17">228,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNC0xLTEtMS00OTAzOA_e1a07b7c-f662-4487-86c5-18dcc37781b6">232,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNC0zLTEtMS00OTAzOA_f6d519b2-49d5-4798-a309-3bde8f3fdd42">155,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNi0xLTEtMS00OTAzOA_ee3e1c45-84b8-4708-93e3-0fe2e91744e3">5,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNi0zLTEtMS00OTAzOA_cceae27f-675c-47c4-a6ee-fb906fca2e6e">10,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNy0xLTEtMS00OTAzOA_d0a1c5b4-64ec-486d-ac24-ffbb4ab5456c">7,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNy0zLTEtMS00OTAzOA_0bef4cbb-4e30-4a35-bf22-2afee9863b95">6,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOC0xLTEtMS00OTAzOA_810f9937-f567-413d-a6e1-b07f1a7bab8e">324,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOC0zLTEtMS00OTAzOA_0ecbdbee-1d8f-4ee9-9c37-b233d533dc0c">399,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOS0xLTEtMS00OTAzOA_0a9adcb4-b04a-4fc3-85a1-b8879f5f203c">20,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOS0zLTEtMS00OTAzOA_0ce835e6-bda1-4251-b0ed-335af578bbd4">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTAtMS0xLTEtNDkwMzg_9b4ae3ee-52f6-4bf4-8612-5ec9a00bb8a7">3,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTAtMy0xLTEtNDkwMzg_7f098d67-e955-499d-8928-fad74521302a">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTEtMS0xLTEtNDkwMzg_d89f31f3-5d9c-4849-86d0-c1af43d42872">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTEtMy0xLTEtNDkwMzg_20eafbe2-0d24-41a4-b079-d33f6d752be8">4,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTItMS0xLTEtNDkwMzg_f4d32a32-6bfa-4697-a7c4-7ee29e1a66e0">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTItMy0xLTEtNDkwMzg_c13610ca-a8e2-4f1a-85e5-363970d746a6">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTMtMS0xLTEtNDkwMzg_5edd8f53-7735-4958-a497-1c304f7c6442">351,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTMtMy0xLTEtNDkwMzg_56398ac0-7ddf-4a27-bb77-7c4c5785db8e">426,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTYtMS0xLTEtNDkwMzg_644fc724-fcf1-4154-8c10-ca1bae948ec1">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTYtMy0xLTEtNDkwMzg_b6d71570-f886-41fc-b4c6-7921d46ca025">3,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTctMS0xLTEtNDkwMzg_ba67a720-e04e-4696-b94e-827cbf910470">17,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTctMy0xLTEtNDkwMzg_fb5987c9-63a5-4304-8111-58d61b9e8788">9,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTgtMS0xLTEtNDkwMzg_1f6baed1-4c20-4741-8d04-76087921019e">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTgtMy0xLTEtNDkwMzg_c78d1c94-88ee-4c0e-be21-e5ea51ab49f2">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjAtMS0xLTEtNDkwMzg_de5d9622-fac2-4f92-8205-6f99d3a18ac3">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjAtMy0xLTEtNDkwMzg_d6b5246b-84c5-4ef1-9f87-b8b170aaa628">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjEtMS0xLTEtNDkwMzg_d53a1601-aca3-4ac0-9c61-8bea8b70612d">22,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjEtMy0xLTEtNDkwMzg_02768c27-1b68-4a18-919f-fcf14d0a35c6">15,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjItMS0xLTEtNDkwMzg_c9f77ef1-61c9-4538-8ffe-540c09f6006c">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjItMy0xLTEtNDkwMzg_924d32c2-c745-46a7-b1e8-b4febd96794f">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjMtMS0xLTEtNDkwMzg_863e52f2-7e3e-4b46-9c32-cc1d03133494">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjMtMy0xLTEtNDkwMzg_51021b18-8a6e-4b80-9355-d368aaaadf33">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonrefundable research deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="adr:NonrefundableResearchDeposit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjQtMS0xLTEtNDkwMzg_fab77a05-1f61-4d82-9bad-262e25477f3b">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="adr:NonrefundableResearchDeposit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjQtMy0xLTEtNDkwMzg_6705f045-2646-4d1f-a96d-dc59c3f66b8c">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjUtMS0xLTEtNDkwMzg_db21940d-257a-49d7-aa5c-c24e751c2adb">45,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjUtMy0xLTEtNDkwMzg_881a104b-e07a-412c-a4cc-39de05913486">39,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjYtMS0xLTEtNDkwMzg_075b37e4-19f2-41d3-a6e8-c8c8fd8df297"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjYtMy0xLTEtNDkwMzg_86c1742d-a27e-4f38-86c8-8051e2a0c472"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity (deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18yMQ_37170f7f-fb12-444b-b7b7-a3f3d307b258"><ix:nonFraction unitRef="usdPerShare" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18yMQ_a943bbe1-e931-45f5-b1f4-80e018ecc2f6">0.000017100448</ix:nonFraction></ix:nonFraction> par value. <ix:nonFraction unitRef="shares" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM180Ng_8f0be365-deb1-47c7-82dd-62792fb470bc">2,923,900,005</ix:nonFraction> shares authorized as of September 30, 2022; <ix:nonFraction unitRef="shares" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM183Nw_35e201c9-d7a5-49ea-bba9-b26e53eb2e9b"><ix:nonFraction unitRef="shares" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM183Nw_f2769e0d-98b3-4534-b7d6-a10dd9109d42">108,353,831</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2022; <ix:nonFraction unitRef="shares" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18xMzk_ca59ca2f-ddee-4c48-954e-0fd2a0fcb7d5">2,923,900,005</ix:nonFraction> shares authorized as of December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18xNzQ_e6533453-0986-47c7-8d04-6dacddaa1ed7"><ix:nonFraction unitRef="shares" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18xNzQ_f2e536fd-ea8c-4df5-9e74-a95d6e67d9f0">107,275,458</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMS0xLTEtNDkwMzg_1d490da1-5840-4eb6-aa16-e3ab0aca5849">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMy0xLTEtNDkwMzg_832bac7e-64f8-460b-98f0-1bf8824ae3f9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjktMS0xLTEtNDkwMzg_8092cbb2-f78f-474d-b49f-897cf49c021b">728,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjktMy0xLTEtNDkwMzg_5b2e2fe3-8b33-4b9d-845f-1a688726a625">713,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzAtMS0xLTEtNDkwMzg_e12f4873-3365-42be-b498-1c88813436d9">3,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzAtMy0xLTEtNDkwMzg_7cbd61c2-874a-4a9d-8bb0-e98b7af2e477">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzEtMS0xLTEtNDkwMzg_18fc1018-52b6-42a3-bdd5-1741cbc126b0">452,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzEtMy0xLTEtNDkwMzg_e1cddaa4-2333-46b5-b6b8-779a677acc6d">360,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total LianBio shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzItMS0xLTEtNDkwMzg_f4857326-ed04-4506-8934-0458265b80de">272,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzItMy0xLTEtNDkwMzg_f352b815-1f7d-47a2-9764-8ced7adc7272">353,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzMtMS0xLTEtNDkwMzg_5660008f-e3b9-42a2-9537-aeffdc647c28">33,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzMtMy0xLTEtNDkwMzg_9fee3ff9-520f-475b-8df0-f8855de1310f">33,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzQtMS0xLTEtNDkwMzg_08bc1cf1-dda8-4626-8fd2-536cf2331e7b">306,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzQtMy0xLTEtNDkwMzg_3b8ef9d3-e5a3-4ab0-98fd-7b7a36fad620">387,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzUtMS0xLTEtNDkwMzg_7c28131b-22af-437d-b612-aaf596e08812">351,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzUtMy0xLTEtNDkwMzg_e5f8ef14-60d0-4047-adfc-f0ca4419004b">426,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LianBio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy0xLTEtMS00OTAzOA_2dbc3095-87bc-4409-909f-613655a3eff8">8,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy0zLTEtMS00OTAzOA_ecc1384c-a6bd-462e-b0e6-1191d8ecbde5">4,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy01LTEtMS00OTAzOA_bf376717-55ee-42e6-bd8f-b9693a21c8e8">49,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy03LTEtMS00OTAzOA_eff00047-1f54-49d1-9630-1e8326d4f399">151,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC0xLTEtMS00OTAzOA_5dc60cf5-a4cb-48f4-8b05-89adf4155199">16,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC0zLTEtMS00OTAzOA_b979e658-9719-4dad-8f5b-7d7efd501b7d">8,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC01LTEtMS00OTAzOA_c4a45be8-8dde-488f-8c76-a93b253ff52c">46,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC03LTEtMS00OTAzOA_d1772b02-c982-46b9-8a74-22be9b24aff9">22,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS0xLTEtMS00OTAzOA_785849c2-a1f4-481c-9b63-64783e6f787a">24,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS0zLTEtMS00OTAzOA_04e9d85b-5f0a-4bef-bb32-0c3be0405dd0">13,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS01LTEtMS00OTAzOA_7e8f6997-73f4-4a4d-8dc6-b942eea124a7">96,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS03LTEtMS00OTAzOA_abcbbe48-df2e-4e4f-b93f-1b95ea281177">173,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtMS0xLTEtNDkwMzg_c0df36cb-9a8f-45c5-9545-4f53ad6792a8">24,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtMy0xLTEtNDkwMzg_63f63980-9883-4485-b93f-701776d5acdd">13,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtNS0xLTEtNDkwMzg_25e94142-8849-4ce2-a8ff-0c71e926400e">96,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtNy0xLTEtNDkwMzg_79eb4507-02b5-4e7a-bb55-716ec013ba10">173,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItMS0xLTEtNDkwMzg_b3ea4171-9f2c-46e6-9dd7-a38fabc46cf0">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItMy0xLTEtNDkwMzg_063507b7-018f-4c70-9bb2-99deacfcdd8b">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItNS0xLTEtNDkwMzg_f13bc254-1f8a-4bb2-b832-5e6bb4b036a7">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItNy0xLTEtNDkwMzg_9dbe31b4-6b08-4037-880a-13005397f143">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtMS0xLTEtNDkwMzg_352e15fd-d53e-4346-af22-ba21a2b56bbe">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtMy0xLTEtNDkwMzg_eddae970-a962-4b14-9494-80d39636f20e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtNS0xLTEtNDkwMzg_ee7031ab-88fd-4b2f-aba6-1478aece3f3c">1,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtNy0xLTEtNDkwMzg_bc20399e-aa38-4e87-9ab3-656086185709">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtMS0xLTEtNDkwMzg_08eb7f40-7abb-476b-b3cf-78ef4e6c63b6">21,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtMy0xLTEtNDkwMzg_2f84b74e-9c2b-459f-9928-4e0713753e1b">13,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtNS0xLTEtNDkwMzg_afea278b-cf40-4d9a-8181-968f73662923">91,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtNy0xLTEtNDkwMzg_3278ea9c-4114-4227-8ab5-6eff5329be58">173,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtMS0xLTEtNDkwMzg_3195ba1d-6c9b-4d23-8aa7-7819c06e45f4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtMy0xLTEtNDkwMzg_8816490a-c7a8-4437-9e27-30055baaceac">397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtNS0xLTEtNDkwMzg_e1b3416e-231c-425d-bbc4-89e04b542050">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtNy0xLTEtNDkwMzg_3f5a658a-e78c-4d88-93b3-8f0e74d667ca">1,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtMS0xLTEtNDkwMzg_7c6a20f2-54d4-480c-b384-8c0d33cbe4f5">21,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtMy0xLTEtNDkwMzg_e5f3456d-7dc6-4883-8de3-1cb703096da4">13,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtNS0xLTEtNDkwMzg_63bddc93-e01d-430a-b232-1f4c9c69dc2f">92,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtNy0xLTEtNDkwMzg_2a80511d-6a79-4756-b07e-e7c10d2df4b4">175,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation (loss) income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtMS0xLTEtNDkwMzg_acd538ce-ba7f-46ed-8fee-fe371196131d">2,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtMy0xLTEtNDkwMzg_bdd9e0cd-4e41-43e0-a0b1-95973c1bc622">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtNS0xLTEtNDkwMzg_3f97b8c8-61a2-4d20-9ec7-dce14508d6da">3,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtNy0xLTEtNDkwMzg_f55a5f07-9def-40e8-a177-9713537e4a00">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktMS0xLTEtNDkwMzg_e4fa4867-b978-445f-a821-e3e4305ba0ad">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktMy0xLTEtNDkwMzg_580b653f-e266-412f-b9d7-84269b30097b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktNS0xLTEtNDkwMzg_727bd0d8-8c84-4ad6-be13-ed43ec735c71">1,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktNy0xLTEtNDkwMzg_ad71f3da-082c-4f93-afa6-8e45e7d2c43f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtMS0xLTEtNDkwMzg_019cd7ee-28f3-4b37-9bf3-dd6331d76b72">24,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtMy0xLTEtNDkwMzg_02297240-60e0-40c8-b01c-e63b19a4201e">13,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtNS0xLTEtNDkwMzg_a2b0e882-3394-47ec-8f0b-089edbb4727c">96,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtNy0xLTEtNDkwMzg_d0699e55-947e-4203-894d-017853a68e3d">175,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMS0xLTEtNDkwMzg_62b47dfe-b1aa-4da6-b2fd-23fa75a95a49"><ix:nonFraction unitRef="usdPerShare" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMS0xLTEtNDkwMzg_6b2e1c5a-5226-4417-b286-219e90bbf508">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMy0xLTEtNDkwMzg_5d6f486e-95a2-4664-b962-a0cea2211872"><ix:nonFraction unitRef="usdPerShare" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMy0xLTEtNDkwMzg_903e9d0d-bfac-4edc-8362-f0c145ccb836">0.63</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNS0xLTEtNDkwMzg_3f1f9d88-9612-40a9-9b94-d6c75e507233"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNS0xLTEtNDkwMzg_715f5ee5-e4fe-4734-b67c-2c7e1e211c5e">0.85</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNy0xLTEtNDkwMzg_4a3138dd-f6ef-4b66-8f0c-98b84d0ff7d1"><ix:nonFraction unitRef="usdPerShare" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNy0xLTEtNDkwMzg_ad950d26-af2c-4462-a13a-0e299bbd1556">8.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMS0xLTEtNDkwMzg_3729ced9-d8cb-4870-8436-8905095edff8"><ix:nonFraction unitRef="shares" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMS0xLTEtNDkwMzg_91a58aaf-315f-402e-addf-89a181cda9e1">108,353,831</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMy0xLTEtNDkwMzg_46bb3e20-78de-486a-9b80-55f9a3e0776a"><ix:nonFraction unitRef="shares" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMy0xLTEtNDkwMzg_55040adc-90d5-4f67-8891-773b93990ec3">20,690,908</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNS0xLTEtNDkwMzg_2357993a-e893-4671-a2ee-cb8afb6f2d83"><ix:nonFraction unitRef="shares" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNS0xLTEtNDkwMzg_821a9465-44ce-43a1-967c-e6cddf245fe6">107,854,547</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNy0xLTEtNDkwMzg_54318147-69af-49ca-b29e-24fa54192e73"><ix:nonFraction unitRef="shares" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNy0xLTEtNDkwMzg_7562811d-1319-4373-92ec-8d3a2e36cf26">20,549,310</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LianBio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Convertible Preferred<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Ordinary Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total LianBio<br/>Shareholders&#8217;<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity (Deficit) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xLTEtMS00OTAzOA_fb98e153-aa14-4b2f-be3e-a9a1fd898ac3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0zLTEtMS00OTAzOA_eb3ab32e-14da-4559-bb8d-bc125210efb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i96883e148f06434c841b1d92a4923249_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi02LTEtMS00OTAzOA_46ebb166-d371-49b8-a598-97b497cec207">107,275,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i96883e148f06434c841b1d92a4923249_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi04LTEtMS00OTAzOA_88b76f21-5bff-42d0-ac30-c7d49e93e3ff">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4f5d825b11064cda8a7136073c98c0d9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xMC0xLTEtNDkwMzg_d256b9dc-f5d1-41a5-9f9c-f26ab0a1cc90">713,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d073cf810c741b19b080eec0ae65138_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xMi0xLTEtNDkwMzg_0a2dca26-f3ad-417c-89ec-d5c72a986d1a">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8ada05c0bc904557aaf7846916d75d12_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xNC0xLTEtNDkwMzg_38b2f2d1-358c-4177-a19b-63d2add3a367">360,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iee8c4f4547c34b3e98e00215a606db47_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xNi0xLTEtNDkwMzg_af7b6493-91e2-4151-b574-a71628e5ee64">353,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ec729d6293a456680bf668222068517_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xOC0xLTEtNDkwMzg_53e61ea4-60b0-4f85-b5b2-0a50c8fce7b4">33,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0yMC0xLTEtNDkwMzg_3184643e-7ced-48e1-9b5a-a13144d19085">387,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i59e7137c17d549fd820917694b08fc47_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMy0xMC0xLTEtNDkwMzg_b92d3dad-9663-4a5d-a2f2-6f371758122d">4,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMy0xNi0xLTEtNDkwMzg_606ad357-a9f6-4ab8-b77b-8cbbc0caa57b">4,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMy0yMC0xLTEtNDkwMzg_bca5eeb2-0f2c-40d7-b44e-cbe8e0082ad8">4,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivable from related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i59e7137c17d549fd820917694b08fc47_D20220101-20220331" decimals="-3" name="adr:APICDueFromRelatedPartiesIncreaseForCostRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNC0xMC0xLTEtNDkwMzg_ff3e061d-e6ba-46be-93e2-87829292855b">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331" decimals="-3" name="adr:APICDueFromRelatedPartiesIncreaseForCostRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNC0xNi0xLTEtNDkwMzg_6c9df8ec-ee0e-4933-aa76-01ede832cbf6">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331" decimals="-3" name="adr:APICDueFromRelatedPartiesIncreaseForCostRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNC0yMC0xLTEtNDkwMzg_94424d76-79b4-4966-9db0-30536c04435a">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5656796fbdd145b3849a36669cab8663_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNS0xNC0xLTEtNDkwMzg_879f36e3-a3da-4e12-894b-556b84517eac">27,726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNS0xNi0xLTEtNDkwMzg_fdf9113a-9b6e-4088-9131-58017a12e9d8">27,726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNS0yMC0xLTEtNDkwMzg_333a4d49-2aed-4acb-8035-82d0239002fa">27,726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8d7799072b4d422aab668bcd4244cab6_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNi0xMi0xLTEtNDkwMzg_47b091a0-ea00-4ec6-8432-3ad54c70f7ef">1,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNi0xNi0xLTEtNDkwMzg_0451721e-8615-421a-93c4-b6b1785c166d">1,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNi0yMC0xLTEtNDkwMzg_1b71f60d-73f8-4425-8673-68070d1646c6">1,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i25d221360f31476098a1fd21dbc69534_I20220331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xLTEtMS00OTAzOA_a1cc5044-479d-4516-a70d-682e001b3336">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25d221360f31476098a1fd21dbc69534_I20220331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0zLTEtMS00OTAzOA_7e05a1e2-39d1-44d8-b00a-7649315c95ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib9322e8463954303aeee1d8f5e12fc8a_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy02LTEtMS00OTAzOA_cd73ea28-3b37-4742-8f3c-ba78817a4a6f">107,275,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib9322e8463954303aeee1d8f5e12fc8a_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy04LTEtMS00OTAzOA_77abb21f-4a64-4758-b883-4e9dbff4dd3a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9466a2c38fce4a91b583d32e765dc4a2_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xMC0xLTEtNDkwMzg_df63cd6e-a69b-4535-b7b8-0a1c3f52ddc4">719,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8d25dc71ceec4fb08e8991e050dccdbd_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xMi0xLTEtNDkwMzg_464b819c-98f5-49c6-8baf-67ac9674bd6b">690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i63c9cc56d5dd4eccb90e6223bdf350c0_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xNC0xLTEtNDkwMzg_cd81a4ec-5bfc-4346-8f57-14fd59bba0b9">387,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="idd6572c181b34370ba0e953f6fa9f119_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xNi0xLTEtNDkwMzg_64806eb8-fc28-4ba3-a422-93202c29c34c">330,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib22bfae9e2b24dca8b5d085801249b58_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xOC0xLTEtNDkwMzg_52124ff4-2069-4158-8738-b2cd61aabd14">33,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i25d221360f31476098a1fd21dbc69534_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0yMC0xLTEtNDkwMzg_d9693ce9-fe25-4085-96d1-298fbd5513d8">364,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i113de41b7dc04d4690e58ef90231b3a7_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOC0xMC0xLTEtNDkwMzg_003ed68f-f06b-42a9-8207-7894cb7a38f8">4,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOC0xNi0xLTEtNDkwMzg_7778ff9e-8f22-482c-b740-a6c159e5ebaf">4,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOC0yMC0xLTEtNDkwMzg_39b06887-03d8-4cc2-8bc5-977d37886fec">4,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:87%">Exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i922676779aab45b998d8c7c8042fb4b1_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOS02LTEtMS00OTAzOA_3e6f1a93-c73d-4706-a48b-47c2f763b5e9">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:87%">Exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i922676779aab45b998d8c7c8042fb4b1_D20220401-20220630" decimals="INF" name="adr:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTAtNi0xLTEtNDkwMzg_734d0b24-bd97-4358-9e83-4a59f2a26c49">78,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iaf64ccfd7d8f40c18123b97e857d709b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTEtMTQtMS0xLTQ5MDM4_1d934628-3282-4dbe-a6cd-85b75d628775">42,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTEtMTYtMS0xLTQ5MDM4_3bfbd65c-14bc-400f-ad8b-26b152c9be5a">42,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTEtMjAtMS0xLTQ5MDM4_3e33e691-88bc-4889-9af6-aecbc68d38db">42,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:87%">Comprehensive Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7a167087705d44768451e899dfad4ed5_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTItMTItMS0xLTQ5MDM4_114cbbee-9908-4179-94ac-a6eba2f33a08">712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTItMTYtMS0xLTQ5MDM4_cd4caaf2-f055-4bdb-bdfd-4dac833b7ec0">712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTItMjAtMS0xLTQ5MDM4_43b39591-f054-4649-8c12-84b045a1d9aa">712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i475ba3da26c54ed1b8be00efe29feec9_I20220630" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMS0xLTEtNDkwMzg_f7e70a9c-fd73-4be3-8bbc-3c4d65fc4cce">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i475ba3da26c54ed1b8be00efe29feec9_I20220630" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMy0xLTEtNDkwMzg_11acd23c-fb01-4211-8a36-78b1f7b615fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i770c7a6615c24dab958345dedaeaca2a_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtNi0xLTEtNDkwMzg_d9c30744-74b6-4b90-9a51-952cfdba8bb6">108,353,831</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i770c7a6615c24dab958345dedaeaca2a_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtOC0xLTEtNDkwMzg_5495d2ad-2125-4620-891f-e28d8ce6e655">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if0afac83be094d4aa4542e69b5679207_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTAtMS0xLTQ5MDM4_a3121d3d-52fc-4b5a-8054-a6b25f9b2537">724,176</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic6ff887c265441c69507be611ce503ac_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTItMS0xLTQ5MDM4_0c41f09a-863c-4d9f-848a-86ce41506374">1,402</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie17b5e7664cc4df68c65d8b884872e95_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTQtMS0xLTQ5MDM4_410d9694-1ac8-4df0-b1d1-c51d45ff068c">430,352</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e238a55eb6949e3bfa3fc5e44d68d66_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTYtMS0xLTQ5MDM4_84f4336d-a320-40b6-b9ee-16b64cfc21e7">292,424</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1b044d6aec8a430b9c9d220877699973_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTgtMS0xLTQ5MDM4_56ec02c4-e90f-4e2b-85d4-af3c0d6b081f">33,774</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i475ba3da26c54ed1b8be00efe29feec9_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMjAtMS0xLTQ5MDM4_1ba25e05-267f-43ac-bbd6-a7933902c8b8">326,198</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i53ad139f307f45f59574c837bac70329_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTQtMTAtMS0xLTQ5NzU2_6ea7c6a8-7740-4a34-b6c5-4058f7ed9f91">4,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTQtMTYtMS0xLTQ5NzU2_13433d91-0d63-4d41-aaae-b2dd74fab8e9">4,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTQtMjAtMS0xLTQ5NzU2_fa6863c2-d068-4562-9f3c-f0af1950e7e4">4,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iea7287c095dd4fb394874127ce8b32e2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTctMTQtMS0xLTQ5NzU2_2d3557cf-b583-4138-a31e-2a50c2599c56">21,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTctMTYtMS0xLTQ5NzU2_bdd1730c-8e5d-403a-b77d-0837d7a39c87">21,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTctMjAtMS0xLTQ5NzU2_ecbb04cd-5108-4b33-8e74-1277a69eb07b">21,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:87%">Comprehensive Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i48907c78fead48129720781ca8df4577_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTgtMTItMS0xLTQ5NzU2_a26842d4-f1ad-49c8-b98a-4bf97bfc4925">2,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTgtMTYtMS0xLTQ5NzU2_cd5a1e3e-b16a-4ed4-a85a-5e6adf2babd5">2,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTgtMjAtMS0xLTQ5NzU2_b899fa62-94d5-44a4-ae9d-dd7d9b5e48c7">2,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMS0xLTEtNDk3NTY_6c963626-429e-45e4-a374-31544f07b137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMy0xLTEtNDk3NTY_b5bce7a6-0c67-4f37-b2d4-84f89e70b860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i664446c89c5d42d18ba427b660facc0a_I20220930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktNi0xLTEtNDk3NTY_3a312ea0-2ccd-479e-99f7-76a3fc56fae4">108,353,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i664446c89c5d42d18ba427b660facc0a_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktOC0xLTEtNDk3NTY_9ecb9016-711d-4244-9aa8-7fafdb6f8c14">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iada45bd66c5c4ac1ad4b3ddabe552196_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTAtMS0xLTQ5NzU2_17f8c9ed-e132-4d35-bba8-5953e7680c65">728,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iff7da7e1062844c99aa94c7bbbe052e3_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTItMS0xLTQ5NzU2_b89e13b7-b400-4e20-b163-abcd54756643">3,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i476a15e732a34295adea0c957a427196_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTQtMS0xLTQ5NzU2_79789b0b-6aa9-4a74-a414-96d97ab82453">452,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iefaabc71b2ab47ae804d1de9bee57351_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTYtMS0xLTQ5NzU2_7bafc4b3-062c-4932-b7e1-222fc730d8d3">272,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d6fbb393f9d410283f46ab5e21666d1_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTgtMS0xLTQ5NzU2_b2cfe8b5-9992-445d-be0f-0e2e0a292d9b">33,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMjAtMS0xLTQ5NzU2_578cf015-f77d-43b1-b3e2-52bf21129968">306,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LianBio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Convertible Preferred<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Ordinary Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total LianBio<br/>Shareholders&#8217;<br/>Equity (Deficit) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity (Deficit) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xLTEtMS00OTAzOA_1e9a8a3b-90ba-479b-a40d-f7f85c04c281">10,971,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0zLTEtMS00OTAzOA_b27e96b3-5eb5-458b-853a-5e024de5e5ac">349,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib12f0d7ec46545459636f4595ce63971_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi02LTEtMS00OTAzOA_035e92cc-c585-4951-9666-45f88044df29">20,477,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib12f0d7ec46545459636f4595ce63971_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi04LTEtMS00OTAzOA_a19ef0f7-ab58-4b17-be7c-4f5c288ef4df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i843b9dc93da54466be692b7fe0e517ce_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xMC0xLTEtNDkwMzg_f2d797cb-04b4-40d8-8b71-51fe27381d64">31,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ibf757ee092794a7b907ffc699c87df97_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xMi0xLTEtNDkwMzg_eff42065-ea3b-4d98-aa1b-fbe5769548b1">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i00ba9d6adbc545c784eb291a888dd93d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xNC0xLTEtNDkwMzg_8a70110a-5250-41b8-8cfe-c800891ff218">163,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="idc809e33c664490faf057840bbfd54f6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xNi0xLTEtNDkwMzg_8e8c55af-61f5-4766-9952-bc9ca7dd1db7">132,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i10c747e16a744468928214dcc9e51ae1_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xOC0xLTEtNDkwMzg_af245dbd-47c3-4ae4-8dad-82bab46b583c">34,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0yMC0xLTEtNDkwMzg_5678659a-9c5b-469a-b327-707784b3505d">98,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icd068d3e42c34c279f69aaf1be33f5c3_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMy0xMC0xLTEtNDkwMzg_f7366560-f8b9-49b0-af57-ca66282521fa">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5e6744690158405abbd221d7a074c791_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMy0xNi0xLTEtNDkwMzg_b772f75f-98f8-447c-84f1-139bb2818cf1">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMy0yMC0xLTEtNDkwMzg_5774cdac-0ccc-4acb-ae0c-ddec971e5c13">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Series A Preferred Shares at $<ix:nonFraction unitRef="usdPerShare" contextRef="if81a8e1bb8e14340b40f2c724b9842a9_I20210331" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNC0wLTEtMS00OTAzOC90ZXh0cmVnaW9uOjliMjIyYTQyNDdiYTQyYTFhMTRmM2JhOGIzNjBmNWZhXzQ1_8b29f2aa-b9b3-470d-a29c-30e627df4853">56.66</ix:nonFraction>, net of issuance costs </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331" decimals="INF" name="adr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNC0xLTEtMS00OTAzOA_1f26c6d2-cf5a-45dd-9e0e-be2ba01104e6">52,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNC0zLTEtMS00OTAzOA_156cb42c-2587-4486-b8a9-cfc0206f99c7">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:87%">Warrants issued in license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5aae9117d3e343aa9c8b422b360bbf8b_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNS0xOC0xLTEtNDkwMzg_b0b12b25-201c-448e-a012-c536443da6fc">9,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNS0yMC0xLTEtNDkwMzg_fafab4e7-763a-4c7e-a087-dbb4e03e3fd0">9,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia555d7f1cdbb4263b3e681f74e9864c7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNi0xNC0xLTEtNDkwMzg_421c6aee-f1a8-484c-8d02-58e18b596206">61,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5e6744690158405abbd221d7a074c791_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNi0xNi0xLTEtNDkwMzg_39011f3c-0b00-4af2-a228-b3a290a1050f">61,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNi0yMC0xLTEtNDkwMzg_033a9106-5fa5-4278-813e-86d236a3ed05">61,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i094e8e47897d4872a7f705af07fdff66_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNy0xMi0xLTEtNDkwMzg_bca29a44-7b67-476f-90a9-86133d788bee">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5e6744690158405abbd221d7a074c791_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNy0xNi0xLTEtNDkwMzg_bf9a6a88-914c-4156-b71a-3d3a28aa15bb">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNy0yMC0xLTEtNDkwMzg_24e644eb-7d12-4f70-bf32-9b8e69ed0faa">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xLTEtMS00OTAzOA_9e09150d-47b5-4234-9d54-109e81beed5f">11,024,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0zLTEtMS00OTAzOA_9c549e56-0cc5-40a0-8543-4e9a84e68a47">352,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id2cfe092feb045dbbc9f7ccb340f1d54_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC02LTEtMS00OTAzOA_38d8e220-9f35-45ec-b47d-d16396dd4549">20,477,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id2cfe092feb045dbbc9f7ccb340f1d54_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC04LTEtMS00OTAzOA_e71264e9-c2d3-45f0-95fa-fd088625121b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i87f9f534bbe64805a759a975c5e89677_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xMC0xLTEtNDkwMzg_24ad817c-1c9e-4530-b0f0-9915793e4e88">32,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8a7631dd76cf40a4b4fcef577ab42fd2_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xMi0xLTEtNDkwMzg_52ff6cc9-3421-4a55-898b-8167a3ea69ab">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9065e3e77be445739a59ac03866a9ce3_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xNC0xLTEtNDkwMzg_523ddd98-8e18-4097-82cf-975d7f1b38fc">225,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i7b1e1b4992c34e169c7d86153c6eb2ce_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xNi0xLTEtNDkwMzg_33614e6d-7da3-454f-990d-3851dd9b3bf2">192,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i344b1e6c929d49dbb0309bbb28a88cbf_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xOC0xLTEtNDkwMzg_fdf841b6-bdd3-4a4a-bfa0-913078221525">44,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0yMC0xLTEtNDkwMzg_09551092-6bab-4a1e-93ae-01ed57d9f579">148,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5f6c3f36b5eb42d299c7131a79fec1a3_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOS0xMC0xLTEtNDkwMzg_893fb9ce-3500-4a3f-9058-4c12be2fdd23">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOS0xNi0xLTEtNDkwMzg_94262935-242b-4d09-a30c-67cf4ea3e709">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOS0yMC0xLTEtNDkwMzg_b1edc9a5-5570-4213-8c92-6227b1ffbb3c">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i97b84f3425ae4c298fafa57dee035528_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTAtMTQtMS0xLTQ5MDM4_2be1972d-2897-4ad6-8762-96de1fe44be2">100,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTAtMTYtMS0xLTQ5MDM4_922bf717-e344-449e-ae71-c6c715ee335a">100,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTAtMjAtMS0xLTQ5MDM4_ad4d2ed4-e757-4e76-a00d-87c73c291bb6">100,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9cf331c6036a4355a4904f3f4bbb1cd2_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTEtMTItMS0xLTQ5MDM4_13f52cb7-319b-4298-a4f3-3914c483c1e4">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTEtMTYtMS0xLTQ5MDM4_27903f87-2bdd-4805-937b-4578febfdb12">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTEtMjAtMS0xLTQ5MDM4_65624381-a2e6-4200-b560-9a880603f4b4">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia7408c111d584b5ab590b62aac211dac_I20210630" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMS0xLTEtNDkwMzg_9ec12628-3b4e-4093-b9be-abaa2d28ab2d">11,024,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia7408c111d584b5ab590b62aac211dac_I20210630" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMy0xLTEtNDkwMzg_7a868f10-4dd2-491a-8062-8469879f8cd5">352,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i19cd0b34a996469990768d290687c7ee_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItNi0xLTEtNDkwMzg_10c60116-9b3a-43d0-b717-902122564d05">20,477,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i19cd0b34a996469990768d290687c7ee_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItOC0xLTEtNDkwMzg_6edb0b76-4395-4a73-9dff-20b5416e8976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib11048778c5e4d0687735a5893af9693_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTAtMS0xLTQ5MDM4_90451877-7d7a-4015-b3a8-2fcbe4c77adc">34,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if8db68d789694f5cb6106efce2a2b3ae_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTItMS0xLTQ5MDM4_cf75872c-ae8b-4697-aca5-9ca1e9531484">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4a99f5ddcd3340849368e824f80c8eb2_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTQtMS0xLTQ5MDM4_9b21c1a6-13fd-44da-915a-e2171973f44b">325,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie5f4de76939f4d41bae02354c1c148b7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTYtMS0xLTQ5MDM4_44249eb6-ddce-4fa2-a2ca-bb959547dcc2">291,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie78c90d28271496cbeedbefdec9b279f_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTgtMS0xLTQ5MDM4_f9e90abe-21ce-4b96-9778-29984b2ea82a">44,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia7408c111d584b5ab590b62aac211dac_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMjAtMS0xLTQ5MDM4_90b53ea4-930f-4c08-a8da-cbe6111dc14d">247,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="idc84f64754e446c292da7857f70711f5_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTMtMTAtMS0xLTQ5Nzcx_d8395c89-952d-40af-8770-af79d281a7f4">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTMtMTYtMS0xLTQ5Nzcx_d44166e7-f0b5-4413-81a0-964d3ea82174">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTMtMjAtMS0xLTQ5Nzcx_12fe6a1f-be05-478d-bdca-813d8e8ace84">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:87%">Exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ibde6fe20c7ce4abcb989cd5740f6517e_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtNi0xLTEtNDk3NzE_a1ddbeb7-ad93-48f8-adc3-106ca87497ad">1,309,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="idc84f64754e446c292da7857f70711f5_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtMTAtMS0xLTQ5Nzcx_c3d7a397-4bde-41db-8ce7-b72616a38642">5,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtMTYtMS0xLTQ5Nzcx_a0796496-79ce-4cfa-8f04-de71e964cbc7">5,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtMjAtMS0xLTQ5Nzcx_c12c3244-d442-4ed5-8c02-a0a6a9adace8">5,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id926e92f71c541b1ae612d23291c8593_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTUtMTQtMS0xLTQ5Nzcx_2c8e78ee-d9e6-4674-b3d6-3e1c13398367">13,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTUtMTYtMS0xLTQ5Nzcx_d8f1a0cb-5d42-4e6e-95b3-96ea1c682704">13,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTUtMjAtMS0xLTQ5Nzcx_bba68486-6b5c-4338-af50-88f98d17bcf0">13,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0b839be2585f4f18bbac068fb248673d_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTYtMTItMS0xLTQ5Nzcx_0f842a1b-6745-4985-9471-0b1b22a9b7d1">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTYtMTYtMS0xLTQ5Nzcx_a4b13af8-54b8-4951-a966-da6e1b751e80">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTYtMjAtMS0xLTQ5Nzcx_65ac3e03-7cd9-4e68-bbde-622e9c898d79">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0a135bc815214ea891762f3528c47479_I20210930" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMS0xLTEtNDk3NzE_99c83ace-17df-43d0-8d42-2af866447e04">11,024,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0a135bc815214ea891762f3528c47479_I20210930" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMy0xLTEtNDk3NzE_d03417c8-0141-4639-b706-8053a378d917">352,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i54f1e96dce0d4efd8b146ffaad7ccb37_I20210930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctNi0xLTEtNDk3NzE_0d8cf5d6-af1a-4a22-97d5-027d200ed814">21,787,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i54f1e96dce0d4efd8b146ffaad7ccb37_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctOC0xLTEtNDk3NzE_614b1e8e-1fd2-435c-a7ad-b9822dd782ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i20f8c40cc106484c8030ad5495b23cfd_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTAtMS0xLTQ5Nzcx_4a02cdfc-8a1b-4eab-be2d-bec9f6356a1b">41,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1be28631775249e1801ff1234f689d4e_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTItMS0xLTQ5Nzcx_08772b83-a417-4a13-a822-442e367a1730">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6a3842c85d9f4a828a8135e64dcab877_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTQtMS0xLTQ5Nzcx_97c861a0-976b-4bb1-8e53-b223fd3fbfae">339,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic5b0e96016484b7d974af94c79a8fb0d_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTYtMS0xLTQ5Nzcx_20332fb2-7460-4c3b-8b58-f98e6aef13fb">297,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i89dd2c9150114f349e9c78a6c5a2a70f_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTgtMS0xLTQ5Nzcx_3cfe1f2d-9aae-4149-95fd-68bf2c83e7cf">44,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0a135bc815214ea891762f3528c47479_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMjAtMS0xLTQ5Nzcx_c6b621da-435e-44c7-a95c-5668e1cc92d5">253,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LianBio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMS0xLTEtMS00OTAzOA_f5aeb2db-0cc3-4d90-b8cb-f70aa03075f2">92,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMS0zLTEtMS00OTAzOA_97f47f4d-df0c-4e3c-bcad-59093a5a7d8f">175,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash share consideration, issued in acquisition of IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="adr:NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMy0xLTEtMS00OTAzOA_de960930-946b-4e2a-9c14-4e27d08d061c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="adr:NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMy0zLTEtMS00OTAzOA_b7061993-ebf4-4535-b5ef-68a37e558466">9,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease expense (benefit) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="adr:NonCashOperatingLeaseExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNC0xLTEtMS00OTAzOA_8af3211f-0129-4ab9-b62d-67f47fafcbfe">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="adr:NonCashOperatingLeaseExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNC0zLTEtMS00OTAzOA_ea8b82e2-2126-400d-b065-1a1ffca21db0">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNS0xLTEtMS00OTAzOA_d49718ba-85db-4180-8fc1-df0e81fd17c3">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNS0zLTEtMS00OTAzOA_f879fb43-2f72-475c-a87a-462525640c48">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNi0xLTEtMS00OTAzOA_23cc0f3d-24f2-4b54-9eaa-8f97b47deb34">13,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNi0zLTEtMS00OTAzOA_9110b540-e725-4bee-8d78-852449a2e648">5,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of discounts on investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNy0xLTEtMS00OTAzOA_db0945f6-c0f9-45fc-aa89-465a47edc39f">481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNy0zLTEtMS00OTAzOA_121d1a84-6800-48c8-987e-68c9754b4063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized foreign currency transaction gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfOC0xLTEtMS00OTAzOA_172452f7-d718-4c79-8319-cc36a429c78f">1,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfOC0zLTEtMS00OTAzOA_5fcc7d48-9932-4376-b238-9bca8e1a3661">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease (increase) in prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTItMS0xLTEtNDkwMzg_3bdb3e97-d301-4be7-998a-ff6978a4781a">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTItMy0xLTEtNDkwMzg_5e4aa0bb-2cfd-473d-9a64-b226bddc101a">3,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Increase) decrease in other receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTMtMS0xLTEtNDkwMzg_81a46dd7-d603-44e2-8a18-38bdd98100eb">1,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTMtMy0xLTEtNDkwMzg_5cc0e53c-b9ca-4c6a-91fc-34da777aa07f">14,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTUtMS0xLTEtNDkwMzg_2a42c9d7-d6d0-4254-9ba0-74ade7072096">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTUtMy0xLTEtNDkwMzg_305c258d-d89b-4a98-b364-e7ff315cb549">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTYtMS0xLTEtNDkwMzg_bf7247ee-bdb0-442b-94ce-72d9945df0bf">1,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTYtMy0xLTEtNDkwMzg_ff8c5d04-07a4-408d-9174-dae686347594">2,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTctMS0xLTEtNDkwMzg_6e952d90-f00a-4c31-a9dd-2fd306cadf0c">8,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTctMy0xLTEtNDkwMzg_59f8017a-2c09-4a22-a848-3544410aa03b">11,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) increase in other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTgtMS0xLTEtNDkwMzg_bd1bc2ac-0907-4252-9fe6-1be950a35d7c">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTgtMy0xLTEtNDkwMzg_dd60274e-ad10-4aba-a28f-c9159ba4daae">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in withholding tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTktMS0xLTEtNTIyMTk_1585c9bb-0df0-4520-95e0-585a0b78fb94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTktMy0xLTEtNTIyMTk_a807d95a-da4d-40c1-9da0-226e619aa167">5,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjAtMS0xLTEtNDkwMzg_47bea8b1-b92d-4956-979f-877a09ccf977">68,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjAtMy0xLTEtNDkwMzg_0f6bbc3c-e976-4767-bb92-0317626c2b0f">133,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjItMS0xLTEtNDkwMzg_7001f378-686a-4cf2-b942-5ce72b11e103">1,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjItMy0xLTEtNDkwMzg_49069cd0-fef6-4720-8eb3-f2247dd5bb0b">159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjMtMS0xLTEtNDkwMzg_1df54921-9796-42e5-a5ee-8fb9d0d1fe72">260,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjMtMy0xLTEtNDkwMzg_ae796e05-cc40-4d7b-b6dd-28af36219722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and redemption of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjQtMS0xLTEtNDkwMzg_0e1bd31b-cf32-453c-aba4-af2ef3fd0878">181,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjQtMy0xLTEtNDkwMzg_ff5ba432-0112-4e95-bff3-9709e18579cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjUtMS0xLTEtNDkwMzg_b061a294-87da-46a5-a4a2-2d08a84ad528">80,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjUtMy0xLTEtNDkwMzg_34cb6b9b-95ee-4684-9ae0-690bd55ea083">159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjgtMS0xLTEtNDkwMzg_deacb168-1fc5-4967-bf0e-203823ae529a">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjgtMy0xLTEtNDkwMzg_c1a34b8f-5b78-4068-8309-87a8b6784040">5,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of redeemable convertible preferred shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjktMS0xLTEtNDkwMzg_abff8737-0032-4d88-b612-bfeb9047e5a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjktMy0xLTEtNDkwMzg_b9bf5152-f720-4796-8eca-17696a976112">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance costs related to redeemable convertible preferred shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzAtMS0xLTEtNDkwMzg_5d9f899d-c410-45e8-81ef-e3c51eb14ce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzAtMy0xLTEtNDkwMzg_ed3020a0-0142-4166-980b-c3bba9fda3e3">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzEtMS0xLTEtNDkwMzg_419cbf1b-9cf1-4c19-be98-82b922f073bb">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzEtMy0xLTEtNDkwMzg_9ca9e909-7bbc-48ba-ba9f-499ef185f703">8,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzItMS0xLTEtNDkwMzg_a574df1c-a8a1-41f1-ba81-11e170dd81f4">2,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzItMy0xLTEtNDkwMzg_5591b865-9d8e-49b9-b9f0-89538ac72190">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzMtMS0xLTEtNDkwMzg_a6b6f2bc-23be-46fc-8e06-9f404f22b98b">149,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzMtMy0xLTEtNDkwMzg_ae51678d-b547-4246-ad12-a603f15af68e">125,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, and restricted cash&#8212;beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzQtMS0xLTEtNDkwMzg_3f5c0edb-9591-4e1d-8d3c-b9c906ca8ac8">248,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzQtMy0xLTEtNDkwMzg_19f319f5-7ecd-46ae-b546-d80cc6bc0b8f">254,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, and restricted cash&#8212;ending of period</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzUtMS0xLTEtNDkwMzg_ee019a6e-ee9f-494e-a0a1-213429e3702d">98,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a135bc815214ea891762f3528c47479_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzUtMy0xLTEtNDkwMzg_b1ca6676-a2b1-40e2-b713-ae733183e587">129,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;end of period</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzYtMS0xLTEtNDkwMzg_dcd3c2fe-08be-49f2-b7f2-2501604fbe4f">78,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a135bc815214ea891762f3528c47479_I20210930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzYtMy0xLTEtNDkwMzg_c0a78ada-bb46-40a4-9945-386e50e82d49">109,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash&#8212;end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzctMS0xLTEtNDkwMzg_cca8bd4e-37d4-4e33-a06f-14adc6283185">20,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a135bc815214ea891762f3528c47479_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzctMy0xLTEtNDkwMzg_ad2fa19f-b93e-4f62-bace-655b7c77a68c">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, and restricted cash&#8212;ending of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzgtMS0xLTEtNDkwMzg_725faa3e-1e29-4897-ac6d-432d1b17a67c">98,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a135bc815214ea891762f3528c47479_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzgtMy0xLTEtNDkwMzg_1a68f0f4-c0aa-460b-8f97-695e08439d3c">129,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of cash information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDAtMS0xLTEtNDkwMzg_1f63f1f6-36bb-49c9-84d1-65f3356cbb07">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDAtMy0xLTEtNDkwMzg_84f877e8-99ad-45cd-95c9-0d11aff1d930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDItMS0xLTEtNDkwMzg_d76f300d-a69c-4473-9d9c-1ed8635e4f39">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDItMy0xLTEtNDkwMzg_62b52018-0e2e-484c-b6fb-9098ad9ee07e">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Issuance costs in accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="adr:DeferredOfferingCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDMtMS0xLTEtNDkwMzg_15c019ad-9c47-4a2d-bf7e-499faf8ae7f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="adr:DeferredOfferingCostsIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDMtMy0xLTEtNDkwMzg_45b2e56c-f316-4691-853c-8ad47f634ef3"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="adr:DeferredOfferingCostsIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDMtMy0xLTEtNDkwMzg_a6e1a6c5-b614-4834-81c0-80417cc2bf74">3,310</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Purchase of property and equipment in accounts payable </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDQtMS0xLTEtNDkwMzg_0a39f92f-9b66-4919-9701-bcc47c9d499a">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDQtMy0xLTEtNDkwMzg_be509217-8edd-43d4-8d47-a4eba2fe4775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Tabular Dollars in Thousands, Except Share and per Share Data) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i7377b691bd58451297fc26cb9421b200_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTQ3OA_2b42de17-d7de-4a3c-b678-276e3c0793cd" continuedAt="i2882554261d24f56807d908da22de891" escape="true">Nature of Business </ix:nonNumeric></span></div><ix:continuation id="i2882554261d24f56807d908da22de891"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LianBio (&#8220;LianBio&#8221; or the &#8220;Company&#8221;) is a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Cayman Islands in July 2019 and maintains its Chinese headquarters in Shanghai, China. The Company conducts its corporate activities at its United States headquarters located in Princeton, New Jersey. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;) through an underwritten sale of <ix:nonFraction unitRef="shares" contextRef="if15bb3d88e144b8fb0462ca6bc65c410_D20211103-20211103" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfNjYw_a22b29cb-6e94-46e3-a37e-6b5f6880729f">20,312,500</ix:nonFraction> American Depositary Shares (&#8220;ADSs") representing <ix:nonFraction unitRef="shares" contextRef="ic9758d92ce7f4beb932f7cfa346c246c_D20211103-20211103" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfNzEy_dbe8bebe-bb89-4f5a-9172-edf5a9907d2a">20,312,500</ix:nonFraction> ordinary shares at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie6621d4b27834cd1a8fdbaa9dae39f18_I20211103" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfNzQ1_fa3f9850-6535-424e-a573-babf31ea7a4a">16.00</ix:nonFraction> per share. Following the close of the IPO, on December 1, 2021, the underwriters partially exercised their option to purchase additional shares and purchased an additional <ix:nonFraction unitRef="shares" contextRef="i5d453bec4c3b4dceb7ea5525faa7b87e_D20211201-20211201" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfOTIw_9b91fd67-6df8-42d6-bc5f-416f6647d74a">593,616</ix:nonFraction> ADSs at the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iff1946c96c304391bdd745ff4abb6f90_I20211201" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfOTQ4_2890e7b6-53e9-430c-bb7b-5139c0cbb646">16.00</ix:nonFraction> per ADS. The Company received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i13e6d021cd914175b381a66b8a7cbb8c_D20211201-20211201" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfOTk5_765c750b-c6b2-4cb7-8767-106082726ce1">334.5</ix:nonFraction> million in connection with the IPO and subsequent exercise of the underwriters&#8217; option and aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i13e6d021cd914175b381a66b8a7cbb8c_D20211201-20211201" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTExOQ_df00594b-b211-46f9-864a-2f3867a88114">304.8</ix:nonFraction> million after deducting underwriting discounts, commissions and other offering expenses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the IPO, all of the Company&#8217;s convertible preferred shares then-outstanding were automatically converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i378fd65bf5a34325aead1a87c2d54e68_I20211103" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTM1Mw_f9106673-cc0a-4fbe-899f-442e0567c1cf">64,467,176</ix:nonFraction> ordinary shares and were reclassified into permanent equity. Following the IPO, there were <ix:nonFraction unitRef="shares" contextRef="i378fd65bf5a34325aead1a87c2d54e68_I20211103" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTQ0Nw_7ef1a139-28d0-4ab9-bd75-5f0629f1d408">no</ix:nonFraction> preferred shares outstanding.</span></div></ix:continuation><div id="i7377b691bd58451297fc26cb9421b200_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc1OA_5b9ee03d-82b0-4759-946b-402ff9808a33" continuedAt="i47e8557f508a4ebbbe487cd1659dcee1" escape="true">Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i47e8557f508a4ebbbe487cd1659dcee1" continuedAt="i64ef6b5063284b08bd2cb823c2844235"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc2Mw_bbca7a30-b3b1-46e8-be86-36d60a35c220" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(A) Basis of presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, which include the People&#8217;s Republic of China (&#8220;PRC&#8221;) registered entities directly owned by the Company. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim balance sheet as of September&#160;30, 2022, and the interim consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred shares and shareholders&#8217; equity (deficit) for the three and nine months ended September&#160;30, 2022 and 2021, and the cash flows for the nine months ended September&#160;30, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial information. The financial data and other information disclosed in these notes related to the three and nine month periods are also unaudited. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc1OQ_a00ed714-137d-4364-ae1c-0ae5d6d72bcc" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B) Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The only material estimates in the accompanying financial statements are the fair value of warrants, share-based compensation, and share options. Actual results could differ from those used in evaluating these accounting estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="i64ef6b5063284b08bd2cb823c2844235" continuedAt="i7031e42f12e1402591276676bb6d2f00"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc2NA_e3ef39de-807b-4a94-9891-29208a9f10e5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak a pandemic. The Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including planned clinical trials. The impact of the COVID-19 pandemic on the Company&#8217;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy continue to be impacted for an extended period, the Company&#8217;s results may be materially adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to material credit risk due to the financial position of the banking institutions. The Company has no off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could affect the Company&#8217;s operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials, uncertainty of regulatory approval of the Company&#8217;s potential product candidates, uncertainty of market acceptance of its product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company&#8217;s product candidates require approvals from the National Medical Products Administration (&#8220;NMPA&#8221;) in China and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, such events could have a materially adverse impact on the Company&#8217;s business.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTM2NQ_e4cfe938-7a8c-4cce-8806-16cf1e82f99e">452.2</ix:nonFraction> million as of September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTM4OQ_4ad586c5-b570-4abd-aad9-ed83c8f19da0">360.2</ix:nonFraction> million as of December&#160;31, 2021. The Company&#8217;s cash and cash equivalents and marketable securities were $<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTQ4MQ_1d186a9b-0e51-4b38-b2c2-37282c210d16">311.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTQ5Ng_1f0f45c8-69e2-4a3a-8fd7-dba0bc51e884">383.2</ix:nonFraction> million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The Company has financed its operations to date primarily through equity capital raises. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that existing capital resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements, though it expects to continue to incur operating losses and negative operating cash flows. The Company will be required to raise additional capital to fund future operations, however, no assurance can be given as to whether additional needed financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail planned activities to preserve cash resources. These factors may adversely impact the Company&#8217;s ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="i7031e42f12e1402591276676bb6d2f00" continuedAt="id8f6aba7d4f24397b17650f297d0989d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(C) Significant Accounting Policies Update</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Annual Report on Form 10-K for the year ended December&#160;31, 2021. There have been no material changes to the Company&#8217;s significant accounting policies during the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc2MQ_987e792a-9e58-4d65-8c6d-a810da0cbfd5" continuedAt="i507557aa32684c1bb76bd63eb0962018" escape="true">(D) Recently Issued Accounting Pronouncements Not Yet Adopted </ix:nonNumeric></span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id8f6aba7d4f24397b17650f297d0989d"><ix:continuation id="i507557aa32684c1bb76bd63eb0962018">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, the Company has elected to &#8220;opt out&#8221; of such extended transition period for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards on the same timeline as other public companies. The Company has evaluated recent accounting pronouncements and believes that there are none that will have a material impact on its financial position or results of operations upon adoption.</ix:continuation></ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="adr:LicenseAndOtherRelatedAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg4NTc_61334b7d-46c5-42e7-a8ba-c01740e871fc" continuedAt="i3297d6b72cca474d8c08b58132b8fce6" escape="true">Material Agreements </ix:nonNumeric></span></div><ix:continuation id="i3297d6b72cca474d8c08b58132b8fce6" continuedAt="iac0c0ebeece94bf9b2e3838e3753944e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with QED Therapeutics, Inc. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a license agreement (as subsequently amended, the &#8220;QED License Agreement&#8221;) with QED Therapeutics, Inc. (&#8220;QED&#8221;), under which the Company obtained an exclusive license under certain patents and know-how (including patents and know-how that QED licensed from QED&#8217;s upstream licensor) to develop, manufacture, use, sell, import, and commercialize QED&#8217;s ATP-competitive, FGFR1-3 tyrosine kinase inhibitor, infigratinib, in pharmaceutical products in the licensed territory of Mainland China, Macau, Hong Kong, Taiwan, Thailand, Singapore and South Korea, in the licensed field of human prophylactic and therapeutic uses in cancer indications. In September 2020, the Company entered into an amendment with QED to reduce the licensed territories to include Mainland China, Macau and Hong Kong. In December 2021, the Company entered into a second amendment with QED to modify the Company&#8217;s development obligations with respect to certain clinical trials, and change the development milestone payments the Company owes to QED and the royalty rates for the tiered royalties on net sales of licensed products the Company will pay to QED. Under the QED License Agreement, QED received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iaeeb6e6bbe6549bc95c5d66955d58c3e_D20191001-20191031" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTMxNg_0214bbf1-d1c6-4d0c-b2a4-984a0d0ebd8b">10.0</ix:nonFraction> million and was granted warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ib952974c6da148e98796252b1f567278_I20191031" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM1Ng_af700e4d-51c5-43fe-97f3-09fe6ce4e454">100,000</ix:nonFraction> ordinary shares in Lian Oncology, a subsidiary of LianBio, valued at $<ix:nonFraction unitRef="usd" contextRef="ib5eacd74781d44f289c25d5872d43093_I20191031" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQyOA_5678effa-5450-4150-a20d-af1238108134">1.0</ix:nonFraction> million. Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model. The warrants were issued in <ix:nonFraction unitRef="tranche" contextRef="i3e2ea8c3730c405aaaa82862d9f64c8c_I20191031" decimals="INF" name="adr:ClassOfWarrantOrRightNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY4OA_b138af0f-0825-465c-9e4f-0cb4c0c67523">three</ix:nonFraction> tranches with the aggregate number of shares across all tranches equaling <ix:nonFraction unitRef="number" contextRef="i696c50ecd8f14eb6b7b9e1bcbc34acce_I20191031" decimals="2" name="adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2NQ_31b73e7c-880d-4e4e-bbd7-a41f4c416387"><ix:nonFraction unitRef="number" contextRef="iad897a5006884c3591079e3c6af4ff9b_I20191031" decimals="2" name="adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2NQ_95a3e155-8a44-4acc-a07d-67dcbd201ac3"><ix:nonFraction unitRef="number" contextRef="ib6353efb7d3e492abdbd9b5ffce7d251_I20191031" decimals="2" name="adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2NQ_df698804-19e0-4423-a4c1-4fe48edbe928">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the fully diluted equity of Lian Oncology as of the issue date. Vesting of the warrant shares are linked to regulatory milestones and the warrants expire <ix:nonNumeric contextRef="ib5eacd74781d44f289c25d5872d43093_I20191031" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTkyNQ_2216f4f9-4353-47c6-b1bb-eff972b4112d">10</ix:nonNumeric> years from the issue date. The amended and restated option agreement also provides QED with the option to choose to either convert the warrant (&#8220;Subsidiary Warrant&#8221;) into ordinary shares of the Company (&#8220;Parent Company Shares&#8221;) or a warrant to purchase a certain number of Parent Company Shares (&#8220;Parent Company Warrant&#8221;) immediately prior to an IPO of the Company. In the event QED chose to convert the Subsidiary Warrant into Parent Company Shares, the number of Parent Company Shares QED is entitled to receive would be calculated as the aggregate fair market value of the ordinary shares of Lian Oncology that are under the Subsidiary Warrant, divided by the per share fair market value of the Parent Company Shares, on a fully diluted and as-converted basis and as of the date the Company sent QED the notice of the IPO. In the event QED chose to convert the Subsidiary Warrant into the Parent Company Warrant, the number of Parent Company Shares under the Parent Company Warrant QED was entitled to receive would have been calculated as the aggregate intrinsic value of the Subsidiary Warrant (the number of the ordinary shares of Lian Oncology under the Subsidiary Warrant multiplied by the difference between the strike price of the Subsidiary Warrant and the per share fair market value of Lian Oncology), divided by the per share intrinsic value of the Parent Company Warrant (the difference between the strike price of the Parent Company Warrant and the per share fair market value of Parent Company Shares), on a fully diluted and as-converted basis on the date of the warrant conversion. This conversion feature was not required to be bifurcated as it is clearly and closely related to the equity host instrument, pursuant to ASC 815. On October&#160;18, 2021, based on the conversion feature, LianBio issued to QED a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i35b7d9bb22284b6badabc23d684178bd_I20211018" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMzc1Ng_000e6c9a-09ce-4bcc-b451-4bca4cc1b2ac">347,569</ix:nonFraction> of its ordinary shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i35b7d9bb22284b6badabc23d684178bd_I20211018" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMzgwNg_42e3f169-9001-45a3-8b47-4ae6437a5841">0.000017100448</ix:nonFraction> per share and, concurrently with such issuance, the Subsidiary Warrant was deemed to be performed and settled in full and was irrevocably terminated. The QED License Agreement also required the Company to refund QED for costs incurred on the study through the execution date which was determined to be $<ix:nonFraction unitRef="usd" contextRef="i48477ba30acc44fda8e1ce1e3f7f5558_I20191231" decimals="-5" name="adr:ReimbursementAmountDueTowardsCostsIncurredForTheStudy" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNDExMQ_9142ab4c-45e1-4b9b-8134-16a3a5c8c6f4">2.8</ix:nonFraction> million. Additionally, QED is entitled to receive from the Company development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i89c392c6026c4ca9864f26feb3f567e3_I20191031" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNDIxMw_59e4551a-f6c6-4618-a9cd-aa7f0972dcfd">7.0</ix:nonFraction> million upon achievement of specified development milestones, and sales milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="id05b0fb48e914379a182a9bec0d03a93_I20191031" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNDMwOA_ecb06d72-e29b-4a4b-824f-7315afc157a0">87.5</ix:nonFraction> million based on cumulative net sales of infigratinib, in addition to tiered royalties on net sales of licensed products at the greater of (a) percentage rates in the mid- to high-teens on the net sales of the licensed products, or (b) the applicable rate payable under QED&#8217;s agreement with its upstream licensor (capped in the mid-teens).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="iac0c0ebeece94bf9b2e3838e3753944e" continuedAt="i75391b77b8e74ad1ac9f033884656bb5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with MyoKardia </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an exclusive license agreement (the &#8220;MyoKardia License Agreement&#8221;) with MyoKardia Inc. (&#8220;MyoKardia,&#8221; now a wholly-owned subsidiary of Bristol-Myers Squibb (&#8220;BMS&#8221;)), under which the Company obtained an exclusive license under certain patents and know-how of MyoKardia to develop, manufacture, use, sell, import and commercialize MyoKardia&#8217;s proprietary compound, mavacamten, in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand and Singapore, and in the licensed field of any indication in humans, which includes any prophylactic or therapeutic use in humans. Under the MyoKardia License Agreement, MyoKardia received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7a57dbf7904a433aa373a461fd34ad40_D20200801-20200831" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTM4OA_643b3956-1505-4f1a-8480-6cb68fbb2034">40.0</ix:nonFraction> million and was granted a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i1c3b0a6c246849aa9cca5199dc89a774_I20200831" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTQyOQ_285b0283-f68e-475f-8e6f-d468a813631f">170,000</ix:nonFraction> ordinary shares in Lian Cardiovascular, a subsidiary of LianBio, valued at $<ix:nonFraction unitRef="usd" contextRef="i1c3b0a6c246849aa9cca5199dc89a774_I20200831" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTUwNw_79440f3d-9a35-4874-84b0-973e0557d140">33.8</ix:nonFraction> million. Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model and the underlying assumptions are discussed in further detail in Note 10 in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. The warrants, representing <ix:nonFraction unitRef="number" contextRef="i1c3b0a6c246849aa9cca5199dc89a774_I20200831" decimals="2" name="adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTkyMQ_64f70097-7e8c-4698-aa91-669dc9a4b454">17</ix:nonFraction>% of the fully diluted equity of Lian Cardiovascular, are exercisable by MyoKardia at any time after issuance. The amended and restated option agreement also provides MyoKardia with the option to choose to either convert the warrant (&#8220;Subsidiary Warrant&#8221;) into ordinary shares of the Company (&#8220;Parent Company Shares&#8221;) or a warrant to purchase a certain number of Parent Company Shares (&#8220;Parent Company Warrant&#8221;) immediately prior to an IPO of the Company. MyoKardia was entitled to choose to convert the Subsidiary Warrant into Parent Company Shares, and the number of Parent Company Shares MyoKardia was entitled to receive would have been calculated as the aggregate fair market value of the ordinary shares of Lian Cardiovascular that are under the Subsidiary Warrant, divided by the per share fair market value of the Parent Company Shares, on a fully diluted and as-converted basis on the date the Company sent MyoKardia the notice of the IPO. Alternatively, MyoKardia was entitled to choose to convert the Subsidiary Warrant into the Parent Company Warrant, the number of Parent Company Shares under the Parent Company Warrant MyoKardia was entitled to receive would be calculated as the aggregate intrinsic value of the Subsidiary Warrant (the number of the ordinary shares of Lian Cardiovascular under the Subsidiary Warrant multiplied by the difference between the strike price of the Subsidiary Warrant and the per share fair market value of Lian Cardiovascular), divided by the per share intrinsic value of the Parent Company Warrant (the difference between the strike price of the Parent Company Warrant and the per share fair market value of Parent Company Shares), on a fully diluted and as-converted basis on the date of the warrant conversion. This conversion feature was not required to be bifurcated as it was clearly and closely related to the equity host instrument, pursuant to ASC 815. As of October&#160;12, 2021, MyoKardia elected not to exercise this option and, therefore, continues to hold its warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i43ad44c91d4b4706b2c2bdfbec79da2a_I20211012" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNzk0NA_fcdc612d-76dc-4b05-9069-384f80be9907">170,000</ix:nonFraction> ordinary shares in Lian Cardiovascular. MyoKardia&#8217;s option to convert the warrant irrevocably terminated upon the completion of the Company&#8217;s IPO. Additionally, MyoKardia was entitled to receive a nonrefundable financing milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i0f92dc83d35344a29383ddc78d8130f2_D20201029-20201029" decimals="-5" name="adr:PaymentOfMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODE4OQ_31546f33-3b7a-4f8a-9473-30efa8218f0f"><ix:nonFraction unitRef="usd" contextRef="iacb5da7838574f67a606a8efb8a5436a_I20200831" decimals="-5" name="adr:MilestonePaymentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODE4OQ_8d1d991a-7453-4188-8705-14d8ba38a1da">35.0</ix:nonFraction></ix:nonFraction> million upon a specified financing event, which occurred on October 29, 2020. The financing milestone was recorded at present value upon execution of the MyoKardia License Agreement, with total imputed interest of $<ix:nonFraction unitRef="usd" contextRef="iacb5da7838574f67a606a8efb8a5436a_I20200831" decimals="-5" name="adr:ImputedInterestOnMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODM5OA_e7050c22-2bf0-43f6-a341-3288725c6086">2.3</ix:nonFraction> million accreted under the effective interest method through the date the liability was settled. The financing milestone was paid to MyoKardia in December 2020 as a result of the Series A Preferred financing. Additionally, MyoKardia is entitled to receive from the Company development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ie45cfe90a52b41838961759bc21b1b6f_I20200831" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODY5NQ_3f0cad85-5aa9-4f10-934e-2f056e9f265d">60.0</ix:nonFraction> million upon achievement of specified development milestones, and sales milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i43f085f46e8c4f39a06df0cb33e0529d_I20200831" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODc5MA_9ac779cb-b554-4e21-a341-c32b56d45fbe">87.5</ix:nonFraction> million based on cumulative net sales of mavacamten, plus tiered royalties on net sales ranging from the low to upper-teens. As of September&#160;30, 2022, the Company has paid $<ix:nonFraction unitRef="usd" contextRef="i4327ccb2e1d04429bc1d974a2a6127be_D20220101-20220930" decimals="-5" name="adr:PaymentOfMilestoneAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODk4MA_9ee69e9a-4fab-4918-a070-3206031747a7">5.0</ix:nonFraction> million to MyoKardia upon the completion of the first development milestone under the MyoKardia License Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Navire</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, pursuant to the BridgeBio exclusivity agreement, the Company entered into an exclusive license agreement with Navire Pharma, Inc. (&#8220;Navire&#8221;), a BridgeBio affiliate. Pursuant to the license agreement, Navire granted to the Company an exclusive, sublicensable license under certain patents and know-how of Navire to develop, manufacture, use, sell, import and commercialize Navire&#8217;s proprietary SHP2 inhibitor, BBP-398 (formerly known as IACS-15509) in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand, Singapore, and South Korea. Under the license agreement, Navire received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i10056a0bfe624fd0bdceedf504ed17c0_D20200801-20200831" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTY1Mw_1a305945-69cf-4204-be12-cf042d8f58c7">8.0</ix:nonFraction> million. Additionally, Navire is entitled to receive from the Company development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ia198b999664b420daab0c08429b7466f_I20200831" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTc1OA_e1a93f8a-ad15-4e9a-af5c-19eb2f853084">24.5</ix:nonFraction> million upon achievement of specified development milestones, and sales milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ieeba3f0d0ce94801b53b3e5f40d513bd_I20200831" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTg1Mw_62c7a201-193e-420f-8fac-0a63528a60fb">357.6</ix:nonFraction> million upon achievement of specified commercialization milestones, plus tiered royalties on net sales ranging from approximately <ix:nonFraction unitRef="number" contextRef="i0f3dfa4fc2174c5aa9f897019cc2c56d_D20200801-20200831" decimals="2" name="adr:TieredRoyaltyAsAPercentageOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTk3OA_5fcda66a-72d3-49e0-a337-d24676793ade">5</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="if317a4c6058f43dc89f8e182c6ba342c_D20200801-20200831" decimals="2" name="adr:TieredRoyaltyAsAPercentageOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTk4MQ_a03d7316-22c0-4d54-acbe-63fa892524af">15</ix:nonFraction>% on the net sales of the licensed products. The Company paid the first development milestone of $<ix:nonFraction unitRef="usd" contextRef="iaea5c2f5b96f411b9b2bb59234cd0005_I20210930" decimals="-5" name="adr:PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTAwNzk_c10c9d69-7938-4a3d-8f23-016ac4addcaf">8.5</ix:nonFraction> million for IND acceptance in the PRC during the third quarter of 2021. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="i75391b77b8e74ad1ac9f033884656bb5" continuedAt="i3671b20044b943c6b39fcc2be309abd3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Strategic Collaboration </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a strategic collaboration agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which Pfizer will contribute up to $<ix:nonFraction unitRef="usd" contextRef="ie9b66761f9ee4964817884acfbe7e816_I20201130" decimals="-5" name="adr:CommitmentToContributeCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTAzNDg_847c4015-1406-40eb-ab26-b48c6006ffc9">70.0</ix:nonFraction> million of restricted, non-dilutive capital (the &#8220;Funds&#8221;), including a $<ix:nonFraction unitRef="usd" contextRef="ie9b66761f9ee4964817884acfbe7e816_I20201130" decimals="-5" name="adr:UpfrontPaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTA0MTQ_6f71fcdb-0a64-480c-ab92-c61224b892ff">20.0</ix:nonFraction> million upfront payment, toward the Company&#8217;s in-licensing and co-development activities in Greater China. The Company has accounted for the Pfizer Agreement as a contract to perform research and development services for others under ASC 730-20 and the consideration received for performing these services will be recognized as contra-R&amp;D in the consolidated statement of operations as the services are performed. Upon receipt of the $<ix:nonFraction unitRef="usd" contextRef="ibd6484953b02463e9394d252438606b9_I20210331" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTA4NDM_830848c6-b6fd-4649-8b16-e45f5a0ce5ba"><ix:nonFraction unitRef="usd" contextRef="ibd6484953b02463e9394d252438606b9_I20210331" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTA4NDM_aa6860a2-4621-46d5-abe2-b0b3f9b33fde">20.0</ix:nonFraction></ix:nonFraction> million  upfront payment in the first quarter of 2021, the upfront payment was recorded as restricted cash within consolidated balance sheet and will remain restricted until such time as the upfront payment is utilized for specified in-licensing and co-development activities or until the Pfizer Agreement terminates. Under the Pfizer Agreement, Pfizer and LianBio will form a joint collaboration committee to discuss potential third party in-license opportunities and development and commercialization of the Company&#8217;s products in Greater China. In the event the Company seeks to engage a third-party commercialization partner with respect to the commercialization of the Company&#8217;s future products in Greater China, Pfizer will have a right to opt into such product. Upon opting in, a portion of the Funds will be used to pay for development and commercialization costs of such product and Pfizer will thereafter have a right of first negotiation and right of last refusal to obtain the commercialization rights of such product in Greater China, in each instance for additional, separate financial consideration. During the collaboration, Pfizer may provide in-kind support to us for marketing, development and regulatory activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with ReViral </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive license agreement (the &#8220;ReViral License Agreement&#8221;) with ReViral Ltd. (&#8220;ReViral,&#8221;  now a wholly-owned subsidiary of Pfizer). Pursuant to the license agreement, ReViral granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize novel antiviral therapeutics that target respiratory syncytial virus in Mainland China, Macau, Hong Kong, and Singapore. Under the license agreement, ReViral received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i63457cea5dad4e09a9dc7c0dc8901912_D20210301-20210331" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI2NTI_22c9c60d-3950-43f2-a076-9cbf1172391a">14.0</ix:nonFraction> million. Additionally, ReViral is entitled to receive payments from the Company totaling an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="i1f5317e2a4b64ef4b0ab307c146b677b_I20210331" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI3NTg_b7baf87c-7d87-42b8-880e-9ed42b160c7d">105.0</ix:nonFraction> million upon the achievement of specified development and commercial milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i1e97b24ff55f44ebbfc3c54fa67ea432_I20210331" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI4NDA_e91e2396-d431-461c-b0d2-56ac76ffd43f">45.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i77f8ab5e29f14552995e67ec5208c971_I20210331" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI4NDc_18fcce04-02c4-4b84-a880-2be5e915788a">60.0</ix:nonFraction> million, respectively, plus tiered royalties on net sales ranging from ten to the low-teens.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="i3671b20044b943c6b39fcc2be309abd3" continuedAt="i5e0f543d02ef481fa08670ec28adc3a0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Tarsus</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive license agreement (the &#8220;Tarsus License Agreement&#8221;) with Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221;). Pursuant to the license agreement, Tarsus granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize TP-03 for the treatment of patients with Demodex blepharitis and Meibomian Gland Disease in Mainland China, Macau, Hong Kong and Taiwan. Under the license agreement, Tarsus received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ieefd544ceaa8467c8b9da24c29b947d0_D20210301-20210331" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM0OTk_410acca6-03f1-43c5-8cfb-e24bf2631c24">15.0</ix:nonFraction> million and was granted <ix:nonFraction unitRef="shares" contextRef="i52f7f825cc684f4eb4def6f2b5dec774_D20210301-20210331" decimals="INF" name="adr:ClassOfWarrantOrRightIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM1MTg_b0280e5b-890e-488c-8c54-8245ae74c4cf">three</ix:nonFraction> warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i0d52b39d0f33473c9075d48ee2705ecf_I20210331" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM1NDI_79c2adbf-e062-4f21-84fc-ae2670455c1e">125,000</ix:nonFraction> ordinary shares in Lian Ophthalmology, a subsidiary of LianBio, valued at $<ix:nonFraction unitRef="usd" contextRef="i0d52b39d0f33473c9075d48ee2705ecf_I20210331" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM2MTk_642140db-2893-4520-aa74-b8e604d6f322">9.4</ix:nonFraction> million (the &#8220;Tarsus Warrants&#8221;). Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model and the underlying assumptions are discussed in further detail in Note 10 in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. The warrants were issued in <ix:nonFraction unitRef="tranche" contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331" decimals="INF" name="adr:ClassOfWarrantOrRightNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQwNTg_5cae6b51-6fb4-4f6e-bb6c-45db57762a27">three</ix:nonFraction> tranches with the aggregate number of shares across all tranches equaling <ix:nonFraction unitRef="number" contextRef="i0796e693bdf44849a2a5a2478fe283e2_I20210331" decimals="3" name="adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQxMzU_1c599e68-11d5-4a59-95c8-390ada8b7cc4"><ix:nonFraction unitRef="number" contextRef="i32b2cc0741f945b3921b5d42fb85ccf0_I20210331" decimals="3" name="adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQxMzU_7cd81636-fbd3-444d-9158-76f02cc54626"><ix:nonFraction unitRef="number" contextRef="i39d96e7903c34602be47c9a10fe1600c_I20210331" decimals="3" name="adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQxMzU_baa8d2b2-5390-464e-b79a-6fdf89127d41">12.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the fully diluted equity of Lian Ophthalmology as of the issue date. Vesting of the warrant shares are linked to regulatory milestones and the warrants expire <ix:nonNumeric contextRef="i0d52b39d0f33473c9075d48ee2705ecf_I20210331" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQzMDA_bafaec8a-db96-4b03-b29b-a7b17b95c941">10</ix:nonNumeric> years from the issue date. Pursuant to a related option agreement (the &#8220;Tarsus Option Agreement&#8221;), Tarsus also had the option to convert the warrants into ordinary shares of the Company or warrants to purchase a certain number of the Company&#8217;s ordinary shares based on appreciation of the value in the Lian Ophthalmology since the inception of the Tarsus License Agreement. This conversion feature was not required to be bifurcated as it was clearly and closely related to the equity host instrument, pursuant to ASC 815.  On October&#160;18, 2021, Tarsus exercised its options to convert the Tarsus Warrants under the Tarsus Option Agreement and the Company subsequently issued to Tarsus <ix:nonFraction unitRef="shares" contextRef="i859df84b6220412c8216feaef8618ca5_D20211018-20211018" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQ5Njc_620e2322-f6e4-4e12-a79c-15ae988a31d0">78,373</ix:nonFraction> of its ordinary shares and <ix:nonFraction unitRef="shares" contextRef="i859df84b6220412c8216feaef8618ca5_D20211018-20211018" decimals="INF" name="adr:ClassOfWarrantOrRightIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQ5OTc_ec390222-fb7f-440a-aa93-a6a93855c694">two</ix:nonFraction> warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ife3c16d3aeff45b0a62a122f3ffc24be_I20211018" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUwMzc_7988805b-daab-437b-8440-5aaba992c89c">156,746</ix:nonFraction> of its ordinary shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1f77cc73d9d490ca49bf061664c20aa_I20211018" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUwODc_58a4cff1-4428-4c27-a3f0-a5d6aafdd014">0.000017100448</ix:nonFraction> per share. Following the issuances, the Tarsus Warrants were irrevocably terminated. On June 6, 2022, Tarsus exercised <ix:nonFraction unitRef="shares" contextRef="ief6faf9500eb46d6b9d7bd6521997ed4_D20220606-20220606" decimals="INF" name="adr:ClassOfWarrantOrRightIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUyMDk_9e264b71-f168-4624-ad74-584876cf2317">one</ix:nonFraction> warrant and the Company subsequently issued <ix:nonFraction unitRef="shares" contextRef="ief6faf9500eb46d6b9d7bd6521997ed4_D20220606-20220606" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUyNTY_b28e218e-2665-49ae-aca2-0b27186dc020">78,373</ix:nonFraction> of its ordinary shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i500e758b45e84882b8dc0bafbe78d9c0_I20220606" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUzMDY_2c38ad97-2623-4310-99e3-f92b926a2d5b">0.000017100448</ix:nonFraction> per share. Additionally, Tarsus is entitled to receive a nonrefundable second milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i5c7315d139a647a8916844403b35fcc1_I20210331" decimals="-5" name="adr:MilestonePaymentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU0MDg_819a29f5-8088-47d5-86c9-6cc4ebc35cf4">10.0</ix:nonFraction> million due and payable within forty-five days following the effective date. Furthermore, Tarsus is entitled to receive payments from the Company totaling an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="i4c0c055d4c454529972b2611f7bf8dde_I20210331" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU1ODA_538a2f0d-eb58-40fc-aee8-1941a6a1cc4a">175.0</ix:nonFraction> million upon the achievement of specified development and commercial milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i901497f9715b416b90b0380aaed8d696_I20210331" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU2NjI_9fa7a856-582e-4367-aeec-efaa1b8b40b0">75.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i439b9dc6a4324951a68387b66378f8af_I20210331" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU2Njk_3ac9e470-3906-42f9-8724-8ff56bd8ac63">100.0</ix:nonFraction> million, respectively, plus tiered royalties at percentage rates ranging from the low- to high-teens on net sales.  In the second quarter of 2022, the Company was notified that Tarsus had achieved a certain development milestone and subsequently paid $<ix:nonFraction unitRef="usd" contextRef="iebb3f515f2af46d9a26d73623709d955_D20220601-20220630" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU5MTU_53a89821-65cc-4403-bc65-cb64b2542081">15</ix:nonFraction>&#160;million in June 2022. As of September&#160;30, 2022, the Company has paid an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i780e8a8772534c3abff5c2590cae6a48_D20220101-20220930" decimals="-5" name="adr:PaymentOfMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU5Nzk_7188839b-c1a9-427f-800f-febba7242bbf">45.0</ix:nonFraction> million to Tarsus as a result of the achievement of various development milestones. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Landos</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement (the &#8220;Landos License Agreement&#8221;) with Landos BioPharma, Inc. (&#8220;Landos&#8221;). Pursuant to the license agreement, Landos granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize novel, gut-restricted small molecule omilancor (formerly known as BT-11) and NX-13 for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway in Mainland China, Hong Kong, Macau, Taiwan, Cambodia, Indonesia, Myanmar, Philippines, Singapore, South Korea, Thailand and Vietnam. Under the license agreement, Landos received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iaf9846b2679d481c9f25e70face7e95d_D20210501-20210531" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY3Nzc_2279e777-a2c2-49ce-a0ab-bd26a69b89f2">18.0</ix:nonFraction> million. Additionally, Landos is entitled to receive payments from the Company totaling an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="i4208c21f9651412684222291161e9b6b_I20210531" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY4ODI_b23ccd63-dc04-4ca9-84d2-1020c44ec886">200.0</ix:nonFraction> million upon the achievement of specified development and commercial milestones, up to $<ix:nonFraction unitRef="usd" contextRef="ie240169bdada412780e909f804cd7899_I20210531" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY5NjQ_bc448a00-ee97-410f-be4a-3c916c620473">95.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icfe5d9ec24324b71b0ae98324e5a1950_I20210531" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY5NzE_cd738642-0404-4a90-9e64-51ac4c5f40cb">105.0</ix:nonFraction> million, respectively, plus tiered royalties at percentage rates ranging from the low- to the mid-teens on net sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Nanobiotix</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement (the &#8220;Nanobiotix License Agreement&#8221;) with Nanobiotix S.A. (&#8220;Nanobiotix&#8221;). Pursuant to the license agreement, Nanobiotix granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop and commercialize NBTXR3, a potential first-in-class radioenhancer in Mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore and Thailand. Under the license agreement, Nanobiotix received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i91dd2f17d34d4482a133ebd0c73e8ac8_D20210501-20210531" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2MzY_8c159d90-ea64-458e-9a29-bd945f212607">20.0</ix:nonFraction> million. Additionally, Nanobiotix is entitled to receive payments from the Company totaling an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="idc8ffc33df4b44f6aac43fc889c6aab4_I20210531" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc3NDU_db88ec7f-b9f4-4a13-b7d9-91ac2c51099e">220.0</ix:nonFraction> million upon the achievement of specified development and commercial milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i8a8f8ab0d9c841ca90cb65c873df8e7a_I20210531" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4Mjc_864c961c-6a95-495f-a164-9ba9e09e85e4">65.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82819a00611e420f849e1cfc3bd4f1b7_I20210531" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4MzQ_c7d8311c-687f-49e2-80a2-97aaf8531fb2">155.0</ix:nonFraction> million, respectively, plus tiered royalties of <ix:nonFraction unitRef="number" contextRef="ica33bd99f1a34aec981651e9aef22732_D20210501-20210531" decimals="2" name="adr:TieredRoyaltyAsAPercentageOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4Nzc_66e082a7-8e2e-44d3-8f11-ba1b966e70b6">10</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="id161c6b8aad740d6bf1489f3fa9c21de_D20210501-20210531" decimals="2" name="adr:TieredRoyaltyAsAPercentageOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4ODA_5458a537-64b8-4dc3-afe2-7ffa9ed8e420">13</ix:nonFraction>% of net sales. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="i5e0f543d02ef481fa08670ec28adc3a0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Lyra</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement (the &#8220;Lyra License Agreement&#8221;) with Lyra Therapeutics, Inc. (&#8220;Lyra&#8221;). Pursuant to the license agreement, Lyra granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop and commercialize LYR-210, an anti-inflammatory, intra-nasal drug matrix in late-stage development that is designed to treat chronic rhinosinusitis in Mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore and Thailand. Under the license agreement, Lyra received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i25c130a8a3d84f3d9196a9765323af46_D20210501-20210531" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg1MDk_84b6aeb9-235b-487a-8829-8fe1f78951f6">12.0</ix:nonFraction> million. Additionally, Lyra is entitled to receive payments from the Company totaling an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="i6eccd0754c4241649e346fd436f9f289_I20210531" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg2MTI_d9cbd338-a565-4197-a55e-7c8b7ae34b05">135.0</ix:nonFraction> million upon the achievement of specified development and commercial milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i2c15a8a30aac4770a88597df9720a6f1_I20210531" decimals="-5" name="adr:AssetAcquisitionMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg2OTQ_254edd7c-7a38-4d2e-8b42-977b69dbd636">40.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib2977a88c5df432e8077c4dacb23d3e2_I20210531" decimals="-5" name="adr:AssetAcquisitionNetSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg3MDE_df8e4527-9b06-4c3f-be23-348802e86afe">95.0</ix:nonFraction> million, respectively, plus tiered royalties from the low- to high-teens on net sales. As of September&#160;30, 2022, the Company has paid for the first development milestone of $<ix:nonFraction unitRef="usd" contextRef="i7a53ee596d2c4c43965805d5c720ab94_I20220930" decimals="-5" name="adr:MilestonePaymentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg4NTM_3ca25328-a713-44cf-98b4-207c38d4ec9e">5.0</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i7377b691bd58451297fc26cb9421b200_40"></div><div><span><br/></span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAxMQ_278939d8-a4b0-49fc-9f7d-d4de5cdf00d5" continuedAt="i408ccaff4ed2451dbb2b40d65c94274f" escape="true">Marketable Securities and Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i408ccaff4ed2451dbb2b40d65c94274f" continuedAt="i2f17b895633045849639ac9fbbc5ed29"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAxMg_113616ed-6be4-454a-9d62-9047bc7ea084" continuedAt="i99a69ff849d344af981e240c2f11029a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of marketable securities accounted for as available-for-sale securities at September&#160;30, 2022 and December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS0xLTEtMS00OTAzOA_1908fe2e-ee0e-4bbe-a5fc-25d11fb79739">155,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS0zLTEtMS00OTAzOA_f98abd4d-873e-4b55-840f-f8d4807d7b90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS01LTEtMS00OTAzOA_e26a46a3-ccd8-4285-adf5-9dc7faadaefa">574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS03LTEtMS00OTAzOA_cae62c7c-c9f7-467d-a31e-3b7fb0b784f1">155,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi0xLTEtMS00OTAzOA_f20a650a-bbca-41c1-a9df-4099be8a997c">14,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi0zLTEtMS00OTAzOA_aa1f0a31-7eb1-4346-8bfe-0ef41f6d51b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi01LTEtMS00OTAzOA_cef9e694-c496-4350-898f-046904bb1d06">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi03LTEtMS00OTAzOA_54954bc3-5b7d-4fa1-9b42-7ae0f185cb6e">14,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy0xLTEtMS00OTAzOA_f24623f0-a862-4731-a5fc-cee42701cdbc">64,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy0zLTEtMS00OTAzOA_d1138b57-7980-46ae-9e08-a4b29a186f71">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy01LTEtMS00OTAzOA_86ed0430-f44a-4740-a220-d6fb84c6cc39">511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy03LTEtMS00OTAzOA_18ea07c2-de3d-44fc-b715-527d94e18d47">63,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC0xLTEtMS00OTAzOA_24677de3-6c66-4be9-9b59-bfee3da0a76c">234,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC0zLTEtMS00OTAzOA_91f26ba0-0568-4a7f-aa7b-b075181ca219">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC01LTEtMS00OTAzOA_e4034143-f889-44ee-a2b6-6b9738b5ccfe">1,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC03LTEtMS00OTAzOA_8836e9ff-8f7e-4be4-a856-3a0c929fdf56">232,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS0xLTEtMS00OTAzOA_71b8d83c-0cbf-4c05-b32b-2ef578e0cf85">145,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS0zLTEtMS00OTAzOA_5cd9e4b8-355c-4397-8a9a-b29b3be13030">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS01LTEtMS00OTAzOA_2276608f-17db-4b3e-a510-65b648fe66fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS03LTEtMS00OTAzOA_bff3cf9a-3a79-4a79-ac25-0c9b3c483888">145,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi0xLTEtMS00OTAzOA_f1c0fe30-a4f4-4024-8739-0999c5a41b90">4,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi0zLTEtMS00OTAzOA_15942552-ccae-4c47-b7bb-f6aeee3cb40c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi01LTEtMS00OTAzOA_a28ce445-4999-4556-a62c-d3eb0ac81cfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi03LTEtMS00OTAzOA_fb3d99ff-a884-4a21-b40f-ff6020027a3d">4,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy0xLTEtMS00OTAzOA_fe5fadd4-c6c4-4663-9ae8-91e0801cd2f8">4,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy0zLTEtMS00OTAzOA_36633e87-4d14-4450-b80d-53864fd6118b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy01LTEtMS00OTAzOA_3a38498a-916c-422d-82a6-dc508a97e4b1">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy03LTEtMS00OTAzOA_5bf6201d-03e0-4c75-b948-9b9ad45ebc95">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC0xLTEtMS00OTAzOA_28e69bb8-a876-4c66-98c0-7caa7b9588c5">155,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC0zLTEtMS00OTAzOA_9f4ca0c9-a5bf-4592-a270-d1d534a6c77b">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC01LTEtMS00OTAzOA_563e35d3-1eba-4842-8337-a574ddf74a15">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC03LTEtMS00OTAzOA_26bb96b9-f30a-4c64-8c4f-02aae30eaf93">155,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAwOA_494e2f3c-452d-4572-8671-46a648c762e2" continuedAt="if0386377937d4a92b17bb5059a197a34" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September&#160;30, 2022 are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi0xLTEtMS00OTAzOA_93b6c76c-53d3-4fda-8155-4c92446836b6">574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi0zLTEtMS00OTAzOA_d233a15a-d89f-448e-8cf0-c08f9bdd2f7e">147,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi01LTEtMS00OTAzOA_3d80b885-a788-478c-af62-24a8c7300a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi03LTEtMS00OTAzOA_7941cd47-10d4-4e13-8ad9-4bdff69a4367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi05LTEtMS00OTAzOA_742ce86d-7244-4a86-bb8d-9ea86944c1c3">574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi0xMS0xLTEtNDkwMzg_d8a996b5-0b85-4d08-86ef-d27f0ad0a50e">147,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy0xLTEtMS00OTAzOA_613255ca-273e-41f5-8d52-3d8d8fba3fd6">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy0zLTEtMS00OTAzOA_ca715ead-e496-458a-bb0f-dbb8ed368a72">14,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy01LTEtMS00OTAzOA_8c83466e-9d47-4a02-96af-5ab6a04195e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy03LTEtMS00OTAzOA_70d92f82-7767-46f3-87d5-f44edc3b908e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy05LTEtMS00OTAzOA_ee567d07-a43c-409e-a984-1786c6b0c4d2">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy0xMS0xLTEtNDkwMzg_220fb255-e9f8-4771-9250-6e0f535e6d70">14,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC0xLTEtMS00OTAzOA_642beb81-8427-4a54-9d32-eee2b8b05008">465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC0zLTEtMS00OTAzOA_608767a3-6ac3-4596-b5df-b0c11123f112">46,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC01LTEtMS00OTAzOA_004b386b-f583-45b1-b8e1-64a76c821d06">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC03LTEtMS00OTAzOA_a9615183-55ec-4180-b038-c999367f3372">14,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC05LTEtMS00OTAzOA_eca55788-6935-4d46-a011-72909210e415">511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC0xMS0xLTEtNDkwMzg_b3785866-abe7-4dcc-8986-6f36d407904e">61,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS0xLTEtMS00OTAzOA_b37908fa-4412-494e-ac95-661cc490b6db">1,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS0zLTEtMS00OTAzOA_8e547cf4-8749-4978-a7c1-62df3ad6c84c">208,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS01LTEtMS00OTAzOA_7abfa5e4-4aef-4ab0-8c40-add410e33407">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS03LTEtMS00OTAzOA_5d405b83-90bb-4918-977d-2deb02f37d36">14,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS05LTEtMS00OTAzOA_7f81d9ed-f2db-4a01-9392-e0155bd0f93d">1,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS0xMS0xLTEtNDkwMzg_5c7de075-ac43-4012-a76e-aa3220ad0854">223,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December&#160;31, 2021 are as follows:</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="i2f17b895633045849639ac9fbbc5ed29" continuedAt="if00e7786707f40ea9a074ee7ce70e25b"><div style="text-indent:8pt"><ix:continuation id="if0386377937d4a92b17bb5059a197a34"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi0xLTEtMS00OTAzOA_38cf32e4-d0e9-42f1-a8f7-901542d72518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi0zLTEtMS00OTAzOA_e048245e-ea96-4c64-b72a-467bdbbd9e70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi01LTEtMS00OTAzOA_fb251377-7107-4ec1-849d-71e9d5ce7f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi03LTEtMS00OTAzOA_2de15d59-b1f0-4f56-aeee-a030abc6335e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi05LTEtMS00OTAzOA_b13a0335-1f3c-4d6a-ab24-27b5c532390d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi0xMS0xLTEtNDkwMzg_ffc18745-7633-4305-a3f8-119cc90e0b89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy0xLTEtMS00OTAzOA_8a5eef18-bc92-4e0a-bda8-5a6fe343ef15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy0zLTEtMS00OTAzOA_27fe2176-95f7-44c6-8e13-6f1520cd34d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy01LTEtMS00OTAzOA_77ea22b7-1571-4704-940c-731612230914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy03LTEtMS00OTAzOA_bc5ff037-d1cf-456d-aab6-0ecdebbbfdd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy05LTEtMS00OTAzOA_30b7f95a-3e0d-4ae3-91c6-223087f227c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy0xMS0xLTEtNDkwMzg_04fa4f63-f5ec-4337-965a-73a3e25ba434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC0xLTEtMS00OTAzOA_83df4fb6-1cd7-4d50-accb-b6563143116b">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC0zLTEtMS00OTAzOA_35a17827-c0b3-42c4-8ccc-911d4e0045e2">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC01LTEtMS00OTAzOA_734f7676-484c-487f-b5ff-0e1526634a4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC03LTEtMS00OTAzOA_fe282954-05b2-4c61-93d1-b3fa19a837fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC05LTEtMS00OTAzOA_8ec000c8-6cd4-461e-bbcf-5705bdbbffb7">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC0xMS0xLTEtNDkwMzg_b0636903-e789-4dc7-85fa-a3243c4ea053">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS0xLTEtMS00OTAzOA_b1a20826-ca5f-429b-9981-e7764e69287a">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS0zLTEtMS00OTAzOA_84aeb672-dfc7-4c35-8266-3ed06aa56e4e">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS01LTEtMS00OTAzOA_ce143fad-a02a-47b6-afb3-74c43c7d7cda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS03LTEtMS00OTAzOA_7d6a36f8-5c66-4e91-8c60-e70f9b060e4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS05LTEtMS00OTAzOA_0b365eae-a414-4892-8944-30f37479b148">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS0xMS0xLTEtNDkwMzg_b55af496-ab1a-40ec-8f1b-97508fbe9eb5">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:8pt"><span><br/></span></div><ix:continuation id="i99a69ff849d344af981e240c2f11029a"><div style="margin-top:12pt;padding-left:27pt;text-indent:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities on the balance sheet at September&#160;30, 2022 and December&#160;31, 2021 are as follows:</span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:0.6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More Than 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMi0xLTEtMS00OTAzOA_f8746c07-cc80-4797-906c-e95d63db99c1">155,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMi0zLTEtMS00OTAzOA_6f9cf3f6-627e-4678-bac4-4a133a22aa85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMy0xLTEtMS00OTAzOA_a7860ec6-5cf8-45a3-981c-081b20a3e936">14,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d53772584519a9e4329929345cab_I20220930" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMy0zLTEtMS00OTAzOA_638dae74-017c-41a9-a216-5572ded91893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNC0xLTEtMS00OTAzOA_f2ff5531-8349-46aa-94ea-4ec22c7298ba">46,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNC0zLTEtMS00OTAzOA_5104a489-6cd7-41b1-8c7e-243438906bf2">16,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNS0xLTEtMS00OTAzOA_03a0f325-6b12-4537-831c-be3cac89a11e">215,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNS0zLTEtMS00OTAzOA_89b87157-9b72-4c14-8127-6c1ab3c78373">16,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More Than 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMi0xLTEtMS00OTAzOA_de708757-d0a6-4298-a042-67364c12ef4a">145,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMi0zLTEtMS00OTAzOA_1cae4cf3-3223-414b-9470-fa47a2329b50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMy0xLTEtMS00OTAzOA_de6ec666-3295-4e41-9c11-7f9c28c9cf45">4,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMy0zLTEtMS00OTAzOA_4c2fff20-f60a-4143-96fd-31f51ba4869c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNC0xLTEtMS00OTAzOA_d463ed64-d9d4-4453-9c0c-f0e19e3b1c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNC0zLTEtMS00OTAzOA_072f4d53-d39a-4dc1-9663-9b939a4bd8c5">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNS0xLTEtMS00OTAzOA_56a36519-1961-466c-ae8e-48c367ed5d74">150,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNS0zLTEtMS00OTAzOA_bd66567b-1c39-413f-a7ca-8feb9f7c6e80">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:8pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its securities as current as they are all available for sale and are available for current operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAxMA_05c71d80-bb7f-4928-8b29-db3df2f9c0a1" continuedAt="ib7da4c799a0c401b88688a9b110490cf" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:28.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Level 2 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c6ba62baae4983b42b842d1aeddb71_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi0xLTEtMS00OTAzOA_41670769-5df7-4467-8cac-dfc4f9bab7aa">53,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica40e054da6d4740987c1dc1a6a68af4_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi0zLTEtMS00OTAzOA_d82b830e-50b2-49b4-93b9-3bceab24769c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1827329195bd45ea9e34da5b92c6a744_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi01LTEtMS00OTAzOA_6de1cc57-1c4d-486c-bcc6-870d05778840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1fee8ff40e474fa97619a866abe5ac_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi03LTEtMS00OTAzOA_c15ed407-b117-4723-b26b-5e8e62630149">53,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i583601b6fd494097a9a15ee54c69d290_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy0xLTEtMS00OTAzOA_ef3c4850-f4cd-40eb-942e-d12d6c7d1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fca3542e3e4d248eba0ca3a2c0a2bd_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy0zLTEtMS00OTAzOA_0a416ae6-a3c5-4ee9-8ab9-fefa51f69b46">4,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88787dac96ce45a1b690973dc5af39ba_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy01LTEtMS00OTAzOA_5b5c48fc-2c23-469a-9d0e-29123dd4c4e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a84181a570474294e31e06040ab171_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy03LTEtMS00OTAzOA_213a11c3-fba4-4636-a49d-aa4336aae182">4,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia40d9c3f368a452aa391f0d7c258b7d6_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi0xLTEtMS00OTAzOA_264d1c84-190a-499c-ae7e-d009473d85ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9e54db697947818a37b65b4445bf1a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi0zLTEtMS00OTAzOA_b20b2d2c-42b5-496e-899a-2afc30fec8e1">155,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77f5c68e566442eaa1bc371b7f5c5e2_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi01LTEtMS00OTAzOA_95328970-88e8-4d9b-bc49-7547b714217a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79217e78f9c54cbe9bc25876957657bd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi03LTEtMS00OTAzOA_9d45823c-8db4-4082-a47d-a07d72e52ed4">155,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dacd15e2cb3482082951305e30bead4_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy0xLTEtMS00OTAzOA_a56aea15-342f-42b2-8e7d-6c8bc197f8a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81645e508a424863b1adaf26443dcfe7_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy0zLTEtMS00OTAzOA_5368a25e-12b2-4b59-8c5e-ee17b286edab">14,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e530e77a5746d1a9a908e7d98f902e_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy01LTEtMS00OTAzOA_7e90271d-844f-4588-8f9b-32ed42053651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1678e1fc3ee4b4c94d479a128462f4e_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy03LTEtMS00OTAzOA_9c022004-3273-4192-8cbe-1a67400d450a">14,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Government obligations &amp; <br/>&#160;&#160;&#160;agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f2de6f0d02407e85017a1bd9af1bcd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC0xLTEtMS00OTAzOA_cba3a002-19b8-4192-aeb8-21bfddfe26ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146df2fb452d4fe6b51355e29fee9c51_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC0zLTEtMS00OTAzOA_c5b5094c-6508-4f85-b4d3-8dd1dbce589f">63,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73431d4fcaa142f5bba2f3bcf88537aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC01LTEtMS00OTAzOA_ce3de697-2358-4bb6-8f67-5723b8258ce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86a2fcbc7d44e0db98ad39b9b8bdd1c_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC03LTEtMS00OTAzOA_f0280510-0d4a-4abe-9602-1fa4194c3b4e">63,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089cc9baca7b42b3a27fc68ddcc75811_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS0xLTEtMS00OTAzOA_a79587a2-24a0-4bc9-84d2-a11ea16f9294">53,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a7c6d6dd994b0e8d6e537613ef7302_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS0zLTEtMS00OTAzOA_4579d4bf-df04-4754-96c7-aaf363aef625">237,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599ef0489ae245fdad40419716223f6c_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS01LTEtMS00OTAzOA_93001025-feb6-47fa-9212-e0cfe3bb770c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6992b347ac814ea5a287b5ea80729400_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS03LTEtMS00OTAzOA_ab214370-ea30-4c65-92f2-f4346b746e80">291,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="text-indent:8pt"><ix:continuation id="if00e7786707f40ea9a074ee7ce70e25b"><ix:continuation id="ib7da4c799a0c401b88688a9b110490cf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:28.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%">Level 2 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908a570e002147ee82ad8f4dcc47db40_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi0xLTEtMS00OTAzOA_8faccdc6-41aa-47ff-bc88-2aee3f7626b2">67,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1ff5fc135e4f3c8cddc485f83622f0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi0zLTEtMS00OTAzOA_9dcf47f8-0b82-4e25-a700-bc05b81d651b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47023580772046b381bbc2733f87fab4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi01LTEtMS00OTAzOA_8f7b310c-6281-4e7d-8e5c-fe3f558e6512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c847b99eb014c07aa341a9479de83f5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi03LTEtMS00OTAzOA_fb884812-e85f-4c07-b03c-f12fe1acb9e0">67,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052630a8432947fbab3f9d75efa151ee_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy0xLTEtMS00OTAzOA_5cc4f189-40b2-4ee7-85e5-d0ee5f058853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb632483a8a4bb5ac50c44b07402ce5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy0zLTEtMS00OTAzOA_002eb15e-3f88-484f-899a-b720b21b630a">80,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9201fc4c854336be93003ee6d57bf8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy01LTEtMS00OTAzOA_8ee37c43-0b90-429c-81da-fc5d770df0d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b9bb6127684414952f21a60b0d3628_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy03LTEtMS00OTAzOA_6818d877-9126-49d5-88e4-697a896134f9">80,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cfb1e63a5a148ea872a48d503461ff2_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC0xLTEtMS00OTAzOA_4fd4a212-ceee-4a39-8f5e-8f555770c975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56571b3d91e404288ff07ea7e32d86b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC0zLTEtMS00OTAzOA_65cc5452-9d09-43d9-adcd-ed0321f5c07f">8,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7923c86f54e4a37aa181f8a66eb944f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC01LTEtMS00OTAzOA_96fe986b-6ac1-42c2-b88f-36acdf33d0fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a9d0cd183640358c221d658d05c903_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC03LTEtMS00OTAzOA_a15aefd2-5f53-4c0f-96b2-e724a45d0111">8,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26445de729ae4d13b1780d0406629bb4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi0xLTEtMS00OTAzOA_31b12e6c-6106-48e6-8778-2325bf6b8944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1bd37354b8447fbbdf6d5058cd03cdb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi0zLTEtMS00OTAzOA_54bd8e4c-f0eb-4a16-b039-abcd5dfedda3">145,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a707e5adbc4b99b70f59775be134fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi01LTEtMS00OTAzOA_45edf0b9-8fec-4cf8-be61-9d7873a249a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbaad0fc47e54c749c1bb25b94d34c50_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi03LTEtMS00OTAzOA_dfe381bf-c78e-4c5b-b76a-2c68580fb35c">145,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ac8403115d4cd3b344dc73c9163e90_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy0xLTEtMS00OTAzOA_f83b23db-f88f-4101-bfa7-048fe44f6b34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b54ba31d4848fc98d64676da86fa94_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy0zLTEtMS00OTAzOA_d7e792d8-ab16-48b1-824a-7cada9dd6048">4,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i006d54f5f1e04251898198b35f13f488_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy01LTEtMS00OTAzOA_6b2d21d3-54b9-4b96-abc1-74572b9a4f9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84c463023764fd7a23b168836df9331_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy03LTEtMS00OTAzOA_23df755f-cdb1-49f3-95a7-f869d700fafa">4,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b91ef85a3c4df0a1c9a6cc175f3af4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC0xLTEtMS00OTAzOA_e7113f5e-5a95-4a2e-9ed2-ec0ce6422fad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8f992a4500455285df2bab55116fb8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC0zLTEtMS00OTAzOA_6b8ce1d0-0eea-417b-930e-09fe8bdcd9dd">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8842f59d8ef141fcafb8b68fe12e360c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC01LTEtMS00OTAzOA_faa7d088-3594-4a7f-a098-883a3089f01a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f313597efa43788e4abcc3748d1537_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC03LTEtMS00OTAzOA_dc8700b4-65bf-4d1b-a173-1b59ebd246dc">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52514ae79d6e4407beb955263f7b7dc0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS0xLTEtMS00OTAzOA_69112a35-d99f-41bc-ba1e-b5f3dc10b0fe">67,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c4d4eb4488417fbbe695608850e678_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS0zLTEtMS00OTAzOA_af9e6a93-ffe8-42b8-bd00-22725b2fcd3a">243,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ea1b268ae24831a9bfec7be1c4c428_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS01LTEtMS00OTAzOA_85876baf-39ce-4833-87f1-23946aa6b7ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i949e844f555744609cfcfdbd4bd385ce_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS03LTEtMS00OTAzOA_5de049bb-601f-4c5c-af16-b9a6d780cdd3">311,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i7377b691bd58451297fc26cb9421b200_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjg2_84e257aa-b708-4139-898b-69e7c2adc1b7" continuedAt="i539e207a6716464881ea911b910305e6" escape="true">Property and Equipment, Net </ix:nonNumeric></span></div><ix:continuation id="i539e207a6716464881ea911b910305e6"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjg3_e3b99fee-ca6c-40a3-b1f5-9e3691bbfcf1" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:70.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id17263b03feb4bf599db6d71049821f1_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMS0xLTEtMS00OTAzOA_dd2ece94-ae86-4bcc-ad87-7d674a7fff5e">2,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4ad1474b304d494cb73a261a3a3b32c7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMS0zLTEtMS00OTAzOA_1a4d5e1d-bbe1-497f-9574-4d115cc38cc0">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i94fe0cda96314d9780ce44c077411b21_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMi0xLTEtMS00OTAzOA_2c84f489-4c90-4417-85e9-3a23bc4dca5c">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia4aa405a5bd447b4a32e03e704b92251_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMi0zLTEtMS00OTAzOA_2afc8695-5c36-4af6-9ec1-550c74831ecf">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4396dac7b05e465b80f79cd6478b8a6e_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMy0xLTEtMS00OTAzOA_b6b6d83f-88a0-47c1-96d4-160865b8bb16">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib959c47e99054dfc80bccef6276320e2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMy0zLTEtMS00OTAzOA_0e24e9a6-a1a3-494a-ab08-da27d5ecb502">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iec0bf146cc074bbb926e252ce7e39da9_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNC0xLTEtMS00OTAzOA_e6f077ea-b09a-48e2-9472-321fc2d3c05b">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3d076d62c9844f5cbc99d095571fcffa_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNC0zLTEtMS00OTAzOA_4a59c1f6-507d-4ced-b59c-24c309af1be1">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNS0xLTEtMS00OTAzOA_aa6bb3b2-9e40-4a30-9cb1-936a2bd20339">4,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNS0zLTEtMS00OTAzOA_17eb2e19-0d4d-4b8b-98b9-b26a572df98f">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNi0xLTEtMS00OTAzOA_eea7ecf1-2ce2-4f1f-bf97-cb1b76fa1247">1,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNi0zLTEtMS00OTAzOA_ed93f167-8e0c-42ca-b406-b1f738382088">606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNy0xLTEtMS00OTAzOA_784167db-81ab-418e-8168-58d5dca18571">3,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNy0zLTEtMS00OTAzOA_4fd2002d-d769-410b-b86e-ed55afeb1561">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMTQ3_a04eceb4-a38a-42f6-bdcf-f1b342d8c115">0.3</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMTYz_45fef99c-b301-4f4e-a622-6de1194aebb2">0.7</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjIw_9cdf2014-7015-458e-a03b-38616300a131">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjM1_1db9a581-22eb-4845-beed-3cab2eb23da5">0.3</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively.</span></div></ix:continuation><div id="i7377b691bd58451297fc26cb9421b200_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="adr:PrepaidExpenseAndOtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RleHRyZWdpb246OGJmOTRkMGYwOTgxNDM4Y2E3ZTE3NWMwNGMzZjU3ZDlfMTE4_ab7411e4-7c4c-4d7f-8aa7-1cc525d8a8f3" continuedAt="i61e6fb1ed22a49e2a43ae988801a56ea" escape="true">Prepaid Expense and Other Current Assets </ix:nonNumeric></span></div><ix:continuation id="i61e6fb1ed22a49e2a43ae988801a56ea"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RleHRyZWdpb246OGJmOTRkMGYwOTgxNDM4Y2E3ZTE3NWMwNGMzZjU3ZDlfMTE5_9daa2bca-cedd-4bef-a1d8-82d97598ee16" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets consist of the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:70.722%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Advance payments to suppliers and rent deposit</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="adr:PrepaidRentAndSupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMS0xLTEtMS00OTAzOA_8f33ff5d-1d2a-48fd-926f-6096e816d469">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="adr:PrepaidRentAndSupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMS0zLTEtMS00OTAzOA_c649b949-3ecf-4c62-9698-fa78d075fe80">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMi0xLTEtMS00OTAzOA_c3db731e-6ae8-471f-8274-063ad85b6d8f">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMi0zLTEtMS00OTAzOA_13f9e1ae-508c-4b1e-b661-94cc6ca4e472">7,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:DeferredCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMy0xLTEtMS00OTAzOA_e84c348c-ff58-4270-b07b-61a835fe1f57">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:DeferredCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMy0zLTEtMS00OTAzOA_b49e2dc9-4d39-413a-83d1-4c405a940d1c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNC0xLTEtMS00OTAzOA_f96e896c-d3fe-4aa1-883c-a150c17f111d">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNC0zLTEtMS00OTAzOA_9863ccfc-d2c4-47ff-8ba4-5372283b06da">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNS0xLTEtMS00OTAzOA_7db0fd31-27c5-41ec-8f6b-202d19c1cb05">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNS0zLTEtMS00OTAzOA_c9d13cc4-221b-4870-aeea-07ce7f31aeef">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNi0xLTEtMS00OTAzOA_e60dd1b7-2ce7-4aeb-bbff-441af84c6933">5,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNi0zLTEtMS00OTAzOA_d214d11f-99a4-437a-93b2-c09e653dfba8">10,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RleHRyZWdpb246ODZjYzc5YzEzNGE3NDRmNWI0NGYyMGFmOGM1ZDNmYjBfNzA_014bc0de-a6ab-42e0-a411-2f89fddc6215" continuedAt="i2b74782c61294acdbab47cd37b1d1b5a" escape="true">Accrued Expenses </ix:nonNumeric></span></div><ix:continuation id="i2b74782c61294acdbab47cd37b1d1b5a"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RleHRyZWdpb246ODZjYzc5YzEzNGE3NDRmNWI0NGYyMGFmOGM1ZDNmYjBfNzE_32fd77ba-0bf8-46b1-8f3c-3ca1692ff46e" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:70.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee compensation and related benefits</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMS0xLTEtMS00OTAzOA_0843d7f6-277f-4714-84fc-1c8bccfb95fe">4,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMS0zLTEtMS00OTAzOA_2f99cd04-6691-48a6-8e91-37c5e00afef3">2,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMi0xLTEtMS00OTAzOA_a29c0456-aba1-41a6-a275-5a8005ea9931">4,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMi0zLTEtMS00OTAzOA_4e629bb2-aafa-4ece-9ec2-834c1f2ae804">3,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consulting and contracted research</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="adr:AccruedConsultingAndContractedResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMy0xLTEtMS00OTAzOA_6b59a25b-7399-4603-97c3-d2099d7cda2d">7,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="adr:AccruedConsultingAndContractedResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMy0zLTEtMS00OTAzOA_e3c4a234-fb69-467d-8b6f-19d4d11bf9b6">3,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNC0xLTEtMS00OTAzOA_29c73450-ee1e-4cc4-9924-6bf78e9862eb">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNC0zLTEtMS00OTAzOA_5b1e6640-e8f3-4f9e-ba4b-1463f6c1d88e">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNS0xLTEtMS00OTAzOA_b7eb0fd2-30d7-42b9-99fc-ba6de892967b">17,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNS0zLTEtMS00OTAzOA_dace3ac5-71a1-4388-95fe-7e3268119076">9,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7377b691bd58451297fc26cb9421b200_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81Mi9mcmFnOmNlNzUzY2JlYWU4YjQ3MzE5M2Q3M2E4OGE4NzljNzIwL3RleHRyZWdpb246Y2U3NTNjYmVhZThiNDczMTkzZDczYTg4YTg3OWM3MjBfNjY0_e90fb73a-d428-4cca-a8a7-0257d9b8e4be" continuedAt="i2b1a9fb50f7d4513a65ae08902247ffc" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2b1a9fb50f7d4513a65ae08902247ffc">The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. As of September&#160;30, 2022 and December&#160;31, 2021, there have been <ix:nonFraction unitRef="usd" contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231" decimals="INF" name="us-gaap:OtherCommitment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81Mi9mcmFnOmNlNzUzY2JlYWU4YjQ3MzE5M2Q3M2E4OGE4NzljNzIwL3RleHRyZWdpb246Y2U3NTNjYmVhZThiNDczMTkzZDczYTg4YTg3OWM3MjBfMzI3_b7dbcf19-99df-410e-aba7-b05617446e3d"><ix:nonFraction unitRef="usd" contextRef="ief76923dc8d8411997af1d7252a67753_I20220930" decimals="INF" name="us-gaap:OtherCommitment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81Mi9mcmFnOmNlNzUzY2JlYWU4YjQ3MzE5M2Q3M2E4OGE4NzljNzIwL3RleHRyZWdpb246Y2U3NTNjYmVhZThiNDczMTkzZDczYTg4YTg3OWM3MjBfMzI3_cd88f1f0-d213-4847-bdbe-03be1cbb9946">no</ix:nonFraction></ix:nonFraction> such matters identified. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within the range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The Company is not currently party to any material legal proceedings.</ix:continuation> </span></div><div id="i7377b691bd58451297fc26cb9421b200_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4Mw_6ecd901e-9056-4e20-8726-fce19a8ac52f" continuedAt="i99eca43a9c3f49a28e3e779a6629d598" escape="true">Share-Based Compensation </ix:nonNumeric></span></div><ix:continuation id="i99eca43a9c3f49a28e3e779a6629d598" continuedAt="i1e4fbd9d7bc14c63a879330748ac1c78"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company adopted a shareholder-approved share-based compensation plan (the &#8220;2019 Plan&#8221;), which permits the granting of incentive share options, nonqualified share options, share awards and certain other awards to its employees, members of its Board of Directors and consultants. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company adopted a shareholder-approved share-based compensation plan (the &#8220;2021 Equity Plan&#8221;), which permits the granting of incentive share options, nonqualified share options, share awards and certain other awards to its employees, members of its Board of Directors and consultants. The maximum number of shares that may be delivered in satisfaction of awards under the 2021 Equity Plan was initially approximately <ix:nonFraction unitRef="shares" contextRef="ibef4c7d268f5402dae0e1b439efb68f4_I20211103" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNzg0_fe74768d-ba64-4576-8a98-cab00c15fc9e">14.2</ix:nonFraction>&#160;million shares, plus the number of shares that remained available for issuance under the 2019 Plan and that may again become available for issuance under such plan, not to exceed approximately <ix:nonFraction unitRef="shares" contextRef="ie0f6b78d38b54b2b9954c7b5a6114f41_I20211103" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfOTcy_eb4c6cd5-ffe0-4336-83ce-34505078a993">10.7</ix:nonFraction>&#160;million shares in the aggregate, and an annual increase, to be added as of January 1st of each year from January 1, 2022, to January 1, 2031, equal to the lesser of (i) four percent (<ix:nonFraction unitRef="number" contextRef="ice923f6c800447bcb1d172a7ed1e741c_D20220101-20220930" decimals="2" name="adr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTE1MA_94d0cec9-f5b3-4312-93b8-747967d9a13b">4</ix:nonFraction>%) of the number of shares outstanding as of such date; and (ii) the number of shares determined by the Board of Directors on or prior to such date for such year. Subsequent to the effectiveness of the 2021 Equity Plan, no additional awards have been made pursuant to the 2019 Plan. However, any outstanding awards granted under the 2019 Plan will remain outstanding, subject to the terms of the 2019 Plan and award agreements. Through September&#160;30, 2022, there were awards outstanding for approximately <ix:nonFraction unitRef="shares" contextRef="i1a0efa3f6688449aa871fe22f08334a7_D20191201-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTYzOQ_ed412905-94e8-4900-905b-be768d7516cb">8.5</ix:nonFraction> million ordinary shares under the 2019 Plan and approximately <ix:nonFraction unitRef="shares" contextRef="iadc7598a210a4dfeab2ec14ba7e4c6e4_D20211103-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTcwNA_d195f2bb-1e59-4530-bd22-eddc51cec99d">5.5</ix:nonFraction> million ordinary shares under the 2021 Equity Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Awards </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company issued options to purchase a total of <ix:nonFraction unitRef="shares" contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTg2Mw_10f29128-3a82-4b63-9575-8872d1f28eb4">464,734</ix:nonFraction> ordinary shares to various employees, directors and board members with a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc475a18a1634df89b155ffac5055809_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTk3NA_91d4fe61-afc6-468d-a171-4fcc52f7ea55">3.37</ix:nonFraction> per share option and a weighted-average fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjAzMQ_1c18b29b-adf3-4125-99ec-8d92ecf053d9">2.31</ix:nonFraction> per share option. The fair-value based method for valuing each share option grant on the grant date uses the Black-Scholes Model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjMyNw_f0eb8256-2876-444f-9261-6ef17412c61a">2.56</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjMzMg_ec07c335-4b2a-4a66-b487-8662f5d350bc">3.90</ix:nonFraction>%; expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjM2Mw_9bb2a44e-32eb-41e2-a945-fab3aed0b710">0.00</ix:nonFraction>%; expected share price volatility of <ix:nonFraction unitRef="number" contextRef="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQwMg_43aaca4c-a6da-4d79-9168-359b40273482">76.83</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQwNw_99018ef3-335b-43b3-8c9a-8c16f25665a5">79.65</ix:nonFraction>%; and expected term of <ix:nonNumeric contextRef="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQzMg_eac00729-ad46-40f4-b75d-88e33f4e0021">5.50</ix:nonNumeric> - <ix:nonNumeric contextRef="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQzNw_659a9609-5143-41c5-840b-2cd9902504eb">6.08</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021 the Company issued options to purchase <ix:nonFraction unitRef="shares" contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjUyOQ_a9eedffc-d09e-4d53-884e-4f585df3af20">3,820,173</ix:nonFraction> ordinary shares with a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia858e3c7efff4cc39fbe4c012eb1ec90_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjU5MA_acb3e898-b22c-47b8-9f08-db6050d506bf">6.84</ix:nonFraction> per share option and a weighted-average fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjY0Nw_88d02256-ffb2-4c02-bd81-7274289bbc57">3.47</ix:nonFraction> per share option. The fair-value based method for valuing each share option grant on the grant date uses the Black-Scholes Model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i11c152c42e3146f894258b2b89a5e956_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjk0Mw_c0be9079-3abb-41dd-ac07-1c25d6994e56">0.09</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia040378a6b2244fa861c27980e968a32_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjk0OA_595f3ff0-4469-49cf-b2e1-6bc9f4ba8016">1.22</ix:nonFraction>%; expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjk3OQ_cf280276-9a3f-4f5e-8afd-2d9d30b74ef9">0.00</ix:nonFraction>%; expected share price volatility of <ix:nonFraction unitRef="number" contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzAxOA_d83a9515-0d38-407d-a850-68d9f1e032dc">60.00</ix:nonFraction>%; and expected term of <ix:nonNumeric contextRef="i11c152c42e3146f894258b2b89a5e956_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzA0Mw_00e96c5a-5db8-4285-8f50-624abfbf1bab">0.50</ix:nonNumeric> - <ix:nonNumeric contextRef="ia040378a6b2244fa861c27980e968a32_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzA0OA_d94fd297-3c25-4f33-a1ad-3c220bd6dbab">6.25</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><ix:continuation id="i1e4fbd9d7bc14c63a879330748ac1c78" continuedAt="i49f2f6531fe447d08a26618d9f8c8a37"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ifc475a18a1634df89b155ffac5055809_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzA2OA_84b00f59-e681-4e06-9087-e881931805ab">38.3</ix:nonFraction> million of total unrecognized expense related to non-vested share options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzIwOA_9d1655f1-8e5e-45be-ac5e-eaaee758116d">2.86</ix:nonNumeric> years from the date of grant. As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="ia858e3c7efff4cc39fbe4c012eb1ec90_I20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzI2Mg_a2620b8a-4786-4e2d-8425-84ac046a2ab0">18.1</ix:nonFraction> million of total unrecognized expense related to non-vested share options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzQwMg_dc5444be-0082-4409-8ec8-13c3c0c5ce45">3.36</ix:nonNumeric> years from the date of grant. Options granted to senior management and employees generally vest in equal annual increments over <ix:nonNumeric contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzUzMw_d401d2d3-e531-42ee-934e-89ad63d53858">four years</ix:nonNumeric> and grants issued subsequent to the IPO generally vest over <ix:nonNumeric contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzU5Ng_8e83f689-7b90-4692-81d5-b4aa7822ce6b">four years</ix:nonNumeric> with <ix:nonFraction unitRef="number" contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzYwNA_fcd4fe16-a12d-41c4-9ac2-bdad56ba33ff">25</ix:nonFraction>% vesting over the first year and monthly thereafter. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Share Awards </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i1c27ecbad78a402aa40e15a813e287a6_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzY5Nw_913303fe-e320-4df7-bf4f-ba0402417f0c"><ix:nonFraction unitRef="shares" contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzY5Nw_cf7e9a9c-1ffd-487a-b18f-61897fa18d03">no</ix:nonFraction></ix:nonFraction> performance share awards granted during the nine months ended September&#160;30, 2022. During the nine months ended September&#160;30, 2021 the Company granted certain option awards with both market-vesting conditions and service-vesting conditions to a member of management. The market condition is based on the Company&#8217;s enterprise value. Per the terms of the award, these options will vest in two equal tranches based on the following thresholds:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt"><ix:nonFraction unitRef="number" contextRef="i163994ff7dd148e6a47533a384b804b8_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDEwNQ_43118f67-7999-4a8e-9ac0-7bb433010181">50</ix:nonFraction>% of the performance options will vest upon satisfaction of the Company achieving an enterprise value of not less than $<ix:nonFraction unitRef="usd" contextRef="ia37aaf2e75dc4f9c8d8fedc3b1cb29f4_D20210101-20210930" decimals="-8" name="adr:PerformanceConditionOnMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDIyNQ_e0cee127-993e-4204-92c3-95cf37091124">2.0</ix:nonFraction>&#160;billion at any time after the grant date in accordance with the service condition described below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. <ix:nonFraction unitRef="number" contextRef="ia37aaf2e75dc4f9c8d8fedc3b1cb29f4_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDMyMg_903f43ba-d7ef-49e2-a7f8-0800b4947180">50</ix:nonFraction>% of the performance options will vest upon the satisfaction of the Company achieving an enterprise value of not less than $<ix:nonFraction unitRef="usd" contextRef="i163994ff7dd148e6a47533a384b804b8_D20210101-20210930" decimals="-8" name="adr:PerformanceConditionOnMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDQ0Nw_2b06dd1c-075b-4d50-b88c-963864b95ecd">4.0</ix:nonFraction>&#160;billion at any time after the grant date in accordance with the service condition described below.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enterprise value shall be equal to the number of outstanding ordinary shares of the Company multiplied by the volume weighted average price of a single ordinary share averaged over a period of thirty days ending one day prior to the date of the valuation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the market conditions described above, the option contains explicit service vesting conditions, with one-fourth vesting each year over <ix:nonNumeric contextRef="i1c27ecbad78a402aa40e15a813e287a6_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4MQ_c4136b74-5d66-4473-a592-bab6287cf70e">four years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issued options are to purchase <ix:nonFraction unitRef="shares" contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDk5Ng_e51ecaf4-90f8-43fd-8e13-4890e586f3f3">1,938,615</ix:nonFraction> ordinary shares with a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTA1Nw_171cba6f-7186-4bd5-b6cf-c310eae6feff">6.90</ix:nonFraction> per share option and a weighted-average fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTExNA_36e1a65f-954d-4bc0-b830-5c3edd6c8730">4.72</ix:nonFraction> per share option. The Company used a Monte-Carlo simulation to determine the grant date fair value for these awards, which takes into consideration the possible outcomes pertaining to the enterprise value market condition based on the following assumptions: risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQwMg_d46fb36e-a268-4e40-98bc-4f6670f76cf3">0.81</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQwNw_a73699a5-25f4-439b-be93-c1bd99363744">1.63</ix:nonFraction>%; expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQzOA_3822c4ee-5f46-4252-9135-bc6ebee2c266">0.0</ix:nonFraction>%; expected share price volatility of <ix:nonFraction unitRef="number" contextRef="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ3Nw_934a1af1-68db-445d-b908-5ecc1a90e7b4">47.07</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ4Mg_8f2fe47e-7947-4576-9866-d610b186b4e4">80.64</ix:nonFraction>%; and expected term of <ix:nonNumeric contextRef="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTUwNw_33ae2ea6-1498-484d-9197-a5a439fee0c7">4.87</ix:nonNumeric> - <ix:nonNumeric contextRef="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTUxMg_443a63a4-00d8-4c3a-a109-f8840cd0c960">10.00</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i790b35dc63d348a8ad805f2a45e3e6a9_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTU0Mg_1deb2da8-1f84-4c64-b6e1-d7dd8401dad6">6.0</ix:nonFraction> million of total unrecognized compensation cost related to outstanding performance share awards. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iae18a04092e5496faf63315837e7fc8c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4Mg_28c05566-2991-4b32-a298-93d88b115139"><ix:nonFraction unitRef="shares" contextRef="i385421b8aac749b6b3bb67d39e04d1d2_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4Mg_87156e45-9134-49e3-9d46-53c624d3a0e1">No</ix:nonFraction></ix:nonFraction> performance-based share units (&#8220;PSUs&#8221;) were granted during the nine months ended September&#160;30, 2022 or 2021. As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ic8b0e7ba818d4c4baf09cc8d2c41d451_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTc4MA_831642bd-a038-4649-89e1-e3ac2aa9feb3">2.1</ix:nonFraction> million of total unrecognized compensation cost related to outstanding PSUs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="i34a4b2db597d4126ab138b1b321c7166_D20220101-20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTkzNQ_caf5f234-b30a-49cd-82f3-52ac049f7682">29,785</ix:nonFraction> non-vested restricted share units (&#8220;RSUs&#8221;) to certain employees, with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i34a4b2db597d4126ab138b1b321c7166_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjA1Mg_9f1e1423-9b56-4e75-92bf-c2bd9a5dfe24">2.56</ix:nonFraction> per RSU. As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i42d2e669f7ca4fe89612a0a784bcd359_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjA5NQ_c6a9e14f-e8bc-435b-8a19-33883367a068">2.4</ix:nonFraction> million of total unrecognized compensation expense related to non-vested RSUs. There were <ix:nonFraction unitRef="shares" contextRef="i4875fecaf1f14bb5b5c2ceef28b17b17_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjE4OA_ba2e8396-29d8-4be6-802d-d87cb248f73d">no</ix:nonFraction> RSUs granted during the nine months ended September&#160;30, 2021.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i49f2f6531fe447d08a26618d9f8c8a37">During the nine months ended September&#160;30, 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="ic09c463503db4ad7ae3248958a79fe4c_D20220101-20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjE5OTAyMzI2MjM0NQ_28d7b96b-5d2f-4a9c-81f8-83f7488aefef">217,985</ix:nonFraction> performance-based RSUs to certain employees, with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic09c463503db4ad7ae3248958a79fe4c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjE5OTAyMzI2MjQ1NA_2ea95df8-c447-4d31-b2d6-0e828998b1ea">2.17</ix:nonFraction> per RSU. <ix:nonFraction unitRef="number" contextRef="i37e42e244697487da44b1a88c9ca695c_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ5NzU1ODIzMTA4_e6a4df33-19b1-426e-9699-910facf95c36">60</ix:nonFraction>% of the total number of RSUs will vest on the one-year anniversary of the date on which the mavacamten New Drug Application (&#8220;NDA&#8221;) acceptance in China is obtained. The remaining <ix:nonFraction unitRef="number" contextRef="id04ab5e91570453bafa51dfcaedd5a80_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ5NzU1ODIzMTEz_f0104825-aa25-4a13-8008-55984d8d4c05">40</ix:nonFraction>% of the RSUs will vest on the six-month anniversary of the date on which the mavacamten NMPA acceptance is obtained in China. Upon termination of an employee&#8217;s service with the Company for any reason, any performance-based RSUs that are outstanding and not yet vested will be immediately forfeited. As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ie7409e8003154a5392e873de4657fb1e_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjE5OTAyMzI2MzAyOA_ccfd4b54-4b07-4d45-b74e-0d9298524658">1.1</ix:nonFraction> million of total unrecognized compensation expense related to non-vested performance-based RSUs. There were no performance-based RSUs granted in the nine months ended September&#160;30, 2021</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RleHRyZWdpb246ZDkwNGJiNzRmYzJlNGZiNDg4OGU0NjNkYTRmNmM0ZmFfODQ0_6ffd3323-f5ae-40c9-94b6-08b9e6195904" continuedAt="i72ddf1c0358149c5a830e9d3a41faf60" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="i72ddf1c0358149c5a830e9d3a41faf60"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding, plus all additional ordinary shares that would have been outstanding, assuming dilutive potential ordinary shares had been issued for other dilutive securities. For the three and nine months ended September&#160;30, 2022 and 2021, diluted and basic net loss per ordinary share were identical since potential ordinary shares were excluded from the calculation, as their effect was anti-dilutive.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RleHRyZWdpb246ZDkwNGJiNzRmYzJlNGZiNDg4OGU0NjNkYTRmNmM0ZmFfODQ1_3341a1da-7e2c-4a10-aff3-cdd7fc6db482" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:1.0%"></td><td style="width:41.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi0xLTEtMS00OTAzOA_88245a1f-0189-4a9f-a03b-496e49e12a40">21,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi0zLTEtMS00OTAzOA_53de6f84-a86f-4de0-8482-d74613f7ade4">13,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi01LTEtMS00OTAzOA_27eaa8d4-bfb8-4850-95d4-863ba506c2cc"><ix:nonFraction unitRef="usd" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi01LTEtMS00OTAzOA_b1fc7194-7175-4046-8cd6-b13cdb0c5272">92,014</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi03LTEtMS00OTAzOA_754b036c-d29f-43d7-9905-978fb2535114"><ix:nonFraction unitRef="usd" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi03LTEtMS00OTAzOA_ea4d70f2-2d01-4d69-8368-94091ef45b1d">175,105</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0xLTEtMS00OTAzOA_1b6ce997-82cb-4145-a36d-a22b603f221d"><ix:nonFraction unitRef="shares" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0xLTEtMS00OTAzOA_d3ec30a7-5632-4103-afe5-38ebc470bd63">108,353,831</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0zLTEtMS00OTAzOA_222e2bb8-e015-49b1-b5c1-8e131b561ac4"><ix:nonFraction unitRef="shares" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0zLTEtMS00OTAzOA_6b107ddb-02bc-4075-bd23-290a70084298">20,690,908</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_00ef4bf9-699d-433c-8722-9985e428523e"><ix:nonFraction unitRef="shares" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_8c38cba3-96df-4a6e-9676-84ba16b75792"><ix:nonFraction unitRef="shares" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_c7192474-5f08-4cbc-9988-162b497230b5"><ix:nonFraction unitRef="shares" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_ef97f2a0-022c-4356-98a9-9626290c9150">107,854,547</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_14a58dd6-e592-49c3-89a2-7454e7445aaa"><ix:nonFraction unitRef="shares" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_4ac98de3-76b8-479d-8c7d-cba28e7752a8"><ix:nonFraction unitRef="shares" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_ab77e2b6-ca26-4a17-b6ff-a1b8648932a1"><ix:nonFraction unitRef="shares" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_e8556ac3-256a-4316-bcc6-8867acae44e1">20,549,310</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per ordinary share &#8211; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0xLTEtMS00OTAzOA_3e6c536b-26bd-4fe6-9a1b-66c6a5ecaf30"><ix:nonFraction unitRef="usdPerShare" contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0xLTEtMS00OTAzOA_583655f3-78a5-4962-b2c2-63a481469f06">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0zLTEtMS00OTAzOA_0a7104df-d567-474f-9287-74e06037c94b"><ix:nonFraction unitRef="usdPerShare" contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0zLTEtMS00OTAzOA_56150c59-ae4d-4982-bc62-b47e06e7adff">0.63</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_356af0b1-3cab-47d5-a557-cd5c0fccf086"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_6acb4257-6a89-4072-a06e-027ee42e50b9"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_f519dbe2-a7bb-40a2-a684-30729fc4fcee"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_f8b4414e-cd68-4100-b851-54243a027bfd">0.85</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_0b7a39c7-c88c-47d9-a5d0-ee1926513a12"><ix:nonFraction unitRef="usdPerShare" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_11e9e699-83cc-4448-916a-7d380404be0f"><ix:nonFraction unitRef="usdPerShare" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_9d16d800-d909-49d1-825d-7fc3f2f54865"><ix:nonFraction unitRef="usdPerShare" contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_d549467c-8a7a-424d-a998-48a721e00ff7">8.52</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RleHRyZWdpb246ZDkwNGJiNzRmYzJlNGZiNDg4OGU0NjNkYTRmNmM0ZmFfODQ2_9d4779cd-70b3-4f1f-bdcf-576ee248c37a" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share, because including them would have been anti-dilutive during each period. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"></td><td style="width:58.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable Convertible Preferred Shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a0e878a4e9940a8ba193c5c8a44bfe7_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMi0xLTEtMS00OTAzOA_6415900f-1046-42c3-915c-1c83e7f33566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia34cd0bfaa564a92bd7ecdce2c826bc7_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMi0zLTEtMS00OTAzOA_4e5fccfe-31d4-469f-9698-7ff2289cce1b">11,024,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Share Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i484a69d178e340c093a1bcad9d0db61c_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMy0xLTEtMS00OTAzOA_745fdfe7-19ff-4eec-b200-195fd035679f">13,163,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i862b94711dca4e4ba65e7ffa96c12b95_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMy0zLTEtMS00OTAzOA_580b0d52-1d78-41a8-bca7-ccdb981235e2">9,746,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i014e8a19793d40bcac2baddf7496bd9d_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNC0xLTEtMS00OTAzOA_f7e725af-7fdb-4064-b7ad-bbef038af2ca">864,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide326c86d4704627b79b2a501c2b05bf_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNC0zLTEtMS00OTAzOA_ac93e4b2-71ef-4c3f-8fd8-c9262967b8a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QED Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05d0df6c0bc4407982ff2dcc72c8d5f7_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNS0xLTEtMS00OTAzOA_44aa893c-75b6-4d5f-a352-1909edff8527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42da493784984b80a81dd34f00fb97ed_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNS0zLTEtMS00OTAzOA_3983fc4a-ad1d-41c9-b351-5a86ddfad18b">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyoKardia Warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dd61e8d2ee742ceacc281b00f2bf38e_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNi0xLTEtMS00OTAzOA_9477e203-316c-46af-b9fa-27bafa0e622c">170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i961337664bec4684bab70b8f50eb6fb4_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNi0zLTEtMS00OTAzOA_408a9839-a043-41d4-bc98-8b99d0c49150">170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarsus Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2547429e3324581bbf6156636e2a767_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNy0xLTEtMS00OTAzOA_29115ff6-503b-4405-8137-4d70fdb73039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a3a509b1bb04448b439c32f4c6b8a98_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNy0zLTEtMS00OTAzOA_79f931fb-4862-46dc-871a-6245a5d911b7">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants in LianBio issued to QED and Tarsus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id423453fa6364ca8947d21bf8eeb83d4_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfOC0xLTEtMS00OTAzOA_b0c2bea2-9d13-42bf-bf88-e3090e729675">425,942</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dbf76887d084a01a1e484f9fc38af0a_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfOC0zLTEtMS00OTAzOA_e129a8fc-f544-49da-9cee-6d6bb05ffd33">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7377b691bd58451297fc26cb9421b200_305"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMDUvZnJhZzo3YWJmMmUyN2U3N2U0MTk0YjllY2Y3ODhiYzE4MDdjOC90ZXh0cmVnaW9uOjdhYmYyZTI3ZTc3ZTQxOTRiOWVjZjc4OGJjMTgwN2M4XzU0OTc1NTgxNDY5NA_6cb78492-9280-4dcf-b85b-9c0dcd9fb93a" continuedAt="i313563505a704b1997de5f60bfe8a5c2" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i313563505a704b1997de5f60bfe8a5c2">In October 2022, the Company was notified that Tarsus had achieved a certain development milestone, which, pursuant to the Tarsus License Agreement, triggered a $<ix:nonFraction unitRef="usd" contextRef="i0378cbfd28884eb698663743fe75feda_D20221201-20221231" decimals="-5" name="adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMDUvZnJhZzo3YWJmMmUyN2U3N2U0MTk0YjllY2Y3ODhiYzE4MDdjOC90ZXh0cmVnaW9uOjdhYmYyZTI3ZTc3ZTQxOTRiOWVjZjc4OGJjMTgwN2M4XzIxOTkwMjMyNTYwMzg_979169bc-a3f0-4ced-9af6-c6cc09edd940">10.0</ix:nonFraction> million milestone payment due in December 2022.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and related notes thereto as of and for the year ended December 31, 2021 and the related management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 31, 2022. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. You should read the &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; sections of this report and the section entitled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K and this Quarterly Report on Form 10-Q for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Some of the numbers included herein have been rounded for the convenience of presentation. </span></div><div id="i7377b691bd58451297fc26cb9421b200_64"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. We have assembled a pipeline of nine assets across five therapeutic areas, each with its own distinct value proposition and the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we completed an IPO of our ordinary shares through the sale and issuance of 20,312,500 American Depositary Shares (&#8220;ADSs&#8221;), at a public offering price of $16.00 per ADS. Following the closing of the IPO, on December 1, 2021, the underwriters partially exercised their option to purchase additional shares and purchased an additional 593,616 ADSs at the initial public offering price of $16.00 per ADS. We received gross proceeds of $334.5 million in connection with the IPO and subsequent exercise of the underwriters&#8217; option and aggregate net proceeds of $304.8 million after deducting underwriting discounts, commissions and other offering expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following diagram depicts our corporate structure as of September&#160;30, 2022. As of September&#160;30, 2022, the shares of each of our subsidiaries are 100% owned by the respective entity displayed immediately above that subsidiary. Certain warrant rights are outstanding and may be exercised in the future for equity interests in our Cayman parent entity, LianBio, and our subsidiary, Lian Cardiovascular, as described in &#8220;Note 10: Equity&#8221; in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 31, 2022. Currently, our corporate structure contains no variable interest entities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:center;text-indent:36pt"><img src="adr-20220930_g1.gif" alt="adr-20220930_g1.gif" style="height:258px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Within the organization, investor cash inflows have all been received by our parent Cayman entity, LianBio. Cash to fund our Chinese operations is transferred from our Cayman parent entity down through our Hong Kong entities and then into our Chinese entities through capital contributions. Cash to fund our operations in the United States is transferred from our Cayman parent entity down to our United States entity through a capital contribution.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Business Highlights and Clinical Development Updates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mavacamten</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that enrollment was completed in the Phase 3 EXPLORER-CN clinical trial in Chinese patients with obstructive hypertrophic cardiomyopathy. We expect to report topline results from the trial in mid-2023.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we collaborated with Beijing Lisheng Cardiovascular Health Foundation to launch Joy from Heart, a hypertrophic cardiomyopathy (&#8220;HCM&#8221;) disease awareness campaign in China. Joy from Heart is China&#8217;s first disease awareness program dedicated to improving HCM diagnosis rates and supporting HCM education initiatives for patients and healthcare providers. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TP-03</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, our partner Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221;) announced the initiation of a Phase 2a clinical trial of TP-03 in patients with meibomian gland disease. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Tarsus announced the submission of an NDA to the United States Food and Drug Administration (&#8220;FDA&#8221;) for TP-03 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis. Tarsus subsequently communicated that the FDA accepted the NDA with a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) target action date of August 25, 2023.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced the initiation of  the Phase 3 LIBRA clinical trial of TP-03 in Chinese </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis patients. We expect to report topline data from the trial in the fourth quarter of 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBTXR3</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we announced that we began treating patients in Asia in the global Phase 3 NANORAY-312 trial evaluating NBTXR3 for the treatment of head and neck cancer.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BBP-398</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced that we began treating patients in China in a Phase 1 monotherapy clinical trial of BBP-398 in patients with advanced solid tumors. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infigratinib</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, we reported that our partner, BridgeBio Pharma, Inc. (&#8220;BridgeBio&#8221;), informed us that Helsinn Healthcare SA, which holds the Truseltiq (infigratinib) NDA in the United States, is permanently discontinuing distribution of the drug and anticipates requesting withdrawal of the NDA in the United States due to business reasons. Due to the planned withdrawal of the NDA, BridgeBio informed us that it intends to close the ongoing global Phase 3 PROOF-301 clinical trial of infigratinib in first-line cholangiocarcinoma (&#8220;CCA&#8221;). Consequently, we are terminating activities related to the PROOF-301 clinical trial in China and no longer plan to pursue development and commercialization of infigratinib in CCA indications in our licensed territories. We intend to continue to support patients who are currently being treated with infigratinib under the special pilot program implemented in the Bo&#8217;ao Lecheng pilot zone in Hainan Province. We expect to continue the ongoing Phase 2a China standalone proof of concept clinical trial of infigratinib in patients with locally advanced, metastatic gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 genetic amplification and other solid tumors with FGFR alterations. We expect to report topline data from this clinical trial in the second half of 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LYR-210   </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2022, we refined our development strategy for LYR-210. We plan to conduct a Phase 3 China standalone trial to support regulatory approval in China, leveraging the results of the ongoing Phase 3 trials of our development partner, Lyra. Lyra is expected to complete enrollment in ENLIGHTEN I, the first trial in Lyra&#8217;s Phase 3 program, in mid-2023. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, Lyra announced that it had initiated ENLIGHTEN II, the second of two global pivotal Phase 3 trials of LYR-210 in surgically naive chronic rhinosinusitis patients.  In November 2022, Lyra further communicated a temporary pause in ENLIGHTEN II enrollment to align with internal manufacturing timelines for clinical trial supply.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NX-13</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, our development partner Landos Biopharma, Inc. (&#8220;Landos&#8221;) announced topline results from the company&#8217;s Phase 1b clinical trial of NX-13. The data showed that NX-13 was well tolerated following evaluation of multiple doses over four weeks compared with a placebo. Based on these data, Landos plans to initiate a Phase 2 clinical trial to evaluate the safety, efficacy and optimal dosing of NX-13 in patients with ulcerative colitis.  </span></div><div id="i7377b691bd58451297fc26cb9421b200_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Factors Affecting Our Results of Operations </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of the COVID-19 pandemic on our operations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in December 2019, the outbreak of the COVID-19 pandemic created business interruptions for companies globally, including us. For example, in the biotechnology sector, companies, including our company, have experienced delays in their ability to enroll patients at clinical trial sites because of the pandemic, potentially leading to delays in the regulatory approval process. Other outbreaks may occur, or there could be further resurgences of the COVID-19 pandemic (</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as current outbreaks in certain locations in China, including locations in which we are conducting clinical trials, which have led to extensive lockdowns)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have caused and could further cause business disruptions in the future. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been carefully monitoring the COVID-19 pandemic and its impact on our business. We have taken important steps to ensure the workplace safety of our employees when working within our administrative offices, or when traveling to our clinical trial sites. We may take further actions as may be required by federal, state or local authorities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have been able to continue our key business activities and advance our clinical programs. However, the COVID pandemic has impacted our clinical trial enrollment and it is possible that our clinical development timelines and business plans could be adversely affected. We maintain regular communication with our vendors and clinical sites to appropriately plan for, and mitigate, the impact of the COVID-19 pandemic on our operations. </span></div><div id="i7377b691bd58451297fc26cb9421b200_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Components of Results of Operations </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to successfully develop product candidates will be a significant factor affecting our long-term competitiveness, as well as our future growth and development. Developing high quality product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investment in this area. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expense to increase significantly in connection with our ongoing activities, particularly as we advance the clinical development of our product candidates and initiate additional clinical trials of, and seek regulatory approval for, these and other future product candidates. These expenses include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments made under third party licensing and asset acquisition agreements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expense, including salaries, related benefits, equity-based compensation and travel expenses for employees engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expense incurred in connection with the clinical development of our product candidates, including expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and amortization, insurance and other direct and allocated expense incurred as a result of research and development activities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of our research and development expenses for the periods indicated:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,038&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing arrangements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations have been, and we expect them to continue to be, affected by our licensing, collaboration and development agreements. We are generally required to make upfront payments upon entry into such agreements and milestone payments upon the achievement of certain development, regulatory and commercial milestones for the relevant product candidate under these agreements, as well as tiered royalties based on net sales of the license products. These upfront payments and milestone payments upon the achievement of certain development and regulatory milestones are recorded in research and development expense in our consolidated financial statements. For the three months ended September&#160;30, 2022 and September&#160;30, 2021, we made no upfront payments or milestone payments. For the nine months ended September&#160;30, 2022 and September&#160;30, 2021, we made upfront payments and milestone payments totaling $25.0 million and $136.9 million, respectively. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a breakdown of licensing fees by program for the periods indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing fees:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mavacamten</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BBP-398</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sisunatovir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TP-03</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BT-11 and NX-13</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NBTXR3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LYR-210</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses consist primarily of salaries and other related costs for personnel in executive, finance and administrative functions. General and administrative expenses also include professional fees for legal, consulting, auditing, tax services and insurance costs. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future to support continued development and commercialization of our product candidates. These increases will likely include increased costs related to hiring additional personnel and fees to outside consultants, attorneys and accountants, among other expenses. Additionally, we have incurred and will continue to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and office insurance costs, and investor and public relations costs. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income, net </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists of interest income received on our cash balances and marketable securities and from the amortization/accretion on the premiums/discounts on marketable securities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists of unrealized gains and losses on foreign currencies held in our China subsidiary, Shanghai LianBio Development Co., Ltd., unrealized foreign exchan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ge activity from the remeasurement of our intercompany payables, bank fees incurred on our cash balances and depositary fees related to our ADSs. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes consists of U.S. federal and state income taxes and income taxes in certain foreign jurisdictions in which we conduct business. We expect income tax expense to increase over time as the Company continues to grow net income.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income tax expense (benefit) of $0.0 million and $0.0 million for the three and nine months ended September&#160;30, 2022 and $(0.4) million and $1.6 million for the three and nine months ended September&#160;30, 2021, respectively. </span></div><div id="i7377b691bd58451297fc26cb9421b200_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of operations </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of the three months ended September&#160;30, 2022 and September&#160;30, 2021 </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our consolidated results of operations for the periods indicated. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"></td><td style="width:68.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Operating expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,549&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,544&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,891)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13,509)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13,112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $3.6 million from $4.7 million for the three months ended September&#160;30, 2021 to $8.3 million for the three months ended September&#160;30, 2022. For the three months ended September&#160;30, 2022, research and development cost was primarily attributable to $3.0 million in personnel-related expenses and $4.4 million attributable to development activities to support our clinical trials. The remaining expense was attributable to professional fees.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2021, research and development cost was primarily attributable to $1.9 million in personnel-related expenses and $2.0 million attributable to development activities to support our clinical trials.  The remaining expense was attributable to professional fees.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $7.4 million from $8.9 million for the three months ended September&#160;30, 2021 to $16.3 million for the three months ended September&#160;30, 2022. The increase was primarily attributable to a $5.3 million increase in payroll and personnel-related expenses (including share-based compensation expense) for increased employee headcount and a $3.2 million increase in additional costs incurred due to operating as a publicly traded company. These increases were partially offset by a $1.1 million decrease in consulting costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $1.4 million from $0.0 million for the three months ended September&#160;30, 2021 to $1.4 million for the three months ended September&#160;30, 2022. The increase was primarily attributable to our investments in marketable securities and interest earned on cash holdings in foreign countries. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income, net </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net increased by $1.3 million from $0.0 million for the three months ended September&#160;30, 2021 to $1.3 million for the three months ended September&#160;30, 2022. The increase is primarily attributable to foreign exchange gains in our foreign entities. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes (benefit)</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income taxes (benefit) was $0.0 million, resulting in an effective income tax rate of 0.0% for the three months ended September&#160;30, 2022. Our income tax benefit was $(0.4) million, resulting in an effective income tax rate of 2.9%, for the three months ended September&#160;30, 2021. The variation in the effective income tax rate was primarily due to the effect of certain nonrecurring taxable income in 2021.</span></div><div style="margin-top:12pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of the nine months ended September&#160;30, 2022 and September&#160;30, 2021 </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our consolidated results of operations for the periods indicated. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:1.0%"></td><td style="width:69.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Operating expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,108&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">173,534&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(96,108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(173,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(91,997)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(173,552)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(92,014)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(175,105)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $101.9 million, from $151.0 million for the nine months ended September&#160;30, 2021 to $49.2 million for the nine months ended September&#160;30, 2022. For the nine months ended September&#160;30, 2022, research and development cost was primarily attributable to (i) $15.0 million related to a development milestone payment payable pursuant with the Tarsus License Agreement, (ii) $5.0 million related to a development milestone payment payable pursuant with the MyoKardia License Agreement, (iii) $5.0 million related to a development milestone payment payable pursuant with the Lyra License Agreement, (vi) $13.5 million attributable to development activities to support our clinical trials and (v) $8.6 million attributable to higher personnel-related expense, including share-based compensation expense, as a result of increased employee headcount. The remaining expense was attributable to professional fees.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2021, research and development cost was primarily attributable to (i) $55.0 million in upfront milestone payments and $9.4 million of expenses related to warrants issued in connection with the Tarsus License Agreement, (ii) a $20.0 million upfront payment pursuant to the Nanobiotix License Agreement, (iii) a $18.0 million upfront payment pursuant to the Landos License Agreement, (iv) a $14.0 million upfront payment pursuant to the ReViral License Agreement, (v) a $12.0 million upfront payment pursuant to the Lyra License Agreement, and (vi) a $8.5 million development milestone payment pursuant to the exclusive license agreement entered into with Navire. The remaining expense was attributable to higher personnel-related expenses, including share-based compensation expense, and development activities to support our clinical trials and professional fees. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $24.4 million from $22.5 million for the nine months ended September&#160;30, 2021 to $46.9 million for the nine months ended September&#160;30, 2022. The increase was primarily attributable to a $15.5 million increase in payroll and personnel-related expenses (including share-based compensation expense) for increased employee headcount, a $9.5 million increase in additional costs incurred due to operating as a publicly traded company. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income, net  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net increased by $2.1 million from $0.2 million for the nine months ended September&#160;30, 2021 to $2.2 million for the nine months ended September&#160;30, 2022. The increase was primarily attributable to our investments in marketable securities and interest earned on cash holdings in foreign countries. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net increased by $2.1 million from $(0.2) million for the nine months ended September&#160;30, 2021 to $1.9 million for the nine months ended September&#160;30, 2022. The increase was primarily attributable to depositary fees related to our ADSs and foreign exchange gains in our foreign entities.  </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax expense was $0.0 million, resulting in an effective income tax rate of 0.0% for the nine months ended September&#160;30, 2022. Our income tax expense was $1.6 million, resulting in an effective income tax rate of (0.9)%, for the nine ended September&#160;30, 2021. The variation in the effective income tax rate was primarily due to the effect of certain nonrecurring taxable income in 2021.</span></div><div id="i7377b691bd58451297fc26cb9421b200_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and capital resources </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of liquidity </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our incorporation, our operations have been substantially financed with proceeds from sales of preferred shares as part of the Series Seed financing, the Series A financing, the issuance of the 2020 Convertible Notes and our IPO, which was completed in November 2021. As of September&#160;30, 2022, we had cash and cash equivalents and marketable securities of $311.7 million.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company with no operations of our own and, as such, we may rely on dividends and other distributions on equity paid by our Chinese subsidiaries to fund any cash and financing requirements we may have, including the funds necessary to pay dividends and other cash distributions to our shareholders or holders of our ADSs or to service any debt we may incur. Deterioration in the financial condition, earnings or cash flow of our subsidiaries for any reason, as well as any changes in Chinese laws or regulations, could limit or impair their ability to pay such distributions. For additional information, see &#8220;Part I&#8212;Item 1A&#8212;Risk Factors&#8212;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks Related to Doing Business in China and Our International Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We may rely on dividends and other distributions on equity paid by our Chinese subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our Chinese subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding requirements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund our operating expenditures, consisting of research and development expense (including activities within our clinical and regulatory initiatives and upfront and milestone payments) and general and administrative expense. Our use of cash is impacted by the timing and extent of the required payments for each of these activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any material revenue. We do not expect to generate revenue from the sale of our products unless and until we (i) complete development of any of our product candidates; (ii) obtain applicable regulatory approvals; and (iii) successfully commercialize or enter into collaborative agreements for our product candidates. We do not know with certainty when, or if, any of these items will ultimately occur. We expect to incur continuing significant losses for the foreseeable future and for our losses to increase as we ramp up our clinical development programs and begin activities related to commercial launch readiness. We may encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business. Moreover, since the completion of our IPO, we have incurred and will continue to incur additional costs associated with operating as a publicly traded company. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional capital to develop our product candidates and fund our operations into the foreseeable future. We anticipate that we will eventually need to raise substantial additional capital, the requirements for which will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of clinical programs we decide to pursue; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing associated with commercializing our product candidates, if they receive regulatory approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive regulatory approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following regulatory approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic and the Russian invasion of Ukraine on our clinical development or operations; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other variables with respect to the development and regulatory approval of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our shareholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our ordinary shares, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our shareholders. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our additional licensing opportunities. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows </span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, operating activities used approximately $68.5 million of cash, primarily due to our net loss of $92.0 million, partially offset by non-cash consideration of $13.9 million related to share-based compensation expense, a decrease of $4.8 million for prepaid expenses and other current assets, an increase of $8.2 million for accrued expenses, and other changes related to operating assets and liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, operating activities used approximately $133.6 million, primarily due to our net loss of $175.1 million, partially offset by non-cash items of $9.4 million related to the warrants granted to Tarsus, $20.0 million of other receivables related to in-licensing and co-development activities related to our strategic collaboration agreement with Pfizer, $5.3 million related to share-based compensation expense, and other changes related to operating assets and liabilities.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, investing activities used approximately $80.2 million, consisting of approximately $260.4 million for the purchases of marketable securities, and approximately $1.6 million for the purchases of property and equipment, partially offset by the sales and redemption of marketable securities of approximately $181.8 million. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, investing activities used approximately $0.2 million, primarily resulting from the purchases of property and equipment.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, financing activities provided approximately $1.7 million, primarily resulting from proceeds from the exercise of share options.   </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, financing activities provided approximately $8.2 million in net proceeds due to our issuance of Series A Preferred shares of $2.9 million and the exercise of share options of $5.3 million. </span></div><div id="i7377b691bd58451297fc26cb9421b200_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="i7377b691bd58451297fc26cb9421b200_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of New Accounting Standards</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of new accounting standards and the impact of recent accounting pronouncements not yet effective on our consolidated financial statements, if any, is discussed in Note 2 to the interim unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q.</span></div><div id="i7377b691bd58451297fc26cb9421b200_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period ended September&#160;30, 2022, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading &#8220;Quantitative and Qualitative Disclosures about Market Risk&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on that evaluation of our disclosure controls and procedures as of September&#160;30, 2022, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i7377b691bd58451297fc26cb9421b200_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of our knowledge, we are not currently the subject of any material governmental investigation, private lawsuit or other legal proceeding. From time to time, we may be involved in legal and regulatory proceedings or investigations concerning matters that arise in the ordinary course of our business and that could result in significant fines or penalties, have an adverse impact on our reputation, business and financial condition or results of operations and divert the attention of our management from the operation of our business. The outcome of any future litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to us. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against us, could materially and adversely affect our business, financial condition or results of operations. </span></div><div id="i7377b691bd58451297fc26cb9421b200_100"></div><div style="margin-top:18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding risk factors appears in Part I, Item 1A, Risk Factors, in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. The Company has reviewed the risk factors, and, except as presented below, there have been no material changes in the Company&#8217;s risk factors since those reported in its Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our and our partners&#8217; third-party research institution collaborators, clinical trial sites, CROs, contract manufacturing organizations (&#8220;CMOs&#8221;), suppliers and other contractors and consultants could be subject to natural or man-made disasters, public health epidemics and pandemics like the COVID-19 pandemic or other business interruptions, for which we are predominantly self-insured. The occurrence of any of these business interruptions could seriously harm our operations and financial condition and increase our costs and expenses. Through our partners, we also rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain supplies of our product candidates could be disrupted if the operations of these suppliers are affected by natural or man-made disasters, public health epidemics and pandemics, such as the COVID-19 pandemic, or other business interruptions. Damage or extended periods of interruption to our or our vendors&#8217; corporate, development, research or manufacturing facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry, public health epidemics, pandemics or other events could cause us to delay or cease development or commercialization of some or all of our product candidates. Although we maintain insurance coverage on our facilities, our insurance might not cover all losses under such circumstances, including damage to third-party facilities, and our business may be seriously harmed by such delays and interruption. For example, the biotechnology sector, including our company, has been impacted by the COVID-19 pandemic and could continue to experience negative impact to business operations. Other outbreaks may occur, or there could be a resurgence of the COVID-19 pandemic (including, for example, the local outbreaks and related extensive lockdowns in certain cities in China, such as Shanghai or other cities where our offices and employees are located and in which we are conducting clinical trials), which have caused and could continue to cause business disruptions. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our or our partners&#8217; clinical development efforts have been and could be further delayed or otherwise negatively impacted, as patients are reluctant or unable to go to hospitals or clinical testing sites to receive treatment. We have experienced delays in the enrollment of patients in our clinical trials due to the pandemic. We believe our business partners have also similarly experienced delays or difficulties in enrollment of patients to their clinical trials due to the outbreak of COVID-19 in their respective territories. The ability to conduct in-person interactions between clinical and medical staff and physicians has also been adversely affected. Additionally, the clinical supply of our product candidates could be negatively impacted due to reduced operations or a shutdown of our third-party manufacturing facilities, distribution channels and transportation systems, or shortages of raw materials and drug product.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and results of operations could be adversely affected by public health crises in the locations in which we, our suppliers, CROs, our licensors&#8217; CMOs and other contractors operate. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations expose us to risks associated with public health crises, such as epidemics and pandemics. Our business operations and those of our and our partners&#8217; suppliers, clinical trial sites, CROs, CMOs and other contractors may potentially suffer interruptions caused by any of these events. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the COVID-19 pandemic has resulted in significant governmental measures being implemented around the globe to control the spread of the virus, including quarantines, lockdowns, travel restrictions, social distancing and business shutdowns. We have taken precautionary measures intended to comply with local regulations and to help minimize the risk of the virus to our employees, such as implementing office closures, including in our China headquarters in Shanghai, and limiting non-essential travel. These measures could negatively affect our business. For instance, if certain of our employees are required to continue to work remotely as a result of local government mandates, company policy updates, or otherwise, absenteeism or employee turnover could increase, or we may experience disruptions to our operations or increased risk of a cybersecurity incident. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to recent outbreaks of the COVID-19 pandemic in China, the Chinese government has imposed restrictive quarantine measures, including extensive shutdowns in certain cities in China in which we operate, which have caused business disruptions. These measures, as well as other efforts and effects related to the continued COVID-19 pandemic, may continue for an indeterminate amount of time and have adversely impacted and may continue to adversely impact our and our partners&#8217; businesses, operations and financial conditions, including our or our business partners&#8217; manufacturing and supply chains, clinical trial operations and ability to advance research and development activities and pursue development of pipeline products. Each of these factors could have a material adverse impact on our business, operations and our financial results, including our ability to conduct our business in the manner and on the timelines presently planned. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may continue to impact our business will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the severity of COVID-19 or the effectiveness of actions to contain and treat COVID-19, particularly in China and the United States and other geographies where we or our partners and our and their third-party suppliers, clinical trial sites and CMOs or CROs, or any other third parties with which we engage, operate. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a company with substantial operations outside of the United States, our business is subject to economic, political, regulatory and other risks associated with international operations, including the effects of Russia&#8217;s invasion of Ukraine. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company with substantial operations in China, our business is subject to risks associated with conducting business outside the United States. Substantially all of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">differing and changing regulatory requirements for product approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potentially reduced protection for intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in non-U.S. regulations and customs, tariffs and trade barriers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in non-U.S. currency exchange rates of the renminbi; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment, especially with respect to a particular country&#8217;s treatment of or stance towards other countries; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain non-U.S. markets; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">negative consequences from changes in tax laws; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad,</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">including, for example, the variable tax treatment in different jurisdictions of options granted under our equity incentive plans; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war, such as the ongoing war between Russia and Ukraine, and terrorism, health epidemics and pandemics, such as the COVID-19 pandemic or natural disasters including earthquakes, typhoons, floods and fires. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="text-indent:36.7pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine. Although we do not conduct business in either Russia or Ukraine, our global operations expose us to geopolitical risks, including, in this instance, with respect to how the United States and China choose to respond to the war between Ukraine and Russia. For instance, in connection with this war, the United States and other nations have raised the possibility of secondary sanctions on China, Chinese banks and Chinese businesses that do business with Russia or its allies. We do not currently conduct business in Russia or with Russian counterparties, but we may be impacted by sanctions if third parties with which we do business, such as business partners, suppliers, intermediaries, services providers or banks, are subject to such sanctions or if broader sanctions are imposed. Our business and operations may also be adversely impacted by any actions taken by China in response to the war or any related sanctions or threatened sanctions. If this war continues or expands, or if it leads to continued political or economic instability or terrorist activity, or if it gives rise to further government actions such as sanctions or increased economic or political tensions, in particular between the United States and China, our business and financial results may be adversely impacted and the value of our ADSs may significantly decline. In addition, although we do not currently conduct any clinical trials in Russia or Ukraine, we or our partners may experience disruptions with respect to clinical trials and operations as a result of the war and its related effects, which could materially adversely impact our or their ability to conduct business, including clinical trials, in the manner and on the timelines presently planned.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial and capital markets volatility may adversely affect access to capital for life sciences companies including us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and capital markets are experiencing significant volatility and the volatility is adversely affecting access to capital and credit for many life sciences companies, but that risk is currently exacerbated for companies like ours with significant operations in China by factors such as the geopolitical tensions between the U.S. and China, the ongoing war between Russia and Ukraine, and the uncertainty about the duration, scope, and effect of COVID-19 restrictions. In the event that these continued adverse market conditions may affect us, we may be unable to obtain adequate capital or credit market financing, obtain that capital or credit on favorable terms, or access such capital or credit in manners most favorable to us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are required to obtain certain permissions from Chinese authorities to transfer certain data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to obtain approval from the Cyberspace Administration of China (&#8220;CAC&#8221;) when the transfers out of mainland China of certain data that is determined to be important data or personal data falls into any of the scenarios requiring a security assessment by CAC specified in the Security Assessment Measures. The cross-border transfer out of mainland China of data requiring such a security assessment will not be allowed if the CAC does not approve the security assessment filing. In addition, the disclosure, sharing or exporting to foreign parties or entities established or actually controlled by them by a Chinese-owned entity of any data derived from human organs, tissues or cells of Chinese individuals that contain human genetic materials requires a separate notification filing to the Human Genetic Resources Administration of China (&#8220;HGRAC&#8221;). The HGRAC also requires submission of a copy of the data to be exported. If our Chinese subsidiaries intend to receive certain clinical or personal data from Chinese-owned entities or transfer certain clinical or personal data out of mainland China, they need to first evaluate whether a security assessment by CAC or a clearance from the HGRAC will be triggered by such data transfer, pass the necessary security assessment, and make the necessary notification filings for such data transfer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our Chinese subsidiaries do not receive or maintain approvals for such data transfers or inadvertently conclude that security assessments, approvals, or notification filings needed for such data transfers are not required, or if there are changes in applicable laws (including regulations) or interpretations of laws and our Chinese subsidiaries are required but unable to pass security assessments, obtain approvals, or make notification filings in the future, then such Chinese subsidiaries may be unable to effectuate such data transfers and this could adversely affect the operations of our Chinese subsidiaries, including limiting or prohibiting the ability of our Chinese subsidiaries to operate, and our relationships with our licensing and other collaboration partners.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We believe we will be classified as a PFIC in the current taxable year ending December 31, 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not believe we were a PFIC for the taxable year ended December 31, 2021, but we believe we will be classified as a PFIC in the current taxable year ending December 31, 2022.  We may or may not be a PFIC in subsequent years.  Our actual PFIC status for any taxable year will not be determinable until after the end of such taxable year as our PFIC status is a factual determination made annually after the end of each taxable year. There can be no assurance that the IRS will agree with our determination and that the IRS would not successfully challenge our position in any taxable year. We will be a PFIC in any taxable year if at least (i) 75% of our gross income is &#8220;passive income&#8221; or (ii) 50% of the average gross value of our assets, determined on a quarterly basis, is attributable to assets that produce, or are held for the production of passive income. Because we expect to be a PFIC for our current taxable year, certain adverse U.S. federal income tax consequences could apply to U.S. persons who have acquired our ADSs or ordinary shares with respect to any &#8220;excess distribution&#8221; received from us and any gain from a sale or other disposition of our ADSs and ordinary shares.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are a PFIC in any taxable year in which a U.S. shareholder holds our ADSs or ordinary shares, we generally will continue to be treated as a PFIC with respect to such U.S. shareholder, regardless of whether we continue to meet the tests described above, unless we cease to be a PFIC and the U.S. shareholder makes the &#8220;deemed sale election&#8221;.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The adverse U.S. federal income tax consequences of holding interests in a PFIC may be mitigated if the U.S. shareholder makes a valid mark-to-market election or makes valid a qualified electing fund (&#8220;QEF&#8221;) election with respect to all taxable years the underlying entity is a PFIC during such U.S. shareholder&#8217;s holding period or makes a purging election to cause a deemed sale of the PFIC shares at their fair market value in connection with a QEF election.  We do not, however, expect to provide U.S. shareholders with the information necessary to make a valid QEF election and U.S. shareholders therefore should assume that a QEF election will not be available with respect to our ADSs or ordinary shares.  Further, no assurance can be given that a mark-to-market election will be available with respect to our ADSs or ordinary shares. For additional information, see Part II&#8212;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation&#8212;of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. </span></div><div id="i7377b691bd58451297fc26cb9421b200_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Use of Proceeds </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, our Registration Statement on Form S-1, as amended (File No. 333-259978), was declared effective in connection with our initial public offering, pursuant to which we sold an aggregate of 20,312,500 ADSs representing 20,312,500 ordinary shares, at a price to the public of $16.00 per ADS. Goldman Sachs &amp; Co. LLC, Jefferies LLC, and BofA Securities, Inc. acted as joint lead book-running managers and Raymond James &amp; Associates, Inc. acted as a lead manager for the offering. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial public offering closed on November 3, 2021. There has been no material change in the planned use of proceeds from our initial public offering as described in our prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on November 2, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Issuer Purchases of Equity Securities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i7377b691bd58451297fc26cb9421b200_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults upon Senior Securities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7377b691bd58451297fc26cb9421b200_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7377b691bd58451297fc26cb9421b200_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed on the Exhibit Index are either filed or furnished with this report or incorporated herein by reference.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-amendmentno1tol.htm">Amendment No. 1 to License and Collaboration Agreement, dated as of September 26, 2022, by and among LianBio Inflammatory Limited and Lyra Therapeutics, Inc. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-certificationof.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-certificationof.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-certificationof.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-certificationof.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Database*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain confidential information contained in this exhibit has been omitted because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><div id="i7377b691bd58451297fc26cb9421b200_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:16.63pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7377b691bd58451297fc26cb9421b200_7"> of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LianBio</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;10, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Yizhe Wang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yizhe Wang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer and Director</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;10, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Yi Larson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yi Larson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-amendmentno1tol.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic071f2b8a16b4d738edd7a08f95b2734_1"></div><div style="min-height:61.92pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">EXECUTION VERSION</font></div></div><div style="margin-top:9.55pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</font></div><div style="margin-top:9.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), entered into as of September 26, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between LianBio Inflammatory Limited, a company limited by shares organized and existing under the laws of Hong Kong Special Administrative Region of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Lyra Therapeutics, Inc., a Delaware corporation, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lyra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Lian and Lyra are each referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:206.47pt;padding-right:206.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INTRODUCTION</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Lian and Lyra entered into a License and Collaboration Agreement, dated May 31, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for the Development, Manufacture, and Commercialization of Compounds and Licensed Products in the Field in the Territory&#59; and</font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Parties wish to amend the Agreement to further clarify certain of Lian&#8217;s and Lyra&#8217;s Development and milestone payment commitments under the Agreement, as provided herein.</font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:5pt;padding-right:32.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.8pt;text-decoration:underline">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Any capitalized term used in this Amendment but not otherwise defined will have the meaning ascribed thereto in the Agreement.</font></div><div style="margin-top:4.6pt;padding-left:5pt;padding-right:32.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.8pt;text-decoration:underline">Development Responsibilities in General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Section 3.1(a) (Development Diligence) of the Agreement is hereby deleted in its entirety and replaced as follows&#58;</font></div><div style="margin-top:9.55pt;padding-left:77pt;padding-right:41.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Development Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. </font></div><div style="margin-top:9.55pt;padding-left:110.55pt;padding-right:41.95pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:11.36pt">Lian (directly, or through their respective Affiliates, Sublicensees and contractors) will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for the Licensed Product in the Territory, and Lyra (directly, or through its respective Affiliates, Sublicensees and contractors) will use Commercially Reasonable Efforts to (A) complete the planned Global Phase III Trial for the Licensed Product (which Global Phase III Trial, notwithstanding any provision to the contrary set forth in Section 3.6(b) (Development Costs), Lyra will conduct at its sole cost and expense), and (B) seek and obtain Regulatory Approval for the Licensed Product in the U.S.</font></div><div style="margin-top:9.55pt;padding-left:110.55pt;padding-right:41.95pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.45pt">Unless otherwise agreed by the Parties, Lian &#91;***&#93; with respect to the conduct of, either of Lyra&#8217;s two planned global registrational Phase III Trials for the Licensed Product, including the Global Phase III Trial (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">ENLIGHTEN Phase 3 Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;). Following &#91;***&#93;, and provided that &#91;***&#93;, including &#91;***&#93; (collectively, the &#8220;Conditions&#8221;), Lian (directly, or through their respective Affiliates, Sublicensees and contractors) will use Commercially Reasonable Efforts to conduct its own independent Phase III Trial in the PRC intended to support Regulatory Approval for the Licensed Product for use in CRS in the PRC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">China Phase III Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;) and dose the first patient in such China Phase III Trial no later than &#91;***&#93; following &#91;***&#93;, and further </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="margin-top:9.55pt;padding-left:110.55pt;padding-right:41.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">that (a) &#91;***&#93;, the Parties will negotiate in good faith and agree to an amendment to the Territory-Specific Development Plan through the JSC in accordance with this Agreement, and (b) if &#91;***&#93; in compliance with all applicable Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> however, nothing herein shall reduce or limit Lian&#8217;s diligence obligations under Section 3.1(a) (Development Diligence) to (directly, or through their respective Affiliates, Sublicensees and contractors) use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for the Licensed Product in the Territory in Indication(s) other than CRS. </font></div><div style="margin-top:9.55pt;padding-left:110.55pt;padding-right:41.95pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:4.78pt">Notwithstanding any provision to the contrary set forth in this Agreement, the Parties hereby agree that (A) Lian&#8217;s conduct of the China Phase III Trial in lieu of its participation in the Global Phase III Trial is not a breach by Lian of any obligations under the Agreement, including Lian&#8217;s diligence obligations under Section 3.1(a) (Development Diligence) of the Agreement and instead is expressly agreed by the Parties to be permitted under the terms of the Agreement&#59; and (B) Lian will have no obligations under the Agreement (1) to participate in the Global Phase III Trial (including enrolling any Clinical Trial subjects in such Global Phase III Trial in the Territory) or (2) with respect to any costs or expenses incurred in connection with such Global Phase III Trial, all of which costs and expenses, as between the Parties, will be borne by Lyra. </font></div><div style="margin-top:4.6pt;padding-left:5pt;padding-right:32.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.8pt;text-decoration:underline">Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Section 3.2 (Development Activities) of the Agreement is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="margin-top:4.6pt;padding-left:40.95pt;padding-right:32.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Subject to the terms and conditions of this Agreement, Lian will lead Development activities for the Licensed Product in the Territory as required to obtain, support and maintain the Regulatory Approval of the Licensed Product for CRS in the Territory. Lian will have the right to determine after considering in good faith Lyra&#8217;s suggestions from which Regions all patients in any Clinical Trial for the Licensed Product conducted in the Territory are enrolled. The Parties will agree upon &#91;***&#93;, in each case, prior to Lian&#8217;s commencement of the foregoing Development activities.</font></div><div style="margin-top:4.6pt;padding-left:5pt;padding-right:32.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.8pt;text-decoration:underline">Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Table 6.1(b) (Development Milestone Payments) of the Agreement is hereby deleted in its entirety and replaced with the following table&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:32.46pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.221%"><tr><td style="width:1.0%"></td><td style="width:65.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:22pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">Table 6.1(b) (Development Milestone Payments)</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e6e6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone Event</font></td><td colspan="3" style="background-color:#e7e6e6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone Payment (in Dollars)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.75pt;padding-right:2.75pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:12.75pt">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:22pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.75pt;padding-right:2.75pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:12.75pt">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:22pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.75pt;padding-right:2.75pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:12.75pt">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:22pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#91;***&#93; </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.75pt;padding-right:2.75pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:12.75pt">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:22pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:22pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">&#91;***&#93;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.65pt;text-decoration:underline">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Section 4.1 (Supply Agreements) of the Agreement is hereby deleted in its entirety and replaced as follows&#58;</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="margin-top:9.55pt;padding-left:113.4pt;padding-right:32.05pt;text-align:justify;text-indent:-29.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:17.2pt">By &#91;***&#93;, the Parties will negotiate in good faith and enter into a supply agreement for the Manufacture and supply of clinical quantities of Licensed Products by Lyra to Lian for use solely in connection with Clinical Trials and other Development of Licensed Products in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Clinical Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;). </font></div><div style="margin-top:9.55pt;padding-left:113.4pt;padding-right:32.05pt;text-align:justify;text-indent:-29.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:16.58pt">Following Lyra&#8217;s receipt of Regulatory Approval for the use of the Licensed Product for CRS in the U.S., the Parties will negotiate in good faith and enter into either an addendum to the Clinical Supply Agreement or a standalone supply agreement for the Manufacture and supply of the Licensed Products to Lian to support any expanded access program, compassionate use program (including named patient program or single patient program), or other program for the supply of the Licensed Product in the Field in any Region before receipt of Regulatory Approval for Commercialization of the Licensed Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Pre-Approval Commercial Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;) in such Region to the extent permitted by and in accordance with applicable Laws, including any such program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, Hong Kong and Guangdong-Hong Kong-Macao Great Bay Area (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">EAP Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;). Such Licensed Product will be in the same labeled, finished form, formulation, and dosage strength(s) that Lyra is, at such time, Manufacturing or having Manufactured for commercial use in the U.S and if such Licensed Product is sold at or below cost such supply shall be at a price equal to &#91;***&#93; and if such Licensed Product is sold above cost such supply shall be at a price equal to &#91;***&#93;. For clarity, any quantities of Licensed Products ordered by Lian but failed to be supplied or caused to be supplied by Lyra under the EAP Supply Agreement in a given Calendar Year shall not be included in determining whether a Supply Failure has occurred for such Calendar Year. </font></div><div style="margin-top:9.55pt;padding-left:113.4pt;padding-right:32.05pt;text-align:justify;text-indent:-29.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:17.2pt">No later than &#91;***&#93; prior to the date Lian anticipates its First Commercial Sale of the Licensed Product in the Territory, the Parties will negotiate in good faith and enter into a supply agreement for the Manufacture and supply of commercial quantities of Licensed Products by Lyra to Lian for the commercial sale and distribution of Licensed Product in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Commercial Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221; and, together with the Clinical Supply Agreement and the EAP Supply Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Supply Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;). Unless otherwise agreed or required by applicable Laws, the Supply Agreements will specify that Lyra will (or will cause its Affiliates to) Manufacture and supply, and Lian will purchase from Lyra, all of Lian&#8217;s, its Affiliates&#8217; and Sublicensees&#8217; requirements for the Licensed Products for the Development, or Commercialization (as applicable) in the Field in the Territory in their finished form and at a price equal to (a) under the Clinical Supply Agreement, &#91;***&#93; and (b) under the Commercial Supply Agreement, &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#91;***&#93;. </font></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.65pt;text-decoration:underline">No Other Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. All other original terms and conditions of the Agreement, except as specifically amended herein, shall remain in full force and effect. To the extent there is a conflict between this Amendment and the Agreement, the provisions of this Amendment shall control.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.65pt;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">.  This Amendment will be effective as of the Amendment Effective Date.</font></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.65pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">.  This Amendment will be construed in accordance with and governed by the laws of the State of New York, without regard to the conflicts of law principles thereof.</font></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:22.65pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">.  If any provision of this Amendment or the application thereof to any Person or circumstance will, for any reason and to any extent, be invalid or unenforceable, the remainder of this Amendment and the application of that provision to other Persons or circumstances will not be affected, but rather will be enforced to the extent permitted by applicable Law.</font></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:17.15pt;text-decoration:underline">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">.  This Amendment may be amended, modified, renewed, or extended only by written instrument executed by all Parties hereto.</font></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:17.15pt;text-decoration:underline">Execution in Counterparts&#59; Facsimile Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. This Amendment may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart. Signatures provided by facsimile transmission or in Adobe</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8482; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures.</font></div><div style="margin-top:9.55pt;padding-left:5.1pt;padding-right:32.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.55pt;padding-left:139.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of this page intentionally blank&#93;</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><div id="ic071f2b8a16b4d738edd7a08f95b2734_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:13.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each Party has caused this Amendment to be duly executed by its authorized representative under seal, in duplicate on the Amendment Effective Date.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LYRA THERAPEUTICS, INC.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Maria Palasis                </font></div><div style="margin-top:0.05pt;padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Maria Palasis</font></div><div style="padding-left:221.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LIANBIO INFLAMMATORY LIMITED</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Raphael Ho                  </font></div><div style="padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Raphael Ho</font></div><div style="padding-left:221.05pt"><font><br></font></div><div style="padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div style="margin-top:3.7pt;padding-right:42.45pt"><font><br></font></div><div style="margin-top:3.7pt;padding-right:13.95pt"><font><br></font></div><div style="margin-top:3.7pt;padding-right:42.45pt"><font><br></font></div><div style="margin-top:3.7pt;padding-right:13.95pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:78.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE TO THE FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT&#93;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311-certificationof.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iec281c46e2504eaba1fcb59d90323f24_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Yizhe Wang, certify that&#58; </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of LianBio&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Omitted pursuant to Rules&#160;13a-14(a)&#160;and&#160;15d-14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93;&#59; </font></div></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font><br></font></div></td></tr></table></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:49.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;10, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Yizhe Wang</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yizhe Wang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312-certificationof.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8f94d34f6f9d4219996f387d1694f15c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Yi Larson, certify that&#58; </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;<br>I have reviewed this Quarterly Report on Form 10-Q of LianBio&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Omitted pursuant to Rules&#160;13a-14(a)&#160;and&#160;15d-14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93;&#59; </font></div></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font><br></font></div></td></tr></table></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:49.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;10, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Yi Larson</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yi Larson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321-certificationof.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic0986f752de54376b0a8b7333a0b7209_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Quarterly Report on Form 10-Q of LianBio (the &#8220;Company&#8221;) for the quarterly period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Yizhe Wang, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:48.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;10, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Yizhe Wang</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yizhe Wang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322-certificationof.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic7a89a81df4e4676be7f94cd0b222770_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Quarterly Report on Form 10-Q of LianBio (the &#8220;Company&#8221;) for the quarterly period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Yi Larson, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:51.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;10, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:12pt;text-indent:-12pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Yi Larson</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yi Larson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>adr-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:10012e6e-b07f-4a8a-83a8-17013968b0f9,g:3852927e-ec92-4d9e-bc45-8785d7c9d0c5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adr="http://lian.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lian.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adr-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adr-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adr-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adr-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://lian.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://lian.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://lian.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit" roleURI="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit">
        <link:definition>0000005 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical" roleURI="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical">
        <link:definition>0000006 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://lian.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://lian.com/role/NatureofBusiness">
        <link:definition>0000008 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://lian.com/role/SignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MaterialAgreements" roleURI="http://lian.com/role/MaterialAgreements">
        <link:definition>0000010 - Disclosure - Material Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>0000011 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://lian.com/role/PropertyandEquipmentNet">
        <link:definition>0000012 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpenseandOtherCurrentAssets" roleURI="http://lian.com/role/PrepaidExpenseandOtherCurrentAssets">
        <link:definition>0000013 - Disclosure - Prepaid Expense and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://lian.com/role/AccruedExpenses">
        <link:definition>0000014 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://lian.com/role/CommitmentsandContingencies">
        <link:definition>0000015 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://lian.com/role/ShareBasedCompensation">
        <link:definition>0000016 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://lian.com/role/NetLossPerShare">
        <link:definition>0000017 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://lian.com/role/SubsequentEvents">
        <link:definition>0000018 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://lian.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>0000019 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>0000020 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://lian.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000021 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpenseandOtherCurrentAssetsTables" roleURI="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsTables">
        <link:definition>0000022 - Disclosure - Prepaid Expense and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://lian.com/role/AccruedExpensesTables">
        <link:definition>0000023 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://lian.com/role/NetLossPerShareTables">
        <link:definition>0000024 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessAdditionalInformationDetail" roleURI="http://lian.com/role/NatureofBusinessAdditionalInformationDetail">
        <link:definition>0000025 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://lian.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000026 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MaterialAgreementsAdditionalInformationDetail" roleURI="http://lian.com/role/MaterialAgreementsAdditionalInformationDetail">
        <link:definition>0000027 - Disclosure - Material Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails">
        <link:definition>0000028 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>0000029 - Disclosure - Marketable Securities and Fair Value Measurements - Available-for-sale Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails" roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails">
        <link:definition>0000030 - Disclosure - Marketable Securities and Fair Value Measurements - Marketable Securities on the Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000031 - Disclosure - Marketable Securities and Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail" roleURI="http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail">
        <link:definition>0000032 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetail" roleURI="http://lian.com/role/PropertyandEquipmentNetAdditionalInformationDetail">
        <link:definition>0000033 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail" roleURI="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail">
        <link:definition>0000034 - Disclosure - Prepaid Expense and Other Current Assets - Summary of Prepaid Expense and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesSummaryofAccruedExpensesDetail" roleURI="http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail">
        <link:definition>0000035 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://lian.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>0000036 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetail" roleURI="http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail">
        <link:definition>0000037 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail" roleURI="http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail">
        <link:definition>0000038 - Disclosure - Net Loss Per Share - Summary of Diluted and Basic Net Loss Per Ordinary Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail" roleURI="http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail">
        <link:definition>0000039 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Were Excluded From Calculation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetail" roleURI="http://lian.com/role/SubsequentEventsAdditionalInformationDetail">
        <link:definition>0000040 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="adr_MilestoneStageTwoMember" abstract="true" name="MilestoneStageTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" abstract="true" name="SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_AssetAcquisitionMilestoneAmount" abstract="false" name="AssetAcquisitionMilestoneAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_APICDueFromRelatedPartiesIncreaseForCostRecognition" abstract="false" name="APICDueFromRelatedPartiesIncreaseForCostRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_RedeemableConvertiblePreferredSharesMember" abstract="true" name="RedeemableConvertiblePreferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_ImputedInterestOnMilestonePayment" abstract="false" name="ImputedInterestOnMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_MilestonePaymentPayable" abstract="false" name="MilestonePaymentPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_NonrefundableResearchDeposit" abstract="false" name="NonrefundableResearchDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_TypeOfMilestoneDomain" abstract="true" name="TypeOfMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_LandosMember" abstract="true" name="LandosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_WarrantsInLianOphthalmologyIssuedToTarsusMember" abstract="true" name="WarrantsInLianOphthalmologyIssuedToTarsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_TypeOfMilestoneAxis" abstract="true" name="TypeOfMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adr_AmendedLicensingAgreementMember" abstract="true" name="AmendedLicensingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_NavireMember" abstract="true" name="NavireMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_ReviralMember" abstract="true" name="ReviralMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_AssetAcquisitionNetSalesMilestone" abstract="false" name="AssetAcquisitionNetSalesMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_NonRefundableFinancingMilestonePaymentMember" abstract="true" name="NonRefundableFinancingMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_MilestoneStageAxis" abstract="true" name="MilestoneStageAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adr_PerformanceConditionOnMarketValue" abstract="false" name="PerformanceConditionOnMarketValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_AccruedConsultingAndContractedResearchCurrent" abstract="false" name="AccruedConsultingAndContractedResearchCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_ClassOfWarrantOrRightNumberOfTranches" abstract="false" name="ClassOfWarrantOrRightNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="adr_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="adr_TwoThousandAndNineteenPlanMember" abstract="true" name="TwoThousandAndNineteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_TarsusWarrantsMember" abstract="true" name="TarsusWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_MyokardiaMember" abstract="true" name="MyokardiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="adr_WarrantsToPurchaseCommonStockMember" abstract="true" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_TrancheThreeMember" abstract="true" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_TarsusPharmaceuticalsMember" abstract="true" name="TarsusPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="adr_UpfrontPaymentReceivable" abstract="false" name="UpfrontPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_NonCashOperatingLeaseExpenseBenefit" abstract="false" name="NonCashOperatingLeaseExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_MilestoneStageDomain" abstract="true" name="MilestoneStageDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_DeferredOfferingCostsIncurredButNotYetPaid" abstract="false" name="DeferredOfferingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" abstract="false" name="PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" abstract="false" name="WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" abstract="false" name="NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_TwoThousandAndTwentyOnePlanMember" abstract="true" name="TwoThousandAndTwentyOnePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_LicenseAndOtherRelatedAgreementsTextBlock" abstract="false" name="LicenseAndOtherRelatedAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adr_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_LianOncologyMember" abstract="true" name="LianOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_LicenseAndOtherRelatedAgreementsAbstract" abstract="true" name="LicenseAndOtherRelatedAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember" abstract="true" name="WarrantsInLianCardiovascularIssuedToMyokardiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_TrancheDomain" abstract="true" name="TrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_PaymentOfMilestoneAmount" abstract="false" name="PaymentOfMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_SeriesARedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesARedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_LyraMember" abstract="true" name="LyraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_WarrantsInLianOncologyIssuedToQedMember" abstract="true" name="WarrantsInLianOncologyIssuedToQedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_PrepaidRentAndSupplies" abstract="false" name="PrepaidRentAndSupplies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_TrancheAxis" abstract="true" name="TrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adr_TieredRoyaltyAsAPercentageOfNetSales" abstract="false" name="TieredRoyaltyAsAPercentageOfNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adr_CommitmentToContributeCapital" abstract="false" name="CommitmentToContributeCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_SpecifiedDevelopmentRegulatoryMilestoneMember" abstract="true" name="SpecifiedDevelopmentRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" abstract="false" name="PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_LicenseAndOtherRelatedAgreementsTable" abstract="true" name="LicenseAndOtherRelatedAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="adr_NanobiotixMember" abstract="true" name="NanobiotixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_LicenseAndOtherRelatedAgreementsLineItems" abstract="true" name="LicenseAndOtherRelatedAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock" abstract="false" name="PrepaidExpenseAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adr_QedMember" abstract="true" name="QedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_PayableToRelatedPartyCurrentMember" abstract="true" name="PayableToRelatedPartyCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy" abstract="false" name="ReimbursementAmountDueTowardsCostsIncurredForTheStudy" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adr_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>adr-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:10012e6e-b07f-4a8a-83a8-17013968b0f9,g:3852927e-ec92-4d9e-bc45-8785d7c9d0c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://lian.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_160b9e0c-0c55-4f6f-924d-58338185f761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c33b7d19-66a7-42af-8cb1-cc6707c76785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_160b9e0c-0c55-4f6f-924d-58338185f761" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c33b7d19-66a7-42af-8cb1-cc6707c76785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_17489650-ebc1-4a12-b844-fe20448e2bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_160b9e0c-0c55-4f6f-924d-58338185f761" xlink:to="loc_us-gaap_AccountsPayableCurrent_17489650-ebc1-4a12-b844-fe20448e2bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef4e891a-e6f6-4f8d-8943-2df9674f9ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_160b9e0c-0c55-4f6f-924d-58338185f761" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef4e891a-e6f6-4f8d-8943-2df9674f9ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0180bb48-5cab-4f2d-a827-0874e7ff18e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_160b9e0c-0c55-4f6f-924d-58338185f761" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0180bb48-5cab-4f2d-a827-0874e7ff18e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f64dbe01-5107-4c37-a1e3-d27aa42eed1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42bf6e63-a03c-459c-a7ee-4a4296be22b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f64dbe01-5107-4c37-a1e3-d27aa42eed1f" xlink:to="loc_us-gaap_StockholdersEquity_42bf6e63-a03c-459c-a7ee-4a4296be22b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4a8773a8-cba3-443f-81b6-1a78e6d3ea00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f64dbe01-5107-4c37-a1e3-d27aa42eed1f" xlink:to="loc_us-gaap_MinorityInterest_4a8773a8-cba3-443f-81b6-1a78e6d3ea00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f3c287ba-5ed0-41ba-9bc8-5faae39538bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5ed0d3db-8666-4729-860a-36eb0716d788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f3c287ba-5ed0-41ba-9bc8-5faae39538bd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5ed0d3db-8666-4729-860a-36eb0716d788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonrefundableResearchDeposit_fbefbbbe-7d0b-4205-b10f-86fd4a97e8b7" xlink:href="adr-20220930.xsd#adr_NonrefundableResearchDeposit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f3c287ba-5ed0-41ba-9bc8-5faae39538bd" xlink:to="loc_adr_NonrefundableResearchDeposit_fbefbbbe-7d0b-4205-b10f-86fd4a97e8b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1674120e-1bf9-4cb7-b02e-ff51ebd3ef0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f3c287ba-5ed0-41ba-9bc8-5faae39538bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_1674120e-1bf9-4cb7-b02e-ff51ebd3ef0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b9cfa7d-9e5a-4243-8d33-7f8563b0401e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f3c287ba-5ed0-41ba-9bc8-5faae39538bd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b9cfa7d-9e5a-4243-8d33-7f8563b0401e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_53e7842e-de60-467b-8b04-973ed1e93a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3e89cc8-2002-487d-bd95-0120eee26f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_53e7842e-de60-467b-8b04-973ed1e93a3d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3e89cc8-2002-487d-bd95-0120eee26f1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c3300448-8eb9-4c61-9129-65086b3df3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_53e7842e-de60-467b-8b04-973ed1e93a3d" xlink:to="loc_us-gaap_Liabilities_c3300448-8eb9-4c61-9129-65086b3df3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f158d2a5-0dea-4d57-b401-305e05d32e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_53e7842e-de60-467b-8b04-973ed1e93a3d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f158d2a5-0dea-4d57-b401-305e05d32e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a047abc9-bdd1-4dca-81d0-8a15a4fc674e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a1c2e547-017f-45e7-bdbd-bdce66e79a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a047abc9-bdd1-4dca-81d0-8a15a4fc674e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a1c2e547-017f-45e7-bdbd-bdce66e79a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6dbf7700-0b47-4040-800a-f032609b4954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a047abc9-bdd1-4dca-81d0-8a15a4fc674e" xlink:to="loc_us-gaap_CommonStockValue_6dbf7700-0b47-4040-800a-f032609b4954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e5668f6-43f8-4c72-b865-5df31c410af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a047abc9-bdd1-4dca-81d0-8a15a4fc674e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e5668f6-43f8-4c72-b865-5df31c410af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aee4d07b-6a49-4fe7-aa07-00dd91c73ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a047abc9-bdd1-4dca-81d0-8a15a4fc674e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aee4d07b-6a49-4fe7-aa07-00dd91c73ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11bb920b-b9e0-4fbf-aadd-f0a13df0e7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_585ee163-7fd9-4fe7-b8aa-abbff97ceb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_11bb920b-b9e0-4fbf-aadd-f0a13df0e7bf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_585ee163-7fd9-4fe7-b8aa-abbff97ceb09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_3fb4f998-4dd6-4f46-b9dd-622f02a23c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_11bb920b-b9e0-4fbf-aadd-f0a13df0e7bf" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_3fb4f998-4dd6-4f46-b9dd-622f02a23c58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7c843a4-39dc-4664-b8ef-20219ab40d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_11bb920b-b9e0-4fbf-aadd-f0a13df0e7bf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7c843a4-39dc-4664-b8ef-20219ab40d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3931f501-5d85-4a3b-98dc-cfcfcf763291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_11bb920b-b9e0-4fbf-aadd-f0a13df0e7bf" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3931f501-5d85-4a3b-98dc-cfcfcf763291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_26ca4c86-ead3-4c97-adaa-d004ad4fd754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9d99ea58-ae6b-41bb-8a9e-e3a86f9087b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26ca4c86-ead3-4c97-adaa-d004ad4fd754" xlink:to="loc_us-gaap_AssetsCurrent_9d99ea58-ae6b-41bb-8a9e-e3a86f9087b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a39bd4f8-1372-4d3b-8f3e-f2f24db76fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26ca4c86-ead3-4c97-adaa-d004ad4fd754" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a39bd4f8-1372-4d3b-8f3e-f2f24db76fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e605109-6bbc-48f7-ab54-6a8205ff755a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26ca4c86-ead3-4c97-adaa-d004ad4fd754" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e605109-6bbc-48f7-ab54-6a8205ff755a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0b79b1f0-bd02-4b5c-a332-ac0779e84235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26ca4c86-ead3-4c97-adaa-d004ad4fd754" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0b79b1f0-bd02-4b5c-a332-ac0779e84235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f2e3bd69-0cd7-4711-bfd9-32ca29a919a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26ca4c86-ead3-4c97-adaa-d004ad4fd754" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f2e3bd69-0cd7-4711-bfd9-32ca29a919a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_cdaaa64c-0303-42d1-85bb-2f697eb5ee9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab02fbec-7d70-42bf-91cb-8a356d5eaa24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cdaaa64c-0303-42d1-85bb-2f697eb5ee9a" xlink:to="loc_us-gaap_OperatingIncomeLoss_ab02fbec-7d70-42bf-91cb-8a356d5eaa24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_88ac4995-496e-4600-9804-a20e4cc89d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cdaaa64c-0303-42d1-85bb-2f697eb5ee9a" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_88ac4995-496e-4600-9804-a20e4cc89d42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_91887d29-3883-4ee5-b6b4-2085d6c44e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cdaaa64c-0303-42d1-85bb-2f697eb5ee9a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_91887d29-3883-4ee5-b6b4-2085d6c44e55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e6d3796f-e4fc-41a1-8a47-f30e1234b2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0e8e9610-997b-4827-8604-da265c0cf45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e6d3796f-e4fc-41a1-8a47-f30e1234b2fb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0e8e9610-997b-4827-8604-da265c0cf45a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b09e106d-466d-4b26-88f4-1bf482269928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e6d3796f-e4fc-41a1-8a47-f30e1234b2fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b09e106d-466d-4b26-88f4-1bf482269928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e88e8f6-6cfe-48b3-9f09-3902e4509c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_186301a2-5fca-4516-8082-4e473ae45890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0e88e8f6-6cfe-48b3-9f09-3902e4509c00" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_186301a2-5fca-4516-8082-4e473ae45890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_442b5be2-c9a3-4c9a-a7de-776272198be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0e88e8f6-6cfe-48b3-9f09-3902e4509c00" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_442b5be2-c9a3-4c9a-a7de-776272198be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_134d2c85-b299-42e3-bb32-29874d5db17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_faaff21c-a33c-4ad4-b944-c61cafb7dac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_134d2c85-b299-42e3-bb32-29874d5db17f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_faaff21c-a33c-4ad4-b944-c61cafb7dac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_23d350fe-565d-4a78-90d7-4eca9ff64583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_134d2c85-b299-42e3-bb32-29874d5db17f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_23d350fe-565d-4a78-90d7-4eca9ff64583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ca81083-4690-482b-afb4-4943caab7d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_134d2c85-b299-42e3-bb32-29874d5db17f" xlink:to="loc_us-gaap_NetIncomeLoss_7ca81083-4690-482b-afb4-4943caab7d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_98662537-c656-4686-8eeb-7bb7607be47f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9550cf1d-f21c-4fde-9ad0-f0ee4a4da9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_98662537-c656-4686-8eeb-7bb7607be47f" xlink:to="loc_us-gaap_OperatingExpenses_9550cf1d-f21c-4fde-9ad0-f0ee4a4da9c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://lian.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD_d5cce4b9-33bc-43fb-b898-b3ae4ae0b378" xlink:href="adr-20220930.xsd#adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD_d5cce4b9-33bc-43fb-b898-b3ae4ae0b378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_460dd8ee-0f0a-46e9-b827-a0ab8c93597c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_460dd8ee-0f0a-46e9-b827-a0ab8c93597c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_c274eeeb-8838-4e7c-b2d4-7fa359367fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_c274eeeb-8838-4e7c-b2d4-7fa359367fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6da1faa9-445e-4c44-9ade-1d21c4b6326e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6da1faa9-445e-4c44-9ade-1d21c4b6326e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_90c8f1f3-ea29-42a4-8998-0532743cae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_Depreciation_90c8f1f3-ea29-42a4-8998-0532743cae8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e1bede30-82e4-4fa1-94d3-1a004dfac4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_ShareBasedCompensation_e1bede30-82e4-4fa1-94d3-1a004dfac4b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0aa7e6cb-c643-443e-844a-3b0fa32b2409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_NetIncomeLoss_0aa7e6cb-c643-443e-844a-3b0fa32b2409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb9492a0-ed5a-45c4-9aca-a22a1811bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb9492a0-ed5a-45c4-9aca-a22a1811bd52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_79c6a483-3748-4b6d-a702-a04e81203dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_79c6a483-3748-4b6d-a702-a04e81203dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c43eb8bb-4a5d-46dd-9859-852fccd58569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c43eb8bb-4a5d-46dd-9859-852fccd58569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ade24bf1-a6a2-49c0-a50a-f927813b4748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ade24bf1-a6a2-49c0-a50a-f927813b4748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d2b6e8d7-5853-4b14-a56a-fcf79e155f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d2b6e8d7-5853-4b14-a56a-fcf79e155f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_e7512285-0a07-45af-94ae-98c9cf229408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_e7512285-0a07-45af-94ae-98c9cf229408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonCashOperatingLeaseExpenseBenefit_7eaf66d5-48a5-4548-a24a-4d86527b3949" xlink:href="adr-20220930.xsd#adr_NonCashOperatingLeaseExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07052893-4f73-44fc-a1fe-fa43a2b05d56" xlink:to="loc_adr_NonCashOperatingLeaseExpenseBenefit_7eaf66d5-48a5-4548-a24a-4d86527b3949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_459964d0-68f0-492d-b92e-e86b1fe45609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_50b3bf25-7732-4963-90cd-8e1ac85cc5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_459964d0-68f0-492d-b92e-e86b1fe45609" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_50b3bf25-7732-4963-90cd-8e1ac85cc5a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8e278f6c-631b-43c2-a0c8-94e30c81f3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_459964d0-68f0-492d-b92e-e86b1fe45609" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8e278f6c-631b-43c2-a0c8-94e30c81f3a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_c08c5725-faec-4da5-91c7-088b11f3a55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_459964d0-68f0-492d-b92e-e86b1fe45609" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_c08c5725-faec-4da5-91c7-088b11f3a55d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2225d994-0df7-484e-922f-fea9a39422e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d4025ba-128c-4b7a-8248-c4efa186883d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2225d994-0df7-484e-922f-fea9a39422e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d4025ba-128c-4b7a-8248-c4efa186883d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_205a1557-a4fb-4f01-b98d-b688cd921703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2225d994-0df7-484e-922f-fea9a39422e0" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_205a1557-a4fb-4f01-b98d-b688cd921703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4747bda-7a05-42c4-af94-79958695bd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c9f560a-ea5d-42e5-9843-cfb19424dd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4747bda-7a05-42c4-af94-79958695bd05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c9f560a-ea5d-42e5-9843-cfb19424dd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73e47387-3a07-4d3a-bd84-191946401370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4747bda-7a05-42c4-af94-79958695bd05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73e47387-3a07-4d3a-bd84-191946401370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6275a8be-da50-4d13-9c21-77b3342ed065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4747bda-7a05-42c4-af94-79958695bd05" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6275a8be-da50-4d13-9c21-77b3342ed065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5fe7bce9-34e1-4f87-a8b1-9163ece8b8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4747bda-7a05-42c4-af94-79958695bd05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5fe7bce9-34e1-4f87-a8b1-9163ece8b8e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fa84305-9d6b-47c5-a8df-a9157aefdf00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8228ae87-a91f-4c2b-8f06-b2a41fb6e32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fa84305-9d6b-47c5-a8df-a9157aefdf00" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8228ae87-a91f-4c2b-8f06-b2a41fb6e32b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f18d5ceb-90f7-408d-b637-8137e810a4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fa84305-9d6b-47c5-a8df-a9157aefdf00" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f18d5ceb-90f7-408d-b637-8137e810a4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_918e6c69-8e17-4a44-9ed7-2d6d53ced817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fa84305-9d6b-47c5-a8df-a9157aefdf00" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_918e6c69-8e17-4a44-9ed7-2d6d53ced817" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbdab7b6-d03d-4b32-8859-a30790b7da9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_55263790-4f18-42fe-8fef-6569bcbc0d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbdab7b6-d03d-4b32-8859-a30790b7da9c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_55263790-4f18-42fe-8fef-6569bcbc0d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c764e9bf-242d-431b-a994-fa6cf6e8ff7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbdab7b6-d03d-4b32-8859-a30790b7da9c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c764e9bf-242d-431b-a994-fa6cf6e8ff7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c31b5e3-b48f-402c-82ff-010e0bdc5dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbdab7b6-d03d-4b32-8859-a30790b7da9c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c31b5e3-b48f-402c-82ff-010e0bdc5dc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_80adbe3d-e692-444e-8913-642ca7037097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_389f8c94-a742-42f0-828c-f249c3edec71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_80adbe3d-e692-444e-8913-642ca7037097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_389f8c94-a742-42f0-828c-f249c3edec71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4e453484-1b99-4775-adf4-48a191d51cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_80adbe3d-e692-444e-8913-642ca7037097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4e453484-1b99-4775-adf4-48a191d51cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2cb93bea-d8d4-44e8-8be5-d1a43119d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7458d8ba-4ab1-48cb-affc-fa1998bbabb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2cb93bea-d8d4-44e8-8be5-d1a43119d39b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7458d8ba-4ab1-48cb-affc-fa1998bbabb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_558dafe4-edd0-4be6-a53e-19079bf36140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2cb93bea-d8d4-44e8-8be5-d1a43119d39b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_558dafe4-edd0-4be6-a53e-19079bf36140" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4c8b582e-0eb8-4b3b-a6b5-c26af5670ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c76a58c-5eb6-4303-addb-06b19875a6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4c8b582e-0eb8-4b3b-a6b5-c26af5670ea3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c76a58c-5eb6-4303-addb-06b19875a6f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_701bc34f-a98d-4444-9879-def438342d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4c8b582e-0eb8-4b3b-a6b5-c26af5670ea3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_701bc34f-a98d-4444-9879-def438342d74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d35947b0-b888-44a4-941c-98a3e148016a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_20d8580e-7576-4940-a68a-8b1d24c18fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d35947b0-b888-44a4-941c-98a3e148016a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_20d8580e-7576-4940-a68a-8b1d24c18fe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fc0c0d82-00a0-4bc2-aa19-ab5dc2ecb598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d35947b0-b888-44a4-941c-98a3e148016a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fc0c0d82-00a0-4bc2-aa19-ab5dc2ecb598" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"/>
  <link:calculationLink xlink:role="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_972c57dc-3336-4b00-879f-bbe3924a5874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PrepaidRentAndSupplies_59876667-15f0-4bd5-aa23-020d7cf0b12b" xlink:href="adr-20220930.xsd#adr_PrepaidRentAndSupplies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_972c57dc-3336-4b00-879f-bbe3924a5874" xlink:to="loc_adr_PrepaidRentAndSupplies_59876667-15f0-4bd5-aa23-020d7cf0b12b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_1216ddac-b907-49c6-8c31-6b720af7dadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_972c57dc-3336-4b00-879f-bbe3924a5874" xlink:to="loc_us-gaap_PrepaidInsurance_1216ddac-b907-49c6-8c31-6b720af7dadd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_e53389de-f6ad-4f2a-bb3b-b35ba287c0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_972c57dc-3336-4b00-879f-bbe3924a5874" xlink:to="loc_us-gaap_DeferredCostsCurrent_e53389de-f6ad-4f2a-bb3b-b35ba287c0db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_aa061023-013a-4ddc-b5f8-fc85b9ad686c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_972c57dc-3336-4b00-879f-bbe3924a5874" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_aa061023-013a-4ddc-b5f8-fc85b9ad686c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_5b78773e-7dc7-4b37-9a07-aaec90cf3fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_972c57dc-3336-4b00-879f-bbe3924a5874" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_5b78773e-7dc7-4b37-9a07-aaec90cf3fde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#AccruedExpensesSummaryofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_487edb68-5562-4b4c-90de-8d0fea1f156d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b267bfa1-1393-4f4c-8182-0463bfc21f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_487edb68-5562-4b4c-90de-8d0fea1f156d" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b267bfa1-1393-4f4c-8182-0463bfc21f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_204f4b49-4826-411f-b235-6a99a11062fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_487edb68-5562-4b4c-90de-8d0fea1f156d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_204f4b49-4826-411f-b235-6a99a11062fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AccruedConsultingAndContractedResearchCurrent_c70373dc-9c04-4d86-9517-8b70adf91674" xlink:href="adr-20220930.xsd#adr_AccruedConsultingAndContractedResearchCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_487edb68-5562-4b4c-90de-8d0fea1f156d" xlink:to="loc_adr_AccruedConsultingAndContractedResearchCurrent_c70373dc-9c04-4d86-9517-8b70adf91674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_08aae5db-6eee-4050-95f8-9e244164c495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_487edb68-5562-4b4c-90de-8d0fea1f156d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_08aae5db-6eee-4050-95f8-9e244164c495" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>adr-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:10012e6e-b07f-4a8a-83a8-17013968b0f9,g:3852927e-ec92-4d9e-bc45-8785d7c9d0c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit" xlink:type="extended" id="i3beaf558876d4082b11b56a7d1988853_ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_86b116d7-7acb-4f55-9263-46059ce82daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_86b116d7-7acb-4f55-9263-46059ce82daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_72ebed48-c6ba-4f74-9f96-7960ba3443c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_72ebed48-c6ba-4f74-9f96-7960ba3443c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c9f1618e-9f40-4e4b-abd1-11665ee49f65" xlink:href="adr-20220930.xsd#adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c9f1618e-9f40-4e4b-abd1-11665ee49f65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ed4d9cee-b6bc-456e-a9aa-289b9f80c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ed4d9cee-b6bc-456e-a9aa-289b9f80c06e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2d6cd83a-2361-42ae-8abf-77aaeb06094a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ea3d662c-d697-4722-bf8a-b45bc6db978d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1633c2b9-3833-45ff-b8ed-afb8887b293d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_SharesOutstanding_1633c2b9-3833-45ff-b8ed-afb8887b293d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0863b271-8304-4cc2-b229-7e4c994563c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0863b271-8304-4cc2-b229-7e4c994563c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1b9c8cf-553a-44e1-832b-5dd42e808733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1b9c8cf-553a-44e1-832b-5dd42e808733" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65561fb3-289d-4332-9712-c8097a34f221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65561fb3-289d-4332-9712-c8097a34f221" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e4819241-d9ca-4694-914e-6496a8e9ec9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e4819241-d9ca-4694-914e-6496a8e9ec9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_StockIssuedDuringPeriodSharesWarrantsExercised_9ed21f0c-4ce9-4a09-b422-249c9c0b2689" xlink:href="adr-20220930.xsd#adr_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_adr_StockIssuedDuringPeriodSharesWarrantsExercised_9ed21f0c-4ce9-4a09-b422-249c9c0b2689" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition_346fa9a7-fadd-40a5-b4ef-15f66c2d944f" xlink:href="adr-20220930.xsd#adr_APICDueFromRelatedPartiesIncreaseForCostRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition_346fa9a7-fadd-40a5-b4ef-15f66c2d944f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4d1c16e7-d8c5-47f6-810f-27514c2a3b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4d1c16e7-d8c5-47f6-810f-27514c2a3b43" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21a641fb-0b9b-4a75-a6f4-a476d3b15c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_NetIncomeLoss_21a641fb-0b9b-4a75-a6f4-a476d3b15c81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aac9dcb2-e0bf-45bb-8342-736bc19f08ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aac9dcb2-e0bf-45bb-8342-736bc19f08ee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b486b39c-24ed-492d-a763-7d5912ed0d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ab31f5b-eefa-4e5a-b9f8-f05da30d3037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_58935968-c307-4c37-a2b7-48b9399eb648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:to="loc_us-gaap_StatementTable_58935968-c307-4c37-a2b7-48b9399eb648" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_58935968-c307-4c37-a2b7-48b9399eb648" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46" xlink:to="loc_us-gaap_EquityComponentDomain_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46" xlink:to="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:to="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e97e7a9c-9e96-4093-aa9b-f6eb3c65f85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_CommonStockMember_e97e7a9c-9e96-4093-aa9b-f6eb3c65f85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dbab94ad-407a-433f-ada8-e93e9849e1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dbab94ad-407a-433f-ada8-e93e9849e1d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d3d7f32-f35b-4e51-9106-e8d2938c8504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d3d7f32-f35b-4e51-9106-e8d2938c8504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_96c05a5a-3b65-4777-80cf-2933aad6608a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_RetainedEarningsMember_96c05a5a-3b65-4777-80cf-2933aad6608a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ebd90424-4a4b-4e80-b69a-d5ecee3c413d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ebd90424-4a4b-4e80-b69a-d5ecee3c413d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical" xlink:type="extended" id="i63958dbe3a654d8ea161004c87d99257_ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0096c15c-674c-43e7-a5db-69f69970ec5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_fb93524f-b4bb-44c7-9213-16155559abcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0096c15c-674c-43e7-a5db-69f69970ec5b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_fb93524f-b4bb-44c7-9213-16155559abcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0971324-b13d-4096-acfe-3ec0a7b147a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0096c15c-674c-43e7-a5db-69f69970ec5b" xlink:to="loc_us-gaap_StatementTable_f0971324-b13d-4096-acfe-3ec0a7b147a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6f680bd0-9de3-465f-b257-b02c6ec3f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f0971324-b13d-4096-acfe-3ec0a7b147a4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6f680bd0-9de3-465f-b257-b02c6ec3f1f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6f680bd0-9de3-465f-b257-b02c6ec3f1f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6f680bd0-9de3-465f-b257-b02c6ec3f1f1" xlink:to="loc_us-gaap_ClassOfStockDomain_6f680bd0-9de3-465f-b257-b02c6ec3f1f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b3e812ce-3698-46d0-85bc-66fc6aaac527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6f680bd0-9de3-465f-b257-b02c6ec3f1f1" xlink:to="loc_us-gaap_ClassOfStockDomain_b3e812ce-3698-46d0-85bc-66fc6aaac527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SeriesARedeemableConvertiblePreferredStockMember_55542bda-9618-41ae-9d62-dd44f0022814" xlink:href="adr-20220930.xsd#adr_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b3e812ce-3698-46d0-85bc-66fc6aaac527" xlink:to="loc_adr_SeriesARedeemableConvertiblePreferredStockMember_55542bda-9618-41ae-9d62-dd44f0022814" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/NatureofBusinessAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#NatureofBusinessAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://lian.com/role/NatureofBusinessAdditionalInformationDetail" xlink:type="extended" id="i19599ac302654a97a7f260eaf8fbc1c7_NatureofBusinessAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc194320-20e2-4e63-8e10-482224599f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc194320-20e2-4e63-8e10-482224599f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dc12bafb-6bae-4fc5-8eec-c33a1894e7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dc12bafb-6bae-4fc5-8eec-c33a1894e7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35bfb719-d0a4-4d13-830d-d523c9627223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35bfb719-d0a4-4d13-830d-d523c9627223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6c2f301-2be1-482f-b4c7-46e0d8449ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6c2f301-2be1-482f-b4c7-46e0d8449ece" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5a680bfe-d32b-4f6b-8dcb-05671b4da17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5a680bfe-d32b-4f6b-8dcb-05671b4da17d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_9a2a7d85-6ef8-4e0c-aea0-715eab2dc59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_9a2a7d85-6ef8-4e0c-aea0-715eab2dc59d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2e9f73ac-6317-47b0-b9a0-8c524cefb941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2e9f73ac-6317-47b0-b9a0-8c524cefb941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e9f73ac-6317-47b0-b9a0-8c524cefb941_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2e9f73ac-6317-47b0-b9a0-8c524cefb941" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e9f73ac-6317-47b0-b9a0-8c524cefb941_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2e9f73ac-6317-47b0-b9a0-8c524cefb941" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_67fc3a83-e190-4704-9f25-11b64ae460f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:to="loc_us-gaap_IPOMember_67fc3a83-e190-4704-9f25-11b64ae460f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2bdb7cf2-0a12-4f46-8ca9-50b0751b1444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2bdb7cf2-0a12-4f46-8ca9-50b0751b1444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09b97e99-cc69-45e4-b03e-c78c315c09f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09b97e99-cc69-45e4-b03e-c78c315c09f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_09b97e99-cc69-45e4-b03e-c78c315c09f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09b97e99-cc69-45e4-b03e-c78c315c09f6" xlink:to="loc_us-gaap_ClassOfStockDomain_09b97e99-cc69-45e4-b03e-c78c315c09f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac277f88-baf4-458b-808a-2ee1da893879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09b97e99-cc69-45e4-b03e-c78c315c09f6" xlink:to="loc_us-gaap_ClassOfStockDomain_ac277f88-baf4-458b-808a-2ee1da893879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_a48b9e7c-7f03-4669-ae25-857be9d52549" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ac277f88-baf4-458b-808a-2ee1da893879" xlink:to="loc_dei_AdrMember_a48b9e7c-7f03-4669-ae25-857be9d52549" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/MaterialAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#MaterialAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://lian.com/role/MaterialAgreementsAdditionalInformationDetail" xlink:type="extended" id="ib6c041f9a17541a2a31bc25bc39f10e7_MaterialAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_340736f4-2f65-4148-bb5e-86abbed44e0e" xlink:href="adr-20220930.xsd#adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_340736f4-2f65-4148-bb5e-86abbed44e0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e0a90c7-c343-4330-8d02-5504d22d41a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e0a90c7-c343-4330-8d02-5504d22d41a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_2b0063b1-8b14-412f-9cd7-7838b293ee46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_2b0063b1-8b14-412f-9cd7-7838b293ee46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ClassOfWarrantOrRightNumberOfTranches_60068dc9-4d95-4f70-b544-f14429a6defb" xlink:href="adr-20220930.xsd#adr_ClassOfWarrantOrRightNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ClassOfWarrantOrRightNumberOfTranches_60068dc9-4d95-4f70-b544-f14429a6defb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity_98a391fd-24b7-4836-8763-a712f8f80cb6" xlink:href="adr-20220930.xsd#adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity_98a391fd-24b7-4836-8763-a712f8f80cb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1c6aeee2-0454-4fac-8c25-4f6aee960ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1c6aeee2-0454-4fac-8c25-4f6aee960ade" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c11e80ac-b865-499a-8ac5-c2a8e16baf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c11e80ac-b865-499a-8ac5-c2a8e16baf31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy_1ae40ee1-c753-4771-b1a4-d7db667d3a77" xlink:href="adr-20220930.xsd#adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy_1ae40ee1-c753-4771-b1a4-d7db667d3a77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AssetAcquisitionMilestoneAmount_9271c1e2-4d83-4023-b91c-8e7763c229e5" xlink:href="adr-20220930.xsd#adr_AssetAcquisitionMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_AssetAcquisitionMilestoneAmount_9271c1e2-4d83-4023-b91c-8e7763c229e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AssetAcquisitionNetSalesMilestone_283f991a-bbcb-4cce-b207-ed170bcc0018" xlink:href="adr-20220930.xsd#adr_AssetAcquisitionNetSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_AssetAcquisitionNetSalesMilestone_283f991a-bbcb-4cce-b207-ed170bcc0018" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestonePaymentPayable_93736536-ae10-401d-9e2d-59521b18caac" xlink:href="adr-20220930.xsd#adr_MilestonePaymentPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_MilestonePaymentPayable_93736536-ae10-401d-9e2d-59521b18caac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentOfMilestoneAmount_664d68fa-3f2e-4b81-9c1e-2f96b9955527" xlink:href="adr-20220930.xsd#adr_PaymentOfMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_PaymentOfMilestoneAmount_664d68fa-3f2e-4b81-9c1e-2f96b9955527" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ImputedInterestOnMilestonePayment_757d1966-5f04-42ef-8d43-8d4dad73a42c" xlink:href="adr-20220930.xsd#adr_ImputedInterestOnMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ImputedInterestOnMilestonePayment_757d1966-5f04-42ef-8d43-8d4dad73a42c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TieredRoyaltyAsAPercentageOfNetSales_de1c3b55-6ebd-4ba7-974c-ba864a0db226" xlink:href="adr-20220930.xsd#adr_TieredRoyaltyAsAPercentageOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_TieredRoyaltyAsAPercentageOfNetSales_de1c3b55-6ebd-4ba7-974c-ba864a0db226" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement_84015088-4cdb-4951-97d7-c8a145603509" xlink:href="adr-20220930.xsd#adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement_84015088-4cdb-4951-97d7-c8a145603509" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_CommitmentToContributeCapital_30a224a9-0710-405b-b5b1-171aadc1a257" xlink:href="adr-20220930.xsd#adr_CommitmentToContributeCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_CommitmentToContributeCapital_30a224a9-0710-405b-b5b1-171aadc1a257" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_UpfrontPaymentReceivable_75d68eef-5cee-4a1b-b858-51a31280fd93" xlink:href="adr-20220930.xsd#adr_UpfrontPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_UpfrontPaymentReceivable_75d68eef-5cee-4a1b-b858-51a31280fd93" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e4dd4fd4-c67c-4bec-9cdd-3dc3c8cd11d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e4dd4fd4-c67c-4bec-9cdd-3dc3c8cd11d7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_bfd5b0ad-c4b5-4c16-992b-aa97ff98098b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_bfd5b0ad-c4b5-4c16-992b-aa97ff98098b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ClassOfWarrantOrRightIssued_365f2973-7110-45a1-a8f0-f54dd1537b61" xlink:href="adr-20220930.xsd#adr_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ClassOfWarrantOrRightIssued_365f2973-7110-45a1-a8f0-f54dd1537b61" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e2fcba3a-f0c1-423c-bcb1-b6b830c207c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e2fcba3a-f0c1-423c-bcb1-b6b830c207c1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_72f24f5d-7471-4fec-8462-71db04af491f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_72f24f5d-7471-4fec-8462-71db04af491f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_173f98b8-a4dd-47d3-8e04-aee40f85961b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_srt_CounterpartyNameAxis_173f98b8-a4dd-47d3-8e04-aee40f85961b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_173f98b8-a4dd-47d3-8e04-aee40f85961b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_173f98b8-a4dd-47d3-8e04-aee40f85961b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_173f98b8-a4dd-47d3-8e04-aee40f85961b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_173f98b8-a4dd-47d3-8e04-aee40f85961b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_QedMember_eb3be98e-a305-4baf-b637-121b4d9a5c57" xlink:href="adr-20220930.xsd#adr_QedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_QedMember_eb3be98e-a305-4baf-b637-121b4d9a5c57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MyokardiaMember_b4349319-9065-466c-90af-5db7d8814116" xlink:href="adr-20220930.xsd#adr_MyokardiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_MyokardiaMember_b4349319-9065-466c-90af-5db7d8814116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PfizerMember_7778a04e-1868-41fc-a6fa-5b6ef6f56d1a" xlink:href="adr-20220930.xsd#adr_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_PfizerMember_7778a04e-1868-41fc-a6fa-5b6ef6f56d1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ReviralMember_8e732de1-e8a8-4207-a405-042bb19818e0" xlink:href="adr-20220930.xsd#adr_ReviralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_ReviralMember_8e732de1-e8a8-4207-a405-042bb19818e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusPharmaceuticalsMember_061b858c-2de3-47f9-9e3d-393784d0856a" xlink:href="adr-20220930.xsd#adr_TarsusPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_TarsusPharmaceuticalsMember_061b858c-2de3-47f9-9e3d-393784d0856a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LandosMember_694eae30-8f6c-4875-b7e9-ae3b0a0a71eb" xlink:href="adr-20220930.xsd#adr_LandosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_LandosMember_694eae30-8f6c-4875-b7e9-ae3b0a0a71eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NanobiotixMember_2cf71c75-9f91-45b9-a81b-57004b261ab2" xlink:href="adr-20220930.xsd#adr_NanobiotixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_NanobiotixMember_2cf71c75-9f91-45b9-a81b-57004b261ab2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LyraMember_9888a23f-3539-4df5-b0b8-07b59bf7ffc8" xlink:href="adr-20220930.xsd#adr_LyraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_LyraMember_9888a23f-3539-4df5-b0b8-07b59bf7ffc8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_735a90b5-e059-4008-8c5a-62848e637c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_735a90b5-e059-4008-8c5a-62848e637c12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_735a90b5-e059-4008-8c5a-62848e637c12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_735a90b5-e059-4008-8c5a-62848e637c12" xlink:to="loc_us-gaap_RelatedPartyDomain_735a90b5-e059-4008-8c5a-62848e637c12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_735a90b5-e059-4008-8c5a-62848e637c12" xlink:to="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LianOncologyMember_5dc71815-009d-4554-b3e4-55ce0391676c" xlink:href="adr-20220930.xsd#adr_LianOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:to="loc_adr_LianOncologyMember_5dc71815-009d-4554-b3e4-55ce0391676c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NavireMember_5321d714-56e8-4ff3-b478-c535713a3649" xlink:href="adr-20220930.xsd#adr_NavireMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:to="loc_adr_NavireMember_5321d714-56e8-4ff3-b478-c535713a3649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_65873c29-a515-40cf-9e25-72231aff333c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_65873c29-a515-40cf-9e25-72231aff333c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_65873c29-a515-40cf-9e25-72231aff333c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65873c29-a515-40cf-9e25-72231aff333c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_65873c29-a515-40cf-9e25-72231aff333c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65873c29-a515-40cf-9e25-72231aff333c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsToPurchaseCommonStockMember_7439f7c5-1d45-4ec9-8636-48fa095b2b71" xlink:href="adr-20220930.xsd#adr_WarrantsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:to="loc_adr_WarrantsToPurchaseCommonStockMember_7439f7c5-1d45-4ec9-8636-48fa095b2b71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusWarrantsMember_3b6a5618-57cb-49b0-ab23-1754b33d0c55" xlink:href="adr-20220930.xsd#adr_TarsusWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:to="loc_adr_TarsusWarrantsMember_3b6a5618-57cb-49b0-ab23-1754b33d0c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TypeOfMilestoneAxis_7cfb254a-9feb-4d65-8f76-5550016cb82b" xlink:href="adr-20220930.xsd#adr_TypeOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_adr_TypeOfMilestoneAxis_7cfb254a-9feb-4d65-8f76-5550016cb82b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TypeOfMilestoneDomain_7cfb254a-9feb-4d65-8f76-5550016cb82b_default" xlink:href="adr-20220930.xsd#adr_TypeOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adr_TypeOfMilestoneAxis_7cfb254a-9feb-4d65-8f76-5550016cb82b" xlink:to="loc_adr_TypeOfMilestoneDomain_7cfb254a-9feb-4d65-8f76-5550016cb82b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:href="adr-20220930.xsd#adr_TypeOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adr_TypeOfMilestoneAxis_7cfb254a-9feb-4d65-8f76-5550016cb82b" xlink:to="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SpecifiedDevelopmentRegulatoryMilestoneMember_c43890da-4c4f-4c7e-97e9-ca0c03bc2805" xlink:href="adr-20220930.xsd#adr_SpecifiedDevelopmentRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_SpecifiedDevelopmentRegulatoryMilestoneMember_c43890da-4c4f-4c7e-97e9-ca0c03bc2805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SalesBasedMilestoneMember_ff3c149c-511d-4166-9e88-ec7cacc0ec48" xlink:href="adr-20220930.xsd#adr_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_SalesBasedMilestoneMember_ff3c149c-511d-4166-9e88-ec7cacc0ec48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonRefundableFinancingMilestonePaymentMember_584ed73c-bb21-4838-9358-641279b597d7" xlink:href="adr-20220930.xsd#adr_NonRefundableFinancingMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_NonRefundableFinancingMilestonePaymentMember_584ed73c-bb21-4838-9358-641279b597d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember_706b79dd-d33d-4711-91fc-6882fa98d57d" xlink:href="adr-20220930.xsd#adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember_706b79dd-d33d-4711-91fc-6882fa98d57d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5344e8b2-f896-430d-84b8-e8bc1ee31dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5344e8b2-f896-430d-84b8-e8bc1ee31dc1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5344e8b2-f896-430d-84b8-e8bc1ee31dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5344e8b2-f896-430d-84b8-e8bc1ee31dc1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5344e8b2-f896-430d-84b8-e8bc1ee31dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ffdbc1e8-918a-4f2b-9627-3bdc0f24e1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5344e8b2-f896-430d-84b8-e8bc1ee31dc1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ffdbc1e8-918a-4f2b-9627-3bdc0f24e1be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PayableToRelatedPartyCurrentMember_ec91fcff-156a-4744-ab15-35504985e20e" xlink:href="adr-20220930.xsd#adr_PayableToRelatedPartyCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ffdbc1e8-918a-4f2b-9627-3bdc0f24e1be" xlink:to="loc_adr_PayableToRelatedPartyCurrentMember_ec91fcff-156a-4744-ab15-35504985e20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheAxis_b930f8ee-de0e-4536-93ba-9a0943a5a035" xlink:href="adr-20220930.xsd#adr_TrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_adr_TrancheAxis_b930f8ee-de0e-4536-93ba-9a0943a5a035" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheDomain_b930f8ee-de0e-4536-93ba-9a0943a5a035_default" xlink:href="adr-20220930.xsd#adr_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adr_TrancheAxis_b930f8ee-de0e-4536-93ba-9a0943a5a035" xlink:to="loc_adr_TrancheDomain_b930f8ee-de0e-4536-93ba-9a0943a5a035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:href="adr-20220930.xsd#adr_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adr_TrancheAxis_b930f8ee-de0e-4536-93ba-9a0943a5a035" xlink:to="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheOneMember_2f773b20-9ff1-4ff1-8396-45e725117b8d" xlink:href="adr-20220930.xsd#adr_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:to="loc_adr_TrancheOneMember_2f773b20-9ff1-4ff1-8396-45e725117b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheTwoMember_8a942d2b-abb2-4841-b09a-fca33b5caa7b" xlink:href="adr-20220930.xsd#adr_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:to="loc_adr_TrancheTwoMember_8a942d2b-abb2-4841-b09a-fca33b5caa7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheThreeMember_7afe9eac-3605-45e5-a872-2631254814bc" xlink:href="adr-20220930.xsd#adr_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:to="loc_adr_TrancheThreeMember_7afe9eac-3605-45e5-a872-2631254814bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f691109e-f92a-45e9-b022-0ff1f71ba83d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_srt_RangeAxis_f691109e-f92a-45e9-b022-0ff1f71ba83d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f691109e-f92a-45e9-b022-0ff1f71ba83d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f691109e-f92a-45e9-b022-0ff1f71ba83d" xlink:to="loc_srt_RangeMember_f691109e-f92a-45e9-b022-0ff1f71ba83d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f691109e-f92a-45e9-b022-0ff1f71ba83d" xlink:to="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e2475c5-d88f-4b01-b201-3cb712e0e7e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:to="loc_srt_MaximumMember_7e2475c5-d88f-4b01-b201-3cb712e0e7e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf23b07-689e-4fb1-a96f-656a0ad1e7ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:to="loc_srt_MinimumMember_7cf23b07-689e-4fb1-a96f-656a0ad1e7ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageAxis_833fb52d-8d1b-4c87-be7e-226abf9fd18c" xlink:href="adr-20220930.xsd#adr_MilestoneStageAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_adr_MilestoneStageAxis_833fb52d-8d1b-4c87-be7e-226abf9fd18c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageDomain_833fb52d-8d1b-4c87-be7e-226abf9fd18c_default" xlink:href="adr-20220930.xsd#adr_MilestoneStageDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adr_MilestoneStageAxis_833fb52d-8d1b-4c87-be7e-226abf9fd18c" xlink:to="loc_adr_MilestoneStageDomain_833fb52d-8d1b-4c87-be7e-226abf9fd18c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageDomain_0a2e560d-b1d3-47b2-bd06-4fd851c6546e" xlink:href="adr-20220930.xsd#adr_MilestoneStageDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adr_MilestoneStageAxis_833fb52d-8d1b-4c87-be7e-226abf9fd18c" xlink:to="loc_adr_MilestoneStageDomain_0a2e560d-b1d3-47b2-bd06-4fd851c6546e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageTwoMember_64334ad2-4688-4652-97a9-aa9982aba9da" xlink:href="adr-20220930.xsd#adr_MilestoneStageTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adr_MilestoneStageDomain_0a2e560d-b1d3-47b2-bd06-4fd851c6546e" xlink:to="loc_adr_MilestoneStageTwoMember_64334ad2-4688-4652-97a9-aa9982aba9da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_004a4e2a-0f21-4b90-ae32-e58a089e846b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_004a4e2a-0f21-4b90-ae32-e58a089e846b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_004a4e2a-0f21-4b90-ae32-e58a089e846b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_004a4e2a-0f21-4b90-ae32-e58a089e846b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_004a4e2a-0f21-4b90-ae32-e58a089e846b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6672991d-c3bf-4db2-9a01-7a956a515c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_004a4e2a-0f21-4b90-ae32-e58a089e846b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6672991d-c3bf-4db2-9a01-7a956a515c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AmendedLicensingAgreementMember_34101381-0d0c-49a8-8dce-5382ae76eae2" xlink:href="adr-20220930.xsd#adr_AmendedLicensingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6672991d-c3bf-4db2-9a01-7a956a515c92" xlink:to="loc_adr_AmendedLicensingAgreementMember_34101381-0d0c-49a8-8dce-5382ae76eae2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="extended" id="iaeeb16f61e024e0c8890fc20ad08a69c_MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_14feb75e-0c9b-476d-971b-473315dad884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_14feb75e-0c9b-476d-971b-473315dad884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8f538ccd-69ca-40b7-b8ef-6fd27b4d6404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8f538ccd-69ca-40b7-b8ef-6fd27b4d6404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d74165f5-a3c1-4d97-8d77-557b72bca6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d74165f5-a3c1-4d97-8d77-557b72bca6cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32347979-e8c4-411a-9436-e1de8fef0778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32347979-e8c4-411a-9436-e1de8fef0778" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0756dd7a-4304-4df7-b69c-dc394000ae04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0756dd7a-4304-4df7-b69c-dc394000ae04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7629185f-4097-495d-a825-ef4d6012d936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0756dd7a-4304-4df7-b69c-dc394000ae04" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7629185f-4097-495d-a825-ef4d6012d936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7629185f-4097-495d-a825-ef4d6012d936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7629185f-4097-495d-a825-ef4d6012d936" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7629185f-4097-495d-a825-ef4d6012d936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7629185f-4097-495d-a825-ef4d6012d936" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4794603d-2cfc-4c17-b3ea-99c9f38ff041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_CommercialPaperMember_4794603d-2cfc-4c17-b3ea-99c9f38ff041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a386c228-a3dc-4b78-9b24-9727045510fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a386c228-a3dc-4b78-9b24-9727045510fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95adb4f8-f48c-4160-8e8b-1ea40439ca45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95adb4f8-f48c-4160-8e8b-1ea40439ca45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e92eed44-da50-4e3e-b7ee-2ff4d3e2ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e92eed44-da50-4e3e-b7ee-2ff4d3e2ceca" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended" id="i286b64ba354646a9a754bdceaa7c5be2_MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_db1d3f0a-690f-4135-bb95-9fbea26a9a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_db1d3f0a-690f-4135-bb95-9fbea26a9a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d016dfb0-3ee1-4943-8d97-fd8d0029f8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d016dfb0-3ee1-4943-8d97-fd8d0029f8df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_49e8ca8b-3cbb-4766-a2a6-7d9a94c00af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_49e8ca8b-3cbb-4766-a2a6-7d9a94c00af2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_587773b7-3e9f-4b8e-a02c-706cd41bf67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_587773b7-3e9f-4b8e-a02c-706cd41bf67f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c56ec22-63f2-4917-9ee5-b97fa5eb8c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c56ec22-63f2-4917-9ee5-b97fa5eb8c1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a6274a19-bdc9-4e07-ad9f-1ba08f350f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a6274a19-bdc9-4e07-ad9f-1ba08f350f41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_95df62cd-3cde-4067-a859-207d883912c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_95df62cd-3cde-4067-a859-207d883912c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c73ff6b7-9856-4053-8307-ee2b246989c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_95df62cd-3cde-4067-a859-207d883912c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c73ff6b7-9856-4053-8307-ee2b246989c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c73ff6b7-9856-4053-8307-ee2b246989c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c73ff6b7-9856-4053-8307-ee2b246989c2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c73ff6b7-9856-4053-8307-ee2b246989c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c73ff6b7-9856-4053-8307-ee2b246989c2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03ea6385-77fb-4646-91e2-0e93491cd5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_CommercialPaperMember_03ea6385-77fb-4646-91e2-0e93491cd5d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_77527d7b-e991-4314-8e8e-a725a7410bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_77527d7b-e991-4314-8e8e-a725a7410bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_39fb68ce-e8ce-4df9-87f5-17991ab57e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_39fb68ce-e8ce-4df9-87f5-17991ab57e67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d9f46c52-d294-4519-913d-e8776d9a908a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d9f46c52-d294-4519-913d-e8776d9a908a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails" xlink:type="extended" id="i83de510a1da64bc786251d1ac02c8759_MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6eb75127-6a8b-4db3-9b4b-b954f51d9c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6eb75127-6a8b-4db3-9b4b-b954f51d9c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_1b7f740a-c1e9-4bb8-a0e8-d733dc822a44" xlink:href="adr-20220930.xsd#adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:to="loc_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_1b7f740a-c1e9-4bb8-a0e8-d733dc822a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_4a807503-c87e-40c8-884e-6e7a1d8e10f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:to="loc_us-gaap_MarketableSecuritiesTable_4a807503-c87e-40c8-884e-6e7a1d8e10f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_dadcc201-3206-4e8f-a883-25a7d602337d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_4a807503-c87e-40c8-884e-6e7a1d8e10f7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_dadcc201-3206-4e8f-a883-25a7d602337d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadcc201-3206-4e8f-a883-25a7d602337d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dadcc201-3206-4e8f-a883-25a7d602337d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadcc201-3206-4e8f-a883-25a7d602337d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dadcc201-3206-4e8f-a883-25a7d602337d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_11182b87-6915-4ae4-91ae-549272eb3133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_CommercialPaperMember_11182b87-6915-4ae4-91ae-549272eb3133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_770120ad-0d76-46df-b6d6-b97c3c53426a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_770120ad-0d76-46df-b6d6-b97c3c53426a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9b09c550-320d-4bcb-9c0d-f5a2678ee880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9b09c550-320d-4bcb-9c0d-f5a2678ee880" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d70b1f26-d764-43c5-a964-9cbc2e1d16c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d70b1f26-d764-43c5-a964-9cbc2e1d16c2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ifcb721acb3f4444c8e622435c154ddeb_MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_40806eb8-21a3-4307-b73f-284f95ef05ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_40806eb8-21a3-4307-b73f-284f95ef05ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bdf5a353-5b5e-4d1f-aaa9-0843af05b637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bdf5a353-5b5e-4d1f-aaa9-0843af05b637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9a053c2e-e455-43d2-8eea-132079eb3cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9a053c2e-e455-43d2-8eea-132079eb3cd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e67d6503-0320-4329-8076-d2fae31be0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e67d6503-0320-4329-8076-d2fae31be0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e67d6503-0320-4329-8076-d2fae31be0e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e67d6503-0320-4329-8076-d2fae31be0e1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e67d6503-0320-4329-8076-d2fae31be0e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e67d6503-0320-4329-8076-d2fae31be0e1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4083f4b1-70f5-4232-836b-19db5b98bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4083f4b1-70f5-4232-836b-19db5b98bc67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9674e241-172c-496d-9b26-66259ae771d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:to="loc_us-gaap_CommercialPaperMember_9674e241-172c-496d-9b26-66259ae771d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6e7eaae5-a144-4854-9131-91f1a9c48664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6e7eaae5-a144-4854-9131-91f1a9c48664" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69559545-74ed-45c5-b787-5feebf780102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69559545-74ed-45c5-b787-5feebf780102" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69559545-74ed-45c5-b787-5feebf780102_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69559545-74ed-45c5-b787-5feebf780102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69559545-74ed-45c5-b787-5feebf780102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69559545-74ed-45c5-b787-5feebf780102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f53f1f75-0254-4d12-a219-289b58df1155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_CommercialPaperMember_f53f1f75-0254-4d12-a219-289b58df1155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c351a85d-862a-4dcb-bfe5-8aa549c05fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c351a85d-862a-4dcb-bfe5-8aa549c05fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_19d3aa2b-d3a8-43c7-a19f-3d96b56bd0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_19d3aa2b-d3a8-43c7-a19f-3d96b56bd0df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_c9f74e17-dae2-4f95-9224-4024416953d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_c9f74e17-dae2-4f95-9224-4024416953d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b2a49a1-697f-403e-987e-c115081f657a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b2a49a1-697f-403e-987e-c115081f657a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b2a49a1-697f-403e-987e-c115081f657a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b2a49a1-697f-403e-987e-c115081f657a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b2a49a1-697f-403e-987e-c115081f657a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b2a49a1-697f-403e-987e-c115081f657a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0cc1d39c-ec6e-4c7e-9ce2-af1d2859d51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0cc1d39c-ec6e-4c7e-9ce2-af1d2859d51b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7fe5dd56-7ca2-41c8-a0ac-bfa8b996e007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7fe5dd56-7ca2-41c8-a0ac-bfa8b996e007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_11e85231-26d3-4d89-b241-05c7c7ffaf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_11e85231-26d3-4d89-b241-05c7c7ffaf05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c2ae34e4-00c5-497a-bb53-e0de9007d977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c2ae34e4-00c5-497a-bb53-e0de9007d977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c2ae34e4-00c5-497a-bb53-e0de9007d977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c2ae34e4-00c5-497a-bb53-e0de9007d977" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c2ae34e4-00c5-497a-bb53-e0de9007d977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_794cc073-cb29-4ee4-99a9-0dd232604cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c2ae34e4-00c5-497a-bb53-e0de9007d977" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_794cc073-cb29-4ee4-99a9-0dd232604cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e08c2420-51f1-4941-8874-15bc707e5cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_794cc073-cb29-4ee4-99a9-0dd232604cee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e08c2420-51f1-4941-8874-15bc707e5cfa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"/>
  <link:definitionLink xlink:role="http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail" xlink:type="extended" id="i5abe3ec5d2fc4b70af94a47e5b3ac458_PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_735fd98d-b435-4feb-8746-67d86d0eb75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_735fd98d-b435-4feb-8746-67d86d0eb75b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b905e88e-d9bf-4c33-b5fb-6f669cdbbcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b905e88e-d9bf-4c33-b5fb-6f669cdbbcc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b41fe43a-a388-4879-9a4d-34d304fe069c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b41fe43a-a388-4879-9a4d-34d304fe069c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969a5d17-efe1-4df8-8afe-1d9721c3811d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969a5d17-efe1-4df8-8afe-1d9721c3811d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de8e73d0-d473-4603-bf38-7a2a64828c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969a5d17-efe1-4df8-8afe-1d9721c3811d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de8e73d0-d473-4603-bf38-7a2a64828c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_de8e73d0-d473-4603-bf38-7a2a64828c34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de8e73d0-d473-4603-bf38-7a2a64828c34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_de8e73d0-d473-4603-bf38-7a2a64828c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de8e73d0-d473-4603-bf38-7a2a64828c34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_681a7b7f-b479-4173-8381-3fad3bcda3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_681a7b7f-b479-4173-8381-3fad3bcda3e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_274df19f-9a5f-4102-803d-971ec9f0d0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_274df19f-9a5f-4102-803d-971ec9f0d0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ComputerEquipmentAndSoftwareMember_946c9b21-41d4-43d3-bcca-e1d9d35f2d7d" xlink:href="adr-20220930.xsd#adr_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_adr_ComputerEquipmentAndSoftwareMember_946c9b21-41d4-43d3-bcca-e1d9d35f2d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_20319194-a81c-4b77-b941-295cb84f61de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_us-gaap_ConstructionInProgressMember_20319194-a81c-4b77-b941-295cb84f61de" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i179d201149714831a021261b3cc246de_ShareBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f9528c4-9cc9-4667-93fd-32e1d67e7d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f9528c4-9cc9-4667-93fd-32e1d67e7d40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares_ea00fe8d-dc05-45b5-a1a5-6e873922add1" xlink:href="adr-20220930.xsd#adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares_ea00fe8d-dc05-45b5-a1a5-6e873922add1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_928407ff-aac4-4d55-b2f4-683578a1f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_928407ff-aac4-4d55-b2f4-683578a1f9f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7512a0f6-83ad-4e5d-8ebc-08829cfab045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7512a0f6-83ad-4e5d-8ebc-08829cfab045" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1fd59999-5273-4def-9403-9c029c07b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1fd59999-5273-4def-9403-9c029c07b07f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d53bee3c-f6b5-40b0-b74f-4639cd1e3f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d53bee3c-f6b5-40b0-b74f-4639cd1e3f9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e051c32f-7cbc-49a2-a639-ef51e61dead0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e051c32f-7cbc-49a2-a639-ef51e61dead0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1dcb4a40-e97f-43eb-b64e-ba074ce9e769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1dcb4a40-e97f-43eb-b64e-ba074ce9e769" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4bcbddc0-ab4d-4b60-8e01-47b4eaa7aae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4bcbddc0-ab4d-4b60-8e01-47b4eaa7aae0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_82e228f6-0173-463d-8889-a7a47efe8510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_82e228f6-0173-463d-8889-a7a47efe8510" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bcdbbb9-6597-4b7b-bf5d-52415d81fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bcdbbb9-6597-4b7b-bf5d-52415d81fad9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb6de3e0-f604-4ca9-b919-b34b3aa2c450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb6de3e0-f604-4ca9-b919-b34b3aa2c450" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fa1fa68e-06a9-4b44-b2c1-6680ff58922e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fa1fa68e-06a9-4b44-b2c1-6680ff58922e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PerformanceConditionOnMarketValue_af88e61b-9efe-4a6d-92ed-71b650ecff2c" xlink:href="adr-20220930.xsd#adr_PerformanceConditionOnMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_adr_PerformanceConditionOnMarketValue_af88e61b-9efe-4a6d-92ed-71b650ecff2c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e759798f-7e94-43fd-9b81-aeacbd63b7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e759798f-7e94-43fd-9b81-aeacbd63b7b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8c5202d-80bc-4e73-8024-097fbad426d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8c5202d-80bc-4e73-8024-097fbad426d4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_84f2ba13-746b-4cf7-86ca-36de7428db11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_84f2ba13-746b-4cf7-86ca-36de7428db11" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b518c04e-6385-441f-83fb-d96954c477b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b518c04e-6385-441f-83fb-d96954c477b6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd8b3525-7ded-4a70-830b-92a2e13eda3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_AwardTypeAxis_bd8b3525-7ded-4a70-830b-92a2e13eda3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd8b3525-7ded-4a70-830b-92a2e13eda3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bd8b3525-7ded-4a70-830b-92a2e13eda3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd8b3525-7ded-4a70-830b-92a2e13eda3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bd8b3525-7ded-4a70-830b-92a2e13eda3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9e8f0fb3-5cbe-49df-8019-2baaf253d0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9e8f0fb3-5cbe-49df-8019-2baaf253d0fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_65b8005a-b1b5-48f1-b594-dd85c4ba1059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:to="loc_us-gaap_PerformanceSharesMember_65b8005a-b1b5-48f1-b594-dd85c4ba1059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c38bae43-2139-41d9-bc1d-c2526383ca75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c38bae43-2139-41d9-bc1d-c2526383ca75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_8942e4c1-36a6-42b0-a57e-7b1c521418f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_GranteeStatusAxis_8942e4c1-36a6-42b0-a57e-7b1c521418f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_8942e4c1-36a6-42b0-a57e-7b1c521418f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_8942e4c1-36a6-42b0-a57e-7b1c521418f7" xlink:to="loc_us-gaap_GranteeStatusDomain_8942e4c1-36a6-42b0-a57e-7b1c521418f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_f0527add-b424-42d7-9edf-413573d307b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_8942e4c1-36a6-42b0-a57e-7b1c521418f7" xlink:to="loc_us-gaap_GranteeStatusDomain_f0527add-b424-42d7-9edf-413573d307b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0307e276-c592-4515-bb6e-dfc12be8afe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_f0527add-b424-42d7-9edf-413573d307b9" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0307e276-c592-4515-bb6e-dfc12be8afe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_298a8c87-8a36-460c-ad99-96081d049bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_PlanNameAxis_298a8c87-8a36-460c-ad99-96081d049bc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_298a8c87-8a36-460c-ad99-96081d049bc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_298a8c87-8a36-460c-ad99-96081d049bc3" xlink:to="loc_us-gaap_PlanNameDomain_298a8c87-8a36-460c-ad99-96081d049bc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_298a8c87-8a36-460c-ad99-96081d049bc3" xlink:to="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TwoThousandAndTwentyOnePlanMember_2abe29eb-5974-4449-9bae-e909e51d8194" xlink:href="adr-20220930.xsd#adr_TwoThousandAndTwentyOnePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:to="loc_adr_TwoThousandAndTwentyOnePlanMember_2abe29eb-5974-4449-9bae-e909e51d8194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TwoThousandAndNineteenPlanMember_3dd4c4eb-2b56-41ae-a413-c60430ddaeb7" xlink:href="adr-20220930.xsd#adr_TwoThousandAndNineteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:to="loc_adr_TwoThousandAndNineteenPlanMember_3dd4c4eb-2b56-41ae-a413-c60430ddaeb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be515562-d750-47fa-80b8-c15f2445970e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_srt_RangeAxis_be515562-d750-47fa-80b8-c15f2445970e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be515562-d750-47fa-80b8-c15f2445970e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_be515562-d750-47fa-80b8-c15f2445970e" xlink:to="loc_srt_RangeMember_be515562-d750-47fa-80b8-c15f2445970e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_be515562-d750-47fa-80b8-c15f2445970e" xlink:to="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_71b5df29-26cf-47ef-a0b9-9f8173ccc190" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:to="loc_srt_MinimumMember_71b5df29-26cf-47ef-a0b9-9f8173ccc190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0dcc108c-7b11-449b-b366-a3e0dcc166a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:to="loc_srt_MaximumMember_0dcc108c-7b11-449b-b366-a3e0dcc166a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_83d0be3c-f5e9-4041-8d34-b789114b1c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_VestingAxis_83d0be3c-f5e9-4041-8d34-b789114b1c19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_83d0be3c-f5e9-4041-8d34-b789114b1c19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_83d0be3c-f5e9-4041-8d34-b789114b1c19" xlink:to="loc_us-gaap_VestingDomain_83d0be3c-f5e9-4041-8d34-b789114b1c19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_83d0be3c-f5e9-4041-8d34-b789114b1c19" xlink:to="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2edcae5b-9c4a-4f68-9eeb-f04a5ff5c6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2edcae5b-9c4a-4f68-9eeb-f04a5ff5c6ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_926cb57a-fc12-485a-bc34-84b9b7d20801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_926cb57a-fc12-485a-bc34-84b9b7d20801" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"/>
  <link:definitionLink xlink:role="http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail" xlink:type="extended" id="i40d1abfd27524032aea7a7e82b1edf13_NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_caf5b48f-5f14-4d02-85ba-aee79b85ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5d3b437-8064-472a-9793-90a4eb608ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_caf5b48f-5f14-4d02-85ba-aee79b85ff5e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5d3b437-8064-472a-9793-90a4eb608ae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2365033-4fb5-4573-82aa-284e8d29ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_caf5b48f-5f14-4d02-85ba-aee79b85ff5e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2365033-4fb5-4573-82aa-284e8d29ad6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2365033-4fb5-4573-82aa-284e8d29ad6b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_RedeemableConvertiblePreferredSharesMember_520693a5-be37-4669-8e5c-503e8db9140a" xlink:href="adr-20220930.xsd#adr_RedeemableConvertiblePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_RedeemableConvertiblePreferredSharesMember_520693a5-be37-4669-8e5c-503e8db9140a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0daa5f48-1f6c-4110-8314-52f593a709bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0daa5f48-1f6c-4110-8314-52f593a709bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_886da918-942a-4044-aad1-88bbd7cc5b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_us-gaap_RestrictedStockMember_886da918-942a-4044-aad1-88bbd7cc5b68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianOncologyIssuedToQedMember_0db8ab5d-d965-4f47-8da5-8cb3e04c92d0" xlink:href="adr-20220930.xsd#adr_WarrantsInLianOncologyIssuedToQedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_WarrantsInLianOncologyIssuedToQedMember_0db8ab5d-d965-4f47-8da5-8cb3e04c92d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember_5f3fec69-1094-46f8-89ae-38c9187c6678" xlink:href="adr-20220930.xsd#adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember_5f3fec69-1094-46f8-89ae-38c9187c6678" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember_da3345af-e50b-4047-8f59-ea9abe1fddb3" xlink:href="adr-20220930.xsd#adr_WarrantsInLianOphthalmologyIssuedToTarsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember_da3345af-e50b-4047-8f59-ea9abe1fddb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5b91e441-698c-447e-90e7-3f28957ea8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_us-gaap_WarrantMember_5b91e441-698c-447e-90e7-3f28957ea8d7" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://lian.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#SubsequentEventsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://lian.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="extended" id="i36a8808ec0ae44f8bf6027593c00345b_SubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ce651b71-7d65-42e3-bbb6-6020735178a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_d0d0a0ff-0ad0-44c9-bf64-e61e2a09938b" xlink:href="adr-20220930.xsd#adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ce651b71-7d65-42e3-bbb6-6020735178a5" xlink:to="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_d0d0a0ff-0ad0-44c9-bf64-e61e2a09938b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_ce651b71-7d65-42e3-bbb6-6020735178a5" xlink:to="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e932bd2c-8900-44c0-b441-02e7ebaf7675" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:to="loc_srt_CounterpartyNameAxis_e932bd2c-8900-44c0-b441-02e7ebaf7675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e932bd2c-8900-44c0-b441-02e7ebaf7675_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e932bd2c-8900-44c0-b441-02e7ebaf7675" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e932bd2c-8900-44c0-b441-02e7ebaf7675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77c3f0c-487e-4ed2-8691-758aa7ea1a90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e932bd2c-8900-44c0-b441-02e7ebaf7675" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77c3f0c-487e-4ed2-8691-758aa7ea1a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusPharmaceuticalsMember_f9e6f56e-3a4a-4765-a69e-b123a41c108d" xlink:href="adr-20220930.xsd#adr_TarsusPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77c3f0c-487e-4ed2-8691-758aa7ea1a90" xlink:to="loc_adr_TarsusPharmaceuticalsMember_f9e6f56e-3a4a-4765-a69e-b123a41c108d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_688df8d7-7590-4720-bbc8-dc1bb090039b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:to="loc_srt_StatementScenarioAxis_688df8d7-7590-4720-bbc8-dc1bb090039b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_688df8d7-7590-4720-bbc8-dc1bb090039b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_688df8d7-7590-4720-bbc8-dc1bb090039b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_688df8d7-7590-4720-bbc8-dc1bb090039b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2a550b20-75b8-42a3-aa8a-6849e0c2a1e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_688df8d7-7590-4720-bbc8-dc1bb090039b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2a550b20-75b8-42a3-aa8a-6849e0c2a1e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce140514-ed26-4a78-88ff-426188b10612" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2a550b20-75b8-42a3-aa8a-6849e0c2a1e8" xlink:to="loc_srt_ScenarioForecastMember_ce140514-ed26-4a78-88ff-426188b10612" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>adr-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:10012e6e-b07f-4a8a-83a8-17013968b0f9,g:3852927e-ec92-4d9e-bc45-8785d7c9d0c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_68fb50d3-71a1-44d9-b3de-7f431cabedf4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f9bf8d9b-ad6b-4a7c-bc4e-1f241cf0c9ed_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_MilestoneStageAxis_3cb33277-aefe-4e12-90b1-ea1bb6d088f4_terseLabel_en-US" xlink:label="lab_adr_MilestoneStageAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Stage [Axis]</link:label>
    <link:label id="lab_adr_MilestoneStageAxis_label_en-US" xlink:label="lab_adr_MilestoneStageAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Stage [Axis]</link:label>
    <link:label id="lab_adr_MilestoneStageAxis_documentation_en-US" xlink:label="lab_adr_MilestoneStageAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone stage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageAxis" xlink:href="adr-20220930.xsd#adr_MilestoneStageAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_MilestoneStageAxis" xlink:to="lab_adr_MilestoneStageAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_c0528d0e-41da-4498-b72c-eb625b7806d5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TwoThousandAndTwentyOnePlanMember_ecccb691-7d7d-4d49-be29-247acfd4d843_terseLabel_en-US" xlink:label="lab_adr_TwoThousandAndTwentyOnePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_adr_TwoThousandAndTwentyOnePlanMember_label_en-US" xlink:label="lab_adr_TwoThousandAndTwentyOnePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand And Twenty One Plan [Member]</link:label>
    <link:label id="lab_adr_TwoThousandAndTwentyOnePlanMember_documentation_en-US" xlink:label="lab_adr_TwoThousandAndTwentyOnePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and Twenty One Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TwoThousandAndTwentyOnePlanMember" xlink:href="adr-20220930.xsd#adr_TwoThousandAndTwentyOnePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TwoThousandAndTwentyOnePlanMember" xlink:to="lab_adr_TwoThousandAndTwentyOnePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c79b481f-50b0-4f11-9f19-fa11e5975fb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TypeOfMilestoneAxis_4e7ec9a0-843d-4291-9e51-9cb81c7a8751_terseLabel_en-US" xlink:label="lab_adr_TypeOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Milestone [Axis]</link:label>
    <link:label id="lab_adr_TypeOfMilestoneAxis_label_en-US" xlink:label="lab_adr_TypeOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Milestone [Axis]</link:label>
    <link:label id="lab_adr_TypeOfMilestoneAxis_documentation_en-US" xlink:label="lab_adr_TypeOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TypeOfMilestoneAxis" xlink:href="adr-20220930.xsd#adr_TypeOfMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TypeOfMilestoneAxis" xlink:to="lab_adr_TypeOfMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a87c0ce0-a3b5-4077-8622-095c726bcbfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AdrMember_54a59215-da2a-4906-8440-035c9e1e0ad0_terseLabel_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADR</link:label>
    <link:label id="lab_dei_AdrMember_label_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AdrMember" xlink:to="lab_dei_AdrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_84f48659-dc14-4cea-b2b9-f7c436fa1d3b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df16f054-cd5b-47a0-a406-c47ffecbdf79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_85256490-663f-4574-8e4a-1da0ecc4bf96_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9c9760ef-2403-4c96-bf88-6d58b286785b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_22c8a3dc-f455-4736-aef7-bd66b8195c3a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to ordinary shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsLineItems_9b318f0f-dd6a-4270-b3b4-aa7adfd39b39_terseLabel_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Other Related Agreements [Line Items]</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsLineItems_label_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Other Related Agreements [Line Items]</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsLineItems_documentation_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other related agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsLineItems" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems" xlink:to="lab_adr_LicenseAndOtherRelatedAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fbfa5c8e-bda0-40ad-965a-df6bd01cbfda_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_AmendedLicensingAgreementMember_8f577374-92e9-405c-8930-4f21daf796b3_terseLabel_en-US" xlink:label="lab_adr_AmendedLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Licensing Agreement</link:label>
    <link:label id="lab_adr_AmendedLicensingAgreementMember_label_en-US" xlink:label="lab_adr_AmendedLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Licensing Agreement [Member]</link:label>
    <link:label id="lab_adr_AmendedLicensingAgreementMember_documentation_en-US" xlink:label="lab_adr_AmendedLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AmendedLicensingAgreementMember" xlink:href="adr-20220930.xsd#adr_AmendedLicensingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_AmendedLicensingAgreementMember" xlink:to="lab_adr_AmendedLicensingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ac4e67a2-5529-45ea-92aa-26a971b638cb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a8248f45-05f3-47f2-8284-50fc09244aae_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8eae0d14-0032-4bf8-8bc1-c71cc7b08ffd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_73ae76e4-aa5e-4823-b076-93faed2b0fd7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_eba2634a-3f47-46e5-8c01-eff60fad4758_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bca3bee6-b559-476e-8750-059469827f6d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_775fab7e-37a0-48f6-8487-fa7db45bf0ee_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f8bb10db-4216-4ebb-b437-bbc325a59853_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ebfe90ff-d1b2-4aeb-bafe-2ac76efc507f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_37687ac1-14e9-4f86-8db1-861adca5ec0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e7ca559e-ebe4-4311-90ce-5f6d27f2bbc0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_98aaf949-d718-4e2e-b6a6-0b456ce762fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6d7172ad-4220-4e7a-98c3-cf28ba830e67_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_NonCashOperatingLeaseExpenseBenefit_870621d8-2147-47d0-b3b7-7cca323edcc3_terseLabel_en-US" xlink:label="lab_adr_NonCashOperatingLeaseExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense (benefit)</link:label>
    <link:label id="lab_adr_NonCashOperatingLeaseExpenseBenefit_label_en-US" xlink:label="lab_adr_NonCashOperatingLeaseExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Operating Lease Expense (Benefit)</link:label>
    <link:label id="lab_adr_NonCashOperatingLeaseExpenseBenefit_documentation_en-US" xlink:label="lab_adr_NonCashOperatingLeaseExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash&#160;operating lease expense (benefit).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonCashOperatingLeaseExpenseBenefit" xlink:href="adr-20220930.xsd#adr_NonCashOperatingLeaseExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_NonCashOperatingLeaseExpenseBenefit" xlink:to="lab_adr_NonCashOperatingLeaseExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_9ea6744e-3963-43c8-9548-1c964c139b7c_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_753e484f-e136-415f-9c64-e6e8f5d9ad5c_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_75476c24-a3fa-4d6e-bf67-3a34638cb2d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_4e61e41c-fae4-4af0-bb23-225941fe3480_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2e7502c1-b034-4cb9-a00e-b51a840dddb9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TrancheTwoMember_ca07f3e4-7a41-4372-9270-4d73a40107f8_terseLabel_en-US" xlink:label="lab_adr_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_adr_TrancheTwoMember_label_en-US" xlink:label="lab_adr_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_adr_TrancheTwoMember_documentation_en-US" xlink:label="lab_adr_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheTwoMember" xlink:href="adr-20220930.xsd#adr_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TrancheTwoMember" xlink:to="lab_adr_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67eed996-d419-46b2-b0b2-c65e2e0a9ded_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_92ce6d98-c2c4-4de5-ab16-ea0d09e7915a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7712732f-2f25-43f1-9110-7e3e74eca816_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72687754-8226-49ce-b772-024b76ffd021_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_77d8d9bd-b261-4136-b5d3-cb7e2ad1d974_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2eb2a056-c6bd-4113-9f2a-8c81a2aebf4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_abc07d02-dda0-4744-ba05-0e84457d839d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e3c4b3d8-7cd4-41d0-91f7-483e7987b667_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05140481-cc21-48a0-a412-cc7279c1c576_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f60c3c43-61f6-4f1a-88a5-8cbaf0b706aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TrancheDomain_bbbfcc61-56ed-4180-ac60-4279026299b3_terseLabel_en-US" xlink:label="lab_adr_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche [Domain]</link:label>
    <link:label id="lab_adr_TrancheDomain_label_en-US" xlink:label="lab_adr_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche [Domain]</link:label>
    <link:label id="lab_adr_TrancheDomain_documentation_en-US" xlink:label="lab_adr_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheDomain" xlink:href="adr-20220930.xsd#adr_TrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TrancheDomain" xlink:to="lab_adr_TrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9cdfb06d-189f-4fec-b34a-021d5f597e92_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9107bd17-8e1e-4fee-8b7c-b900140bb4cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in withholding tax payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_80506b91-6bde-47c2-b8b6-205f2e4b2890_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_MyokardiaMember_f5b8055a-d5cb-4946-bc84-72cad2c8a1a8_terseLabel_en-US" xlink:label="lab_adr_MyokardiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myokardia</link:label>
    <link:label id="lab_adr_MyokardiaMember_label_en-US" xlink:label="lab_adr_MyokardiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myokardia [Member]</link:label>
    <link:label id="lab_adr_MyokardiaMember_documentation_en-US" xlink:label="lab_adr_MyokardiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myokardia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MyokardiaMember" xlink:href="adr-20220930.xsd#adr_MyokardiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_MyokardiaMember" xlink:to="lab_adr_MyokardiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_02f218f0-bfe9-4f70-9d80-47eb1a4e4673_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_92ed9eb2-58bb-4abc-b4e3-bad2f9ca57ca_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce29ba7f-3d9e-4b58-b6bb-b06192706299_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_143d4f72-0cba-4fbe-8a09-d2f08c7338e7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c611a835-8a36-4649-b3c2-44343bc9414f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_QedMember_da377d40-38a6-4804-93e5-90693b651a7a_terseLabel_en-US" xlink:label="lab_adr_QedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QED</link:label>
    <link:label id="lab_adr_QedMember_label_en-US" xlink:label="lab_adr_QedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QED [Member]</link:label>
    <link:label id="lab_adr_QedMember_documentation_en-US" xlink:label="lab_adr_QedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QED.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_QedMember" xlink:href="adr-20220930.xsd#adr_QedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_QedMember" xlink:to="lab_adr_QedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_23e1eed9-a5b5-4512-972a-8a8b126d4b66_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13305fb0-43f7-435d-a619-59fa86a41c95_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_96cb0480-ab96-4583-86f0-4302442c8d43_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f500e0ad-3bd3-4451-b48a-e94c7b6f2a78_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_88316cb5-eb2d-48b3-abe2-893a9fb95f98_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2952f8e-39d7-4370-835c-7b00d462e170_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_cd003609-81cb-497d-b645-1f6c656dc602_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_UpfrontPaymentReceivable_ec6784b8-c9dd-40c3-9e44-48aea5796d1a_terseLabel_en-US" xlink:label="lab_adr_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment receivable</link:label>
    <link:label id="lab_adr_UpfrontPaymentReceivable_label_en-US" xlink:label="lab_adr_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Receivable</link:label>
    <link:label id="lab_adr_UpfrontPaymentReceivable_documentation_en-US" xlink:label="lab_adr_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_UpfrontPaymentReceivable" xlink:href="adr-20220930.xsd#adr_UpfrontPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_UpfrontPaymentReceivable" xlink:to="lab_adr_UpfrontPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_ef2d5e9a-b962-4107-8860-7e42c4bc51d0_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_5fe4e8ae-ff10-4f86-9b7d-0fc661c6a6ba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_MilestoneStageDomain_4d07559e-00a7-44f3-809a-58f7e51664ff_terseLabel_en-US" xlink:label="lab_adr_MilestoneStageDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Stage [Domain]</link:label>
    <link:label id="lab_adr_MilestoneStageDomain_label_en-US" xlink:label="lab_adr_MilestoneStageDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Stage [Domain]</link:label>
    <link:label id="lab_adr_MilestoneStageDomain_documentation_en-US" xlink:label="lab_adr_MilestoneStageDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone stage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageDomain" xlink:href="adr-20220930.xsd#adr_MilestoneStageDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_MilestoneStageDomain" xlink:to="lab_adr_MilestoneStageDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e910120-e266-4c04-ab49-bb4f629157dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3018741b-c635-4979-a46a-21c86202d635_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average grant date fair value per stock option (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_ComputerEquipmentAndSoftwareMember_b4966467-447e-4fe2-8849-1449e4ebd371_terseLabel_en-US" xlink:label="lab_adr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_adr_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_adr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_adr_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_adr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ComputerEquipmentAndSoftwareMember" xlink:href="adr-20220930.xsd#adr_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_ComputerEquipmentAndSoftwareMember" xlink:to="lab_adr_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e465523e-2d3e-45ff-999a-970b377612aa_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_badc059b-b7c6-4c1a-a289-881823a165db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_736445e7-c8a2-47a3-9830-aaeba143c447_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in period under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_643f2cf8-a6d3-4452-bf90-525d63b13012_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_944ba455-df7a-4182-a754-ed2471e9ee4a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_CommitmentToContributeCapital_fa6e11cf-63a9-4c62-b216-d78047cf39f7_terseLabel_en-US" xlink:label="lab_adr_CommitmentToContributeCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to contribute capital</link:label>
    <link:label id="lab_adr_CommitmentToContributeCapital_label_en-US" xlink:label="lab_adr_CommitmentToContributeCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Contribute Capital</link:label>
    <link:label id="lab_adr_CommitmentToContributeCapital_documentation_en-US" xlink:label="lab_adr_CommitmentToContributeCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to contribute capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_CommitmentToContributeCapital" xlink:href="adr-20220930.xsd#adr_CommitmentToContributeCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_CommitmentToContributeCapital" xlink:to="lab_adr_CommitmentToContributeCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b90c07b5-2228-4099-ae92-19cdc8f1e94e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsTable_d9138dc0-922e-4b91-bd61-ce06a95e6474_terseLabel_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Other Related Agreements [Table]</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsTable_label_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Other Related Agreements [Table]</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsTable_documentation_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other related agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsTable" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable" xlink:to="lab_adr_LicenseAndOtherRelatedAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5e78b5a9-c6c8-4ef7-847b-c857b61ee4ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_87bf9643-56d9-47bd-98a3-4d001f0e16a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares_9bcb216e-b287-4f99-b6df-04473612fa6f_terseLabel_en-US" xlink:label="lab_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in shares available for issuance, percentage of outstanding shares</link:label>
    <link:label id="lab_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares_label_en-US" xlink:label="lab_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Available for Issuance, Percentage of Outstanding Shares</link:label>
    <link:label id="lab_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares_documentation_en-US" xlink:label="lab_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Available for Issuance, Percentage of Outstanding Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" xlink:href="adr-20220930.xsd#adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" xlink:to="lab_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_ecffb6c2-a4c9-4f80-bb17-be0478d46a2f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_fef11d12-f9fd-4730-94f6-3d47d3e8889a_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash&#8212;end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14200486-25f3-4d90-972a-a0b20d124dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_9789db87-e8f1-4cd1-91f7-6138acc6df82_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1bf96f66-4cb5-46fd-8c5d-409a31b7a67b_terseLabel_en-US" xlink:label="lab_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A Preferred Shares at $56.66, net of issuance costs (in shares)</link:label>
    <link:label id="lab_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="adr-20220930.xsd#adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_bbc1a204-e160-48a6-b28e-e8aaee47d472_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ed074278-98fc-4db7-8c99-be7742a2a09d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0cb02aa7-89aa-4089-9320-f007f77f7a51_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_08d9136e-1f1d-4230-8094-1944b6b56792_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_726996ca-8189-427c-86d0-423592d24661_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_e96f9412-8027-4a88-8bb7-842f9b643834_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7b22b9e8-2083-48ea-999d-c2d613bf031a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a554a8c2-7aa0-4aee-b0ad-55257255fa50_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_e76d3cff-1254-4300-95f6-5eddafda5441_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity_3989eb1d-57f4-4c70-9d0d-b3d727dc331e_terseLabel_en-US" xlink:label="lab_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants or rights issuable as a percentage of fully diluted equity</link:label>
    <link:label id="lab_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity_label_en-US" xlink:label="lab_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Or Rights Issuable As A Percentage Of Fully Diluted Equity</link:label>
    <link:label id="lab_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity_documentation_en-US" xlink:label="lab_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants or rights issuable as a percentage of fully diluted equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" xlink:href="adr-20220930.xsd#adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" xlink:to="lab_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_NavireMember_83b8e1ac-54ee-4839-8202-73fcfb1673f8_terseLabel_en-US" xlink:label="lab_adr_NavireMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Navire</link:label>
    <link:label id="lab_adr_NavireMember_label_en-US" xlink:label="lab_adr_NavireMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Navire [Member]</link:label>
    <link:label id="lab_adr_NavireMember_documentation_en-US" xlink:label="lab_adr_NavireMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Navire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NavireMember" xlink:href="adr-20220930.xsd#adr_NavireMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_NavireMember" xlink:to="lab_adr_NavireMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_d6c8a199-17fc-4ea6-8422-48f39c325b72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_78ba74e8-d15d-4bd6-b773-af7aae2a0bd0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_03012190-478e-4876-b167-a110c858fef7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember_6d90988e-5b58-4292-a079-e05b4659675e_terseLabel_en-US" xlink:label="lab_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Development Regulatory And Sales Based Milestone</link:label>
    <link:label id="lab_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember_label_en-US" xlink:label="lab_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Development Regulatory And Sales Based Milestone [Member]</link:label>
    <link:label id="lab_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified development regulatory and sales based milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" xlink:href="adr-20220930.xsd#adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" xlink:to="lab_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_SalesBasedMilestoneMember_2aa8e09b-452b-42eb-90e4-08a5778c2d65_terseLabel_en-US" xlink:label="lab_adr_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone</link:label>
    <link:label id="lab_adr_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_adr_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone [Member]</link:label>
    <link:label id="lab_adr_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_adr_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales based milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SalesBasedMilestoneMember" xlink:href="adr-20220930.xsd#adr_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_SalesBasedMilestoneMember" xlink:to="lab_adr_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efb97360-4424-4dfb-b492-f62295d7b99a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ebc21231-5a65-414f-95e7-fc36942b86a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a5bcefe8-b3df-4061-9514-c61dc265e39c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_WarrantsToPurchaseCommonStockMember_9445d13e-7200-4d2f-adf6-9b8c87d573bf_terseLabel_en-US" xlink:label="lab_adr_WarrantsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants To Purchase Common Stock</link:label>
    <link:label id="lab_adr_WarrantsToPurchaseCommonStockMember_label_en-US" xlink:label="lab_adr_WarrantsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants To Purchase Common Stock [Member]</link:label>
    <link:label id="lab_adr_WarrantsToPurchaseCommonStockMember_documentation_en-US" xlink:label="lab_adr_WarrantsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsToPurchaseCommonStockMember" xlink:href="adr-20220930.xsd#adr_WarrantsToPurchaseCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_WarrantsToPurchaseCommonStockMember" xlink:to="lab_adr_WarrantsToPurchaseCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PayableToRelatedPartyCurrentMember_14a6deb0-e0ba-4a66-ab19-5463cae487ca_terseLabel_en-US" xlink:label="lab_adr_PayableToRelatedPartyCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable To Related Party Current</link:label>
    <link:label id="lab_adr_PayableToRelatedPartyCurrentMember_label_en-US" xlink:label="lab_adr_PayableToRelatedPartyCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable To Related Party Current [Member]</link:label>
    <link:label id="lab_adr_PayableToRelatedPartyCurrentMember_documentation_en-US" xlink:label="lab_adr_PayableToRelatedPartyCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable to related party current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PayableToRelatedPartyCurrentMember" xlink:href="adr-20220930.xsd#adr_PayableToRelatedPartyCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PayableToRelatedPartyCurrentMember" xlink:to="lab_adr_PayableToRelatedPartyCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1238a5e5-5ed4-4676-8756-ea58b2e87954_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_4e85f30b-0426-4773-ac6b-b31664b5a1c3_terseLabel_en-US" xlink:label="lab_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More Than 12 Months</link:label>
    <link:label id="lab_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_label_en-US" xlink:label="lab_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One</link:label>
    <link:label id="lab_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_documentation_en-US" xlink:label="lab_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:href="adr-20220930.xsd#adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:to="lab_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_cb773c4d-1233-43a1-9b65-51f2a5d4eb12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_494a1b64-b1f1-4b11-9f2c-554732202031_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a4c78ff5-2dc3-4b7e-b26c-3721cce122d8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e6af4afb-edfe-4fa0-b413-3027671bb4b2_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fe5f52d0-68c6-4c11-8507-eec43c9c4307_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_47208aaf-cf25-4073-964e-3d33b7a59d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bdd48388-a50d-4545-b6e3-f3542a47b552_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Diluted and Basic Net Loss Per Ordinary Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c1d55821-67e6-4d99-8635-f2b81f7bf16c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_4042f83a-b911-4abf-9b90-f1e3d1fb2dad_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_558196f2-75b4-4749-891a-267aecfe41ce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_8be361c2-3521-4769-ac25-76ba22f313db_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_f5ef659a-ff0e-4648-9be8-4b35b0166396_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PaymentOfMilestoneAmount_309e13da-326f-4fcb-bf40-8745f476d41f_terseLabel_en-US" xlink:label="lab_adr_PaymentOfMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of milestone amount</link:label>
    <link:label id="lab_adr_PaymentOfMilestoneAmount_label_en-US" xlink:label="lab_adr_PaymentOfMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Milestone Amount</link:label>
    <link:label id="lab_adr_PaymentOfMilestoneAmount_documentation_en-US" xlink:label="lab_adr_PaymentOfMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of milestone amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentOfMilestoneAmount" xlink:href="adr-20220930.xsd#adr_PaymentOfMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PaymentOfMilestoneAmount" xlink:to="lab_adr_PaymentOfMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PfizerMember_690aebe6-accb-4c2d-96ed-c53d577ff00f_terseLabel_en-US" xlink:label="lab_adr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_adr_PfizerMember_label_en-US" xlink:label="lab_adr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_adr_PfizerMember_documentation_en-US" xlink:label="lab_adr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PfizerMember" xlink:href="adr-20220930.xsd#adr_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PfizerMember" xlink:to="lab_adr_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fd94fd22-982b-48ce-ae3f-13687834cb8c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_05a608ad-8bf1-44c0-8369-6e37708e5c9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ec51f979-a739-46ef-ba34-05b6a5c1c0f2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_NonrefundableResearchDeposit_4d2ad285-376d-4abf-8d19-c278c1d13638_terseLabel_en-US" xlink:label="lab_adr_NonrefundableResearchDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable research deposit</link:label>
    <link:label id="lab_adr_NonrefundableResearchDeposit_label_en-US" xlink:label="lab_adr_NonrefundableResearchDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Research Deposit</link:label>
    <link:label id="lab_adr_NonrefundableResearchDeposit_documentation_en-US" xlink:label="lab_adr_NonrefundableResearchDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable research deposit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonrefundableResearchDeposit" xlink:href="adr-20220930.xsd#adr_NonrefundableResearchDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_NonrefundableResearchDeposit" xlink:to="lab_adr_NonrefundableResearchDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_aa6ff02f-3382-45ee-9ce7-97c27892fbcb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_374af9a8-b268-47fc-9a05-9ce86dd1a436_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PrepaidRentAndSupplies_d2505f01-9d7b-49bc-903b-75c6bb987222_terseLabel_en-US" xlink:label="lab_adr_PrepaidRentAndSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance payments to suppliers and rent deposit</link:label>
    <link:label id="lab_adr_PrepaidRentAndSupplies_label_en-US" xlink:label="lab_adr_PrepaidRentAndSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent And Supplies</link:label>
    <link:label id="lab_adr_PrepaidRentAndSupplies_documentation_en-US" xlink:label="lab_adr_PrepaidRentAndSupplies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid rent and supplies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PrepaidRentAndSupplies" xlink:href="adr-20220930.xsd#adr_PrepaidRentAndSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PrepaidRentAndSupplies" xlink:to="lab_adr_PrepaidRentAndSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition_a504aea6-eb0f-4863-b93b-adbf1fe194e4_terseLabel_en-US" xlink:label="lab_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from related party</link:label>
    <link:label id="lab_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition_label_en-US" xlink:label="lab_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Due From Related Parties, Increase for Cost Recognition</link:label>
    <link:label id="lab_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition_documentation_en-US" xlink:label="lab_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Due From Related Parties, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition" xlink:href="adr-20220930.xsd#adr_APICDueFromRelatedPartiesIncreaseForCostRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition" xlink:to="lab_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d0f1b23c-e37b-406e-95fb-2e4ada431866_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_ImputedInterestOnMilestonePayment_c677847d-5f3e-4a4b-9a52-61cc0ed257a6_terseLabel_en-US" xlink:label="lab_adr_ImputedInterestOnMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest on milestone payment</link:label>
    <link:label id="lab_adr_ImputedInterestOnMilestonePayment_label_en-US" xlink:label="lab_adr_ImputedInterestOnMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed Interest On Milestone Payment</link:label>
    <link:label id="lab_adr_ImputedInterestOnMilestonePayment_documentation_en-US" xlink:label="lab_adr_ImputedInterestOnMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest on milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ImputedInterestOnMilestonePayment" xlink:href="adr-20220930.xsd#adr_ImputedInterestOnMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_ImputedInterestOnMilestonePayment" xlink:to="lab_adr_ImputedInterestOnMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_aa674aeb-a409-4556-ba76-81d93bae34b8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_33577890-4b7e-459a-bc14-2fe29ff1a45d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per ordinary share&#160;&#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2b78ffa3-7cbc-4b87-a8a5-81c9905d6925_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_e2436bda-b645-48b2-84d4-b985da3e3996_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8e094ab5-2be9-4b9b-919e-440bb61e98f3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa25828a-ffc3-48cb-8b9c-6b76ebee5aed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_WarrantsInLianOncologyIssuedToQedMember_cbe1fadf-3991-48a0-a8e2-d5256957ac38_terseLabel_en-US" xlink:label="lab_adr_WarrantsInLianOncologyIssuedToQedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QED Warrants</link:label>
    <link:label id="lab_adr_WarrantsInLianOncologyIssuedToQedMember_label_en-US" xlink:label="lab_adr_WarrantsInLianOncologyIssuedToQedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants in Lian Oncology issued to QED [Member]</link:label>
    <link:label id="lab_adr_WarrantsInLianOncologyIssuedToQedMember_documentation_en-US" xlink:label="lab_adr_WarrantsInLianOncologyIssuedToQedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants in Lian Oncology issued to QED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianOncologyIssuedToQedMember" xlink:href="adr-20220930.xsd#adr_WarrantsInLianOncologyIssuedToQedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_WarrantsInLianOncologyIssuedToQedMember" xlink:to="lab_adr_WarrantsInLianOncologyIssuedToQedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fdf2b596-a8bf-4815-8148-e3ef174ef31b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_ClassOfWarrantOrRightIssued_352d0365-64f6-4536-a4f0-780f8854c725_terseLabel_en-US" xlink:label="lab_adr_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued during period (in shares)</link:label>
    <link:label id="lab_adr_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_adr_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_adr_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_adr_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ClassOfWarrantOrRightIssued" xlink:href="adr-20220930.xsd#adr_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_ClassOfWarrantOrRightIssued" xlink:to="lab_adr_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b1c0fec0-2071-451f-a404-7a2dbaf00409_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_ccd8f5b9-ded7-4e96-9c54-25d814803b49_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and other receivables, net, current</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_383da2b2-94bf-4859-9c79-bd5e25d1ebee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TwoThousandAndNineteenPlanMember_abd5a2b5-0f10-4ffe-8d7d-d0588925fa3e_terseLabel_en-US" xlink:label="lab_adr_TwoThousandAndNineteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_adr_TwoThousandAndNineteenPlanMember_label_en-US" xlink:label="lab_adr_TwoThousandAndNineteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and Nineteen Plan [Member]</link:label>
    <link:label id="lab_adr_TwoThousandAndNineteenPlanMember_documentation_en-US" xlink:label="lab_adr_TwoThousandAndNineteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and Nineteen Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TwoThousandAndNineteenPlanMember" xlink:href="adr-20220930.xsd#adr_TwoThousandAndNineteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TwoThousandAndNineteenPlanMember" xlink:to="lab_adr_TwoThousandAndNineteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_a5715f0f-90c4-4915-aa12-be10f1a81030_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d3c7557b-8ba1-4bc9-8293-48aaab22cca5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_51b6d23a-2831-4a5f-8f55-fc489c82d707_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum availability of ordinary shares under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TrancheOneMember_4ab2a561-f031-4b20-b323-e79ae4a6c4ec_terseLabel_en-US" xlink:label="lab_adr_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_adr_TrancheOneMember_label_en-US" xlink:label="lab_adr_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_adr_TrancheOneMember_documentation_en-US" xlink:label="lab_adr_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheOneMember" xlink:href="adr-20220930.xsd#adr_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TrancheOneMember" xlink:to="lab_adr_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_aafa0142-80c8-43e7-bca7-ee949fbc45d3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_75bc079d-827b-4d63-99e1-471b77fd0d55_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9498a8cf-cf18-48a5-9ead-1aaf13175ffb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0d34e9c0-d264-4926-b23e-294784d1bf3f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6fc034d2-a10c-4bc1-b2e3-f92631a04a89_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c98c0150-326d-41a6-94d0-3e251226bcf0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per ordinary share&#160;&#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TypeOfMilestoneDomain_df0cd733-f370-4f07-816e-1b63c4ebc123_terseLabel_en-US" xlink:label="lab_adr_TypeOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Milestone [Domain]</link:label>
    <link:label id="lab_adr_TypeOfMilestoneDomain_label_en-US" xlink:label="lab_adr_TypeOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Milestone [Domain]</link:label>
    <link:label id="lab_adr_TypeOfMilestoneDomain_documentation_en-US" xlink:label="lab_adr_TypeOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TypeOfMilestoneDomain" xlink:href="adr-20220930.xsd#adr_TypeOfMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TypeOfMilestoneDomain" xlink:to="lab_adr_TypeOfMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock_e68c43c1-2dc4-4a72-9dc4-5b12eef650b3_terseLabel_en-US" xlink:label="lab_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense And Other Current Assets [Text Block]</link:label>
    <link:label id="lab_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock_documentation_en-US" xlink:label="lab_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:href="adr-20220930.xsd#adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:to="lab_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_da5d9fd5-2cc1-45de-b35b-2910a4d06123_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_ce20494d-27f3-426d-8976-6ef88c31c068_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_eb09c6b3-fdb8-43ad-a825-eed3771d7113_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_21d07e13-30ae-4d8e-9e91-a79cbfee152c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_LandosMember_cf5bbae7-450a-4cfa-aba8-96230b649653_terseLabel_en-US" xlink:label="lab_adr_LandosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landos</link:label>
    <link:label id="lab_adr_LandosMember_label_en-US" xlink:label="lab_adr_LandosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landos [Member]</link:label>
    <link:label id="lab_adr_LandosMember_documentation_en-US" xlink:label="lab_adr_LandosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landos.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LandosMember" xlink:href="adr-20220930.xsd#adr_LandosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_LandosMember" xlink:to="lab_adr_LandosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f06da853-db9c-45d3-9d94-296b67a8daf8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b2244eda-8960-4606-bda9-9f87124b4694_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fe6b86b5-f4d8-41a5-9a5e-dd150c813261_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6792b993-3069-4172-9ba6-0f6d7aab4ce0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d33677b8-b608-4c7f-a6fc-9b639e02487a_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency transaction gain, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_aafca78f-0edc-4eed-8260-645ab7f06726_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d03d2a10-05a6-4b5e-80e6-0dc139af36fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cf847fec-e2a9-486b-8fa8-bbd7cfe7d551_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_018f391b-0c7a-44c6-85c2-c0264ca1898d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_ClassOfWarrantOrRightNumberOfTranches_3e86cf21-1c4d-451e-a04f-126a654e0bfb_terseLabel_en-US" xlink:label="lab_adr_ClassOfWarrantOrRightNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_adr_ClassOfWarrantOrRightNumberOfTranches_label_en-US" xlink:label="lab_adr_ClassOfWarrantOrRightNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Tranches</link:label>
    <link:label id="lab_adr_ClassOfWarrantOrRightNumberOfTranches_documentation_en-US" xlink:label="lab_adr_ClassOfWarrantOrRightNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ClassOfWarrantOrRightNumberOfTranches" xlink:href="adr-20220930.xsd#adr_ClassOfWarrantOrRightNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_ClassOfWarrantOrRightNumberOfTranches" xlink:to="lab_adr_ClassOfWarrantOrRightNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d1e644b8-43db-41f3-a52a-265b3fd0002f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_5f4fb285-c21b-493b-ada9-c3a9469c3eef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9e7b1b9a-347b-4974-a711-55634e118145_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsAbstract_e515f982-7577-444e-8c15-d638d6221825_terseLabel_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Other Related Agreements [Abstract]</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsAbstract_label_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Other Related Agreements [Abstract]</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsAbstract_documentation_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other related agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsAbstract" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsAbstract" xlink:to="lab_adr_LicenseAndOtherRelatedAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_943766a9-abc0-4ecf-b35c-3cfea1284823_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_68f5ce85-9387-4e05-bad7-7a660dc9a39b_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_9127fda0-19fb-4ccf-8b2f-715afe155e22_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4daeef0d-f2b4-47f0-a170-4d24b38c12ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_0250c12f-eea4-4bd2-8a46-67f36be87135_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total LianBio Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_92681372-5122-4a1d-8ef2-c5a886e69904_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81810562-0c8a-44e2-856a-b6a8aaa2c23e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_57840ea2-889d-4631-8dae-fba1adffaeee_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance IPO</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_aa62c42f-fba2-4fef-be6a-41b55bfb4ff7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_202cf189-cfc2-4be4-b425-14514613c90b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_e58acb4e-e6d3-49f2-bed8-6f2fa1a4bd02_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_NonRefundableFinancingMilestonePaymentMember_00278ec3-b196-4eb3-b2f4-1b6aec161060_terseLabel_en-US" xlink:label="lab_adr_NonRefundableFinancingMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Financing Milestone Payment</link:label>
    <link:label id="lab_adr_NonRefundableFinancingMilestonePaymentMember_label_en-US" xlink:label="lab_adr_NonRefundableFinancingMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Financing Milestone Payment [Member]</link:label>
    <link:label id="lab_adr_NonRefundableFinancingMilestonePaymentMember_documentation_en-US" xlink:label="lab_adr_NonRefundableFinancingMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non refundable financing milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonRefundableFinancingMilestonePaymentMember" xlink:href="adr-20220930.xsd#adr_NonRefundableFinancingMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_NonRefundableFinancingMilestonePaymentMember" xlink:to="lab_adr_NonRefundableFinancingMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PerformanceConditionOnMarketValue_e530489e-3206-40ca-9108-8b6fda989ba1_terseLabel_en-US" xlink:label="lab_adr_PerformanceConditionOnMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance condition on market value</link:label>
    <link:label id="lab_adr_PerformanceConditionOnMarketValue_label_en-US" xlink:label="lab_adr_PerformanceConditionOnMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Condition On Market Value</link:label>
    <link:label id="lab_adr_PerformanceConditionOnMarketValue_documentation_en-US" xlink:label="lab_adr_PerformanceConditionOnMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance condition on market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PerformanceConditionOnMarketValue" xlink:href="adr-20220930.xsd#adr_PerformanceConditionOnMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PerformanceConditionOnMarketValue" xlink:to="lab_adr_PerformanceConditionOnMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b3138d28-34d8-492a-89d1-4089ce0854ed_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dacd50b-3725-4adf-a7ac-d626476b0e5e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a5e13689-e669-42be-9cf4-d9c2c31d52f5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6f53825e-c92b-42b1-abe7-8a70319589c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_36c5c58c-1958-4d22-b8b1-eacb0a678fae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_01c079a8-7059-472e-8bd4-8be773c9a3e1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c21929e5-84d8-462e-8a87-8b4c09274705_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_774da5b5-faf9-44a0-80dd-58a89ad39974_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_19149e2f-da50-4d3a-9565-7997f641e139_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a004247b-0d63-49cb-8c5d-e3cc0e3ee47b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_040eaa16-7cff-4a05-93e9-78ef5d690397_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3686b128-6db8-49b3-ad1c-47bd4e25c00a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_90f224d5-b3c5-4ee6-9f64-e9be51569258_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_DeferredOfferingCostsIncurredButNotYetPaid_27a1513e-7796-4a63-88fb-ea4b08dc4dd5_terseLabel_en-US" xlink:label="lab_adr_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs in accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_adr_DeferredOfferingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_adr_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_adr_DeferredOfferingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_adr_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs incurred but not yet paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_DeferredOfferingCostsIncurredButNotYetPaid" xlink:href="adr-20220930.xsd#adr_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_DeferredOfferingCostsIncurredButNotYetPaid" xlink:to="lab_adr_DeferredOfferingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bdae0518-98b6-4c1a-a09e-0a9e64742c8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_035cd473-927f-4123-977f-fda6989e952e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_26f0e93b-c06c-407f-a97a-f4cb68ab2a00_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_70087980-2dfc-4655-b287-753b5343d58c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember_dd298b5b-be78-4b34-b347-603bbb8efb59_terseLabel_en-US" xlink:label="lab_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tarsus Warrants</link:label>
    <link:label id="lab_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember_label_en-US" xlink:label="lab_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants in Lian Ophthalmology issued to Tarsus [Member]</link:label>
    <link:label id="lab_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember_documentation_en-US" xlink:label="lab_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants in Lian Ophthalmology issued to Tarsus [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember" xlink:href="adr-20220930.xsd#adr_WarrantsInLianOphthalmologyIssuedToTarsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember" xlink:to="lab_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_81da328d-0ad6-4e80-979f-c13123fb855b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b9ae44bd-beae-4b08-b6da-84043b413435_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d0bba889-6ad0-4a26-beaa-22c6f796f83e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e1226f88-b7cd-40f3-a671-230723433504_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_69f2e942-7b41-4b2e-be00-a46af2603ca8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b6ef67a0-a87a-4bce-b0a9-5ddda470d10a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c8875193-c999-483d-85d0-58ed7a62d5b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8740829a-0029-4b42-8b25-20fe9bf98548_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8c0b65b2-2827-4123-9ca7-e2e8976f8dd5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position greater than 12 months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_d4cdee13-85ca-4b96-a878-fc8298a94782_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrent" xlink:to="lab_us-gaap_DeferredCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_20310fa3-0d50-4c5c-879b-7f52ef705a2b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0aca086c-4e52-4777-a9a9-f567a3e24d62_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_a6947269-b13c-498a-befc-77504e4eb237_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5934e34d-e0df-4a15-8591-64163245aa6a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_82c3a997-7e7b-42cd-a1c7-d84a3c36e0a7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_2ca53366-a1fc-4b8d-977c-fafacdd1f770_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3ef1dd30-0a6f-43e9-8ae6-6c83f9214d86_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_AccruedConsultingAndContractedResearchCurrent_c0b3be27-c3df-4c68-8881-2c8439ac6c2a_terseLabel_en-US" xlink:label="lab_adr_AccruedConsultingAndContractedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and contracted research</link:label>
    <link:label id="lab_adr_AccruedConsultingAndContractedResearchCurrent_label_en-US" xlink:label="lab_adr_AccruedConsultingAndContractedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Consulting And Contracted Research Current</link:label>
    <link:label id="lab_adr_AccruedConsultingAndContractedResearchCurrent_documentation_en-US" xlink:label="lab_adr_AccruedConsultingAndContractedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Consulting And Contracted Research Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AccruedConsultingAndContractedResearchCurrent" xlink:href="adr-20220930.xsd#adr_AccruedConsultingAndContractedResearchCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_AccruedConsultingAndContractedResearchCurrent" xlink:to="lab_adr_AccruedConsultingAndContractedResearchCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_981f0c7d-7ef0-4e26-ac5e-01052f452872_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6cd35128-c00e-4b8f-8570-e4e4900f5c02_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government obligations &amp; agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement_3e3e58a2-fc74-4de1-83b8-70fd8b15772f_verboseLabel_en-US" xlink:label="lab_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment towards development amount in connection with license agreement</link:label>
    <link:label id="lab_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement_label_en-US" xlink:label="lab_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Towards Development Amount In Connection With License Agreement</link:label>
    <link:label id="lab_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement_documentation_en-US" xlink:label="lab_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Towards Development Amount In Connection With License Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" xlink:href="adr-20220930.xsd#adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" xlink:to="lab_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_d93eb3f2-961f-4003-a63b-9e04c397131d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e6525574-833e-4286-96b6-dc4a9b502b18_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c1b0404c-0cbe-4e87-a885-e511846615ff_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f59cde59-c3f9-4b91-b9bf-85bb969846c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_882ae826-b5f4-4d83-977b-338a4a1e89de_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b57e9561-4d18-4f46-9689-9fdbac5f48ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f8be1ad7-82ad-40de-83d2-94dc4ab7ea78_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_RedeemableConvertiblePreferredSharesMember_dbdc60ee-6cd0-4471-847d-6e81ff3ad2c8_verboseLabel_en-US" xlink:label="lab_adr_RedeemableConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Shares</link:label>
    <link:label id="lab_adr_RedeemableConvertiblePreferredSharesMember_label_en-US" xlink:label="lab_adr_RedeemableConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Shares [Member]</link:label>
    <link:label id="lab_adr_RedeemableConvertiblePreferredSharesMember_documentation_en-US" xlink:label="lab_adr_RedeemableConvertiblePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_RedeemableConvertiblePreferredSharesMember" xlink:href="adr-20220930.xsd#adr_RedeemableConvertiblePreferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_RedeemableConvertiblePreferredSharesMember" xlink:to="lab_adr_RedeemableConvertiblePreferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_55e9c539-5d5b-4c47-a448-8f887626acb1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d37a9108-c79d-49fc-ad04-c5d6b96a61a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_bea96524-1d64-4999-a3a2-998adb4f305e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f30e235f-5e63-40e2-bb7b-ed67e836245e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0656b066-c065-4a1d-bad6-61c57e932d3a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Unrealized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_657aae1f-70b8-449f-b03b-9bcdbf440522_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares upon initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fd22fba9-ad3b-45d9-85f7-bac8b48439b2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrants or rights exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_9b56b5d2-670d-4378-80b8-a1e3a150c6e3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs related to redeemable convertible preferred shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_LianOncologyMember_4df25893-71d0-414d-b387-93b9fcabf259_terseLabel_en-US" xlink:label="lab_adr_LianOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lian Oncology</link:label>
    <link:label id="lab_adr_LianOncologyMember_label_en-US" xlink:label="lab_adr_LianOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lian Oncology [Member]</link:label>
    <link:label id="lab_adr_LianOncologyMember_documentation_en-US" xlink:label="lab_adr_LianOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lian oncology.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LianOncologyMember" xlink:href="adr-20220930.xsd#adr_LianOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_LianOncologyMember" xlink:to="lab_adr_LianOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_70d6319e-93e3-456f-9484-c4fe13a0fbd1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD_a0a21097-b4b8-43c5-8841-658e1e3715e4_terseLabel_en-US" xlink:label="lab_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash share consideration, issued in acquisition of IPR&amp;D</link:label>
    <link:label id="lab_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD_label_en-US" xlink:label="lab_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Share Consideration Issued In Acquisition Of I P R And D</link:label>
    <link:label id="lab_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD_documentation_en-US" xlink:label="lab_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Share Consideration Issued in Acquisition of IPR&amp;D.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" xlink:href="adr-20220930.xsd#adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" xlink:to="lab_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b4620688-6020-4dbc-a470-9cd145c253f0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TarsusPharmaceuticalsMember_3f5be045-8ee3-4400-9fb3-a6ccbc926f03_terseLabel_en-US" xlink:label="lab_adr_TarsusPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tarsus Pharmaceuticals</link:label>
    <link:label id="lab_adr_TarsusPharmaceuticalsMember_label_en-US" xlink:label="lab_adr_TarsusPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tarsus Pharmaceuticals [Member]</link:label>
    <link:label id="lab_adr_TarsusPharmaceuticalsMember_documentation_en-US" xlink:label="lab_adr_TarsusPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tarsus pharmaceuticals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusPharmaceuticalsMember" xlink:href="adr-20220930.xsd#adr_TarsusPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TarsusPharmaceuticalsMember" xlink:to="lab_adr_TarsusPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_a3070746-2855-4145-8213-03187600ad30_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants in LianBio issued to QED and Tarsus</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7cefde0c-113e-4c7a-94b8-daba4e5c0477_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares, $0.000017100448 par value. 2,923,900,005 shares authorized as of September 30, 2022; 108,353,831 shares issued and outstanding as of September 30, 2022; 2,923,900,005 shares authorized as of December&#160;31, 2021; 107,275,458 shares issued and outstanding as of December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_8c982e61-99d3-4691-a402-813ae0ebe13a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrants or rights expiry period</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_98d607bb-8578-4c9f-ac85-4ee2a4c97b50_terseLabel_en-US" xlink:label="lab_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment towards upfront amount in connection with license agreement</link:label>
    <link:label id="lab_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_label_en-US" xlink:label="lab_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Towards Upfront Amount In Connection With License Agreement</link:label>
    <link:label id="lab_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_documentation_en-US" xlink:label="lab_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment towards upfront amount in connection with license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" xlink:href="adr-20220930.xsd#adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" xlink:to="lab_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b072fecb-cf8b-4b33-ba77-d685427ee9ec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition for unrecognized expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8bdd37c4-b714-4359-a79c-54eb6230d6e7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_8e49b2b4-a577-4a45-a5ff-7511e3038a63_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_33f3235d-4d19-4d53-84ec-aadfef4ce7da_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2d5b6982-d644-404a-927c-ba46aeca42b0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ac3fb1f4-fabf-4e29-a7c4-959e38137c3d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_44111ecb-69e6-4f7b-b035-c0aa4bc9299f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TrancheAxis_1233f8bf-1857-429e-95bd-1b0089b2ed5d_terseLabel_en-US" xlink:label="lab_adr_TrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche [Axis]</link:label>
    <link:label id="lab_adr_TrancheAxis_label_en-US" xlink:label="lab_adr_TrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche [Axis]</link:label>
    <link:label id="lab_adr_TrancheAxis_documentation_en-US" xlink:label="lab_adr_TrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheAxis" xlink:href="adr-20220930.xsd#adr_TrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TrancheAxis" xlink:to="lab_adr_TrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_LyraMember_db25602f-fbfd-4188-a358-2a7c6cbac491_terseLabel_en-US" xlink:label="lab_adr_LyraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyra</link:label>
    <link:label id="lab_adr_LyraMember_label_en-US" xlink:label="lab_adr_LyraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyra [Member]</link:label>
    <link:label id="lab_adr_LyraMember_documentation_en-US" xlink:label="lab_adr_LyraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lyra.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LyraMember" xlink:href="adr-20220930.xsd#adr_LyraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_LyraMember" xlink:to="lab_adr_LyraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6901111d-df70-44fb-b94e-91f988c54001_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_672dbf05-fa72-4a7a-b786-f64152116cb6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested restricted share units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_e553d2bd-ec60-42ee-a545-0fefe5a11b66_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_87ea3a19-f091-4d9f-8f09-d6fdb5d1886b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued in license agreement</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c2f08adf-0587-44e8-bfc9-18b149196c52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discounts on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c5b96bf5-727c-4a76-9a2b-87430369a634_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4f99fe42-2da0-4d53-9420-e5002c616123_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_072b44d4-2b6b-4d97-8aee-3805cd0bfe9d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_fa64586f-73f1-44b9-b810-ede0f0d6f136_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_de16c053-37be-407a-89cf-b4ab4ecd5af7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_14097323-3014-4405-85fe-04382e434276_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74e6a53e-4770-4fd0-bff0-cc173a4290fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, and restricted cash&#8212;beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6845b77a-6939-4f7b-8733-1e46bffde128_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, and restricted cash&#8212;ending of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ab4e61f-1abc-4cab-a60d-d66f4c9fc581_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, and restricted cash&#8212;ending of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_dc32d6ff-1928-4c2d-9b8f-dfa911ed3220_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_00d6ebe6-fd56-4c80-8e79-2a2fd065d50e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0a38a01a-7847-4d04-b664-91bd2ef57b1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0371eb8b-ab8b-48e7-aa51-3e34b0c67743_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_d2ab7b22-e6ef-489d-bdff-6d7c4210296e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_14521688-b4ee-472d-b9df-a2806ddbd525_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_84828436-51bf-4c8d-b81d-784b96aeccbb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f8ee1769-95df-42f5-b95a-bde63d6c3c6f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_94ad19dc-513f-4a3d-a72d-90eb87aec81e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f6c17baf-1343-4af5-9aa3-d6ba6d065ef8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e18004f-57ea-4518-974a-1b8d4fd76310_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5dc0d596-aea9-4e10-9bba-5028d9254d5d_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cd99672b-0a03-446f-be73-2989c1612f0a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04ecd4d2-6fcf-4aa6-9b18-2f33f900e351_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_80588648-7ff6-445c-99e7-a17353e9c904_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_d033063a-923a-443c-be67-17b6c5bad768_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding value</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fa3280c9-b69b-4e2e-b907-544ecf5d7b49_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f56163e7-95b1-4638-9728-fd1be136bce4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_312a37ed-3c36-465e-bc5a-d4e75c41fa8c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember_f472f079-ea91-45ed-a25c-38aa73e4b817_terseLabel_en-US" xlink:label="lab_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MyoKardia Warrant</link:label>
    <link:label id="lab_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember_label_en-US" xlink:label="lab_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants in Lian Cardiovascular issued to MyoKardia [Member]</link:label>
    <link:label id="lab_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember_documentation_en-US" xlink:label="lab_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants in Lian Cardiovascular issued to MyoKardia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember" xlink:href="adr-20220930.xsd#adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember" xlink:to="lab_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6d686c52-d113-4adf-a5e8-cb206e7e46bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_dcd2459d-e8fd-48f2-b146-0dd44b5567b4_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_d33296b6-7229-4751-87b0-09e171a99b72_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b457f7fd-7b1c-4520-9a39-b35582cb1cac_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_StockIssuedDuringPeriodSharesWarrantsExercised_04d4be49-c938-4688-8ef6-77153b046fc2_terseLabel_en-US" xlink:label="lab_adr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_adr_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_adr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_adr_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_adr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="adr-20220930.xsd#adr_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_adr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_fabe5425-d9b7-4945-9d11-9befcfb5e0a1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by each warrant or right (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_NanobiotixMember_39bd38fd-47c3-4f42-8f59-dc2ca26eeecf_terseLabel_en-US" xlink:label="lab_adr_NanobiotixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nanobiotix</link:label>
    <link:label id="lab_adr_NanobiotixMember_label_en-US" xlink:label="lab_adr_NanobiotixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nanobiotix [Member]</link:label>
    <link:label id="lab_adr_NanobiotixMember_documentation_en-US" xlink:label="lab_adr_NanobiotixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nanobiotix.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NanobiotixMember" xlink:href="adr-20220930.xsd#adr_NanobiotixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_NanobiotixMember" xlink:to="lab_adr_NanobiotixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_abdfbced-87c7-4d69-8d53-0939ccb3a653_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Share Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2472fe1b-aaec-4ed4-ae08-2fb295b9342f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fcd589eb-10fd-4db6-9e81-7d3eac6aa3a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_bac06702-852d-4080-b0f8-ebfcdff36a2f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_MilestonePaymentPayable_3ca1677c-752c-4fae-a853-ad812d8b2c05_terseLabel_en-US" xlink:label="lab_adr_MilestonePaymentPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment payable</link:label>
    <link:label id="lab_adr_MilestonePaymentPayable_label_en-US" xlink:label="lab_adr_MilestonePaymentPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Payable</link:label>
    <link:label id="lab_adr_MilestonePaymentPayable_documentation_en-US" xlink:label="lab_adr_MilestonePaymentPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestonePaymentPayable" xlink:href="adr-20220930.xsd#adr_MilestonePaymentPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_MilestonePaymentPayable" xlink:to="lab_adr_MilestonePaymentPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy_901659ec-5e89-4301-b050-42e363a378ca_terseLabel_en-US" xlink:label="lab_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement amount due towards costs incurred for the study</link:label>
    <link:label id="lab_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy_label_en-US" xlink:label="lab_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Amount Due Towards Costs Incurred For The Study</link:label>
    <link:label id="lab_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy_documentation_en-US" xlink:label="lab_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement amount due towards costs incurred for the study.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy" xlink:href="adr-20220930.xsd#adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy" xlink:to="lab_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_21a9e693-29b0-43ce-b81f-d0bef89eecab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0bbd7ada-f075-4a70-bf41-3b6b58396536_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d40d654d-5641-4ba2-bd1f-23e0cc0edf55_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position less than 12 months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3522b5f2-350c-4a16-84df-31781aea6ceb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_14c37075-480a-49db-a74f-baa882369bab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_23c3e175-c89a-4772-8717-9903d949177b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used for investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_2586eb78-2f43-432a-804e-07ea6e22b60b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04c62906-0866-44e2-a83a-8db18afad13d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b913da9-f255-4e25-b0c5-c0b2811e8897_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_8b46e4b7-af6a-4358-9c6e-34d6c1b462da_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_568d4059-2705-42aa-a9bd-574923bc6a2b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_008a59be-9143-4979-9262-73623053bf98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cfbf1b20-4637-4f52-9ef2-df1c936aea39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e0bb2227-8f39-416c-90cd-9ab5047fb444_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_38b48676-6438-4f2c-92e4-334a71bfa7fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6869b69c-987a-4416-8c94-a463d922c489_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e2b6af89-d3df-4a22-8596-187ceddbb3e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dc6782c1-4f57-4593-bafa-d6a6a1151345_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_AssetAcquisitionMilestoneAmount_2ae9b259-4bb7-4f23-b80b-20971f351c71_terseLabel_en-US" xlink:label="lab_adr_AssetAcquisitionMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, milestone, amount</link:label>
    <link:label id="lab_adr_AssetAcquisitionMilestoneAmount_label_en-US" xlink:label="lab_adr_AssetAcquisitionMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Milestone, Amount</link:label>
    <link:label id="lab_adr_AssetAcquisitionMilestoneAmount_documentation_en-US" xlink:label="lab_adr_AssetAcquisitionMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Milestone, Amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AssetAcquisitionMilestoneAmount" xlink:href="adr-20220930.xsd#adr_AssetAcquisitionMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_AssetAcquisitionMilestoneAmount" xlink:to="lab_adr_AssetAcquisitionMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_a9e373ce-b060-420f-a055-5de3031ade3b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A Preferred Shares at $56.66, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_bbb2ea06-f537-420b-b02f-14af1c530800_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_bb5d9fb1-e03d-4341-a1cb-641c9a76aa4a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_91181fec-ffd5-421b-8fdc-f8f488fd659c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a14a688f-2b4a-4ca8-930e-1e511a1cdaf8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_ad0edbb0-39df-4a05-849b-a211b243bd42_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_46eb2e19-187b-4022-8089-30682287e864_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8392ab92-0abb-4e9c-884f-fe104486d02c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6956a4ff-7f2c-4408-9b9a-2f32d16d7ffc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69515820-f6b5-43ca-a640-7ae1f7e9d71f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4132597a-ae01-49b8-a7e0-0bec6b3dbca3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3c5265f0-cf23-4c73-9ef0-3143870e47f6_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9cbe37f8-0d8e-4a9d-8999-8e5495f3d5df_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_fc0b1156-93f3-4366-afc2-509e8c93ff73_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_9ecd0627-0ff7-48d5-92cf-001942077409_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d42eae96-0761-41f5-b18d-740104bb5054_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_SpecifiedDevelopmentRegulatoryMilestoneMember_4957572a-ef3e-43d2-8ebe-9c9c8d29bc45_terseLabel_en-US" xlink:label="lab_adr_SpecifiedDevelopmentRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Development Regulatory Milestone</link:label>
    <link:label id="lab_adr_SpecifiedDevelopmentRegulatoryMilestoneMember_label_en-US" xlink:label="lab_adr_SpecifiedDevelopmentRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Development Regulatory Milestone [Member]</link:label>
    <link:label id="lab_adr_SpecifiedDevelopmentRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_adr_SpecifiedDevelopmentRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified development regulatory milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SpecifiedDevelopmentRegulatoryMilestoneMember" xlink:href="adr-20220930.xsd#adr_SpecifiedDevelopmentRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_SpecifiedDevelopmentRegulatoryMilestoneMember" xlink:to="lab_adr_SpecifiedDevelopmentRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_e18ed86f-8359-4193-ba5c-3f31fa820a87_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1176954d-393b-439b-bae6-1377d56d55e9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrants or rights number of securities covered by the warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_145ef655-d911-4034-833a-34d765a87418_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_699053a9-e3d9-4793-80b1-98010d64c790_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6185d896-7021-4482-89e1-d18bbaa42bb8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_MilestoneStageTwoMember_c391ed49-cef0-4254-ac9c-69b81f7dedc7_terseLabel_en-US" xlink:label="lab_adr_MilestoneStageTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Stage Two</link:label>
    <link:label id="lab_adr_MilestoneStageTwoMember_label_en-US" xlink:label="lab_adr_MilestoneStageTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Stage Two [Member]</link:label>
    <link:label id="lab_adr_MilestoneStageTwoMember_documentation_en-US" xlink:label="lab_adr_MilestoneStageTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone stage two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageTwoMember" xlink:href="adr-20220930.xsd#adr_MilestoneStageTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_MilestoneStageTwoMember" xlink:to="lab_adr_MilestoneStageTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ea11a17b-03a0-4c84-8970-0ebce00051ec_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_646149da-73a1-4876-bfd4-a76798f80463_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_93ad5ebb-ba57-4f44-95f8-9fa419725d35_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b0649b61-87b2-4ac7-b7c4-d8211c375dd2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_b4f658ce-1371-477c-8a4a-95996b2ae71a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2fe800fc-a935-4b76-9ec9-cd2d75329d76_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_7b178d8d-4e15-4825-9c09-19aed1a5454a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government obligations</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0aaea48-2e37-4dd6-9500-e1577c04b90e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9a3de584-0a7d-4735-b04a-141ed4c0abf5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_64f98bbf-6fa8-4f77-aafb-c9d52e24f9f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TieredRoyaltyAsAPercentageOfNetSales_4705ee26-d4c3-4672-9efa-3bc406b549b5_terseLabel_en-US" xlink:label="lab_adr_TieredRoyaltyAsAPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty as a percentage of net sales</link:label>
    <link:label id="lab_adr_TieredRoyaltyAsAPercentageOfNetSales_label_en-US" xlink:label="lab_adr_TieredRoyaltyAsAPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty As A Percentage Of Net Sales</link:label>
    <link:label id="lab_adr_TieredRoyaltyAsAPercentageOfNetSales_documentation_en-US" xlink:label="lab_adr_TieredRoyaltyAsAPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty as a percentage of net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TieredRoyaltyAsAPercentageOfNetSales" xlink:href="adr-20220930.xsd#adr_TieredRoyaltyAsAPercentageOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TieredRoyaltyAsAPercentageOfNetSales" xlink:to="lab_adr_TieredRoyaltyAsAPercentageOfNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_53cc37e8-c4a7-48c7-9a51-8ff08417b36d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in other receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dd1791a2-26fd-4425-a328-dacb8b38ddd3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_05881398-efe9-4914-8492-e51324cc2573_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cbac3c79-89e0-4aca-b531-a1252e8fd8e6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e5ea7268-e7d1-4aba-842d-81bd2d7c756b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TarsusWarrantsMember_f404027a-a79e-44f1-bf0e-d63f2700da31_terseLabel_en-US" xlink:label="lab_adr_TarsusWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tarsus Warrants</link:label>
    <link:label id="lab_adr_TarsusWarrantsMember_label_en-US" xlink:label="lab_adr_TarsusWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tarsus Warrants [Member]</link:label>
    <link:label id="lab_adr_TarsusWarrantsMember_documentation_en-US" xlink:label="lab_adr_TarsusWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tarsus Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusWarrantsMember" xlink:href="adr-20220930.xsd#adr_TarsusWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TarsusWarrantsMember" xlink:to="lab_adr_TarsusWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c27920c3-f9e2-4147-9f6a-1f61cc27999a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_863e76d7-1880-4aa1-b174-4fe0f14c4634_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_f08bd61f-89a4-4692-9691-e8b7b4371e10_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_94d1eec6-48ef-4802-88cd-1accf326e44e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_238a5c6f-56a9-4244-b8d3-8aabf1d47a8f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total LianBio shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_955bd933-2947-40d1-ad7c-1a6b7f64a60b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position less than 12 months, Unrealized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9304c1e3-91e1-4a0e-9449-9c6df6b4f5de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_SeriesARedeemableConvertiblePreferredStockMember_e74d9ea0-222a-46e8-a0be-8c6091faeee6_terseLabel_en-US" xlink:label="lab_adr_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_adr_SeriesARedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_adr_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_adr_SeriesARedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_adr_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A redeemable convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SeriesARedeemableConvertiblePreferredStockMember" xlink:href="adr-20220930.xsd#adr_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="lab_adr_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9f74aa55-248e-425d-bff1-b50bcd0a9ed6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_ReviralMember_2e756141-dae9-4804-be33-1a74b4aac6c3_terseLabel_en-US" xlink:label="lab_adr_ReviralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reviral</link:label>
    <link:label id="lab_adr_ReviralMember_label_en-US" xlink:label="lab_adr_ReviralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reviral [Member]</link:label>
    <link:label id="lab_adr_ReviralMember_documentation_en-US" xlink:label="lab_adr_ReviralMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reviral.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ReviralMember" xlink:href="adr-20220930.xsd#adr_ReviralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_ReviralMember" xlink:to="lab_adr_ReviralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_283f87ad-4f5e-4daa-80d5-9d97a659e091_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_efe4231a-c25f-4259-9e97-48432aa029a4_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e605cf7c-c1e5-4b31-875a-00d94cbb5ee0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsTextBlock_f0e95456-44f9-4ef1-b21f-79a9a30fc896_terseLabel_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Agreements</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsTextBlock_label_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Other Related Agreements [Text Block]</link:label>
    <link:label id="lab_adr_LicenseAndOtherRelatedAgreementsTextBlock_documentation_en-US" xlink:label="lab_adr_LicenseAndOtherRelatedAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other related agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsTextBlock" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTextBlock" xlink:to="lab_adr_LicenseAndOtherRelatedAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_13d4a5fb-7e85-48b2-aef3-889d26246c06_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6c83dccf-ac16-4dd2-958e-1bd054c098f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_c88343e7-c600-44d7-852a-40a57ef132e3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_TrancheThreeMember_da5f0c5c-9133-4555-b295-b53097364190_terseLabel_en-US" xlink:label="lab_adr_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_adr_TrancheThreeMember_label_en-US" xlink:label="lab_adr_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three [Member]</link:label>
    <link:label id="lab_adr_TrancheThreeMember_documentation_en-US" xlink:label="lab_adr_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheThreeMember" xlink:href="adr-20220930.xsd#adr_TrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_TrancheThreeMember" xlink:to="lab_adr_TrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a775d2f7-7fed-4e06-89fc-084b10f212d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position greater than 12 months, Unrealized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_adr_AssetAcquisitionNetSalesMilestone_ebfd3261-40db-4dd5-8ea8-f37dced4955c_terseLabel_en-US" xlink:label="lab_adr_AssetAcquisitionNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, net sales milestone</link:label>
    <link:label id="lab_adr_AssetAcquisitionNetSalesMilestone_label_en-US" xlink:label="lab_adr_AssetAcquisitionNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Sales Milestone</link:label>
    <link:label id="lab_adr_AssetAcquisitionNetSalesMilestone_documentation_en-US" xlink:label="lab_adr_AssetAcquisitionNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Sales Milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AssetAcquisitionNetSalesMilestone" xlink:href="adr-20220930.xsd#adr_AssetAcquisitionNetSalesMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adr_AssetAcquisitionNetSalesMilestone" xlink:to="lab_adr_AssetAcquisitionNetSalesMilestone" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>adr-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:10012e6e-b07f-4a8a-83a8-17013968b0f9,g:3852927e-ec92-4d9e-bc45-8785d7c9d0c5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lian.com/role/CoverPage" xlink:type="simple" xlink:href="adr-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://lian.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bda3adee-4ab8-4b84-935c-44d39a937ae4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_DocumentType_bda3adee-4ab8-4b84-935c-44d39a937ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0cae8ac0-e016-4dac-bbc7-5df4e28672a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_DocumentQuarterlyReport_0cae8ac0-e016-4dac-bbc7-5df4e28672a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4a2f6525-09eb-40fb-9cd9-4286119251d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_DocumentPeriodEndDate_4a2f6525-09eb-40fb-9cd9-4286119251d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_73ca6ba2-17c2-4c48-ac00-3c3d2c27c9ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_DocumentTransitionReport_73ca6ba2-17c2-4c48-ac00-3c3d2c27c9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_43ca6db7-c0bd-498a-a593-1d8bc79653b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityFileNumber_43ca6db7-c0bd-498a-a593-1d8bc79653b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a765e207-d648-43a7-a04b-01f573184845" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityRegistrantName_a765e207-d648-43a7-a04b-01f573184845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dbfefefc-ff99-4c69-a79e-5db58abb63a0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dbfefefc-ff99-4c69-a79e-5db58abb63a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_696933ac-f859-4d0f-94ae-1c7225ad9297" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityTaxIdentificationNumber_696933ac-f859-4d0f-94ae-1c7225ad9297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_132be727-a12b-4b5a-ad31-6a430a128a63" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityAddressAddressLine1_132be727-a12b-4b5a-ad31-6a430a128a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8299c7c5-fb41-4f35-a3ce-05f53efc1b66" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityAddressAddressLine2_8299c7c5-fb41-4f35-a3ce-05f53efc1b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c1e69d21-33ac-4c5a-b3a3-830a407c9789" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityAddressCityOrTown_c1e69d21-33ac-4c5a-b3a3-830a407c9789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_837540a4-4632-4043-9ef4-ae8b0546da33" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityAddressStateOrProvince_837540a4-4632-4043-9ef4-ae8b0546da33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_757a693d-5b52-4594-9954-f4895752abe2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityAddressPostalZipCode_757a693d-5b52-4594-9954-f4895752abe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5e25c418-4987-43ea-94ce-c8c8801d2ce1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_CityAreaCode_5e25c418-4987-43ea-94ce-c8c8801d2ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_292cc3bd-4d94-4ee6-91f6-acfc938bbe2c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_LocalPhoneNumber_292cc3bd-4d94-4ee6-91f6-acfc938bbe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_de7d48d9-78ca-4d47-92fb-e6c65db5e482" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_Security12bTitle_de7d48d9-78ca-4d47-92fb-e6c65db5e482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9492df17-2605-4ae6-addd-8484b639a9cb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_TradingSymbol_9492df17-2605-4ae6-addd-8484b639a9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7acda6fa-60e4-4fcc-a266-f69cbfb71623" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_SecurityExchangeName_7acda6fa-60e4-4fcc-a266-f69cbfb71623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_fff3fe6d-7634-4f59-b12e-c943fbe9df0d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityCurrentReportingStatus_fff3fe6d-7634-4f59-b12e-c943fbe9df0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_090dbed1-60d1-4a82-852a-4dcc0c62d80e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityInteractiveDataCurrent_090dbed1-60d1-4a82-852a-4dcc0c62d80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_79b63e53-036a-4924-8fa0-300fa8fa085e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityFilerCategory_79b63e53-036a-4924-8fa0-300fa8fa085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b79c574c-a287-451f-8a47-f423cd5b721b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntitySmallBusiness_b79c574c-a287-451f-8a47-f423cd5b721b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f0672193-4421-4c8b-86e7-125e0cad1819" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityEmergingGrowthCompany_f0672193-4421-4c8b-86e7-125e0cad1819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_77442d3a-798d-44fc-abf8-41f9485f6277" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityExTransitionPeriod_77442d3a-798d-44fc-abf8-41f9485f6277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_90b6f80f-62c3-42df-b48d-c3f235743395" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityShellCompany_90b6f80f-62c3-42df-b48d-c3f235743395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ac025680-a333-466c-bc87-6866863ac3d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ac025680-a333-466c-bc87-6866863ac3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e17e7ce3-68fe-4814-8e08-daf1d7558005" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_EntityCentralIndexKey_e17e7ce3-68fe-4814-8e08-daf1d7558005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bdb0ee14-3f96-4704-a1f8-dae6dad1d6a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_CurrentFiscalYearEndDate_bdb0ee14-3f96-4704-a1f8-dae6dad1d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d22b2f44-045b-4bc7-b40f-e2db63b4a5a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_DocumentFiscalYearFocus_d22b2f44-045b-4bc7-b40f-e2db63b4a5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_69e29dad-7b15-42d9-b2c9-4e139e8e036e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_69e29dad-7b15-42d9-b2c9-4e139e8e036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0e5a49cb-b615-4901-a915-9314ea2914bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a73cf8af-28d2-4d61-b832-b6debca77fa7" xlink:to="loc_dei_AmendmentFlag_0e5a49cb-b615-4901-a915-9314ea2914bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://lian.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_40963613-3515-4690-aaad-99a494f0ab03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_40963613-3515-4690-aaad-99a494f0ab03" xlink:to="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5537d269-72be-49cb-b757-aaf460c55e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5537d269-72be-49cb-b757-aaf460c55e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a7381e7-f622-4fc3-b7f3-f08c70582aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5537d269-72be-49cb-b757-aaf460c55e14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a7381e7-f622-4fc3-b7f3-f08c70582aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b69e8ff7-1ddd-4f3c-9b3d-5710574cd1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5537d269-72be-49cb-b757-aaf460c55e14" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b69e8ff7-1ddd-4f3c-9b3d-5710574cd1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a59e6788-cbe8-43e9-b4ac-0bd21fe6f52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5537d269-72be-49cb-b757-aaf460c55e14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a59e6788-cbe8-43e9-b4ac-0bd21fe6f52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_e0d6ea53-e168-46f8-8d93-f844db9b511f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5537d269-72be-49cb-b757-aaf460c55e14" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_e0d6ea53-e168-46f8-8d93-f844db9b511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_61e5582b-895b-469a-8211-32931e2f0fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5537d269-72be-49cb-b757-aaf460c55e14" xlink:to="loc_us-gaap_AssetsCurrent_61e5582b-895b-469a-8211-32931e2f0fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_54582f79-391a-41b8-af3d-040f1eed40ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_54582f79-391a-41b8-af3d-040f1eed40ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f6acb81d-731f-4fac-9e6e-7bba8a907799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f6acb81d-731f-4fac-9e6e-7bba8a907799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_62d29d7a-786c-446f-8716-c59366298d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_62d29d7a-786c-446f-8716-c59366298d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_20f0c41a-f322-4166-ba68-e76647234a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_20f0c41a-f322-4166-ba68-e76647234a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_62b7c5c0-0c8b-4381-b59c-5e64f47150d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9264ba47-99b3-45f8-b913-4b47eb29da98" xlink:to="loc_us-gaap_Assets_62b7c5c0-0c8b-4381-b59c-5e64f47150d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_40963613-3515-4690-aaad-99a494f0ab03" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_89174851-128f-4cfd-bc14-886934bf8e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_89174851-128f-4cfd-bc14-886934bf8e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_80b799c7-59ee-40c6-b4ae-daa6c1171c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_89174851-128f-4cfd-bc14-886934bf8e87" xlink:to="loc_us-gaap_AccountsPayableCurrent_80b799c7-59ee-40c6-b4ae-daa6c1171c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3df2ca92-5fed-4218-b559-9efb00edc4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_89174851-128f-4cfd-bc14-886934bf8e87" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3df2ca92-5fed-4218-b559-9efb00edc4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6302e59d-96ec-4072-84e0-e4e668131373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_89174851-128f-4cfd-bc14-886934bf8e87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6302e59d-96ec-4072-84e0-e4e668131373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4a79c8e2-2cb3-4729-9c54-81ed6de211d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_89174851-128f-4cfd-bc14-886934bf8e87" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4a79c8e2-2cb3-4729-9c54-81ed6de211d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c08df1cc-40f0-4b92-a7aa-6b8c2943ed66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_89174851-128f-4cfd-bc14-886934bf8e87" xlink:to="loc_us-gaap_LiabilitiesCurrent_c08df1cc-40f0-4b92-a7aa-6b8c2943ed66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d7586497-b1b0-4f46-bd62-320e95e7b74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d7586497-b1b0-4f46-bd62-320e95e7b74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b338a2a9-b82c-4422-b872-07db81e3c732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b338a2a9-b82c-4422-b872-07db81e3c732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonrefundableResearchDeposit_4c1d7484-3b36-40ca-9a9e-111b84ca98e6" xlink:href="adr-20220930.xsd#adr_NonrefundableResearchDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_adr_NonrefundableResearchDeposit_4c1d7484-3b36-40ca-9a9e-111b84ca98e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2da2657e-8f9e-4278-a8fd-1302847f2a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_us-gaap_Liabilities_2da2657e-8f9e-4278-a8fd-1302847f2a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b1770f1d-169d-4b3c-8855-743c65f7022b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b1770f1d-169d-4b3c-8855-743c65f7022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0e122944-f217-4958-93c1-75ed04b94eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:to="loc_us-gaap_CommonStockValue_0e122944-f217-4958-93c1-75ed04b94eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_97e6085d-3ee7-4555-bf62-1c2045a545fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_97e6085d-3ee7-4555-bf62-1c2045a545fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d1b0080-65b7-4998-94a1-58f6477641b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d1b0080-65b7-4998-94a1-58f6477641b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3344883b-e922-40c6-8944-6bc8fbc303de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3344883b-e922-40c6-8944-6bc8fbc303de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bef9c9d0-155a-4c53-a846-167b1261d348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:to="loc_us-gaap_StockholdersEquity_bef9c9d0-155a-4c53-a846-167b1261d348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9a4abad3-ceee-4505-ab00-327fa0664ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:to="loc_us-gaap_MinorityInterest_9a4abad3-ceee-4505-ab00-327fa0664ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25b0b9ac-d23f-463a-919c-7fc8f1e28334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_063b87e3-759d-4bd9-95d4-266dc7dca805" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25b0b9ac-d23f-463a-919c-7fc8f1e28334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f91ffc98-67fd-4fe6-8ae7-bbcf0851be1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93315873-663f-4360-9010-11afe5c1095a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f91ffc98-67fd-4fe6-8ae7-bbcf0851be1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://lian.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0323d1-b078-4d39-b9a3-93bec73ab3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_881ddfd6-4eb5-4fc4-a83b-08a144e279d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0323d1-b078-4d39-b9a3-93bec73ab3ac" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_881ddfd6-4eb5-4fc4-a83b-08a144e279d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_36395d81-1057-4f7a-b98a-bd1b147deaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0323d1-b078-4d39-b9a3-93bec73ab3ac" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_36395d81-1057-4f7a-b98a-bd1b147deaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b0f72e24-af2a-42b6-bc17-e4bf4ab183c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0323d1-b078-4d39-b9a3-93bec73ab3ac" xlink:to="loc_us-gaap_CommonStockSharesIssued_b0f72e24-af2a-42b6-bc17-e4bf4ab183c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f0e6a594-2abb-487c-b096-1af15f871691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0323d1-b078-4d39-b9a3-93bec73ab3ac" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f0e6a594-2abb-487c-b096-1af15f871691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ac53e3f1-0c65-4c74-b7c2-3359559653f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ac53e3f1-0c65-4c74-b7c2-3359559653f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4dce6032-76b9-4251-b3ee-b35e067121a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac53e3f1-0c65-4c74-b7c2-3359559653f9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4dce6032-76b9-4251-b3ee-b35e067121a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b5d9f462-e2a0-469f-8c5d-e94310cf0599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac53e3f1-0c65-4c74-b7c2-3359559653f9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b5d9f462-e2a0-469f-8c5d-e94310cf0599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2fe9bd32-5342-4c5f-bb32-a5a84d303151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac53e3f1-0c65-4c74-b7c2-3359559653f9" xlink:to="loc_us-gaap_OperatingExpenses_2fe9bd32-5342-4c5f-bb32-a5a84d303151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4034822e-22ef-4370-85c4-3f495856244f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_OperatingIncomeLoss_4034822e-22ef-4370-85c4-3f495856244f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c3dadc17-19f8-4b74-89c8-d944b228c004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c3dadc17-19f8-4b74-89c8-d944b228c004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_913a0e2e-640a-457e-af7b-271cdbbd0e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c3dadc17-19f8-4b74-89c8-d944b228c004" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_913a0e2e-640a-457e-af7b-271cdbbd0e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c8dd9c8f-fe57-494d-8527-17d5e1043209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c3dadc17-19f8-4b74-89c8-d944b228c004" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c8dd9c8f-fe57-494d-8527-17d5e1043209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f4d879b9-2f97-4c65-b4b2-3f68c64652b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c3dadc17-19f8-4b74-89c8-d944b228c004" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f4d879b9-2f97-4c65-b4b2-3f68c64652b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78504583-e2a1-46e5-a7fc-93a32ba39a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c3dadc17-19f8-4b74-89c8-d944b228c004" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78504583-e2a1-46e5-a7fc-93a32ba39a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0857da5b-48f5-4c75-b355-c9fbd7831c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_NetIncomeLoss_0857da5b-48f5-4c75-b355-c9fbd7831c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_209e5a5e-3e5e-4f3c-bcc9-70f09f230ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_209e5a5e-3e5e-4f3c-bcc9-70f09f230ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2c556213-0e3c-4afe-bf0d-f63d66186f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_209e5a5e-3e5e-4f3c-bcc9-70f09f230ba0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2c556213-0e3c-4afe-bf0d-f63d66186f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b437a7c2-8d0b-45e9-9b04-2b1cada22e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_209e5a5e-3e5e-4f3c-bcc9-70f09f230ba0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b437a7c2-8d0b-45e9-9b04-2b1cada22e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1b7a59e7-cc3f-436c-ae31-24b61fc52642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_209e5a5e-3e5e-4f3c-bcc9-70f09f230ba0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1b7a59e7-cc3f-436c-ae31-24b61fc52642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_83a238fc-f766-4d44-aa96-03e295ca590c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_EarningsPerShareBasic_83a238fc-f766-4d44-aa96-03e295ca590c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2eaa9ffc-8b2f-4e20-a683-6ad939109adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2eaa9ffc-8b2f-4e20-a683-6ad939109adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f3b3a2f-6880-4bd7-848e-e007e1429359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f3b3a2f-6880-4bd7-848e-e007e1429359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70873ed7-cdf4-4035-972c-0e2a208dcc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d84be75f-93a1-4bb7-8347-c74d709fac57" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70873ed7-cdf4-4035-972c-0e2a208dcc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d0fee4e3-e6ab-4cbf-afd8-9c404be515d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_58935968-c307-4c37-a2b7-48b9399eb648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d0fee4e3-e6ab-4cbf-afd8-9c404be515d4" xlink:to="loc_us-gaap_StatementTable_58935968-c307-4c37-a2b7-48b9399eb648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_58935968-c307-4c37-a2b7-48b9399eb648" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56593d28-d3c4-4ae0-bb6a-5ab76fe90f46" xlink:to="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:to="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e97e7a9c-9e96-4093-aa9b-f6eb3c65f85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_CommonStockMember_e97e7a9c-9e96-4093-aa9b-f6eb3c65f85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dbab94ad-407a-433f-ada8-e93e9849e1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dbab94ad-407a-433f-ada8-e93e9849e1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d3d7f32-f35b-4e51-9106-e8d2938c8504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d3d7f32-f35b-4e51-9106-e8d2938c8504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_96c05a5a-3b65-4777-80cf-2933aad6608a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_865c9ac0-32d0-4b6e-ae49-a873abb37536" xlink:to="loc_us-gaap_RetainedEarningsMember_96c05a5a-3b65-4777-80cf-2933aad6608a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ebd90424-4a4b-4e80-b69a-d5ecee3c413d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9510881e-3515-45df-add3-2e4bf3965689" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ebd90424-4a4b-4e80-b69a-d5ecee3c413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_58935968-c307-4c37-a2b7-48b9399eb648" xlink:to="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_86b116d7-7acb-4f55-9263-46059ce82daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_86b116d7-7acb-4f55-9263-46059ce82daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_72ebed48-c6ba-4f74-9f96-7960ba3443c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_72ebed48-c6ba-4f74-9f96-7960ba3443c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c9f1618e-9f40-4e4b-abd1-11665ee49f65" xlink:href="adr-20220930.xsd#adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c9f1618e-9f40-4e4b-abd1-11665ee49f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ed4d9cee-b6bc-456e-a9aa-289b9f80c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ed4d9cee-b6bc-456e-a9aa-289b9f80c06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2d6cd83a-2361-42ae-8abf-77aaeb06094a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2d6cd83a-2361-42ae-8abf-77aaeb06094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ea3d662c-d697-4722-bf8a-b45bc6db978d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6756f318-7388-4883-8892-949446dadb8b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ea3d662c-d697-4722-bf8a-b45bc6db978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d50eb43-78f4-4090-9bd8-e1516b95b554" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1633c2b9-3833-45ff-b8ed-afb8887b293d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_SharesOutstanding_1633c2b9-3833-45ff-b8ed-afb8887b293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0863b271-8304-4cc2-b229-7e4c994563c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0863b271-8304-4cc2-b229-7e4c994563c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1b9c8cf-553a-44e1-832b-5dd42e808733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1b9c8cf-553a-44e1-832b-5dd42e808733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65561fb3-289d-4332-9712-c8097a34f221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65561fb3-289d-4332-9712-c8097a34f221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e4819241-d9ca-4694-914e-6496a8e9ec9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e4819241-d9ca-4694-914e-6496a8e9ec9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_StockIssuedDuringPeriodSharesWarrantsExercised_9ed21f0c-4ce9-4a09-b422-249c9c0b2689" xlink:href="adr-20220930.xsd#adr_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_adr_StockIssuedDuringPeriodSharesWarrantsExercised_9ed21f0c-4ce9-4a09-b422-249c9c0b2689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition_346fa9a7-fadd-40a5-b4ef-15f66c2d944f" xlink:href="adr-20220930.xsd#adr_APICDueFromRelatedPartiesIncreaseForCostRecognition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition_346fa9a7-fadd-40a5-b4ef-15f66c2d944f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4d1c16e7-d8c5-47f6-810f-27514c2a3b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4d1c16e7-d8c5-47f6-810f-27514c2a3b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21a641fb-0b9b-4a75-a6f4-a476d3b15c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_NetIncomeLoss_21a641fb-0b9b-4a75-a6f4-a476d3b15c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aac9dcb2-e0bf-45bb-8342-736bc19f08ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aac9dcb2-e0bf-45bb-8342-736bc19f08ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b486b39c-24ed-492d-a763-7d5912ed0d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_SharesOutstanding_b486b39c-24ed-492d-a763-7d5912ed0d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ab31f5b-eefa-4e5a-b9f8-f05da30d3037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e4ad0d5-17da-402e-8335-0834074ce462" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ab31f5b-eefa-4e5a-b9f8-f05da30d3037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a9e85d92-adae-4efb-9683-5d2420132c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0971324-b13d-4096-acfe-3ec0a7b147a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a9e85d92-adae-4efb-9683-5d2420132c42" xlink:to="loc_us-gaap_StatementTable_f0971324-b13d-4096-acfe-3ec0a7b147a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6f680bd0-9de3-465f-b257-b02c6ec3f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0971324-b13d-4096-acfe-3ec0a7b147a4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6f680bd0-9de3-465f-b257-b02c6ec3f1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b3e812ce-3698-46d0-85bc-66fc6aaac527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6f680bd0-9de3-465f-b257-b02c6ec3f1f1" xlink:to="loc_us-gaap_ClassOfStockDomain_b3e812ce-3698-46d0-85bc-66fc6aaac527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SeriesARedeemableConvertiblePreferredStockMember_55542bda-9618-41ae-9d62-dd44f0022814" xlink:href="adr-20220930.xsd#adr_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b3e812ce-3698-46d0-85bc-66fc6aaac527" xlink:to="loc_adr_SeriesARedeemableConvertiblePreferredStockMember_55542bda-9618-41ae-9d62-dd44f0022814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0096c15c-674c-43e7-a5db-69f69970ec5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0971324-b13d-4096-acfe-3ec0a7b147a4" xlink:to="loc_us-gaap_StatementLineItems_0096c15c-674c-43e7-a5db-69f69970ec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_fb93524f-b4bb-44c7-9213-16155559abcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0096c15c-674c-43e7-a5db-69f69970ec5b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_fb93524f-b4bb-44c7-9213-16155559abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="adr-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://lian.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ef091a09-98d9-47d6-8c65-70fa3361eb60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_NetIncomeLoss_ef091a09-98d9-47d6-8c65-70fa3361eb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD_1fad743b-e984-42b0-b193-5715e960bdb3" xlink:href="adr-20220930.xsd#adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:to="loc_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD_1fad743b-e984-42b0-b193-5715e960bdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonCashOperatingLeaseExpenseBenefit_8a083955-ed86-4ef4-9022-52fbb148c46d" xlink:href="adr-20220930.xsd#adr_NonCashOperatingLeaseExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:to="loc_adr_NonCashOperatingLeaseExpenseBenefit_8a083955-ed86-4ef4-9022-52fbb148c46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bbef48ee-2cb9-4f16-b637-ab378897a41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:to="loc_us-gaap_Depreciation_bbef48ee-2cb9-4f16-b637-ab378897a41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8512c778-b705-4562-8d36-66ac2f8b9f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:to="loc_us-gaap_ShareBasedCompensation_8512c778-b705-4562-8d36-66ac2f8b9f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6d9786bb-dd3b-4bb9-9398-f32d65a65069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6d9786bb-dd3b-4bb9-9398-f32d65a65069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dce2da21-5cac-41d0-bbb0-5e06b28bed50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9658d9b-0e4e-42b2-9847-4878f936816e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dce2da21-5cac-41d0-bbb0-5e06b28bed50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b7e82146-fdf1-4d88-b9d2-8c0744da9b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b7e82146-fdf1-4d88-b9d2-8c0744da9b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_eaeb01db-ac60-4c33-b254-78b7cffa36fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_eaeb01db-ac60-4c33-b254-78b7cffa36fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_79399056-db18-46cf-998e-9dbfc9f3c8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_79399056-db18-46cf-998e-9dbfc9f3c8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e778756e-e4ae-47ae-b9ed-cb89adfd7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e778756e-e4ae-47ae-b9ed-cb89adfd7e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_572fa6c3-f0c1-4dbd-acde-546c840f1f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_572fa6c3-f0c1-4dbd-acde-546c840f1f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_68d78db9-c185-44ff-88f2-7af426256cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_68d78db9-c185-44ff-88f2-7af426256cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9d19611a-1e8a-4464-97dd-326b84962913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9d19611a-1e8a-4464-97dd-326b84962913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a81ab814-eec3-46c3-be7a-eabff8e56993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cbe3a198-2b23-4bc8-8634-93f9f834a0f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a81ab814-eec3-46c3-be7a-eabff8e56993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e8a7ca34-6021-40ec-b0df-0cd60bb89525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e8a7ca34-6021-40ec-b0df-0cd60bb89525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_228262c4-e74e-4bd5-8584-baba38686b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e8a7ca34-6021-40ec-b0df-0cd60bb89525" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_228262c4-e74e-4bd5-8584-baba38686b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_edda9df4-c95f-40ab-af22-2833acb9d303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e8a7ca34-6021-40ec-b0df-0cd60bb89525" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_edda9df4-c95f-40ab-af22-2833acb9d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f3017e78-0e73-4f61-8d20-be3f70564380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e8a7ca34-6021-40ec-b0df-0cd60bb89525" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f3017e78-0e73-4f61-8d20-be3f70564380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cea33a88-324d-4e5b-b821-873dffd5e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e8a7ca34-6021-40ec-b0df-0cd60bb89525" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cea33a88-324d-4e5b-b821-873dffd5e9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42474ccf-d942-4dbd-b84f-0efeb421584b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42474ccf-d942-4dbd-b84f-0efeb421584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_31ba04ba-190f-4d6c-9aa9-7d00abb91695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42474ccf-d942-4dbd-b84f-0efeb421584b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_31ba04ba-190f-4d6c-9aa9-7d00abb91695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_e322ff04-8e35-443e-be85-da9f80a75547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42474ccf-d942-4dbd-b84f-0efeb421584b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_e322ff04-8e35-443e-be85-da9f80a75547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_dee41f35-af9f-46ab-9e66-95ee11039711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42474ccf-d942-4dbd-b84f-0efeb421584b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_dee41f35-af9f-46ab-9e66-95ee11039711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3aa54dcd-2777-4a8c-ad51-d7a7be822b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42474ccf-d942-4dbd-b84f-0efeb421584b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3aa54dcd-2777-4a8c-ad51-d7a7be822b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e573d567-6c1d-4e93-af1e-5992d435dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e573d567-6c1d-4e93-af1e-5992d435dc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c75dd9fe-f875-4aae-ba82-967d67f6904c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c75dd9fe-f875-4aae-ba82-967d67f6904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56c5a71f-29be-47b4-8bc9-a79a154ebef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56c5a71f-29be-47b4-8bc9-a79a154ebef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b802b5f-be73-4945-8000-e80c5db0939b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b802b5f-be73-4945-8000-e80c5db0939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75c14662-773d-4494-ac32-dc9d530efc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75c14662-773d-4494-ac32-dc9d530efc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b73af7fc-40c3-473d-8bbd-b43183e7ae68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b73af7fc-40c3-473d-8bbd-b43183e7ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c1fe0da7-c2e8-471a-90e4-56870a3f632f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c1fe0da7-c2e8-471a-90e4-56870a3f632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c322dc8a-fe21-4fea-af1f-4b9df13eeb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c322dc8a-fe21-4fea-af1f-4b9df13eeb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_2c5556e6-996a-42bc-a02f-39fed5887aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c322dc8a-fe21-4fea-af1f-4b9df13eeb44" xlink:to="loc_us-gaap_IncomeTaxesPaid_2c5556e6-996a-42bc-a02f-39fed5887aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e9cf4ed1-a202-4b6b-93bd-298ed4351332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e5d228f3-5af8-4632-ab8e-ae56ed87a6f0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e9cf4ed1-a202-4b6b-93bd-298ed4351332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f5649e4a-3fbf-4c36-9952-99a1386d7124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e9cf4ed1-a202-4b6b-93bd-298ed4351332" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f5649e4a-3fbf-4c36-9952-99a1386d7124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_DeferredOfferingCostsIncurredButNotYetPaid_7594b07d-5adf-45f9-897e-618024b8f3a0" xlink:href="adr-20220930.xsd#adr_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e9cf4ed1-a202-4b6b-93bd-298ed4351332" xlink:to="loc_adr_DeferredOfferingCostsIncurredButNotYetPaid_7594b07d-5adf-45f9-897e-618024b8f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6e842e82-1d0c-42f0-8c2f-424347f503ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e9cf4ed1-a202-4b6b-93bd-298ed4351332" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6e842e82-1d0c-42f0-8c2f-424347f503ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/NatureofBusiness" xlink:type="simple" xlink:href="adr-20220930.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://lian.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_357cb5e3-3458-466e-a630-9da6107c3855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_95545519-3151-48e9-bfad-49e9388ca9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_357cb5e3-3458-466e-a630-9da6107c3855" xlink:to="loc_us-gaap_NatureOfOperations_95545519-3151-48e9-bfad-49e9388ca9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="adr-20220930.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://lian.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9a2e533c-9894-4f52-ac12-602051ad9941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0b09b891-c41b-4b14-96f1-ef385ed4a7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a2e533c-9894-4f52-ac12-602051ad9941" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0b09b891-c41b-4b14-96f1-ef385ed4a7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MaterialAgreements" xlink:type="simple" xlink:href="adr-20220930.xsd#MaterialAgreements"/>
  <link:presentationLink xlink:role="http://lian.com/role/MaterialAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsAbstract_100285ad-73a2-4acf-a7a4-057226bd07f0" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsTextBlock_96c08eda-056d-4897-be44-8acb2f877727" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsAbstract_100285ad-73a2-4acf-a7a4-057226bd07f0" xlink:to="loc_adr_LicenseAndOtherRelatedAgreementsTextBlock_96c08eda-056d-4897-be44-8acb2f877727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_09fe021b-ab45-4f2c-870e-d20d09dbf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_dfce2a7b-ad11-49a8-8cee-594b769443e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_09fe021b-ab45-4f2c-870e-d20d09dbf16f" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_dfce2a7b-ad11-49a8-8cee-594b769443e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="adr-20220930.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://lian.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0fbe4f53-4cae-4855-a2b6-f640dc3f5286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c7f2c193-1dac-4600-8237-3dc6eb1a263f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0fbe4f53-4cae-4855-a2b6-f640dc3f5286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c7f2c193-1dac-4600-8237-3dc6eb1a263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/PrepaidExpenseandOtherCurrentAssets" xlink:type="simple" xlink:href="adr-20220930.xsd#PrepaidExpenseandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://lian.com/role/PrepaidExpenseandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_73b7c489-4714-42f7-a144-0c7c199d3fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock_bf19a7e3-082f-4f3c-8a5e-7a5ba78738f4" xlink:href="adr-20220930.xsd#adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_73b7c489-4714-42f7-a144-0c7c199d3fe8" xlink:to="loc_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock_bf19a7e3-082f-4f3c-8a5e-7a5ba78738f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/AccruedExpenses" xlink:type="simple" xlink:href="adr-20220930.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://lian.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ad6911a6-e0cd-4af8-83e2-b8f5ab4d133b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_61feddcb-2bab-428f-86be-f2958603ea85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_ad6911a6-e0cd-4af8-83e2-b8f5ab4d133b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_61feddcb-2bab-428f-86be-f2958603ea85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="adr-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://lian.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7be60ed1-2093-4239-84e7-d68be6ddf9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7ba7f850-0e20-42e9-87c2-26e987c827f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7be60ed1-2093-4239-84e7-d68be6ddf9ee" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7ba7f850-0e20-42e9-87c2-26e987c827f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="adr-20220930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://lian.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8f2396-b016-4350-9489-cb4fffffa03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_447f9610-09eb-45ff-b56f-cb0f3c84f67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8f2396-b016-4350-9489-cb4fffffa03a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_447f9610-09eb-45ff-b56f-cb0f3c84f67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/NetLossPerShare" xlink:type="simple" xlink:href="adr-20220930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://lian.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_78d5532b-b5d6-4064-b9ea-e94ead07a73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8614b69e-b6e4-475c-9778-00b4a25f33d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_78d5532b-b5d6-4064-b9ea-e94ead07a73a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8614b69e-b6e4-475c-9778-00b4a25f33d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/SubsequentEvents" xlink:type="simple" xlink:href="adr-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://lian.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_aab88e91-8c16-4f29-9c0c-5546ce019d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ca7522bb-0cce-4067-818e-10ab8f608104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_aab88e91-8c16-4f29-9c0c-5546ce019d70" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ca7522bb-0cce-4067-818e-10ab8f608104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adr-20220930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://lian.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d2d0eb27-3575-4b91-9b58-000e19ea483f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6d45e571-8790-4d20-b260-7b6879831eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d2d0eb27-3575-4b91-9b58-000e19ea483f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6d45e571-8790-4d20-b260-7b6879831eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a90c8f97-923e-4509-a2f4-cc1c2c50ec94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d2d0eb27-3575-4b91-9b58-000e19ea483f" xlink:to="loc_us-gaap_UseOfEstimates_a90c8f97-923e-4509-a2f4-cc1c2c50ec94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4e0e2865-f70b-458a-aba3-95f2a257cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d2d0eb27-3575-4b91-9b58-000e19ea483f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4e0e2865-f70b-458a-aba3-95f2a257cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9c1b7bae-15b7-4ec1-8ea5-dca09282ed38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d2d0eb27-3575-4b91-9b58-000e19ea483f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9c1b7bae-15b7-4ec1-8ea5-dca09282ed38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bce1b054-49bd-4fe6-97c0-c546c3d7ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_a9aa1cec-e46d-4bc0-8872-18c20d406d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bce1b054-49bd-4fe6-97c0-c546c3d7ce62" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_a9aa1cec-e46d-4bc0-8872-18c20d406d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5578b257-7959-4d7c-918b-e12657deb8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bce1b054-49bd-4fe6-97c0-c546c3d7ce62" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5578b257-7959-4d7c-918b-e12657deb8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8e20beac-8ea8-4949-8a4d-3f21e2707072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bce1b054-49bd-4fe6-97c0-c546c3d7ce62" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8e20beac-8ea8-4949-8a4d-3f21e2707072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="adr-20220930.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://lian.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b09e4fba-06cd-4058-9531-77ab4de48131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e364e526-cbb5-4ccd-87dd-d237bb1d1678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b09e4fba-06cd-4058-9531-77ab4de48131" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e364e526-cbb5-4ccd-87dd-d237bb1d1678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="adr-20220930.xsd#PrepaidExpenseandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_293b12d8-b9e6-4503-ab86-0c630c977a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_db4a3716-33a3-4a1c-99bf-7c00441751ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_293b12d8-b9e6-4503-ab86-0c630c977a07" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_db4a3716-33a3-4a1c-99bf-7c00441751ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="adr-20220930.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://lian.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_e49ae6bb-692a-46b0-9b36-a56b3c7ec0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ea54705d-5c95-4ae7-893f-f4fa765f17ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_e49ae6bb-692a-46b0-9b36-a56b3c7ec0f8" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ea54705d-5c95-4ae7-893f-f4fa765f17ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="adr-20220930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://lian.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ff728f2-66c2-4351-875f-1aae7ddbf226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8a3397d6-e08b-4164-851f-eb4017bcf983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ff728f2-66c2-4351-875f-1aae7ddbf226" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8a3397d6-e08b-4164-851f-eb4017bcf983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a30194d1-79cf-4ea2-9e5d-e40282238e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ff728f2-66c2-4351-875f-1aae7ddbf226" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a30194d1-79cf-4ea2-9e5d-e40282238e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/NatureofBusinessAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#NatureofBusinessAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/NatureofBusinessAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3d06571-5e2f-4222-b0c8-c240d4ed1bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3d06571-5e2f-4222-b0c8-c240d4ed1bce" xlink:to="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2e9f73ac-6317-47b0-b9a0-8c524cefb941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2e9f73ac-6317-47b0-b9a0-8c524cefb941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2e9f73ac-6317-47b0-b9a0-8c524cefb941" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_67fc3a83-e190-4704-9f25-11b64ae460f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:to="loc_us-gaap_IPOMember_67fc3a83-e190-4704-9f25-11b64ae460f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2bdb7cf2-0a12-4f46-8ca9-50b0751b1444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eb13b70-05ae-40b7-bdb4-fa6305781a11" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2bdb7cf2-0a12-4f46-8ca9-50b0751b1444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09b97e99-cc69-45e4-b03e-c78c315c09f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09b97e99-cc69-45e4-b03e-c78c315c09f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac277f88-baf4-458b-808a-2ee1da893879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09b97e99-cc69-45e4-b03e-c78c315c09f6" xlink:to="loc_us-gaap_ClassOfStockDomain_ac277f88-baf4-458b-808a-2ee1da893879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_a48b9e7c-7f03-4669-ae25-857be9d52549" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ac277f88-baf4-458b-808a-2ee1da893879" xlink:to="loc_dei_AdrMember_a48b9e7c-7f03-4669-ae25-857be9d52549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffba71d3-1e1f-40bd-891e-436da1bedb1b" xlink:to="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc194320-20e2-4e63-8e10-482224599f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc194320-20e2-4e63-8e10-482224599f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dc12bafb-6bae-4fc5-8eec-c33a1894e7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dc12bafb-6bae-4fc5-8eec-c33a1894e7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35bfb719-d0a4-4d13-830d-d523c9627223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35bfb719-d0a4-4d13-830d-d523c9627223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6c2f301-2be1-482f-b4c7-46e0d8449ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e6c2f301-2be1-482f-b4c7-46e0d8449ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5a680bfe-d32b-4f6b-8dcb-05671b4da17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5a680bfe-d32b-4f6b-8dcb-05671b4da17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_9a2a7d85-6ef8-4e0c-aea0-715eab2dc59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91f8f6ce-dc82-4099-80c8-a6acbaad794f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_9a2a7d85-6ef8-4e0c-aea0-715eab2dc59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#SignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_302443ad-36e5-4561-8d9b-f79933eda357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f2f9b22-eb53-419e-8db5-cf7c77e4183a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_302443ad-36e5-4561-8d9b-f79933eda357" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f2f9b22-eb53-419e-8db5-cf7c77e4183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_74a3b324-94ce-4ae6-9bf7-becd32fac68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_302443ad-36e5-4561-8d9b-f79933eda357" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_74a3b324-94ce-4ae6-9bf7-becd32fac68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MaterialAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#MaterialAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/MaterialAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsAbstract_67393cd4-011a-4b8e-99ed-6ac1847f49c2" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsAbstract_67393cd4-011a-4b8e-99ed-6ac1847f49c2" xlink:to="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_173f98b8-a4dd-47d3-8e04-aee40f85961b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_srt_CounterpartyNameAxis_173f98b8-a4dd-47d3-8e04-aee40f85961b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_173f98b8-a4dd-47d3-8e04-aee40f85961b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_QedMember_eb3be98e-a305-4baf-b637-121b4d9a5c57" xlink:href="adr-20220930.xsd#adr_QedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_QedMember_eb3be98e-a305-4baf-b637-121b4d9a5c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MyokardiaMember_b4349319-9065-466c-90af-5db7d8814116" xlink:href="adr-20220930.xsd#adr_MyokardiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_MyokardiaMember_b4349319-9065-466c-90af-5db7d8814116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PfizerMember_7778a04e-1868-41fc-a6fa-5b6ef6f56d1a" xlink:href="adr-20220930.xsd#adr_PfizerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_PfizerMember_7778a04e-1868-41fc-a6fa-5b6ef6f56d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ReviralMember_8e732de1-e8a8-4207-a405-042bb19818e0" xlink:href="adr-20220930.xsd#adr_ReviralMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_ReviralMember_8e732de1-e8a8-4207-a405-042bb19818e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusPharmaceuticalsMember_061b858c-2de3-47f9-9e3d-393784d0856a" xlink:href="adr-20220930.xsd#adr_TarsusPharmaceuticalsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_TarsusPharmaceuticalsMember_061b858c-2de3-47f9-9e3d-393784d0856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LandosMember_694eae30-8f6c-4875-b7e9-ae3b0a0a71eb" xlink:href="adr-20220930.xsd#adr_LandosMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_LandosMember_694eae30-8f6c-4875-b7e9-ae3b0a0a71eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NanobiotixMember_2cf71c75-9f91-45b9-a81b-57004b261ab2" xlink:href="adr-20220930.xsd#adr_NanobiotixMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_NanobiotixMember_2cf71c75-9f91-45b9-a81b-57004b261ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LyraMember_9888a23f-3539-4df5-b0b8-07b59bf7ffc8" xlink:href="adr-20220930.xsd#adr_LyraMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84dd5dc0-20c7-4db4-95f1-17256213f063" xlink:to="loc_adr_LyraMember_9888a23f-3539-4df5-b0b8-07b59bf7ffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_735a90b5-e059-4008-8c5a-62848e637c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_735a90b5-e059-4008-8c5a-62848e637c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_735a90b5-e059-4008-8c5a-62848e637c12" xlink:to="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LianOncologyMember_5dc71815-009d-4554-b3e4-55ce0391676c" xlink:href="adr-20220930.xsd#adr_LianOncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:to="loc_adr_LianOncologyMember_5dc71815-009d-4554-b3e4-55ce0391676c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NavireMember_5321d714-56e8-4ff3-b478-c535713a3649" xlink:href="adr-20220930.xsd#adr_NavireMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_567d7b3a-6bbe-4ca9-8ef9-e1d9f6027bad" xlink:to="loc_adr_NavireMember_5321d714-56e8-4ff3-b478-c535713a3649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_65873c29-a515-40cf-9e25-72231aff333c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_65873c29-a515-40cf-9e25-72231aff333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65873c29-a515-40cf-9e25-72231aff333c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsToPurchaseCommonStockMember_7439f7c5-1d45-4ec9-8636-48fa095b2b71" xlink:href="adr-20220930.xsd#adr_WarrantsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:to="loc_adr_WarrantsToPurchaseCommonStockMember_7439f7c5-1d45-4ec9-8636-48fa095b2b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusWarrantsMember_3b6a5618-57cb-49b0-ab23-1754b33d0c55" xlink:href="adr-20220930.xsd#adr_TarsusWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b3c9cfe6-35bb-4e13-83d7-262c6aa8147b" xlink:to="loc_adr_TarsusWarrantsMember_3b6a5618-57cb-49b0-ab23-1754b33d0c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TypeOfMilestoneAxis_7cfb254a-9feb-4d65-8f76-5550016cb82b" xlink:href="adr-20220930.xsd#adr_TypeOfMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_adr_TypeOfMilestoneAxis_7cfb254a-9feb-4d65-8f76-5550016cb82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:href="adr-20220930.xsd#adr_TypeOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TypeOfMilestoneAxis_7cfb254a-9feb-4d65-8f76-5550016cb82b" xlink:to="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SpecifiedDevelopmentRegulatoryMilestoneMember_c43890da-4c4f-4c7e-97e9-ca0c03bc2805" xlink:href="adr-20220930.xsd#adr_SpecifiedDevelopmentRegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_SpecifiedDevelopmentRegulatoryMilestoneMember_c43890da-4c4f-4c7e-97e9-ca0c03bc2805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SalesBasedMilestoneMember_ff3c149c-511d-4166-9e88-ec7cacc0ec48" xlink:href="adr-20220930.xsd#adr_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_SalesBasedMilestoneMember_ff3c149c-511d-4166-9e88-ec7cacc0ec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_NonRefundableFinancingMilestonePaymentMember_584ed73c-bb21-4838-9358-641279b597d7" xlink:href="adr-20220930.xsd#adr_NonRefundableFinancingMilestonePaymentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_NonRefundableFinancingMilestonePaymentMember_584ed73c-bb21-4838-9358-641279b597d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember_706b79dd-d33d-4711-91fc-6882fa98d57d" xlink:href="adr-20220930.xsd#adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TypeOfMilestoneDomain_8b80b32c-755f-47d3-a3b7-3e662e498aba" xlink:to="loc_adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember_706b79dd-d33d-4711-91fc-6882fa98d57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5344e8b2-f896-430d-84b8-e8bc1ee31dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5344e8b2-f896-430d-84b8-e8bc1ee31dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ffdbc1e8-918a-4f2b-9627-3bdc0f24e1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5344e8b2-f896-430d-84b8-e8bc1ee31dc1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ffdbc1e8-918a-4f2b-9627-3bdc0f24e1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PayableToRelatedPartyCurrentMember_ec91fcff-156a-4744-ab15-35504985e20e" xlink:href="adr-20220930.xsd#adr_PayableToRelatedPartyCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ffdbc1e8-918a-4f2b-9627-3bdc0f24e1be" xlink:to="loc_adr_PayableToRelatedPartyCurrentMember_ec91fcff-156a-4744-ab15-35504985e20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheAxis_b930f8ee-de0e-4536-93ba-9a0943a5a035" xlink:href="adr-20220930.xsd#adr_TrancheAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_adr_TrancheAxis_b930f8ee-de0e-4536-93ba-9a0943a5a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:href="adr-20220930.xsd#adr_TrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TrancheAxis_b930f8ee-de0e-4536-93ba-9a0943a5a035" xlink:to="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheOneMember_2f773b20-9ff1-4ff1-8396-45e725117b8d" xlink:href="adr-20220930.xsd#adr_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:to="loc_adr_TrancheOneMember_2f773b20-9ff1-4ff1-8396-45e725117b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheTwoMember_8a942d2b-abb2-4841-b09a-fca33b5caa7b" xlink:href="adr-20220930.xsd#adr_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:to="loc_adr_TrancheTwoMember_8a942d2b-abb2-4841-b09a-fca33b5caa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TrancheThreeMember_7afe9eac-3605-45e5-a872-2631254814bc" xlink:href="adr-20220930.xsd#adr_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_TrancheDomain_99948efa-4093-49ef-8d60-0d578957cdda" xlink:to="loc_adr_TrancheThreeMember_7afe9eac-3605-45e5-a872-2631254814bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f691109e-f92a-45e9-b022-0ff1f71ba83d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_srt_RangeAxis_f691109e-f92a-45e9-b022-0ff1f71ba83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f691109e-f92a-45e9-b022-0ff1f71ba83d" xlink:to="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e2475c5-d88f-4b01-b201-3cb712e0e7e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:to="loc_srt_MaximumMember_7e2475c5-d88f-4b01-b201-3cb712e0e7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf23b07-689e-4fb1-a96f-656a0ad1e7ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4721be9b-fe01-4ffd-b340-0d699e731081" xlink:to="loc_srt_MinimumMember_7cf23b07-689e-4fb1-a96f-656a0ad1e7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageAxis_833fb52d-8d1b-4c87-be7e-226abf9fd18c" xlink:href="adr-20220930.xsd#adr_MilestoneStageAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_adr_MilestoneStageAxis_833fb52d-8d1b-4c87-be7e-226abf9fd18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageDomain_0a2e560d-b1d3-47b2-bd06-4fd851c6546e" xlink:href="adr-20220930.xsd#adr_MilestoneStageDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_MilestoneStageAxis_833fb52d-8d1b-4c87-be7e-226abf9fd18c" xlink:to="loc_adr_MilestoneStageDomain_0a2e560d-b1d3-47b2-bd06-4fd851c6546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestoneStageTwoMember_64334ad2-4688-4652-97a9-aa9982aba9da" xlink:href="adr-20220930.xsd#adr_MilestoneStageTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_MilestoneStageDomain_0a2e560d-b1d3-47b2-bd06-4fd851c6546e" xlink:to="loc_adr_MilestoneStageTwoMember_64334ad2-4688-4652-97a9-aa9982aba9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_004a4e2a-0f21-4b90-ae32-e58a089e846b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_004a4e2a-0f21-4b90-ae32-e58a089e846b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6672991d-c3bf-4db2-9a01-7a956a515c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_004a4e2a-0f21-4b90-ae32-e58a089e846b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6672991d-c3bf-4db2-9a01-7a956a515c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AmendedLicensingAgreementMember_34101381-0d0c-49a8-8dce-5382ae76eae2" xlink:href="adr-20220930.xsd#adr_AmendedLicensingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6672991d-c3bf-4db2-9a01-7a956a515c92" xlink:to="loc_adr_AmendedLicensingAgreementMember_34101381-0d0c-49a8-8dce-5382ae76eae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:href="adr-20220930.xsd#adr_LicenseAndOtherRelatedAgreementsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsTable_9a9b80e1-8453-4cca-ae1f-1d6bf50537a5" xlink:to="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_340736f4-2f65-4148-bb5e-86abbed44e0e" xlink:href="adr-20220930.xsd#adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_340736f4-2f65-4148-bb5e-86abbed44e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e0a90c7-c343-4330-8d02-5504d22d41a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e0a90c7-c343-4330-8d02-5504d22d41a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_2b0063b1-8b14-412f-9cd7-7838b293ee46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_2b0063b1-8b14-412f-9cd7-7838b293ee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ClassOfWarrantOrRightNumberOfTranches_60068dc9-4d95-4f70-b544-f14429a6defb" xlink:href="adr-20220930.xsd#adr_ClassOfWarrantOrRightNumberOfTranches"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ClassOfWarrantOrRightNumberOfTranches_60068dc9-4d95-4f70-b544-f14429a6defb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity_98a391fd-24b7-4836-8763-a712f8f80cb6" xlink:href="adr-20220930.xsd#adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity_98a391fd-24b7-4836-8763-a712f8f80cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1c6aeee2-0454-4fac-8c25-4f6aee960ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1c6aeee2-0454-4fac-8c25-4f6aee960ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c11e80ac-b865-499a-8ac5-c2a8e16baf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c11e80ac-b865-499a-8ac5-c2a8e16baf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy_1ae40ee1-c753-4771-b1a4-d7db667d3a77" xlink:href="adr-20220930.xsd#adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy_1ae40ee1-c753-4771-b1a4-d7db667d3a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AssetAcquisitionMilestoneAmount_9271c1e2-4d83-4023-b91c-8e7763c229e5" xlink:href="adr-20220930.xsd#adr_AssetAcquisitionMilestoneAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_AssetAcquisitionMilestoneAmount_9271c1e2-4d83-4023-b91c-8e7763c229e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AssetAcquisitionNetSalesMilestone_283f991a-bbcb-4cce-b207-ed170bcc0018" xlink:href="adr-20220930.xsd#adr_AssetAcquisitionNetSalesMilestone"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_AssetAcquisitionNetSalesMilestone_283f991a-bbcb-4cce-b207-ed170bcc0018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_MilestonePaymentPayable_93736536-ae10-401d-9e2d-59521b18caac" xlink:href="adr-20220930.xsd#adr_MilestonePaymentPayable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_MilestonePaymentPayable_93736536-ae10-401d-9e2d-59521b18caac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentOfMilestoneAmount_664d68fa-3f2e-4b81-9c1e-2f96b9955527" xlink:href="adr-20220930.xsd#adr_PaymentOfMilestoneAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_PaymentOfMilestoneAmount_664d68fa-3f2e-4b81-9c1e-2f96b9955527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ImputedInterestOnMilestonePayment_757d1966-5f04-42ef-8d43-8d4dad73a42c" xlink:href="adr-20220930.xsd#adr_ImputedInterestOnMilestonePayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ImputedInterestOnMilestonePayment_757d1966-5f04-42ef-8d43-8d4dad73a42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TieredRoyaltyAsAPercentageOfNetSales_de1c3b55-6ebd-4ba7-974c-ba864a0db226" xlink:href="adr-20220930.xsd#adr_TieredRoyaltyAsAPercentageOfNetSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_TieredRoyaltyAsAPercentageOfNetSales_de1c3b55-6ebd-4ba7-974c-ba864a0db226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement_84015088-4cdb-4951-97d7-c8a145603509" xlink:href="adr-20220930.xsd#adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement_84015088-4cdb-4951-97d7-c8a145603509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_CommitmentToContributeCapital_30a224a9-0710-405b-b5b1-171aadc1a257" xlink:href="adr-20220930.xsd#adr_CommitmentToContributeCapital"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_CommitmentToContributeCapital_30a224a9-0710-405b-b5b1-171aadc1a257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_UpfrontPaymentReceivable_75d68eef-5cee-4a1b-b858-51a31280fd93" xlink:href="adr-20220930.xsd#adr_UpfrontPaymentReceivable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_UpfrontPaymentReceivable_75d68eef-5cee-4a1b-b858-51a31280fd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e4dd4fd4-c67c-4bec-9cdd-3dc3c8cd11d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e4dd4fd4-c67c-4bec-9cdd-3dc3c8cd11d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_bfd5b0ad-c4b5-4c16-992b-aa97ff98098b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_bfd5b0ad-c4b5-4c16-992b-aa97ff98098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ClassOfWarrantOrRightIssued_365f2973-7110-45a1-a8f0-f54dd1537b61" xlink:href="adr-20220930.xsd#adr_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_adr_ClassOfWarrantOrRightIssued_365f2973-7110-45a1-a8f0-f54dd1537b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e2fcba3a-f0c1-423c-bcb1-b6b830c207c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e2fcba3a-f0c1-423c-bcb1-b6b830c207c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_72f24f5d-7471-4fec-8462-71db04af491f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adr_LicenseAndOtherRelatedAgreementsLineItems_162d6de0-d70c-477d-9cee-a3650c60a661" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_72f24f5d-7471-4fec-8462-71db04af491f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b377fa6b-e229-4d2a-b320-fc6bf2558f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0756dd7a-4304-4df7-b69c-dc394000ae04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b377fa6b-e229-4d2a-b320-fc6bf2558f15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0756dd7a-4304-4df7-b69c-dc394000ae04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7629185f-4097-495d-a825-ef4d6012d936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0756dd7a-4304-4df7-b69c-dc394000ae04" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7629185f-4097-495d-a825-ef4d6012d936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7629185f-4097-495d-a825-ef4d6012d936" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4794603d-2cfc-4c17-b3ea-99c9f38ff041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_CommercialPaperMember_4794603d-2cfc-4c17-b3ea-99c9f38ff041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a386c228-a3dc-4b78-9b24-9727045510fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a386c228-a3dc-4b78-9b24-9727045510fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95adb4f8-f48c-4160-8e8b-1ea40439ca45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95adb4f8-f48c-4160-8e8b-1ea40439ca45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e92eed44-da50-4e3e-b7ee-2ff4d3e2ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0013a7f2-9416-4566-8976-9db43c3283e6" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e92eed44-da50-4e3e-b7ee-2ff4d3e2ceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0756dd7a-4304-4df7-b69c-dc394000ae04" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_14feb75e-0c9b-476d-971b-473315dad884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_14feb75e-0c9b-476d-971b-473315dad884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8f538ccd-69ca-40b7-b8ef-6fd27b4d6404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8f538ccd-69ca-40b7-b8ef-6fd27b4d6404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d74165f5-a3c1-4d97-8d77-557b72bca6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d74165f5-a3c1-4d97-8d77-557b72bca6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32347979-e8c4-411a-9436-e1de8fef0778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6800f3cd-0a12-4b6f-930c-a5e4dbe8eea0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32347979-e8c4-411a-9436-e1de8fef0778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1d66162a-3ff8-4275-af0a-c6518a13e1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_95df62cd-3cde-4067-a859-207d883912c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1d66162a-3ff8-4275-af0a-c6518a13e1fb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_95df62cd-3cde-4067-a859-207d883912c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c73ff6b7-9856-4053-8307-ee2b246989c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_95df62cd-3cde-4067-a859-207d883912c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c73ff6b7-9856-4053-8307-ee2b246989c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c73ff6b7-9856-4053-8307-ee2b246989c2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03ea6385-77fb-4646-91e2-0e93491cd5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_CommercialPaperMember_03ea6385-77fb-4646-91e2-0e93491cd5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_77527d7b-e991-4314-8e8e-a725a7410bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_77527d7b-e991-4314-8e8e-a725a7410bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_39fb68ce-e8ce-4df9-87f5-17991ab57e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_39fb68ce-e8ce-4df9-87f5-17991ab57e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d9f46c52-d294-4519-913d-e8776d9a908a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6dbe300a-735d-4091-8e56-a2a6cf254464" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d9f46c52-d294-4519-913d-e8776d9a908a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_95df62cd-3cde-4067-a859-207d883912c2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_db1d3f0a-690f-4135-bb95-9fbea26a9a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_db1d3f0a-690f-4135-bb95-9fbea26a9a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d016dfb0-3ee1-4943-8d97-fd8d0029f8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d016dfb0-3ee1-4943-8d97-fd8d0029f8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_49e8ca8b-3cbb-4766-a2a6-7d9a94c00af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_49e8ca8b-3cbb-4766-a2a6-7d9a94c00af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_587773b7-3e9f-4b8e-a02c-706cd41bf67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_587773b7-3e9f-4b8e-a02c-706cd41bf67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c56ec22-63f2-4917-9ee5-b97fa5eb8c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8c56ec22-63f2-4917-9ee5-b97fa5eb8c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a6274a19-bdc9-4e07-ad9f-1ba08f350f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dfc84de-ced0-4700-afcf-0b45c6b43603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a6274a19-bdc9-4e07-ad9f-1ba08f350f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97195d5c-9039-4cd2-afe4-73de1e9cc358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_4a807503-c87e-40c8-884e-6e7a1d8e10f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97195d5c-9039-4cd2-afe4-73de1e9cc358" xlink:to="loc_us-gaap_MarketableSecuritiesTable_4a807503-c87e-40c8-884e-6e7a1d8e10f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_dadcc201-3206-4e8f-a883-25a7d602337d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_4a807503-c87e-40c8-884e-6e7a1d8e10f7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_dadcc201-3206-4e8f-a883-25a7d602337d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dadcc201-3206-4e8f-a883-25a7d602337d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_11182b87-6915-4ae4-91ae-549272eb3133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_CommercialPaperMember_11182b87-6915-4ae4-91ae-549272eb3133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_770120ad-0d76-46df-b6d6-b97c3c53426a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_770120ad-0d76-46df-b6d6-b97c3c53426a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9b09c550-320d-4bcb-9c0d-f5a2678ee880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9b09c550-320d-4bcb-9c0d-f5a2678ee880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_d70b1f26-d764-43c5-a964-9cbc2e1d16c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10d256ce-47c8-452f-928b-696039a1d389" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_d70b1f26-d764-43c5-a964-9cbc2e1d16c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_4a807503-c87e-40c8-884e-6e7a1d8e10f7" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6eb75127-6a8b-4db3-9b4b-b954f51d9c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6eb75127-6a8b-4db3-9b4b-b954f51d9c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_1b7f740a-c1e9-4bb8-a0e8-d733dc822a44" xlink:href="adr-20220930.xsd#adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_5f770fa1-167e-4c18-aef8-c6d0af3c43f2" xlink:to="loc_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_1b7f740a-c1e9-4bb8-a0e8-d733dc822a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="adr-20220930.xsd#MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9a99cd0d-d3d9-47c0-ae02-2fc30ee9bfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9a99cd0d-d3d9-47c0-ae02-2fc30ee9bfaa" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e67d6503-0320-4329-8076-d2fae31be0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e67d6503-0320-4329-8076-d2fae31be0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e67d6503-0320-4329-8076-d2fae31be0e1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4083f4b1-70f5-4232-836b-19db5b98bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4083f4b1-70f5-4232-836b-19db5b98bc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9674e241-172c-496d-9b26-66259ae771d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:to="loc_us-gaap_CommercialPaperMember_9674e241-172c-496d-9b26-66259ae771d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6e7eaae5-a144-4854-9131-91f1a9c48664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_899d35ab-cbe2-472d-8c40-00984ba277bb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6e7eaae5-a144-4854-9131-91f1a9c48664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69559545-74ed-45c5-b787-5feebf780102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69559545-74ed-45c5-b787-5feebf780102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69559545-74ed-45c5-b787-5feebf780102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f53f1f75-0254-4d12-a219-289b58df1155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_CommercialPaperMember_f53f1f75-0254-4d12-a219-289b58df1155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c351a85d-862a-4dcb-bfe5-8aa549c05fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c351a85d-862a-4dcb-bfe5-8aa549c05fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_19d3aa2b-d3a8-43c7-a19f-3d96b56bd0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_19d3aa2b-d3a8-43c7-a19f-3d96b56bd0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_c9f74e17-dae2-4f95-9224-4024416953d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07e07175-c48d-4796-9e44-058e04aa1183" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_c9f74e17-dae2-4f95-9224-4024416953d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b2a49a1-697f-403e-987e-c115081f657a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b2a49a1-697f-403e-987e-c115081f657a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b2a49a1-697f-403e-987e-c115081f657a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0cc1d39c-ec6e-4c7e-9ce2-af1d2859d51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0cc1d39c-ec6e-4c7e-9ce2-af1d2859d51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7fe5dd56-7ca2-41c8-a0ac-bfa8b996e007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7fe5dd56-7ca2-41c8-a0ac-bfa8b996e007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_11e85231-26d3-4d89-b241-05c7c7ffaf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2e9a298-2cc0-4cfb-ba7e-8db4b93e56e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_11e85231-26d3-4d89-b241-05c7c7ffaf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c2ae34e4-00c5-497a-bb53-e0de9007d977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c2ae34e4-00c5-497a-bb53-e0de9007d977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_794cc073-cb29-4ee4-99a9-0dd232604cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c2ae34e4-00c5-497a-bb53-e0de9007d977" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_794cc073-cb29-4ee4-99a9-0dd232604cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e08c2420-51f1-4941-8874-15bc707e5cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_794cc073-cb29-4ee4-99a9-0dd232604cee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e08c2420-51f1-4941-8874-15bc707e5cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3beba1c9-8cb8-4903-8199-fdc97f0c3683" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_40806eb8-21a3-4307-b73f-284f95ef05ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_40806eb8-21a3-4307-b73f-284f95ef05ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bdf5a353-5b5e-4d1f-aaa9-0843af05b637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bdf5a353-5b5e-4d1f-aaa9-0843af05b637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9a053c2e-e455-43d2-8eea-132079eb3cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f1d441f9-7960-42ae-8d0d-290339f9b0f0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9a053c2e-e455-43d2-8eea-132079eb3cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d375b369-be01-435d-a417-159b0a41ecdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969a5d17-efe1-4df8-8afe-1d9721c3811d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d375b369-be01-435d-a417-159b0a41ecdb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969a5d17-efe1-4df8-8afe-1d9721c3811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de8e73d0-d473-4603-bf38-7a2a64828c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969a5d17-efe1-4df8-8afe-1d9721c3811d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de8e73d0-d473-4603-bf38-7a2a64828c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de8e73d0-d473-4603-bf38-7a2a64828c34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_681a7b7f-b479-4173-8381-3fad3bcda3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_681a7b7f-b479-4173-8381-3fad3bcda3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_274df19f-9a5f-4102-803d-971ec9f0d0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_274df19f-9a5f-4102-803d-971ec9f0d0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ComputerEquipmentAndSoftwareMember_946c9b21-41d4-43d3-bcca-e1d9d35f2d7d" xlink:href="adr-20220930.xsd#adr_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_adr_ComputerEquipmentAndSoftwareMember_946c9b21-41d4-43d3-bcca-e1d9d35f2d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_20319194-a81c-4b77-b941-295cb84f61de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65640b9c-97d2-44f6-9a15-0dedb6709f9f" xlink:to="loc_us-gaap_ConstructionInProgressMember_20319194-a81c-4b77-b941-295cb84f61de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969a5d17-efe1-4df8-8afe-1d9721c3811d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_735fd98d-b435-4feb-8746-67d86d0eb75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_735fd98d-b435-4feb-8746-67d86d0eb75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b905e88e-d9bf-4c33-b5fb-6f669cdbbcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b905e88e-d9bf-4c33-b5fb-6f669cdbbcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b41fe43a-a388-4879-9a4d-34d304fe069c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_beb0936b-6c2d-4f0e-b1a1-e643e444ba32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b41fe43a-a388-4879-9a4d-34d304fe069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/PropertyandEquipmentNetAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#PropertyandEquipmentNetAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/PropertyandEquipmentNetAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_007a5bb3-80d5-4b54-b609-35f23db31f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b654789d-53da-487c-bf47-1dfda32f5a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_007a5bb3-80d5-4b54-b609-35f23db31f3e" xlink:to="loc_us-gaap_Depreciation_b654789d-53da-487c-bf47-1dfda32f5a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_54ad2973-6f20-422c-88fb-2f790393c5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PrepaidRentAndSupplies_3e767fbd-003d-48fb-88bb-317c4a5f1f89" xlink:href="adr-20220930.xsd#adr_PrepaidRentAndSupplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_54ad2973-6f20-422c-88fb-2f790393c5fa" xlink:to="loc_adr_PrepaidRentAndSupplies_3e767fbd-003d-48fb-88bb-317c4a5f1f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_a7652664-07dd-456b-a474-d1874a7b16f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_54ad2973-6f20-422c-88fb-2f790393c5fa" xlink:to="loc_us-gaap_PrepaidInsurance_a7652664-07dd-456b-a474-d1874a7b16f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_2aa37358-83a5-4e7a-9ac6-ef0b846f5742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_54ad2973-6f20-422c-88fb-2f790393c5fa" xlink:to="loc_us-gaap_DeferredCostsCurrent_2aa37358-83a5-4e7a-9ac6-ef0b846f5742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_63cd3a90-afa3-481e-b912-caa548fc1ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_54ad2973-6f20-422c-88fb-2f790393c5fa" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_63cd3a90-afa3-481e-b912-caa548fc1ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_57f7b62f-126a-45e0-ba1e-9c97a6db87d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_54ad2973-6f20-422c-88fb-2f790393c5fa" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_57f7b62f-126a-45e0-ba1e-9c97a6db87d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_783dac13-eab4-436b-b78b-2853230a4839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_54ad2973-6f20-422c-88fb-2f790393c5fa" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_783dac13-eab4-436b-b78b-2853230a4839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#AccruedExpensesSummaryofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_856e3c13-308b-4499-b717-d6dc68e2a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ab1df4cc-88be-4212-9af6-ad98be754bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_856e3c13-308b-4499-b717-d6dc68e2a35b" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ab1df4cc-88be-4212-9af6-ad98be754bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e1831e2b-b8b5-450a-a878-f8296880f5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_856e3c13-308b-4499-b717-d6dc68e2a35b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e1831e2b-b8b5-450a-a878-f8296880f5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_AccruedConsultingAndContractedResearchCurrent_8fb27511-8373-4afe-a980-fce650da16d9" xlink:href="adr-20220930.xsd#adr_AccruedConsultingAndContractedResearchCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_856e3c13-308b-4499-b717-d6dc68e2a35b" xlink:to="loc_adr_AccruedConsultingAndContractedResearchCurrent_8fb27511-8373-4afe-a980-fce650da16d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c1e7e0b-5cd7-4e0b-9a60-2700f2c12a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_856e3c13-308b-4499-b717-d6dc68e2a35b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c1e7e0b-5cd7-4e0b-9a60-2700f2c12a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5822c7ed-4218-4c54-8b38-360514ea9f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_856e3c13-308b-4499-b717-d6dc68e2a35b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5822c7ed-4218-4c54-8b38-360514ea9f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6eedf7c8-63c8-43f3-90f5-327c4a6b2fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_d45b075e-aaaf-46f6-9374-8cb37fca8a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6eedf7c8-63c8-43f3-90f5-327c4a6b2fd8" xlink:to="loc_us-gaap_OtherCommitment_d45b075e-aaaf-46f6-9374-8cb37fca8a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3f53a9-b478-4a84-a8a5-72f0c71fbaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3f53a9-b478-4a84-a8a5-72f0c71fbaf3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd8b3525-7ded-4a70-830b-92a2e13eda3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_AwardTypeAxis_bd8b3525-7ded-4a70-830b-92a2e13eda3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bd8b3525-7ded-4a70-830b-92a2e13eda3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9e8f0fb3-5cbe-49df-8019-2baaf253d0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9e8f0fb3-5cbe-49df-8019-2baaf253d0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_65b8005a-b1b5-48f1-b594-dd85c4ba1059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:to="loc_us-gaap_PerformanceSharesMember_65b8005a-b1b5-48f1-b594-dd85c4ba1059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c38bae43-2139-41d9-bc1d-c2526383ca75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d61d4cfa-cb63-493a-918a-7f746631f87b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c38bae43-2139-41d9-bc1d-c2526383ca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_8942e4c1-36a6-42b0-a57e-7b1c521418f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_GranteeStatusAxis_8942e4c1-36a6-42b0-a57e-7b1c521418f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_f0527add-b424-42d7-9edf-413573d307b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_8942e4c1-36a6-42b0-a57e-7b1c521418f7" xlink:to="loc_us-gaap_GranteeStatusDomain_f0527add-b424-42d7-9edf-413573d307b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0307e276-c592-4515-bb6e-dfc12be8afe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_f0527add-b424-42d7-9edf-413573d307b9" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0307e276-c592-4515-bb6e-dfc12be8afe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_298a8c87-8a36-460c-ad99-96081d049bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_PlanNameAxis_298a8c87-8a36-460c-ad99-96081d049bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_298a8c87-8a36-460c-ad99-96081d049bc3" xlink:to="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TwoThousandAndTwentyOnePlanMember_2abe29eb-5974-4449-9bae-e909e51d8194" xlink:href="adr-20220930.xsd#adr_TwoThousandAndTwentyOnePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:to="loc_adr_TwoThousandAndTwentyOnePlanMember_2abe29eb-5974-4449-9bae-e909e51d8194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TwoThousandAndNineteenPlanMember_3dd4c4eb-2b56-41ae-a413-c60430ddaeb7" xlink:href="adr-20220930.xsd#adr_TwoThousandAndNineteenPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0295135e-fb34-4541-875a-ba98fb132b81" xlink:to="loc_adr_TwoThousandAndNineteenPlanMember_3dd4c4eb-2b56-41ae-a413-c60430ddaeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be515562-d750-47fa-80b8-c15f2445970e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_srt_RangeAxis_be515562-d750-47fa-80b8-c15f2445970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_be515562-d750-47fa-80b8-c15f2445970e" xlink:to="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_71b5df29-26cf-47ef-a0b9-9f8173ccc190" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:to="loc_srt_MinimumMember_71b5df29-26cf-47ef-a0b9-9f8173ccc190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0dcc108c-7b11-449b-b366-a3e0dcc166a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d92cc16-a1f4-4c0d-aeb8-0954fdf2a6b7" xlink:to="loc_srt_MaximumMember_0dcc108c-7b11-449b-b366-a3e0dcc166a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_83d0be3c-f5e9-4041-8d34-b789114b1c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_VestingAxis_83d0be3c-f5e9-4041-8d34-b789114b1c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_83d0be3c-f5e9-4041-8d34-b789114b1c19" xlink:to="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2edcae5b-9c4a-4f68-9eeb-f04a5ff5c6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2edcae5b-9c4a-4f68-9eeb-f04a5ff5c6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_926cb57a-fc12-485a-bc34-84b9b7d20801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_51897ca3-d4ed-4c89-be54-ca8f9ceb62f4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_926cb57a-fc12-485a-bc34-84b9b7d20801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d841659b-5d2c-4098-87e0-1af0ff0b60a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f9528c4-9cc9-4667-93fd-32e1d67e7d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f9528c4-9cc9-4667-93fd-32e1d67e7d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares_ea00fe8d-dc05-45b5-a1a5-6e873922add1" xlink:href="adr-20220930.xsd#adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares_ea00fe8d-dc05-45b5-a1a5-6e873922add1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_928407ff-aac4-4d55-b2f4-683578a1f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_928407ff-aac4-4d55-b2f4-683578a1f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7512a0f6-83ad-4e5d-8ebc-08829cfab045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7512a0f6-83ad-4e5d-8ebc-08829cfab045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1fd59999-5273-4def-9403-9c029c07b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1fd59999-5273-4def-9403-9c029c07b07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d53bee3c-f6b5-40b0-b74f-4639cd1e3f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d53bee3c-f6b5-40b0-b74f-4639cd1e3f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e051c32f-7cbc-49a2-a639-ef51e61dead0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e051c32f-7cbc-49a2-a639-ef51e61dead0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1dcb4a40-e97f-43eb-b64e-ba074ce9e769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1dcb4a40-e97f-43eb-b64e-ba074ce9e769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4bcbddc0-ab4d-4b60-8e01-47b4eaa7aae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4bcbddc0-ab4d-4b60-8e01-47b4eaa7aae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_82e228f6-0173-463d-8889-a7a47efe8510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_82e228f6-0173-463d-8889-a7a47efe8510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bcdbbb9-6597-4b7b-bf5d-52415d81fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bcdbbb9-6597-4b7b-bf5d-52415d81fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb6de3e0-f604-4ca9-b919-b34b3aa2c450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb6de3e0-f604-4ca9-b919-b34b3aa2c450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fa1fa68e-06a9-4b44-b2c1-6680ff58922e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fa1fa68e-06a9-4b44-b2c1-6680ff58922e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PerformanceConditionOnMarketValue_af88e61b-9efe-4a6d-92ed-71b650ecff2c" xlink:href="adr-20220930.xsd#adr_PerformanceConditionOnMarketValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_adr_PerformanceConditionOnMarketValue_af88e61b-9efe-4a6d-92ed-71b650ecff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e759798f-7e94-43fd-9b81-aeacbd63b7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e759798f-7e94-43fd-9b81-aeacbd63b7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8c5202d-80bc-4e73-8024-097fbad426d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8c5202d-80bc-4e73-8024-097fbad426d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_84f2ba13-746b-4cf7-86ca-36de7428db11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_84f2ba13-746b-4cf7-86ca-36de7428db11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b518c04e-6385-441f-83fb-d96954c477b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3cf71bb-b3bc-4140-8b0f-bb0674edf47e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b518c04e-6385-441f-83fb-d96954c477b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_99c1c737-954b-4cc7-9920-7ad08e59c350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd3b1bea-8d48-4d99-aa98-df3223892938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99c1c737-954b-4cc7-9920-7ad08e59c350" xlink:to="loc_us-gaap_NetIncomeLoss_fd3b1bea-8d48-4d99-aa98-df3223892938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_327988ab-21d9-43f4-a579-1bffe65c3e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99c1c737-954b-4cc7-9920-7ad08e59c350" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_327988ab-21d9-43f4-a579-1bffe65c3e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52719b2d-99d4-40a3-984e-2fb90b2f4655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99c1c737-954b-4cc7-9920-7ad08e59c350" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52719b2d-99d4-40a3-984e-2fb90b2f4655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dc668f35-be87-45ee-8b44-609160a213b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99c1c737-954b-4cc7-9920-7ad08e59c350" xlink:to="loc_us-gaap_EarningsPerShareBasic_dc668f35-be87-45ee-8b44-609160a213b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ba2748dd-ba86-4c87-b79d-1d455abd2d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99c1c737-954b-4cc7-9920-7ad08e59c350" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ba2748dd-ba86-4c87-b79d-1d455abd2d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_537965cd-82e4-437b-930d-6791ef7df03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2365033-4fb5-4573-82aa-284e8d29ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_537965cd-82e4-437b-930d-6791ef7df03a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2365033-4fb5-4573-82aa-284e8d29ad6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2365033-4fb5-4573-82aa-284e8d29ad6b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9bd0293-8a8f-4fc4-9ef6-170db5b0564f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_RedeemableConvertiblePreferredSharesMember_520693a5-be37-4669-8e5c-503e8db9140a" xlink:href="adr-20220930.xsd#adr_RedeemableConvertiblePreferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_RedeemableConvertiblePreferredSharesMember_520693a5-be37-4669-8e5c-503e8db9140a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0daa5f48-1f6c-4110-8314-52f593a709bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0daa5f48-1f6c-4110-8314-52f593a709bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_886da918-942a-4044-aad1-88bbd7cc5b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_us-gaap_RestrictedStockMember_886da918-942a-4044-aad1-88bbd7cc5b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianOncologyIssuedToQedMember_0db8ab5d-d965-4f47-8da5-8cb3e04c92d0" xlink:href="adr-20220930.xsd#adr_WarrantsInLianOncologyIssuedToQedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_WarrantsInLianOncologyIssuedToQedMember_0db8ab5d-d965-4f47-8da5-8cb3e04c92d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember_5f3fec69-1094-46f8-89ae-38c9187c6678" xlink:href="adr-20220930.xsd#adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember_5f3fec69-1094-46f8-89ae-38c9187c6678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember_da3345af-e50b-4047-8f59-ea9abe1fddb3" xlink:href="adr-20220930.xsd#adr_WarrantsInLianOphthalmologyIssuedToTarsusMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_adr_WarrantsInLianOphthalmologyIssuedToTarsusMember_da3345af-e50b-4047-8f59-ea9abe1fddb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5b91e441-698c-447e-90e7-3f28957ea8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e7ce92f-85c8-46cd-907f-d1a2abad1a05" xlink:to="loc_us-gaap_WarrantMember_5b91e441-698c-447e-90e7-3f28957ea8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_caf5b48f-5f14-4d02-85ba-aee79b85ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2365033-4fb5-4573-82aa-284e8d29ad6b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_caf5b48f-5f14-4d02-85ba-aee79b85ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5d3b437-8064-472a-9793-90a4eb608ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_caf5b48f-5f14-4d02-85ba-aee79b85ff5e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5d3b437-8064-472a-9793-90a4eb608ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://lian.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="simple" xlink:href="adr-20220930.xsd#SubsequentEventsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://lian.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_dbb31860-2cb6-4b6a-86b2-c32f619b3c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_dbb31860-2cb6-4b6a-86b2-c32f619b3c6a" xlink:to="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e932bd2c-8900-44c0-b441-02e7ebaf7675" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:to="loc_srt_CounterpartyNameAxis_e932bd2c-8900-44c0-b441-02e7ebaf7675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77c3f0c-487e-4ed2-8691-758aa7ea1a90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e932bd2c-8900-44c0-b441-02e7ebaf7675" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77c3f0c-487e-4ed2-8691-758aa7ea1a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_TarsusPharmaceuticalsMember_f9e6f56e-3a4a-4765-a69e-b123a41c108d" xlink:href="adr-20220930.xsd#adr_TarsusPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77c3f0c-487e-4ed2-8691-758aa7ea1a90" xlink:to="loc_adr_TarsusPharmaceuticalsMember_f9e6f56e-3a4a-4765-a69e-b123a41c108d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_688df8d7-7590-4720-bbc8-dc1bb090039b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:to="loc_srt_StatementScenarioAxis_688df8d7-7590-4720-bbc8-dc1bb090039b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2a550b20-75b8-42a3-aa8a-6849e0c2a1e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_688df8d7-7590-4720-bbc8-dc1bb090039b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2a550b20-75b8-42a3-aa8a-6849e0c2a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce140514-ed26-4a78-88ff-426188b10612" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2a550b20-75b8-42a3-aa8a-6849e0c2a1e8" xlink:to="loc_srt_ScenarioForecastMember_ce140514-ed26-4a78-88ff-426188b10612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ce651b71-7d65-42e3-bbb6-6020735178a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_57daff95-f8c6-4525-80ff-181c6e390fc8" xlink:to="loc_us-gaap_SubsequentEventLineItems_ce651b71-7d65-42e3-bbb6-6020735178a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_d0d0a0ff-0ad0-44c9-bf64-e61e2a09938b" xlink:href="adr-20220930.xsd#adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ce651b71-7d65-42e3-bbb6-6020735178a5" xlink:to="loc_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement_d0d0a0ff-0ad0-44c9-bf64-e61e2a09938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>adr-20220930_g1.gif
<TEXT>
begin 644 adr-20220930_g1.gif
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M^R(G*_#Q\;6WN%UA9!H@)%197
M
M
M
M
M
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M/HW%K6^=)"< #/&HI(%2 7XB)4&>$+F( N"D=_K;F5XW.TPJ9(P"C6KB"-I
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MA"__,CV+XE;6T; ;P;-_4E1^R@%>\DNA^EB0]3CCTZ[3__BH H*T=\,_OP0
MFP!.P\)DD-)8@0H;C?!?*.6OR,1] > ) O$)FQ(S%-18C1 ;W!>H=QL #Q@S
MWF<&HQH *3NNZ?JVL-&HX)2V/AJI,-NXJBFSF'JGO[I%<&L29A!.:5H2@7JF
MG=JYPBJFQ-I)_X(QKMI83L(J;X(UAM(I7M0\20NZ#BLZ&$2U7T QTY,])W,J
M/M!/X\2Q,\I'NG4W*<L\.P,IA()6"H,"A#IE3&4\R>0EMT0X*PLNV3(VLMH]
MXX0S4$)+=\,J>C*J72"R 7,^%]LQI)L>+N*RCKN^&P"YBXL1F>L[X)JUG;JY
M?&27#$&X$-$M"+"\)8$Z>KJO!?\AK:@Z$01<$I>;LKX+NQI1K(:",>(2/4 K
MM-;3*CPK-&U2J"%1K25!.Q@$LI(3OAC\I]GC)+H2M (QM0NL&> 1 %S;-P '
M*;M#*L,D)BM[-^/3/NYSOSF60"1#.,N' G=#JQGL-OBBK0JC/2;K?Z1"2Y63
M-^^;I0(Z!AV !\CY!!T  NS[G0R<$)X@N$]+1;%1P%2$M/0KP*RRK0VQLG>2
M? ;!ORD1,]\3P#IZN:^CPPN!3'P+/FX, %^,MQ0A1$\UOTH[N2 !3IOP,[4C
M+DQ2-_K")#T<)_X:*MFSPI[K$7OSP:W3*OP"P>JT)J<R/H<07A"BM1[[2E&R
M-LQ#OGK_(B8N<P,XK&.TXCB\ D1\Y"B;@C0$43=K,S-CX#9I[#::HU<L0R?+
M(SJR$[F,NYTHH 0=\ 2EV04=X &QB0<=<,U5O $?D,75G,VE*0(=@)HC<,TB
M$)_NJZD44:P4(:V*RBJ*2T6*]KH"W*Q:Z,( L+=[G"W>5[E^*DA(!K8BXU+>
MYTS]ZRFQ\4N!.C;9,@9G6[*? !L/Z$<N=;=]VJYN$\-]>@B'H #I&L4QZCH3
ML=#Y!',%(3(;  !LO,%F7,@UB[.7W!&4+"^[ T !, :V.SEE,C6+W&<BT:TJ
MT<(KQ,L?(\./TLJJLAQWTR;?(\AED#TU9#P>HRU,B\HH0#))_[R]R8O$O7PR
MCLQ'<Q,G\^/1[_J>(= !'V"<=- !7; !X%R<'C#-IMG6ICD"(U":(&#%[WG.
M!C81_0HIWA< W'>WWL>Y4R9=F[#)@PVP%'2N 6"QHQ+#?HJWC0VP7YNS[HK$
M2NQ:49(MM"3(<#P0&Q!T-&RR)0,I!,VSF^#$!R.^LEHE,7,Z.76Q>(  XZ,K
M,0,O5;)+VW*&FEEE =! K W(@?JWD@,OJERRD+U8?</&EPL;?=K0 '"Y>QN]
MF)M,@&U!;PNVR0H XPK&ERLR7J/0@"W6=&R.+#V1IBP;OE6\U6(N,SPGQ\M,
MCGQ8_Y73[K).]TT=]319 !8;;P(EQ__K*FZSU<7",5GUU3-3T\J,J]U9UIU0
MFAS0 8;0S-ALQ2#0 <[< 72P 6_- 6P=S@B X:6)S>&LFF^]X=]<XAM@S7@=
MH'K]F7PMNI!2);+:+7'B Y6-TM<1RI"RT5,F);1TL?ZJ5[LK("ZE &FKT<F+
MQ^4]LP0!P!ZKQRC L[;\V0/1W>]C)N/C,@C *S>4*TSBJBRS0176D$;[XR7D
M/:-#Y._1VP0!TCM,XT.M)VL3TWK"+T5.*O,+3F;"*D >.38PLMWRO<LQ0MER
M/F60PK]M-:A,3)$SZ. S3.6ZUUWLC^=MZ1T+%1!DR1*AOMI9UF>] 1%N"!N
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M'#].7,[E3&L#M!0SY%+@@Q4EG]TI [O@77^0W%Z1INR&;]K@*R_J$A[BAK
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MB2^ZN*&,&4*TXHLXU@B3AR/Z^".0W)5(XXY$PECDC#<BZ:"12S*DHXI./1%
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M,QTGQ!1':W%,&!.$ *$ N-Q7KP@ <(!<CL7J6!<FZTN0#_\.+'%(COFYZ,Q
M(3!$UF*?/>@!DLH[*4%T6#LTTRX9C33A02K-]M0/-PSUXC$F/NU+5F,; !UG
M_^RWUS^+;2ZA> ]*!T$#"+VVLRBY#+/> "C@I6,(8%VHW5FK/D#J-M#N\=\V
M$1QX08-O0$<':1#810=X$ N\\85/=WCI42M^T28T2*6GP+I+/*6B-HT$0"-[
M:L^?U A%CY$/ZL:$_;J0NR0YW7B<;8-<77\MUZM# ("KR9*F+#OI+-ODV+O@
M)BG:5<MU67L5 NX6@+SU#/]LBVH4X'AW$DR-H /3 5X7O ."#G"P V/8 "$Z
MX('M5+"#3R 0\$9(K U^ 3O,\Y\$(^:IBDS)#/"ZW43NM1'S6815FDG2]O@4
M@+=)Y%$!L&%$9H6[:\5$B3"<H1"1.$"-_$1Z /#!Z!0"J !XPB)]<LB]]."X
MYZ&D6AM1 -9 9T;X 0!S/@L;4$H6@('H+ "4LE[S3+*UC:! 9@ 8&?P,"+K8
M[4R DA),!&,(DC+=0 06%- &$;"!$8S@.Y243@@Z0(@!>: #="C6!CG@0F1)
M$$<ITAA&9G6M &SB(I)+WQ-EI2.5 4 $&XB(#W:GD%SF44D%0:5O>'(ZB#BF
M2KW_BM7Z<D?&I3T+<6S2)>\PY<@+BG #CN3@!T4P@FM^<(,?V$ ';$D\$&S@
M"1VT)74Z4$GIA).='+3E):UI07-RD)PIW$ B.J@$%'2B QML)SB5P,$1X*&>
MTBDH-JU)20X^ :$ K<X+;57*93H$F HHUY0V(CT]?$NC!MG MPK2M4'IT(IE
MB=1* B!&JW6/6P#;8;7$6#,H2O2*D]%82F/E"91M!)D<4^:\?M)%CNHI2YO8
M"!N/J;6?V) &_[K72WUEQ%AYZXA;^5< I#< N60TJZ:Z5Z2:1E.+8K2* ""J
M1^O"D\WQ$@#;\E5!AJE4D&[$AASM:0WQ-;E"==0*= V _[IZI5= V7!*>@);
MENK218-0[7&Q9!8T R?-1VZ@DR/LA'2TN8!,XH$3[31$!X.W 0[X,Z ;&$-I
MI7.#>,K3FK9$@#]#>8,.A "<AMA 0;M@67/>-H4?X"!NBP?.#MP >+:<)O$R
MF$EY9K #3E@ :$5)(E+RSI06>1V\RI6Q(0ZJE:_RZ3 ) L!!E2MVVD)!QU17
M+HQ]UZW6>M7D>(#= ;22IKXL2%OWNK$KMA)LN5* %6.F-H)<Z[LZ(\@Q#]RU
M*;VK5T-0:DBOY8/^UG=R?J(=?4U%.R5N]UU\;-;#L+LH[0J1 ]V]GZ^ \B]>
M\@M@!AG9A^O"!Q0C( L5GE*Y%O^<M0_7@<!9L]H7CXEC 2_5IZ:B;C-[::G(
M,FVRT['L!D#;P0U8H0-#V  -*NG-*'>  Z0U!/%4N$WJ;&($-\CL"#P;VA#
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MK4S1:=BF_+5P7>[(6,?AO&<Z?QG/A]AM9=O=ZR@&[\N:+1>L?:$]0\1ZT_&
MW0#<SH&6^]O:[<V_!0J]ZDWR=TTAJ\B4##RX'I"X.A/>@85KYWGU7/9R!VY+
MV]%VX.#3B6<F,[@"RDI'RK4%9\4K*\+?WE;DO[5@G4?XYVHJ_,O4@;DM13[S
M,0;.NC2D'+SD1?=>E4WH6H?7WP:UOX$,&]8H<. 4,=:Z-_HLB\]V/]7W_O6;
M$NI*?I+U_&J=1:Q!)@M])&  E!UD^ T/*!BLT(V?M)A@Y0T"UH7VF0H>N(W/
MS ^^>8FS;5_B,1N(C17V"1 &=A_Y9:"W85C:M4K(O)C3X5NTZ1VE$ K6Y%@
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M#:L=.KLW!*W#.T-"NN>9=R5:AK5TP0!J2U/B09>^RP$,0*L,@)&M9K/=#@]
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M&,T%!RR6[Q][2G2]_(#]MCF;3+KQPXIQGU]^1JS]9.9BO[R]K\0M0!P(@ )
M00 !?  0B,=@0X</(49T&$!B18L7,6;4N)%C1X\9-H04.9)D29,B070(V6%$
MR$X=G)R4:9)#!T,;:MZ<.3/E3I\S,WB$2%&HQ2X) : @>I!A%QL.#W0Y2'#
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M5F<#KB")Q@"3\>.E6@>5^Z-0.J&'8%EU?>@^Z,"(WP0$;"I]$VPE1/F2?SF
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MQ=,-M)^HGH(Y8#N&0"E.'2T$W>F57O0 XLF0 '@ < @P!$" +  4#@!@PP:
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ML7-/0L*H*C.2&(AOB !CSV0@35$)G$N4$"*QUR*J<U^7J()L(]U(E-LA<-V
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M+%W@$Q2A3Y9LR44D)OC#$",R '$V(QKC)?Y1T1CH'S; +-1RQ8%CP6CR(D^
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MLE@'Z]W>'PX O[U5_VT7WR3,@U'<]0T;][T!('#8-F9C8AS@DSK@>:, M7(
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MYE)1<,,F5$*&%B- )@E "L]N1 .1%23J4FNZ_EYR@Q\DP%7+]+8+U$ @%@-
M:VN(3?\&6,I3YLN +XQ'$"#"*"+0,E+<>M(\1&6M'(B*!S3@@B9H( ' U0!<
MKUS/#$\Q.33%"5(-8-Z&:/<GJ,2;4T\GO(( X2$OG*0&Q]!9 F@0D,A+90?<
MMC?Y5I%^,@VJ&450H)#A72"[C 7 !:CY 1ZRER" CC2537W_:IY8^<UU%(&9
M-=!J!8,E! _6  ?R8)0L>UG6JY9GG#^F'.?:Q+M"M<B(?5+4IJ(7=24>JHL)
MLE>)BKJ9'8XL./OKX_F:CJFCM/1#KTF"_2B4('QN" 4Z'%]LHUK=ZZ:)JGDM
M1PZXFLNQ;LJL-S#F6VL !!W0@%OY=^]WVQ.F[.8+BL]H+P((&B$F_D .H8WH
MY3D4 "\4B+6#;;H?E^X.;M/SD#])MVA6FGC@O+1 '@KN*!-<Y2IW=\!]!VL-
M="#!NJXWK>.-:WX#O+A5F;7+=>GK<Z[<)P9'8[V4-^JH5OO9 XGV 4;M!8E6
M]IDI#]_IZ P (+2$D 1!!$X)VG$@_]P-Q,-\*+)1*W2TK[OE/G_*OHUR@ WP
MN]\@V'E2[#UF5^\;[K,&@5/<S/9< OU\:8>EGTU'Z@\N[PY9D/I>-_D\:3M4
MR(D )Z737?C361X%"RVLMW$:<F/O[<X . "G_^G5LQ->]5)>.^"1T@'DF@>X
M==_ W6N==WXC0BM,<$K=7:]'P6MO]0,?.OU6?)#2@[:@2W\FY)UNR$P+1 $6
M[7'J,0]DC'"WL_X$ "(4&6ZWA?V9H'THLTL]?/27M?6_[[=*]8B("[!_C\'?
M;/KS6GS4,=4O%\ SQK-MNJ/SBVN[//LK0(U:/_:C*WI20/G+(_I+,0,,.N*+
MFHO;BPHLG66,T[@0&XK5HKH(_$!:0L#?@[UYLK &=, )!$$YNS[30;>]T#\"
MK+K3&<"]8 $F.S\5S$%7$L$3[,& >\"#T\$@5",A[#,6+,+,0D(E7",>]$$G
MO#(@+#HA)#JB6\)=D30K3,(LW-W"J&G")_Q"NXK"*D0[*N1"8/L_,RR.,4Q#
M-B0.+P1#."0I,6S#,FQ#-41#._R+/-Q#37G#./S#>)I#-JQ#/M1#+"Q$0T1$
M1;01/P1$1PR\%%Q"0EQ$93M"2L2_2\Q$Y&C$1^Q$%)1!+IQ$33S$2!Q%(C1%
M5.P+3O1$5J0C04Q#44S%4RQ%662N6KS%GUC%5MQ%7P+%+8Q%7+1%2PQ&#2-&
M8VPW7DQ&Y:+%(@3&8QP\?'K&^Y-&:CP(751&;/R=*X1%<JI&"9Q&;QS"<+S%
M:\S&9'Q%,W1&;\S <93"=J*4Q7(TQUU$QU#LQG=TQU\+QS6\1S/, '_\1X ,
M2($<2((L2(,\2(1,2(5<2(9L2(=\2(',BR2:2(JL2(N\2(S,2(V<R+S92(_\
M2) ,29$<29'\$Y(\291,295<22SB1Y=\29B,29F<29JL29N\29S,29W<29[L
M29_\2: ,2J$<2J(L2J,\2J1,2J5<2J9L2J=\2JB,2JF<2JJL2JN\2JS,2JU#
MW$JN[$JO_$JP#$NQ'$NR+$NS/$NT3$NU7$NV;$NW?$NXC$NYG$NZK$N[O$N\
MS$N]W$N^[$N__$O #$S!'$S"+$S#/#Q,Q$Q,Q5Q,QFQ,QWQ,R(Q,R9Q,RJQ,
MR[Q,S,Q,S=Q,SNQ,S_Q,T Q-T1Q-TBQ-TSQ-U$Q-U5Q-UFQ-UWP/3=B,3=F<
+3=JL3=MTR8   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076090000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LianBio<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1594670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">103 Carnegie Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">486-2308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 1 ordinary share, par value $0.000017100448 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIAN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,353,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076291520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 78,862<span></span>
</td>
<td class="nump">$ 228,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">232,866<span></span>
</td>
<td class="nump">155,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,117<span></span>
</td>
<td class="nump">10,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">7,393<span></span>
</td>
<td class="nump">6,044<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">324,238<span></span>
</td>
<td class="nump">399,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">20,070<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,135<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,362<span></span>
</td>
<td class="nump">4,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">351,842<span></span>
</td>
<td class="nump">426,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">3,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">17,871<span></span>
</td>
<td class="nump">9,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,027<span></span>
</td>
<td class="nump">15,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_NonrefundableResearchDeposit', window );">Nonrefundable research deposit</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">45,244<span></span>
</td>
<td class="nump">39,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, $0.000017100448 par value. 2,923,900,005 shares authorized as of September 30, 2022; 108,353,831 shares issued and outstanding as of September 30, 2022; 2,923,900,005 shares authorized as of December&#160;31, 2021; 107,275,458 shares issued and outstanding as of December&#160;31, 2021</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">728,915<span></span>
</td>
<td class="nump">713,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(3,844)<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(452,249)<span></span>
</td>
<td class="num">(360,235)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total LianBio shareholders&#8217; equity</a></td>
<td class="nump">272,824<span></span>
</td>
<td class="nump">353,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">33,774<span></span>
</td>
<td class="nump">33,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">306,598<span></span>
</td>
<td class="nump">387,336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 351,842<span></span>
</td>
<td class="nump">$ 426,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_NonrefundableResearchDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable research deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_NonrefundableResearchDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076275600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.000017100448<span></span>
</td>
<td class="nump">$ 0.000017100448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">2,923,900,005<span></span>
</td>
<td class="nump">2,923,900,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">108,353,831<span></span>
</td>
<td class="nump">107,275,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">108,353,831<span></span>
</td>
<td class="nump">107,275,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076653056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,258<span></span>
</td>
<td class="nump">$ 4,655<span></span>
</td>
<td class="nump">$ 49,178<span></span>
</td>
<td class="nump">$ 151,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,291<span></span>
</td>
<td class="nump">8,889<span></span>
</td>
<td class="nump">46,930<span></span>
</td>
<td class="nump">22,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">24,549<span></span>
</td>
<td class="nump">13,544<span></span>
</td>
<td class="nump">96,108<span></span>
</td>
<td class="nump">173,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(24,549)<span></span>
</td>
<td class="num">(13,544)<span></span>
</td>
<td class="num">(96,108)<span></span>
</td>
<td class="num">(173,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">2,238<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income taxes</a></td>
<td class="num">(21,891)<span></span>
</td>
<td class="num">(13,509)<span></span>
</td>
<td class="num">(91,997)<span></span>
</td>
<td class="num">(173,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (benefit)</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,897)<span></span>
</td>
<td class="num">(13,112)<span></span>
</td>
<td class="num">(92,014)<span></span>
</td>
<td class="num">(175,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation (loss) income, net of tax</a></td>
<td class="num">(2,282)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(3,096)<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,274)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (24,339)<span></span>
</td>
<td class="num">$ (13,138)<span></span>
</td>
<td class="num">$ (96,384)<span></span>
</td>
<td class="num">$ (175,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (8.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (8.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, basic (in shares)</a></td>
<td class="nump">108,353,831<span></span>
</td>
<td class="nump">20,690,908<span></span>
</td>
<td class="nump">107,854,547<span></span>
</td>
<td class="nump">20,549,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, diluted (in shares)</a></td>
<td class="nump">108,353,831<span></span>
</td>
<td class="nump">20,690,908<span></span>
</td>
<td class="nump">107,854,547<span></span>
</td>
<td class="nump">20,549,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915071110816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total LianBio Shareholders&#8217; Equity</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">10,971,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 349,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A Preferred Shares at $56.66, net of issuance costs (in shares)</a></td>
<td class="nump">52,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred Shares at $56.66, net of issuance costs</a></td>
<td class="nump">$ 2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">11,024,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 352,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,477,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(98,070)<span></span>
</td>
<td class="num">$ (132,843)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,132<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (163,935)<span></span>
</td>
<td class="nump">$ 34,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Warrants issued in license agreement</a></td>
<td class="nump">9,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(61,565)<span></span>
</td>
<td class="num">(61,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive Income (Loss)</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,477,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="num">$ (148,538)<span></span>
</td>
<td class="num">(192,726)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">32,806<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(225,500)<span></span>
</td>
<td class="nump">44,188<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">10,971,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 349,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">11,024,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 352,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,477,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(98,070)<span></span>
</td>
<td class="num">(132,843)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,132<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(163,935)<span></span>
</td>
<td class="nump">34,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(175,105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,787,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="num">$ (253,062)<span></span>
</td>
<td class="num">(297,250)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41,726<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="num">(339,040)<span></span>
</td>
<td class="nump">44,188<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">11,024,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">$ 352,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">11,024,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 352,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,477,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="num">(148,538)<span></span>
</td>
<td class="num">(192,726)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">32,806<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(225,500)<span></span>
</td>
<td class="nump">44,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(100,428)<span></span>
</td>
<td class="num">(100,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive Income (Loss)</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,477,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="num">$ (247,401)<span></span>
</td>
<td class="num">(291,589)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">34,249<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="num">(325,928)<span></span>
</td>
<td class="nump">44,188<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">11,024,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 352,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">2,168<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">5,309<span></span>
</td>
<td class="nump">5,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(13,112)<span></span>
</td>
<td class="num">(13,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive Income (Loss)</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,787,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="num">$ (253,062)<span></span>
</td>
<td class="num">(297,250)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41,726<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="num">(339,040)<span></span>
</td>
<td class="nump">44,188<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,275,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">387,336<span></span>
</td>
<td class="nump">353,562<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">713,269<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="num">(360,235)<span></span>
</td>
<td class="nump">33,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">4,669<span></span>
</td>
<td class="nump">4,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition', window );">Receivable from related party</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(27,726)<span></span>
</td>
<td class="num">(27,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive Income (Loss)</a></td>
<td class="num">(1,216)<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,275,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 364,773<span></span>
</td>
<td class="nump">330,999<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">719,648<span></span>
</td>
<td class="num">(690)<span></span>
</td>
<td class="num">(387,961)<span></span>
</td>
<td class="nump">33,774<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,275,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">387,336<span></span>
</td>
<td class="nump">353,562<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">713,269<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="num">(360,235)<span></span>
</td>
<td class="nump">33,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(92,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,353,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 306,598<span></span>
</td>
<td class="nump">272,824<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">728,915<span></span>
</td>
<td class="num">(3,844)<span></span>
</td>
<td class="num">(452,249)<span></span>
</td>
<td class="nump">33,774<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,275,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">364,773<span></span>
</td>
<td class="nump">330,999<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">719,648<span></span>
</td>
<td class="num">(690)<span></span>
</td>
<td class="num">(387,961)<span></span>
</td>
<td class="nump">33,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">4,528<span></span>
</td>
<td class="nump">4,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(42,391)<span></span>
</td>
<td class="num">(42,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive Income (Loss)</a></td>
<td class="num">(712)<span></span>
</td>
<td class="num">(712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,353,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 326,198<span></span>
</td>
<td class="nump">292,424<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">724,176<span></span>
</td>
<td class="num">(1,402)<span></span>
</td>
<td class="num">(430,352)<span></span>
</td>
<td class="nump">33,774<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">4,739<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(21,897)<span></span>
</td>
<td class="num">(21,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive Income (Loss)</a></td>
<td class="num">(2,442)<span></span>
</td>
<td class="num">(2,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,353,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 306,598<span></span>
</td>
<td class="nump">$ 272,824<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 728,915<span></span>
</td>
<td class="num">$ (3,844)<span></span>
</td>
<td class="num">$ (452,249)<span></span>
</td>
<td class="nump">$ 33,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_APICDueFromRelatedPartiesIncreaseForCostRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>APIC, Due From Related Parties, Increase for Cost Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_APICDueFromRelatedPartiesIncreaseForCostRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078575056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adr_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="nump">$ 56.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adr_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adr_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076374304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (92,014)<span></span>
</td>
<td class="num">$ (175,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD', window );">Non-cash share consideration, issued in acquisition of IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_NonCashOperatingLeaseExpenseBenefit', window );">Non-cash operating lease expense (benefit)</a></td>
<td class="nump">354<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">13,936<span></span>
</td>
<td class="nump">5,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discounts on investments, net</a></td>
<td class="num">(481)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency transaction gain, net</a></td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in prepaid expenses and other current assets</a></td>
<td class="nump">4,794<span></span>
</td>
<td class="num">(3,801)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">(Increase) decrease in other receivable</a></td>
<td class="num">(1,244)<span></span>
</td>
<td class="nump">14,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Decrease in other non-current assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Decrease in accounts payable</a></td>
<td class="num">(1,091)<span></span>
</td>
<td class="num">(2,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase in accrued expenses</a></td>
<td class="nump">8,197<span></span>
</td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">(Decrease) increase in other current liabilities</a></td>
<td class="num">(248)<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Increase in withholding tax payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,957<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,472)<span></span>
</td>
<td class="num">(133,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,610)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(260,367)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and redemption of marketable securities</a></td>
<td class="nump">181,780<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(80,197)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">5,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs related to redeemable convertible preferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">8,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(2,291)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(149,250)<span></span>
</td>
<td class="num">(125,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash&#8212;beginning of period</a></td>
<td class="nump">248,182<span></span>
</td>
<td class="nump">254,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash&#8212;ending of period</a></td>
<td class="nump">98,932<span></span>
</td>
<td class="nump">129,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents&#8212;end of period</a></td>
<td class="nump">78,862<span></span>
</td>
<td class="nump">109,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash&#8212;end of period</a></td>
<td class="nump">20,070<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash&#8212;ending of period</a></td>
<td class="nump">98,932<span></span>
</td>
<td class="nump">129,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_DeferredOfferingCostsIncurredButNotYetPaid', window );">Issuance costs in accounts payable and other accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment in accounts payable</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_DeferredOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_DeferredOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_NonCashOperatingLeaseExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash&#160;operating lease expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_NonCashOperatingLeaseExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Share Consideration Issued in Acquisition of IPR&amp;D.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078681152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of Business <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LianBio (&#8220;LianBio&#8221; or the &#8220;Company&#8221;) is a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Cayman Islands in July 2019 and maintains its Chinese headquarters in Shanghai, China. The Company conducts its corporate activities at its United States headquarters located in Princeton, New Jersey. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;) through an underwritten sale of 20,312,500 American Depositary Shares (&#8220;ADSs") representing 20,312,500 ordinary shares at a price of $16.00 per share. Following the close of the IPO, on December 1, 2021, the underwriters partially exercised their option to purchase additional shares and purchased an additional 593,616 ADSs at the IPO price of $16.00 per ADS. The Company received gross proceeds of $334.5 million in connection with the IPO and subsequent exercise of the underwriters&#8217; option and aggregate net proceeds of $304.8 million after deducting underwriting discounts, commissions and other offering expenses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the IPO, all of the Company&#8217;s convertible preferred shares then-outstanding were automatically converted into an aggregate of 64,467,176 ordinary shares and were reclassified into permanent equity. Following the IPO, there were no preferred shares outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915081926656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(A) Basis of presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, which include the People&#8217;s Republic of China (&#8220;PRC&#8221;) registered entities directly owned by the Company. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim balance sheet as of September&#160;30, 2022, and the interim consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred shares and shareholders&#8217; equity (deficit) for the three and nine months ended September&#160;30, 2022 and 2021, and the cash flows for the nine months ended September&#160;30, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial information. The financial data and other information disclosed in these notes related to the three and nine month periods are also unaudited. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B) Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The only material estimates in the accompanying financial statements are the fair value of warrants, share-based compensation, and share options. Actual results could differ from those used in evaluating these accounting estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak a pandemic. The Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including planned clinical trials. The impact of the COVID-19 pandemic on the Company&#8217;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy continue to be impacted for an extended period, the Company&#8217;s results may be materially adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to material credit risk due to the financial position of the banking institutions. The Company has no off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could affect the Company&#8217;s operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials, uncertainty of regulatory approval of the Company&#8217;s potential product candidates, uncertainty of market acceptance of its product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company&#8217;s product candidates require approvals from the National Medical Products Administration (&#8220;NMPA&#8221;) in China and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, such events could have a materially adverse impact on the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and had an accumulated deficit of $452.2 million as of September&#160;30, 2022 and $360.2 million as of December&#160;31, 2021. The Company&#8217;s cash and cash equivalents and marketable securities were $311.7 million and $383.2 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The Company has financed its operations to date primarily through equity capital raises. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that existing capital resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements, though it expects to continue to incur operating losses and negative operating cash flows. The Company will be required to raise additional capital to fund future operations, however, no assurance can be given as to whether additional needed financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail planned activities to preserve cash resources. These factors may adversely impact the Company&#8217;s ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(C) Significant Accounting Policies Update</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Annual Report on Form 10-K for the year ended December&#160;31, 2021. There have been no material changes to the Company&#8217;s significant accounting policies during the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(D) Recently Issued Accounting Pronouncements Not Yet Adopted </span></div>The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, the Company has elected to &#8220;opt out&#8221; of such extended transition period for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards on the same timeline as other public companies. The Company has evaluated recent accounting pronouncements and believes that there are none that will have a material impact on its financial position or results of operations upon adoption.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078630464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsAbstract', window );"><strong>License And Other Related Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsTextBlock', window );">Material Agreements</a></td>
<td class="text">Material Agreements <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with QED Therapeutics, Inc. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a license agreement (as subsequently amended, the &#8220;QED License Agreement&#8221;) with QED Therapeutics, Inc. (&#8220;QED&#8221;), under which the Company obtained an exclusive license under certain patents and know-how (including patents and know-how that QED licensed from QED&#8217;s upstream licensor) to develop, manufacture, use, sell, import, and commercialize QED&#8217;s ATP-competitive, FGFR1-3 tyrosine kinase inhibitor, infigratinib, in pharmaceutical products in the licensed territory of Mainland China, Macau, Hong Kong, Taiwan, Thailand, Singapore and South Korea, in the licensed field of human prophylactic and therapeutic uses in cancer indications. In September 2020, the Company entered into an amendment with QED to reduce the licensed territories to include Mainland China, Macau and Hong Kong. In December 2021, the Company entered into a second amendment with QED to modify the Company&#8217;s development obligations with respect to certain clinical trials, and change the development milestone payments the Company owes to QED and the royalty rates for the tiered royalties on net sales of licensed products the Company will pay to QED. Under the QED License Agreement, QED received a nonrefundable upfront payment of $10.0 million and was granted warrants to purchase 100,000 ordinary shares in Lian Oncology, a subsidiary of LianBio, valued at $1.0 million. Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model. The warrants were issued in three tranches with the aggregate number of shares across all tranches equaling 10% of the fully diluted equity of Lian Oncology as of the issue date. Vesting of the warrant shares are linked to regulatory milestones and the warrants expire 10 years from the issue date. The amended and restated option agreement also provides QED with the option to choose to either convert the warrant (&#8220;Subsidiary Warrant&#8221;) into ordinary shares of the Company (&#8220;Parent Company Shares&#8221;) or a warrant to purchase a certain number of Parent Company Shares (&#8220;Parent Company Warrant&#8221;) immediately prior to an IPO of the Company. In the event QED chose to convert the Subsidiary Warrant into Parent Company Shares, the number of Parent Company Shares QED is entitled to receive would be calculated as the aggregate fair market value of the ordinary shares of Lian Oncology that are under the Subsidiary Warrant, divided by the per share fair market value of the Parent Company Shares, on a fully diluted and as-converted basis and as of the date the Company sent QED the notice of the IPO. In the event QED chose to convert the Subsidiary Warrant into the Parent Company Warrant, the number of Parent Company Shares under the Parent Company Warrant QED was entitled to receive would have been calculated as the aggregate intrinsic value of the Subsidiary Warrant (the number of the ordinary shares of Lian Oncology under the Subsidiary Warrant multiplied by the difference between the strike price of the Subsidiary Warrant and the per share fair market value of Lian Oncology), divided by the per share intrinsic value of the Parent Company Warrant (the difference between the strike price of the Parent Company Warrant and the per share fair market value of Parent Company Shares), on a fully diluted and as-converted basis on the date of the warrant conversion. This conversion feature was not required to be bifurcated as it is clearly and closely related to the equity host instrument, pursuant to ASC 815. On October&#160;18, 2021, based on the conversion feature, LianBio issued to QED a warrant to purchase 347,569 of its ordinary shares at an exercise price of $0.000017100448 per share and, concurrently with such issuance, the Subsidiary Warrant was deemed to be performed and settled in full and was irrevocably terminated. The QED License Agreement also required the Company to refund QED for costs incurred on the study through the execution date which was determined to be $2.8 million. Additionally, QED is entitled to receive from the Company development milestone payments of up to $7.0 million upon achievement of specified development milestones, and sales milestone payments of up to $87.5 million based on cumulative net sales of infigratinib, in addition to tiered royalties on net sales of licensed products at the greater of (a) percentage rates in the mid- to high-teens on the net sales of the licensed products, or (b) the applicable rate payable under QED&#8217;s agreement with its upstream licensor (capped in the mid-teens).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with MyoKardia </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an exclusive license agreement (the &#8220;MyoKardia License Agreement&#8221;) with MyoKardia Inc. (&#8220;MyoKardia,&#8221; now a wholly-owned subsidiary of Bristol-Myers Squibb (&#8220;BMS&#8221;)), under which the Company obtained an exclusive license under certain patents and know-how of MyoKardia to develop, manufacture, use, sell, import and commercialize MyoKardia&#8217;s proprietary compound, mavacamten, in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand and Singapore, and in the licensed field of any indication in humans, which includes any prophylactic or therapeutic use in humans. Under the MyoKardia License Agreement, MyoKardia received a nonrefundable upfront payment of $40.0 million and was granted a warrant to purchase 170,000 ordinary shares in Lian Cardiovascular, a subsidiary of LianBio, valued at $33.8 million. Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model and the underlying assumptions are discussed in further detail in Note 10 in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. The warrants, representing 17% of the fully diluted equity of Lian Cardiovascular, are exercisable by MyoKardia at any time after issuance. The amended and restated option agreement also provides MyoKardia with the option to choose to either convert the warrant (&#8220;Subsidiary Warrant&#8221;) into ordinary shares of the Company (&#8220;Parent Company Shares&#8221;) or a warrant to purchase a certain number of Parent Company Shares (&#8220;Parent Company Warrant&#8221;) immediately prior to an IPO of the Company. MyoKardia was entitled to choose to convert the Subsidiary Warrant into Parent Company Shares, and the number of Parent Company Shares MyoKardia was entitled to receive would have been calculated as the aggregate fair market value of the ordinary shares of Lian Cardiovascular that are under the Subsidiary Warrant, divided by the per share fair market value of the Parent Company Shares, on a fully diluted and as-converted basis on the date the Company sent MyoKardia the notice of the IPO. Alternatively, MyoKardia was entitled to choose to convert the Subsidiary Warrant into the Parent Company Warrant, the number of Parent Company Shares under the Parent Company Warrant MyoKardia was entitled to receive would be calculated as the aggregate intrinsic value of the Subsidiary Warrant (the number of the ordinary shares of Lian Cardiovascular under the Subsidiary Warrant multiplied by the difference between the strike price of the Subsidiary Warrant and the per share fair market value of Lian Cardiovascular), divided by the per share intrinsic value of the Parent Company Warrant (the difference between the strike price of the Parent Company Warrant and the per share fair market value of Parent Company Shares), on a fully diluted and as-converted basis on the date of the warrant conversion. This conversion feature was not required to be bifurcated as it was clearly and closely related to the equity host instrument, pursuant to ASC 815. As of October&#160;12, 2021, MyoKardia elected not to exercise this option and, therefore, continues to hold its warrant to purchase 170,000 ordinary shares in Lian Cardiovascular. MyoKardia&#8217;s option to convert the warrant irrevocably terminated upon the completion of the Company&#8217;s IPO. Additionally, MyoKardia was entitled to receive a nonrefundable financing milestone payment of $35.0 million upon a specified financing event, which occurred on October 29, 2020. The financing milestone was recorded at present value upon execution of the MyoKardia License Agreement, with total imputed interest of $2.3 million accreted under the effective interest method through the date the liability was settled. The financing milestone was paid to MyoKardia in December 2020 as a result of the Series A Preferred financing. Additionally, MyoKardia is entitled to receive from the Company development milestone payments of up to $60.0 million upon achievement of specified development milestones, and sales milestone payments of up to $87.5 million based on cumulative net sales of mavacamten, plus tiered royalties on net sales ranging from the low to upper-teens. As of September&#160;30, 2022, the Company has paid $5.0 million to MyoKardia upon the completion of the first development milestone under the MyoKardia License Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Navire</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, pursuant to the BridgeBio exclusivity agreement, the Company entered into an exclusive license agreement with Navire Pharma, Inc. (&#8220;Navire&#8221;), a BridgeBio affiliate. Pursuant to the license agreement, Navire granted to the Company an exclusive, sublicensable license under certain patents and know-how of Navire to develop, manufacture, use, sell, import and commercialize Navire&#8217;s proprietary SHP2 inhibitor, BBP-398 (formerly known as IACS-15509) in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand, Singapore, and South Korea. Under the license agreement, Navire received a nonrefundable upfront payment of $8.0 million. Additionally, Navire is entitled to receive from the Company development milestone payments of up to $24.5 million upon achievement of specified development milestones, and sales milestone payments of up to $357.6 million upon achievement of specified commercialization milestones, plus tiered royalties on net sales ranging from approximately 5-15% on the net sales of the licensed products. The Company paid the first development milestone of $8.5 million for IND acceptance in the PRC during the third quarter of 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Strategic Collaboration </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a strategic collaboration agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which Pfizer will contribute up to $70.0 million of restricted, non-dilutive capital (the &#8220;Funds&#8221;), including a $20.0 million upfront payment, toward the Company&#8217;s in-licensing and co-development activities in Greater China. The Company has accounted for the Pfizer Agreement as a contract to perform research and development services for others under ASC 730-20 and the consideration received for performing these services will be recognized as contra-R&amp;D in the consolidated statement of operations as the services are performed. Upon receipt of the $20.0 million  upfront payment in the first quarter of 2021, the upfront payment was recorded as restricted cash within consolidated balance sheet and will remain restricted until such time as the upfront payment is utilized for specified in-licensing and co-development activities or until the Pfizer Agreement terminates. Under the Pfizer Agreement, Pfizer and LianBio will form a joint collaboration committee to discuss potential third party in-license opportunities and development and commercialization of the Company&#8217;s products in Greater China. In the event the Company seeks to engage a third-party commercialization partner with respect to the commercialization of the Company&#8217;s future products in Greater China, Pfizer will have a right to opt into such product. Upon opting in, a portion of the Funds will be used to pay for development and commercialization costs of such product and Pfizer will thereafter have a right of first negotiation and right of last refusal to obtain the commercialization rights of such product in Greater China, in each instance for additional, separate financial consideration. During the collaboration, Pfizer may provide in-kind support to us for marketing, development and regulatory activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with ReViral </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive license agreement (the &#8220;ReViral License Agreement&#8221;) with ReViral Ltd. (&#8220;ReViral,&#8221;  now a wholly-owned subsidiary of Pfizer). Pursuant to the license agreement, ReViral granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize novel antiviral therapeutics that target respiratory syncytial virus in Mainland China, Macau, Hong Kong, and Singapore. Under the license agreement, ReViral received a nonrefundable upfront payment of $14.0 million. Additionally, ReViral is entitled to receive payments from the Company totaling an aggregate of up to $105.0 million upon the achievement of specified development and commercial milestones, up to $45.0 million and $60.0 million, respectively, plus tiered royalties on net sales ranging from ten to the low-teens.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Tarsus</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive license agreement (the &#8220;Tarsus License Agreement&#8221;) with Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221;). Pursuant to the license agreement, Tarsus granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize TP-03 for the treatment of patients with Demodex blepharitis and Meibomian Gland Disease in Mainland China, Macau, Hong Kong and Taiwan. Under the license agreement, Tarsus received a nonrefundable upfront payment of $15.0 million and was granted three warrants to purchase 125,000 ordinary shares in Lian Ophthalmology, a subsidiary of LianBio, valued at $9.4 million (the &#8220;Tarsus Warrants&#8221;). Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model and the underlying assumptions are discussed in further detail in Note 10 in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. The warrants were issued in three tranches with the aggregate number of shares across all tranches equaling 12.5% of the fully diluted equity of Lian Ophthalmology as of the issue date. Vesting of the warrant shares are linked to regulatory milestones and the warrants expire 10 years from the issue date. Pursuant to a related option agreement (the &#8220;Tarsus Option Agreement&#8221;), Tarsus also had the option to convert the warrants into ordinary shares of the Company or warrants to purchase a certain number of the Company&#8217;s ordinary shares based on appreciation of the value in the Lian Ophthalmology since the inception of the Tarsus License Agreement. This conversion feature was not required to be bifurcated as it was clearly and closely related to the equity host instrument, pursuant to ASC 815.  On October&#160;18, 2021, Tarsus exercised its options to convert the Tarsus Warrants under the Tarsus Option Agreement and the Company subsequently issued to Tarsus 78,373 of its ordinary shares and two warrants to purchase an aggregate of 156,746 of its ordinary shares at an exercise price of $0.000017100448 per share. Following the issuances, the Tarsus Warrants were irrevocably terminated. On June 6, 2022, Tarsus exercised one warrant and the Company subsequently issued 78,373 of its ordinary shares at an exercise price of $0.000017100448 per share. Additionally, Tarsus is entitled to receive a nonrefundable second milestone payment of $10.0 million due and payable within forty-five days following the effective date. Furthermore, Tarsus is entitled to receive payments from the Company totaling an aggregate of up to $175.0 million upon the achievement of specified development and commercial milestones, up to $75.0 million and $100.0 million, respectively, plus tiered royalties at percentage rates ranging from the low- to high-teens on net sales.  In the second quarter of 2022, the Company was notified that Tarsus had achieved a certain development milestone and subsequently paid $15&#160;million in June 2022. As of September&#160;30, 2022, the Company has paid an aggregate of $45.0 million to Tarsus as a result of the achievement of various development milestones. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Landos</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement (the &#8220;Landos License Agreement&#8221;) with Landos BioPharma, Inc. (&#8220;Landos&#8221;). Pursuant to the license agreement, Landos granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize novel, gut-restricted small molecule omilancor (formerly known as BT-11) and NX-13 for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway in Mainland China, Hong Kong, Macau, Taiwan, Cambodia, Indonesia, Myanmar, Philippines, Singapore, South Korea, Thailand and Vietnam. Under the license agreement, Landos received a nonrefundable upfront payment of $18.0 million. Additionally, Landos is entitled to receive payments from the Company totaling an aggregate of up to $200.0 million upon the achievement of specified development and commercial milestones, up to $95.0 million and $105.0 million, respectively, plus tiered royalties at percentage rates ranging from the low- to the mid-teens on net sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Nanobiotix</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement (the &#8220;Nanobiotix License Agreement&#8221;) with Nanobiotix S.A. (&#8220;Nanobiotix&#8221;). Pursuant to the license agreement, Nanobiotix granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop and commercialize NBTXR3, a potential first-in-class radioenhancer in Mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore and Thailand. Under the license agreement, Nanobiotix received a nonrefundable upfront payment of $20.0 million. Additionally, Nanobiotix is entitled to receive payments from the Company totaling an aggregate of up to $220.0 million upon the achievement of specified development and commercial milestones, up to $65.0 million and $155.0 million, respectively, plus tiered royalties of 10-13% of net sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Lyra</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement (the &#8220;Lyra License Agreement&#8221;) with Lyra Therapeutics, Inc. (&#8220;Lyra&#8221;). Pursuant to the license agreement, Lyra granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop and commercialize LYR-210, an anti-inflammatory, intra-nasal drug matrix in late-stage development that is designed to treat chronic rhinosinusitis in Mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore and Thailand. Under the license agreement, Lyra received a nonrefundable upfront payment of $12.0 million. Additionally, Lyra is entitled to receive payments from the Company totaling an aggregate of up to $135.0 million upon the achievement of specified development and commercial milestones, up to $40.0 million and $95.0 million, respectively, plus tiered royalties from the low- to high-teens on net sales. As of September&#160;30, 2022, the Company has paid for the first development milestone of $5.0&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_LicenseAndOtherRelatedAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and other related agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_LicenseAndOtherRelatedAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_LicenseAndOtherRelatedAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and other related agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_LicenseAndOtherRelatedAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078536864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text">Marketable Securities and Fair Value Measurements<div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of marketable securities accounted for as available-for-sale securities at September&#160;30, 2022 and December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,652&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,894&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,067&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September&#160;30, 2022 are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.480%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,581&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,581&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,175)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,952&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December&#160;31, 2021 are as follows:</span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.480%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:27pt;text-indent:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities on the balance sheet at September&#160;30, 2022 and December&#160;31, 2021 are as follows:</span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:0.6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More Than 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More Than 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its securities as current as they are all available for sale and are available for current operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"/><td style="width:28.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.079%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Level 2 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Government obligations &amp; <br/>&#160;&#160;&#160;agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"/><td style="width:28.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.079%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%">Level 2 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078544064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net <div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:70.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,717&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">807&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,347&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,488&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation related to property and equipment was $0.3 million and  $0.7 million for the three and nine months ended September&#160;30, 2022, respectively, and $0.1 million and $0.3 million for the three and nine months ended September&#160;30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078640288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expense and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock', window );">Prepaid Expense and Other Current Assets</a></td>
<td class="text">Prepaid Expense and Other Current Assets <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets consist of the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:70.722%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Advance payments to suppliers and rent deposit</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,499&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expense and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078494720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:70.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.403%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee compensation and related benefits</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,801&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consulting and contracted research</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078465232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. As of September&#160;30, 2022 and December&#160;31, 2021, there have been no such matters identified. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within the range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The Company is not currently party to any material legal proceedings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078640288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company adopted a shareholder-approved share-based compensation plan (the &#8220;2019 Plan&#8221;), which permits the granting of incentive share options, nonqualified share options, share awards and certain other awards to its employees, members of its Board of Directors and consultants. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company adopted a shareholder-approved share-based compensation plan (the &#8220;2021 Equity Plan&#8221;), which permits the granting of incentive share options, nonqualified share options, share awards and certain other awards to its employees, members of its Board of Directors and consultants. The maximum number of shares that may be delivered in satisfaction of awards under the 2021 Equity Plan was initially approximately 14.2&#160;million shares, plus the number of shares that remained available for issuance under the 2019 Plan and that may again become available for issuance under such plan, not to exceed approximately 10.7&#160;million shares in the aggregate, and an annual increase, to be added as of January 1st of each year from January 1, 2022, to January 1, 2031, equal to the lesser of (i) four percent (4%) of the number of shares outstanding as of such date; and (ii) the number of shares determined by the Board of Directors on or prior to such date for such year. Subsequent to the effectiveness of the 2021 Equity Plan, no additional awards have been made pursuant to the 2019 Plan. However, any outstanding awards granted under the 2019 Plan will remain outstanding, subject to the terms of the 2019 Plan and award agreements. Through September&#160;30, 2022, there were awards outstanding for approximately 8.5 million ordinary shares under the 2019 Plan and approximately 5.5 million ordinary shares under the 2021 Equity Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Awards </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company issued options to purchase a total of 464,734 ordinary shares to various employees, directors and board members with a weighted-average exercise price of $3.37 per share option and a weighted-average fair value of $2.31 per share option. The fair-value based method for valuing each share option grant on the grant date uses the Black-Scholes Model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 2.56% - 3.90%; expected dividend yield of 0.00%; expected share price volatility of 76.83% - 79.65%; and expected term of 5.50 - 6.08 years. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021 the Company issued options to purchase 3,820,173 ordinary shares with a weighted-average exercise price of $6.84 per share option and a weighted-average fair value of $3.47 per share option. The fair-value based method for valuing each share option grant on the grant date uses the Black-Scholes Model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 0.09% - 1.22%; expected dividend yield of 0.00%; expected share price volatility of 60.00%; and expected term of 0.50 - 6.25 years.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, $38.3 million of total unrecognized expense related to non-vested share options is expected to be recognized over a weighted average period of 2.86 years from the date of grant. As of September&#160;30, 2021, $18.1 million of total unrecognized expense related to non-vested share options is expected to be recognized over a weighted average period of 3.36 years from the date of grant. Options granted to senior management and employees generally vest in equal annual increments over four years and grants issued subsequent to the IPO generally vest over four years with 25% vesting over the first year and monthly thereafter. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Share Awards </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no performance share awards granted during the nine months ended September&#160;30, 2022. During the nine months ended September&#160;30, 2021 the Company granted certain option awards with both market-vesting conditions and service-vesting conditions to a member of management. The market condition is based on the Company&#8217;s enterprise value. Per the terms of the award, these options will vest in two equal tranches based on the following thresholds:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">50% of the performance options will vest upon satisfaction of the Company achieving an enterprise value of not less than $2.0&#160;billion at any time after the grant date in accordance with the service condition described below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. 50% of the performance options will vest upon the satisfaction of the Company achieving an enterprise value of not less than $4.0&#160;billion at any time after the grant date in accordance with the service condition described below.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enterprise value shall be equal to the number of outstanding ordinary shares of the Company multiplied by the volume weighted average price of a single ordinary share averaged over a period of thirty days ending one day prior to the date of the valuation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the market conditions described above, the option contains explicit service vesting conditions, with one-fourth vesting each year over four years. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issued options are to purchase 1,938,615 ordinary shares with a weighted-average exercise price of $6.90 per share option and a weighted-average fair value of $4.72 per share option. The Company used a Monte-Carlo simulation to determine the grant date fair value for these awards, which takes into consideration the possible outcomes pertaining to the enterprise value market condition based on the following assumptions: risk-free interest rate of 0.81% - 1.63%; expected dividend yield of 0.0%; expected share price volatility of 47.07% - 80.64%; and expected term of 4.87 - 10.00 years.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there was $6.0 million of total unrecognized compensation cost related to outstanding performance share awards. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No performance-based share units (&#8220;PSUs&#8221;) were granted during the nine months ended September&#160;30, 2022 or 2021. As of September&#160;30, 2022, there was $2.1 million of total unrecognized compensation cost related to outstanding PSUs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company granted 29,785 non-vested restricted share units (&#8220;RSUs&#8221;) to certain employees, with a weighted-average grant date fair value of $2.56 per RSU. As of September&#160;30, 2022, there was $2.4 million of total unrecognized compensation expense related to non-vested RSUs. There were no RSUs granted during the nine months ended September&#160;30, 2021.</span></div>During the nine months ended September&#160;30, 2022, the Company granted 217,985 performance-based RSUs to certain employees, with a weighted-average grant date fair value of $2.17 per RSU. 60% of the total number of RSUs will vest on the one-year anniversary of the date on which the mavacamten New Drug Application (&#8220;NDA&#8221;) acceptance in China is obtained. The remaining 40% of the RSUs will vest on the six-month anniversary of the date on which the mavacamten NMPA acceptance is obtained in China. Upon termination of an employee&#8217;s service with the Company for any reason, any performance-based RSUs that are outstanding and not yet vested will be immediately forfeited. As of September&#160;30, 2022, there was $1.1 million of total unrecognized compensation expense related to non-vested performance-based RSUs. There were no performance-based RSUs granted in the nine months ended September&#160;30, 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078464000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding, plus all additional ordinary shares that would have been outstanding, assuming dilutive potential ordinary shares had been issued for other dilutive securities. For the three and nine months ended September&#160;30, 2022 and 2021, diluted and basic net loss per ordinary share were identical since potential ordinary shares were excluded from the calculation, as their effect was anti-dilutive.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:1.0%"/><td style="width:41.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.096%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,353,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,690,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,854,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,549,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per ordinary share &#8211; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share, because including them would have been anti-dilutive during each period. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable Convertible Preferred Shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,024,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Share Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,163,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QED Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyoKardia Warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarsus Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants in LianBio issued to QED and Tarsus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,942&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078423856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsIn October 2022, the Company was notified that Tarsus had achieved a certain development milestone, which, pursuant to the Tarsus License Agreement, triggered a $10.0 million milestone payment due in December 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076769632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(A) Basis of presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, which include the People&#8217;s Republic of China (&#8220;PRC&#8221;) registered entities directly owned by the Company. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim balance sheet as of September&#160;30, 2022, and the interim consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred shares and shareholders&#8217; equity (deficit) for the three and nine months ended September&#160;30, 2022 and 2021, and the cash flows for the nine months ended September&#160;30, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial information. The financial data and other information disclosed in these notes related to the three and nine month periods are also unaudited. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B) Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The only material estimates in the accompanying financial statements are the fair value of warrants, share-based compensation, and share options. Actual results could differ from those used in evaluating these accounting estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak a pandemic. The Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including planned clinical trials. The impact of the COVID-19 pandemic on the Company&#8217;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy continue to be impacted for an extended period, the Company&#8217;s results may be materially adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to material credit risk due to the financial position of the banking institutions. The Company has no off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could affect the Company&#8217;s operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials, uncertainty of regulatory approval of the Company&#8217;s potential product candidates, uncertainty of market acceptance of its product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company&#8217;s product candidates require approvals from the National Medical Products Administration (&#8220;NMPA&#8221;) in China and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, such events could have a materially adverse impact on the Company&#8217;s business.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">(D) Recently Issued Accounting Pronouncements Not Yet Adopted The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, the Company has elected to &#8220;opt out&#8221; of such extended transition period for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards on the same timeline as other public companies. The Company has evaluated recent accounting pronouncements and believes that there are none that will have a material impact on its financial position or results of operations upon adoption.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915070890928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of marketable securities accounted for as available-for-sale securities at September&#160;30, 2022 and December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,652&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,894&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,067&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities on the balance sheet at September&#160;30, 2022 and December&#160;31, 2021 are as follows:</span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:0.6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More Than 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More Than 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September&#160;30, 2022 are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.480%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,581&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,581&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,175)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,952&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:8pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December&#160;31, 2021 are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.480%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><span><br/></span></div><div style="text-indent:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"/><td style="width:28.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.079%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2022 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Level 2 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Government obligations &amp; <br/>&#160;&#160;&#160;agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"/><td style="width:28.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.079%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2021 (in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%">Level 2 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915080060944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:70.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,717&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">807&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,347&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,488&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078503008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expense and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expense and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets consist of the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:70.722%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Advance payments to suppliers and rent deposit</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,499&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078497152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:70.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.403%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee compensation and related benefits</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,801&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consulting and contracted research</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915078475488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Diluted and Basic Net Loss Per Ordinary Share</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:1.0%"/><td style="width:41.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.096%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,353,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,690,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,854,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,549,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per ordinary share &#8211; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share, because including them would have been anti-dilutive during each period. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable Convertible Preferred Shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,024,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Share Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,163,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QED Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyoKardia Warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarsus Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants in LianBio issued to QED and Tarsus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,942&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915073472816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Nov. 03, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,467,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,024,178<span></span>
</td>
<td class="nump">11,024,178<span></span>
</td>
<td class="nump">11,024,178<span></span>
</td>
<td class="nump">10,971,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance IPO</a></td>
<td class="nump">$ 334.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="nump">$ 304.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | ADR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | ADR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">593,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076019728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (452,249)<span></span>
</td>
<td class="num">$ (360,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 311,700<span></span>
</td>
<td class="nump">$ 383,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915062528736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Agreements - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 06, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_ClassOfWarrantOrRightNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,070<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adr_TarsusWarrantsMember', window );">Tarsus Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_NavireMember', window );">Navire | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement', window );">Payment towards development amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_NavireMember', window );">Navire | Maximum | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_TieredRoyaltyAsAPercentageOfNetSales', window );">Tiered royalty as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_NavireMember', window );">Navire | Minimum | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_TieredRoyaltyAsAPercentageOfNetSales', window );">Tiered royalty as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_NavireMember', window );">Navire | Specified Development Regulatory Milestone | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_NavireMember', window );">Navire | Sales Based Milestone | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Payable To Related Party Current | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy', window );">Reimbursement amount due towards costs incurred for the study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Specified Development Regulatory Milestone | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Sales Based Milestone | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Lian Oncology | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Class of warrants or rights expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Lian Oncology | Tranche One | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity', window );">Warrants or rights issuable as a percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Lian Oncology | Tranche Two | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity', window );">Warrants or rights issuable as a percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Lian Oncology | Tranche Three | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity', window );">Warrants or rights issuable as a percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_QedMember', window );">QED | Lian Oncology | Warrants To Purchase Common Stock | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants or rights exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000017100448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_MyokardiaMember', window );">Myokardia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_MyokardiaMember', window );">Myokardia | Specified Development Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentOfMilestoneAmount', window );">Payment of milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_MyokardiaMember', window );">Myokardia | Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_MyokardiaMember', window );">Myokardia | Non Refundable Financing Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_MilestonePaymentPayable', window );">Milestone payment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_ImputedInterestOnMilestonePayment', window );">Imputed interest on milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_MyokardiaMember', window );">Myokardia | Non Refundable Financing Milestone Payment | Amended Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentOfMilestoneAmount', window );">Payment of milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_MyokardiaMember', window );">Myokardia | Warrants To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity', window );">Warrants or rights issuable as a percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_CommitmentToContributeCapital', window );">Commitment to contribute capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_UpfrontPaymentReceivable', window );">Upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts and other receivables, net, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_ReviralMember', window );">Reviral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_ReviralMember', window );">Reviral | Specified Development Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_ReviralMember', window );">Reviral | Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_ReviralMember', window );">Reviral | Specified Development Regulatory And Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentOfMilestoneAmount', window );">Payment of milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Milestone Stage Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_MilestonePaymentPayable', window );">Milestone payment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Specified Development Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Specified Development Regulatory And Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Warrants To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Class of warrants or rights expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants or rights exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000017100448<span></span>
</td>
<td class="nump">$ 0.000017100448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_ClassOfWarrantOrRightIssued', window );">Warrants issued during period (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares upon initial public offering, net of issuance costs (in shares) | shares</a></td>
<td class="nump">78,373<span></span>
</td>
<td class="nump">78,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity', window );">Warrants or rights issuable as a percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity', window );">Warrants or rights issuable as a percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity', window );">Warrants or rights issuable as a percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LandosMember', window );">Landos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LandosMember', window );">Landos | Specified Development Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LandosMember', window );">Landos | Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LandosMember', window );">Landos | Specified Development Regulatory And Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_NanobiotixMember', window );">Nanobiotix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_NanobiotixMember', window );">Nanobiotix | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_TieredRoyaltyAsAPercentageOfNetSales', window );">Tiered royalty as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_NanobiotixMember', window );">Nanobiotix | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_TieredRoyaltyAsAPercentageOfNetSales', window );">Tiered royalty as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_NanobiotixMember', window );">Nanobiotix | Specified Development Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_NanobiotixMember', window );">Nanobiotix | Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_NanobiotixMember', window );">Nanobiotix | Specified Development Regulatory And Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LyraMember', window );">Lyra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LyraMember', window );">Lyra | Specified Development Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LyraMember', window );">Lyra | Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_LyraMember', window );">Lyra | Specified Development Regulatory And Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_LicenseAndOtherRelatedAgreementsLineItems', window );"><strong>License And Other Related Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_MilestonePaymentPayable', window );">Milestone payment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_AssetAcquisitionMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Milestone, Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_AssetAcquisitionMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_AssetAcquisitionNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Net Sales Milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_AssetAcquisitionNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_ClassOfWarrantOrRightNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_ClassOfWarrantOrRightNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_CommitmentToContributeCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment to contribute capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_CommitmentToContributeCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_ImputedInterestOnMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Imputed interest on milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_ImputedInterestOnMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_LicenseAndOtherRelatedAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and other related agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_LicenseAndOtherRelatedAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_MilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_MilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_PaymentOfMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_PaymentOfMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Towards Development Amount In Connection With License Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment towards upfront amount in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement amount due towards costs incurred for the study.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TieredRoyaltyAsAPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tiered royalty as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TieredRoyaltyAsAPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_UpfrontPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_UpfrontPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants or rights issuable as a percentage of fully diluted equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adr_TarsusWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adr_TarsusWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_NavireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_NavireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adr_AmendedLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adr_AmendedLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TypeOfMilestoneAxis=adr_SpecifiedDevelopmentRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TypeOfMilestoneAxis=adr_SpecifiedDevelopmentRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TypeOfMilestoneAxis=adr_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TypeOfMilestoneAxis=adr_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_QedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_QedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=adr_PayableToRelatedPartyCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=adr_PayableToRelatedPartyCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_LianOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adr_LianOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TrancheAxis=adr_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TrancheAxis=adr_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TrancheAxis=adr_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TrancheAxis=adr_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TrancheAxis=adr_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TrancheAxis=adr_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adr_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adr_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_MyokardiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_MyokardiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TypeOfMilestoneAxis=adr_NonRefundableFinancingMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TypeOfMilestoneAxis=adr_NonRefundableFinancingMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_ReviralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_ReviralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_TypeOfMilestoneAxis=adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_TypeOfMilestoneAxis=adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_MilestoneStageAxis=adr_MilestoneStageTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_MilestoneStageAxis=adr_MilestoneStageTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_LandosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_LandosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_NanobiotixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_NanobiotixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_LyraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_LyraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076413680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 234,086<span></span>
</td>
<td class="nump">$ 155,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,221)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">232,866<span></span>
</td>
<td class="nump">155,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">155,652<span></span>
</td>
<td class="nump">145,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(574)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">155,078<span></span>
</td>
<td class="nump">145,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,202<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(136)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">14,066<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">64,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 63,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076628224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Available-for-sale Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months, Unrealized losses</a></td>
<td class="num">$ (1,175)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Securities in an unrealized loss position less than 12 months, Fair Value</a></td>
<td class="nump">208,441<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months, Unrealized losses</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Securities in an unrealized loss position greater than 12 months, Fair Value</a></td>
<td class="nump">14,952<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized losses</a></td>
<td class="num">(1,221)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">223,393<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months, Unrealized losses</a></td>
<td class="num">(574)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Securities in an unrealized loss position less than 12 months, Fair Value</a></td>
<td class="nump">147,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months, Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Securities in an unrealized loss position greater than 12 months, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized losses</a></td>
<td class="num">(574)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">147,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months, Unrealized losses</a></td>
<td class="num">(136)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Securities in an unrealized loss position less than 12 months, Fair Value</a></td>
<td class="nump">14,065<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months, Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Securities in an unrealized loss position greater than 12 months, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized losses</a></td>
<td class="num">(136)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">14,065<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months, Unrealized losses</a></td>
<td class="num">(465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Securities in an unrealized loss position less than 12 months, Fair Value</a></td>
<td class="nump">46,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months, Unrealized losses</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Securities in an unrealized loss position greater than 12 months, Fair Value</a></td>
<td class="nump">14,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized losses</a></td>
<td class="num">(511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">$ 61,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months, Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Securities in an unrealized loss position less than 12 months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months, Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Securities in an unrealized loss position greater than 12 months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915070951904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Marketable Securities on the Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 12 Months</a></td>
<td class="nump">$ 215,939<span></span>
</td>
<td class="nump">$ 150,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne', window );">More Than 12 Months</a></td>
<td class="nump">16,927<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 12 Months</a></td>
<td class="nump">155,078<span></span>
</td>
<td class="nump">145,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne', window );">More Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 12 Months</a></td>
<td class="nump">14,066<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne', window );">More Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 12 Months</a></td>
<td class="nump">46,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne', window );">More Than 12 Months</a></td>
<td class="nump">$ 16,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne', window );">More Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915072808688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">$ 232,866<span></span>
</td>
<td class="nump">$ 155,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">291,326<span></span>
</td>
<td class="nump">311,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">53,472<span></span>
</td>
<td class="nump">67,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">237,854<span></span>
</td>
<td class="nump">243,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">155,078<span></span>
</td>
<td class="nump">145,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">155,078<span></span>
</td>
<td class="nump">145,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">155,078<span></span>
</td>
<td class="nump">145,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">14,066<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">14,065<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">14,065<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">63,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">63,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities | Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities | Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">63,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government obligations &amp; agency securities | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations | Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations | Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government obligations | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">53,472<span></span>
</td>
<td class="nump">67,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">53,472<span></span>
</td>
<td class="nump">67,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">4,988<span></span>
</td>
<td class="nump">80,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">4,988<span></span>
</td>
<td class="nump">80,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915073105696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,347<span></span>
</td>
<td class="nump">$ 2,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,212)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">3,135<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,717<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adr_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915075959600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915072219760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expense and Other Current Assets - Summary of Prepaid Expense and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PrepaidRentAndSupplies', window );">Advance payments to suppliers and rent deposit</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">7,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,117<span></span>
</td>
<td class="nump">$ 10,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_PrepaidRentAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid rent and supplies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_PrepaidRentAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915077595264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and related benefits</a></td>
<td class="nump">$ 4,801<span></span>
</td>
<td class="nump">$ 2,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">4,949<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_AccruedConsultingAndContractedResearchCurrent', window );">Consulting and contracted research</a></td>
<td class="nump">7,968<span></span>
</td>
<td class="nump">3,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 17,871<span></span>
</td>
<td class="nump">$ 9,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_AccruedConsultingAndContractedResearchCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Consulting And Contracted Research Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_AccruedConsultingAndContractedResearchCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076778192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915071959712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adr_TwoThousandAndTwentyOnePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum availability of ordinary shares under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares', window );">Annual increase in shares available for issuance, percentage of outstanding shares</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adr_TwoThousandAndNineteenPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum availability of ordinary shares under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period under plan (in shares)</a></td>
<td class="nump">464,734<span></span>
</td>
<td class="nump">3,820,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average grant date fair value per stock option (in dollars per share)</a></td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 38.3<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 38.3<span></span>
</td>
<td class="nump">$ 38.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition for unrecognized expense</a></td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
<td class="text">3 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Share Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.56%<span></span>
</td>
<td class="nump">0.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">76.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Share Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">79.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period under plan (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average grant date fair value per stock option (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,938,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PerformanceConditionOnMarketValue', window );">Performance condition on market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PerformanceConditionOnMarketValue', window );">Performance condition on market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period under plan (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">29,785<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">217,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Employee | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Employee | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_PerformanceConditionOnMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance condition on market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_PerformanceConditionOnMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Available for Issuance, Percentage of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adr_TwoThousandAndTwentyOnePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adr_TwoThousandAndTwentyOnePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adr_TwoThousandAndNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adr_TwoThousandAndNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915073130512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Diluted and Basic Net Loss Per Ordinary Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (21,897)<span></span>
</td>
<td class="num">$ (42,391)<span></span>
</td>
<td class="num">$ (27,726)<span></span>
</td>
<td class="num">$ (13,112)<span></span>
</td>
<td class="num">$ (100,428)<span></span>
</td>
<td class="num">$ (61,565)<span></span>
</td>
<td class="num">$ (92,014)<span></span>
</td>
<td class="num">$ (175,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares - basic (in shares)</a></td>
<td class="nump">108,353,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,690,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,854,547<span></span>
</td>
<td class="nump">20,549,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares - diluted (in shares)</a></td>
<td class="nump">108,353,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,690,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,854,547<span></span>
</td>
<td class="nump">20,549,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share&#160;&#8211; basic (in dollars per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (8.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share&#160;&#8211; diluted (in dollars per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (8.52)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915076668288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Potentially Dilutive Securities Were Excluded From Calculation of Diluted Net Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_RedeemableConvertiblePreferredSharesMember', window );">Redeemable Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,024,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">13,163,954<span></span>
</td>
<td class="nump">9,746,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Non-vested restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">864,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianOncologyIssuedToQedMember', window );">QED Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember', window );">MyoKardia Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianOphthalmologyIssuedToTarsusMember', window );">Tarsus Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants in LianBio issued to QED and Tarsus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">425,942<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_RedeemableConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_RedeemableConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianOncologyIssuedToQedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianOncologyIssuedToQedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianOphthalmologyIssuedToTarsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adr_WarrantsInLianOphthalmologyIssuedToTarsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139915077592608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - Tarsus Pharmaceuticals - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement', window );">Payment towards upfront amount in connection with license agreement</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment towards upfront amount in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adr_TarsusPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>adr-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adr="http://lian.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adr-20220930.xsd" xlink:type="simple"/>
    <context id="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19d8ab4f70d646d79d381b547e990263_I20221107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="ief76923dc8d8411997af1d7252a67753_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id77363498db642a188305f503a88fef2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i96883e148f06434c841b1d92a4923249_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f5d825b11064cda8a7136073c98c0d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d073cf810c741b19b080eec0ae65138_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ada05c0bc904557aaf7846916d75d12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee8c4f4547c34b3e98e00215a606db47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ec729d6293a456680bf668222068517_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59e7137c17d549fd820917694b08fc47_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ied110c888d57481db184f6175b1e2860_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5656796fbdd145b3849a36669cab8663_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8d7799072b4d422aab668bcd4244cab6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25d221360f31476098a1fd21dbc69534_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib9322e8463954303aeee1d8f5e12fc8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9466a2c38fce4a91b583d32e765dc4a2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d25dc71ceec4fb08e8991e050dccdbd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63c9cc56d5dd4eccb90e6223bdf350c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd6572c181b34370ba0e953f6fa9f119_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib22bfae9e2b24dca8b5d085801249b58_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i113de41b7dc04d4690e58ef90231b3a7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i922676779aab45b998d8c7c8042fb4b1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaf64ccfd7d8f40c18123b97e857d709b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a167087705d44768451e899dfad4ed5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i475ba3da26c54ed1b8be00efe29feec9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i770c7a6615c24dab958345dedaeaca2a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if0afac83be094d4aa4542e69b5679207_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic6ff887c265441c69507be611ce503ac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie17b5e7664cc4df68c65d8b884872e95_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6e238a55eb6949e3bfa3fc5e44d68d66_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1b044d6aec8a430b9c9d220877699973_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i53ad139f307f45f59574c837bac70329_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iea7287c095dd4fb394874127ce8b32e2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i48907c78fead48129720781ca8df4577_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i664446c89c5d42d18ba427b660facc0a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iada45bd66c5c4ac1ad4b3ddabe552196_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iff7da7e1062844c99aa94c7bbbe052e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i476a15e732a34295adea0c957a427196_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iefaabc71b2ab47ae804d1de9bee57351_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d6fbb393f9d410283f46ab5e21666d1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib12f0d7ec46545459636f4595ce63971_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i843b9dc93da54466be692b7fe0e517ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf757ee092794a7b907ffc699c87df97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00ba9d6adbc545c784eb291a888dd93d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc809e33c664490faf057840bbfd54f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10c747e16a744468928214dcc9e51ae1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd068d3e42c34c279f69aaf1be33f5c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5e6744690158405abbd221d7a074c791_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if81a8e1bb8e14340b40f2c724b9842a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adr:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5aae9117d3e343aa9c8b422b360bbf8b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia555d7f1cdbb4263b3e681f74e9864c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i094e8e47897d4872a7f705af07fdff66_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1d15540792024becacd6f0a5ad4ad608_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id2cfe092feb045dbbc9f7ccb340f1d54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i87f9f534bbe64805a759a975c5e89677_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8a7631dd76cf40a4b4fcef577ab42fd2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9065e3e77be445739a59ac03866a9ce3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7b1e1b4992c34e169c7d86153c6eb2ce_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i344b1e6c929d49dbb0309bbb28a88cbf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5f6c3f36b5eb42d299c7131a79fec1a3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i97b84f3425ae4c298fafa57dee035528_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9cf331c6036a4355a4904f3f4bbb1cd2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia7408c111d584b5ab590b62aac211dac_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i19cd0b34a996469990768d290687c7ee_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib11048778c5e4d0687735a5893af9693_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if8db68d789694f5cb6106efce2a2b3ae_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4a99f5ddcd3340849368e824f80c8eb2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie5f4de76939f4d41bae02354c1c148b7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie78c90d28271496cbeedbefdec9b279f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc84f64754e446c292da7857f70711f5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibde6fe20c7ce4abcb989cd5740f6517e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id926e92f71c541b1ae612d23291c8593_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b839be2585f4f18bbac068fb248673d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a135bc815214ea891762f3528c47479_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i54f1e96dce0d4efd8b146ffaad7ccb37_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i20f8c40cc106484c8030ad5495b23cfd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1be28631775249e1801ff1234f689d4e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a3842c85d9f4a828a8135e64dcab877_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic5b0e96016484b7d974af94c79a8fb0d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i89dd2c9150114f349e9c78a6c5a2a70f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if15bb3d88e144b8fb0462ca6bc65c410_D20211103-20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="ic9758d92ce7f4beb932f7cfa346c246c_D20211103-20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="ie6621d4b27834cd1a8fdbaa9dae39f18_I20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-03</instant>
        </period>
    </context>
    <context id="i5d453bec4c3b4dceb7ea5525faa7b87e_D20211201-20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="iff1946c96c304391bdd745ff4abb6f90_I20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="i13e6d021cd914175b381a66b8a7cbb8c_D20211201-20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="i378fd65bf5a34325aead1a87c2d54e68_I20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2021-11-03</instant>
        </period>
    </context>
    <context id="iaeeb6e6bbe6549bc95c5d66955d58c3e_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="ib952974c6da148e98796252b1f567278_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="ib5eacd74781d44f289c25d5872d43093_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i3e2ea8c3730c405aaaa82862d9f64c8c_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i696c50ecd8f14eb6b7b9e1bcbc34acce_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="iad897a5006884c3591079e3c6af4ff9b_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="ib6353efb7d3e492abdbd9b5ffce7d251_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i35b7d9bb22284b6badabc23d684178bd_I20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:LianOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-18</instant>
        </period>
    </context>
    <context id="i48477ba30acc44fda8e1ce1e3f7f5558_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">adr:PayableToRelatedPartyCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89c392c6026c4ca9864f26feb3f567e3_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="id05b0fb48e914379a182a9bec0d03a93_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:QedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i7a57dbf7904a433aa373a461fd34ad40_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i1c3b0a6c246849aa9cca5199dc89a774_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i43ad44c91d4b4706b2c2bdfbec79da2a_I20211012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-12</instant>
        </period>
    </context>
    <context id="i0f92dc83d35344a29383ddc78d8130f2_D20201029-20201029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:NonRefundableFinancingMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-29</startDate>
            <endDate>2020-10-29</endDate>
        </period>
    </context>
    <context id="iacb5da7838574f67a606a8efb8a5436a_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:NonRefundableFinancingMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ie45cfe90a52b41838961759bc21b1b6f_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i43f085f46e8c4f39a06df0cb33e0529d_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i4327ccb2e1d04429bc1d974a2a6127be_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:MyokardiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i10056a0bfe624fd0bdceedf504ed17c0_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ia198b999664b420daab0c08429b7466f_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ieeba3f0d0ce94801b53b3e5f40d513bd_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i0f3dfa4fc2174c5aa9f897019cc2c56d_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="if317a4c6058f43dc89f8e182c6ba342c_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iaea5c2f5b96f411b9b2bb59234cd0005_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adr:NavireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adr:AmendedLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie9b66761f9ee4964817884acfbe7e816_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ibd6484953b02463e9394d252438606b9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i63457cea5dad4e09a9dc7c0dc8901912_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f5317e2a4b64ef4b0ab307c146b677b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e97b24ff55f44ebbfc3c54fa67ea432_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i77f8ab5e29f14552995e67ec5208c971_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:ReviralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieefd544ceaa8467c8b9da24c29b947d0_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i52f7f825cc684f4eb4def6f2b5dec774_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d52b39d0f33473c9075d48ee2705ecf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0796e693bdf44849a2a5a2478fe283e2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i32b2cc0741f945b3921b5d42fb85ccf0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i39d96e7903c34602be47c9a10fe1600c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TrancheAxis">adr:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i859df84b6220412c8216feaef8618ca5_D20211018-20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-18</startDate>
            <endDate>2021-10-18</endDate>
        </period>
    </context>
    <context id="ife3c16d3aeff45b0a62a122f3ffc24be_I20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:TarsusWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-18</instant>
        </period>
    </context>
    <context id="ia1f77cc73d9d490ca49bf061664c20aa_I20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-18</instant>
        </period>
    </context>
    <context id="ief6faf9500eb46d6b9d7bd6521997ed4_D20220606-20220606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-06</startDate>
            <endDate>2022-06-06</endDate>
        </period>
    </context>
    <context id="i500e758b45e84882b8dc0bafbe78d9c0_I20220606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adr:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-06</instant>
        </period>
    </context>
    <context id="i5c7315d139a647a8916844403b35fcc1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:MilestoneStageAxis">adr:MilestoneStageTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4c0c055d4c454529972b2611f7bf8dde_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i901497f9715b416b90b0380aaed8d696_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i439b9dc6a4324951a68387b66378f8af_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iebb3f515f2af46d9a26d73623709d955_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i780e8a8772534c3abff5c2590cae6a48_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaf9846b2679d481c9f25e70face7e95d_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i4208c21f9651412684222291161e9b6b_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ie240169bdada412780e909f804cd7899_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="icfe5d9ec24324b71b0ae98324e5a1950_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LandosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i91dd2f17d34d4482a133ebd0c73e8ac8_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="idc8ffc33df4b44f6aac43fc889c6aab4_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i8a8f8ab0d9c841ca90cb65c873df8e7a_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i82819a00611e420f849e1cfc3bd4f1b7_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ica33bd99f1a34aec981651e9aef22732_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="id161c6b8aad740d6bf1489f3fa9c21de_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:NanobiotixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i25c130a8a3d84f3d9196a9765323af46_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i6eccd0754c4241649e346fd436f9f289_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i2c15a8a30aac4770a88597df9720a6f1_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ib2977a88c5df432e8077c4dacb23d3e2_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i7a53ee596d2c4c43965805d5c720ab94_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:LyraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adr:TypeOfMilestoneAxis">adr:SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i53ab1032d3924cd1b2dbf2289e458967_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i51c7d53772584519a9e4329929345cab_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie515765f7aaa42f68cd4e053d2b602bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85be39f95e554d6a8acaa6fff436b274_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i513f6fb095174b909385f721f0d3cf39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53c6ba62baae4983b42b842d1aeddb71_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ica40e054da6d4740987c1dc1a6a68af4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1827329195bd45ea9e34da5b92c6a744_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8b1fee8ff40e474fa97619a866abe5ac_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i583601b6fd494097a9a15ee54c69d290_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i97fca3542e3e4d248eba0ca3a2c0a2bd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i88787dac96ce45a1b690973dc5af39ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i92a84181a570474294e31e06040ab171_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia40d9c3f368a452aa391f0d7c258b7d6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d9e54db697947818a37b65b4445bf1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id77f5c68e566442eaa1bc371b7f5c5e2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i79217e78f9c54cbe9bc25876957657bd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8dacd15e2cb3482082951305e30bead4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i81645e508a424863b1adaf26443dcfe7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i52e530e77a5746d1a9a908e7d98f902e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if1678e1fc3ee4b4c94d479a128462f4e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i19f2de6f0d02407e85017a1bd9af1bcd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i146df2fb452d4fe6b51355e29fee9c51_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i73431d4fcaa142f5bba2f3bcf88537aa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib86a2fcbc7d44e0db98ad39b9b8bdd1c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i089cc9baca7b42b3a27fc68ddcc75811_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i02a7c6d6dd994b0e8d6e537613ef7302_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i599ef0489ae245fdad40419716223f6c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6992b347ac814ea5a287b5ea80729400_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i908a570e002147ee82ad8f4dcc47db40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b1ff5fc135e4f3c8cddc485f83622f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47023580772046b381bbc2733f87fab4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c847b99eb014c07aa341a9479de83f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i052630a8432947fbab3f9d75efa151ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4cb632483a8a4bb5ac50c44b07402ce5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e9201fc4c854336be93003ee6d57bf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04b9bb6127684414952f21a60b0d3628_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cfb1e63a5a148ea872a48d503461ff2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib56571b3d91e404288ff07ea7e32d86b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7923c86f54e4a37aa181f8a66eb944f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16a9d0cd183640358c221d658d05c903_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26445de729ae4d13b1780d0406629bb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1bd37354b8447fbbdf6d5058cd03cdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92a707e5adbc4b99b70f59775be134fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbaad0fc47e54c749c1bb25b94d34c50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05ac8403115d4cd3b344dc73c9163e90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4b54ba31d4848fc98d64676da86fa94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i006d54f5f1e04251898198b35f13f488_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia84c463023764fd7a23b168836df9331_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67b91ef85a3c4df0a1c9a6cc175f3af4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f8f992a4500455285df2bab55116fb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8842f59d8ef141fcafb8b68fe12e360c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76f313597efa43788e4abcc3748d1537_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52514ae79d6e4407beb955263f7b7dc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72c4d4eb4488417fbbe695608850e678_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36ea1b268ae24831a9bfec7be1c4c428_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i949e844f555744609cfcfdbd4bd385ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id17263b03feb4bf599db6d71049821f1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4ad1474b304d494cb73a261a3a3b32c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94fe0cda96314d9780ce44c077411b21_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4aa405a5bd447b4a32e03e704b92251_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4396dac7b05e465b80f79cd6478b8a6e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib959c47e99054dfc80bccef6276320e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec0bf146cc074bbb926e252ce7e39da9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3d076d62c9844f5cbc99d095571fcffa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibef4c7d268f5402dae0e1b439efb68f4_I20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-03</instant>
        </period>
    </context>
    <context id="ie0f6b78d38b54b2b9954c7b5a6114f41_I20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-03</instant>
        </period>
    </context>
    <context id="ice923f6c800447bcb1d172a7ed1e741c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1a0efa3f6688449aa871fe22f08334a7_D20191201-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iadc7598a210a4dfeab2ec14ba7e4c6e4_D20211103-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adr:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifc475a18a1634df89b155ffac5055809_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia858e3c7efff4cc39fbe4c012eb1ec90_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i11c152c42e3146f894258b2b89a5e956_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia040378a6b2244fa861c27980e968a32_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c27ecbad78a402aa40e15a813e287a6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib1340243c4b74132babad381c7136bc2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i163994ff7dd148e6a47533a384b804b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia37aaf2e75dc4f9c8d8fedc3b1cb29f4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i790b35dc63d348a8ad805f2a45e3e6a9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iae18a04092e5496faf63315837e7fc8c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i385421b8aac749b6b3bb67d39e04d1d2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8b0e7ba818d4c4baf09cc8d2c41d451_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i34a4b2db597d4126ab138b1b321c7166_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i42d2e669f7ca4fe89612a0a784bcd359_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4875fecaf1f14bb5b5c2ceef28b17b17_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic09c463503db4ad7ae3248958a79fe4c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37e42e244697487da44b1a88c9ca695c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id04ab5e91570453bafa51dfcaedd5a80_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie7409e8003154a5392e873de4657fb1e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6a0e878a4e9940a8ba193c5c8a44bfe7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:RedeemableConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia34cd0bfaa564a92bd7ecdce2c826bc7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:RedeemableConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i484a69d178e340c093a1bcad9d0db61c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i862b94711dca4e4ba65e7ffa96c12b95_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i014e8a19793d40bcac2baddf7496bd9d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide326c86d4704627b79b2a501c2b05bf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05d0df6c0bc4407982ff2dcc72c8d5f7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOncologyIssuedToQedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i42da493784984b80a81dd34f00fb97ed_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOncologyIssuedToQedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3dd61e8d2ee742ceacc281b00f2bf38e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianCardiovascularIssuedToMyokardiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i961337664bec4684bab70b8f50eb6fb4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianCardiovascularIssuedToMyokardiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2547429e3324581bbf6156636e2a767_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOphthalmologyIssuedToTarsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a3a509b1bb04448b439c32f4c6b8a98_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adr:WarrantsInLianOphthalmologyIssuedToTarsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id423453fa6364ca8947d21bf8eeb83d4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5dbf76887d084a01a1e484f9fc38af0a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0378cbfd28884eb698663743fe75feda_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831283</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adr:TarsusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="tranche">
        <measure>adr:tranche</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl8yLTEtMS0xLTQ5MDM4_e01e1975-4709-4727-b82e-d458fb35dfbe">0001831283</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl8zLTEtMS0xLTQ5MDM4_81228561-1e72-4431-8493-fcb841494a14">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl80LTEtMS0xLTQ5MDM4_8d0daa6d-b783-4e2a-8368-e986784de98c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl81LTEtMS0xLTQ5MDM4_62728bb5-3dbe-4c86-8136-d6d3fda678f0">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80L2ZyYWc6ODVjM2VjNGZmNGI3NDcwMzhjMTUyODBjMWNjNjA3ZmIvdGFibGU6YWQxOTBmYzQzNWVjNGQyYzgzNjE2NjFiZGQyNDE2YzYvdGFibGVyYW5nZTphZDE5MGZjNDM1ZWM0ZDJjODM2MTY2MWJkZDI0MTZjNl82LTEtMS0xLTQ5MDM4_bd523e9a-72cf-4c01-ab6b-3081430fea4a">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk3_a0aab789-0bfc-4b1b-8a95-22c449f4c3ba">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YzgzY2NkMGE0ODAyNDg0MzhiMzZhYTdiODBhNzhhNmMvdGFibGVyYW5nZTpjODNjY2QwYTQ4MDI0ODQzOGIzNmFhN2I4MGE3OGE2Y18wLTEtMS0xLTQ5MDM4_9225f0a0-bb37-42b0-b9ad-1a4922e263d2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN181NDk3NTU4MTYwNDA_d9f8d5d4-c255-4329-a0d4-32d02422842c">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6NjdlZTg0MWNlMWU5NDllMWFlZGIwMGRiZTMwZDUxNjAvdGFibGVyYW5nZTo2N2VlODQxY2UxZTk0OWUxYWVkYjAwZGJlMzBkNTE2MF8wLTEtMS0xLTQ5MDM4_c623c4dc-1ef5-48c2-b666-69a54fde5fd0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk4_c4d70b5e-dcb0-48db-a8df-2cc5fe324241">001-40947</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk5_933dbcc2-7906-47c2-830d-26ed130257cd">LianBio</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8wLTAtMS0xLTQ5MDM4_93e744f8-4f80-44f5-8395-fc6692afd78f">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8wLTEtMS0xLTQ5MDM4_e6eb6f5f-a75a-4c7e-a1a2-a9df4696069c">98-1594670</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfNA_f0ff1629-5aea-4041-a3e6-f7722a93d26d">103 Carnegie Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfOA_fb0eecd7-f53d-4dd8-9fb4-37ed8a6b4735">Suite 309</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfMTE_2b1c8631-d2e7-42ff-82c2-6a7010ef9aaa">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTAtMS0xLTQ5MDM4L3RleHRyZWdpb246OTZmNGE4N2VlNzExNDhlZjkwMjAxMTNjYzk2M2I5MjFfMTU_4aa82cfb-d3ae-4776-b97f-0625e825bb99">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6YWZmODM5ZWZiN2YwNGVlYWFkYzNiMjJiNDcyM2I5MmUvdGFibGVyYW5nZTphZmY4MzllZmI3ZjA0ZWVhYWRjM2IyMmI0NzIzYjkyZV8zLTEtMS0xLTQ5MDM4_33eb5697-e3f0-4e47-9f71-7e935dc84ad1">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDkx_9e387e75-18ea-4683-ba31-f9c5dcc5129b">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMTAw_4af4fe6b-08b4-4df8-8f06-f8567079c088">486-2308</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZTgxNzU3YmYzYTAzNDVlY2FlODQzZjQyYzEyMDcwZWEvdGFibGVyYW5nZTplODE3NTdiZjNhMDM0NWVjYWU4NDNmNDJjMTIwNzBlYV8xLTAtMS0xLTQ5MDM4_c07b5871-19a3-472e-906b-f28bfa6e5035">American Depositary Shares, each representing 1 ordinary share, par value $0.000017100448 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZTgxNzU3YmYzYTAzNDVlY2FlODQzZjQyYzEyMDcwZWEvdGFibGVyYW5nZTplODE3NTdiZjNhMDM0NWVjYWU4NDNmNDJjMTIwNzBlYV8xLTItMS0xLTQ5MDM4_89b7d02e-cdd1-40ea-9cdd-3f4a97fb2180">LIAN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZTgxNzU3YmYzYTAzNDVlY2FlODQzZjQyYzEyMDcwZWEvdGFibGVyYW5nZTplODE3NTdiZjNhMDM0NWVjYWU4NDNmNDJjMTIwNzBlYV8xLTQtMS0xLTQ5MDM4_83d3e585-034c-4e50-8b08-5b9b7a061434">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMTAx_e56d727b-92c7-4f6a-88fd-5c5a444c4001">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk0_68ea2e28-c5f5-42e9-bd89-a72e045e5d03">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZGI2MGMzYmE5NDU3NGJkNDliZTA1MjQ5OWRkMjI2MDIvdGFibGVyYW5nZTpkYjYwYzNiYTk0NTc0YmQ0OWJlMDUyNDk5ZGQyMjYwMl8yLTAtMS0xLTQ5MDM4_3c81e06d-ba39-4916-8dc1-3c6410e494be">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZGI2MGMzYmE5NDU3NGJkNDliZTA1MjQ5OWRkMjI2MDIvdGFibGVyYW5nZTpkYjYwYzNiYTk0NTc0YmQ0OWJlMDUyNDk5ZGQyMjYwMl8yLTQtMS0xLTQ5MDM4_22a9235a-c7db-4984-aede-fd8a435a91c3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGFibGU6ZGI2MGMzYmE5NDU3NGJkNDliZTA1MjQ5OWRkMjI2MDIvdGFibGVyYW5nZTpkYjYwYzNiYTk0NTc0YmQ0OWJlMDUyNDk5ZGQyMjYwMl80LTEtMS0xLTQ5MDM4_06db575d-c29d-4cb2-a463-d7773b99dd64">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDkz_f4fe57c0-0eea-4fc1-9369-a23aa8998fc3">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18yMDk1_39a0e226-23f4-436f-b133-a4ba19e2c653">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i19d8ab4f70d646d79d381b547e990263_I20221107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xL2ZyYWc6MGRhMTdjOWQ0MTZjNDI3NjgyMGM4MGI5NzExNTAwYTcvdGV4dHJlZ2lvbjowZGExN2M5ZDQxNmM0Mjc2ODIwYzgwYjk3MTE1MDBhN18xOTMw_175c98ee-1575-4e3b-bf81-7ddd52339853"
      unitRef="shares">108353831</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMy0xLTEtMS00OTAzOA_ed555ac4-f075-4e0c-a92b-3143e4182d2d"
      unitRef="usd">78862000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMy0zLTEtMS00OTAzOA_6bb75d11-9fae-471d-87e5-748874661f17"
      unitRef="usd">228182000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNC0xLTEtMS00OTAzOA_e1a07b7c-f662-4487-86c5-18dcc37781b6"
      unitRef="usd">232866000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNC0zLTEtMS00OTAzOA_f6d519b2-49d5-4798-a309-3bde8f3fdd42"
      unitRef="usd">155067000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNi0xLTEtMS00OTAzOA_ee3e1c45-84b8-4708-93e3-0fe2e91744e3"
      unitRef="usd">5117000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNi0zLTEtMS00OTAzOA_cceae27f-675c-47c4-a6ee-fb906fca2e6e"
      unitRef="usd">10354000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNy0xLTEtMS00OTAzOA_d0a1c5b4-64ec-486d-ac24-ffbb4ab5456c"
      unitRef="usd">7393000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfNy0zLTEtMS00OTAzOA_0bef4cbb-4e30-4a35-bf22-2afee9863b95"
      unitRef="usd">6044000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOC0xLTEtMS00OTAzOA_810f9937-f567-413d-a6e1-b07f1a7bab8e"
      unitRef="usd">324238000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOC0zLTEtMS00OTAzOA_0ecbdbee-1d8f-4ee9-9c37-b233d533dc0c"
      unitRef="usd">399647000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOS0xLTEtMS00OTAzOA_0a9adcb4-b04a-4fc3-85a1-b8879f5f203c"
      unitRef="usd">20070000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfOS0zLTEtMS00OTAzOA_0ce835e6-bda1-4251-b0ed-335af578bbd4"
      unitRef="usd">20000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTAtMS0xLTEtNDkwMzg_9b4ae3ee-52f6-4bf4-8612-5ec9a00bb8a7"
      unitRef="usd">3135000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTAtMy0xLTEtNDkwMzg_7f098d67-e955-499d-8928-fad74521302a"
      unitRef="usd">1882000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTEtMS0xLTEtNDkwMzg_d89f31f3-5d9c-4849-86d0-c1af43d42872"
      unitRef="usd">4362000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTEtMy0xLTEtNDkwMzg_20eafbe2-0d24-41a4-b079-d33f6d752be8"
      unitRef="usd">4763000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTItMS0xLTEtNDkwMzg_f4d32a32-6bfa-4697-a7c4-7ee29e1a66e0"
      unitRef="usd">37000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTItMy0xLTEtNDkwMzg_c13610ca-a8e2-4f1a-85e5-363970d746a6"
      unitRef="usd">51000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTMtMS0xLTEtNDkwMzg_5edd8f53-7735-4958-a497-1c304f7c6442"
      unitRef="usd">351842000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTMtMy0xLTEtNDkwMzg_56398ac0-7ddf-4a27-bb77-7c4c5785db8e"
      unitRef="usd">426343000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTYtMS0xLTEtNDkwMzg_644fc724-fcf1-4154-8c10-ca1bae948ec1"
      unitRef="usd">2019000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTYtMy0xLTEtNDkwMzg_b6d71570-f886-41fc-b4c6-7921d46ca025"
      unitRef="usd">3231000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTctMS0xLTEtNDkwMzg_ba67a720-e04e-4696-b94e-827cbf910470"
      unitRef="usd">17871000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTctMy0xLTEtNDkwMzg_fb5987c9-63a5-4304-8111-58d61b9e8788"
      unitRef="usd">9976000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTgtMS0xLTEtNDkwMzg_1f6baed1-4c20-4741-8d04-76087921019e"
      unitRef="usd">1750000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMTgtMy0xLTEtNDkwMzg_c78d1c94-88ee-4c0e-be21-e5ea51ab49f2"
      unitRef="usd">1125000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjAtMS0xLTEtNDkwMzg_de5d9622-fac2-4f92-8205-6f99d3a18ac3"
      unitRef="usd">387000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjAtMy0xLTEtNDkwMzg_d6b5246b-84c5-4ef1-9f87-b8b170aaa628"
      unitRef="usd">760000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjEtMS0xLTEtNDkwMzg_d53a1601-aca3-4ac0-9c61-8bea8b70612d"
      unitRef="usd">22027000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjEtMy0xLTEtNDkwMzg_02768c27-1b68-4a18-919f-fcf14d0a35c6"
      unitRef="usd">15092000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjItMS0xLTEtNDkwMzg_c9f77ef1-61c9-4538-8ffe-540c09f6006c"
      unitRef="usd">3017000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjItMy0xLTEtNDkwMzg_924d32c2-c745-46a7-b1e8-b4febd96794f"
      unitRef="usd">3709000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjMtMS0xLTEtNDkwMzg_863e52f2-7e3e-4b46-9c32-cc1d03133494"
      unitRef="usd">200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjMtMy0xLTEtNDkwMzg_51021b18-8a6e-4b80-9355-d368aaaadf33"
      unitRef="usd">206000</us-gaap:OtherLiabilitiesNoncurrent>
    <adr:NonrefundableResearchDeposit
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjQtMS0xLTEtNDkwMzg_fab77a05-1f61-4d82-9bad-262e25477f3b"
      unitRef="usd">20000000</adr:NonrefundableResearchDeposit>
    <adr:NonrefundableResearchDeposit
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjQtMy0xLTEtNDkwMzg_6705f045-2646-4d1f-a96d-dc59c3f66b8c"
      unitRef="usd">20000000</adr:NonrefundableResearchDeposit>
    <us-gaap:Liabilities
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjUtMS0xLTEtNDkwMzg_db21940d-257a-49d7-aa5c-c24e751c2adb"
      unitRef="usd">45244000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjUtMy0xLTEtNDkwMzg_881a104b-e07a-412c-a4cc-39de05913486"
      unitRef="usd">39007000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjYtMS0xLTEtNDkwMzg_075b37e4-19f2-41d3-a6e8-c8c8fd8df297"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjYtMy0xLTEtNDkwMzg_86c1742d-a27e-4f38-86c8-8051e2a0c472"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18yMQ_37170f7f-fb12-444b-b7b7-a3f3d307b258"
      unitRef="usdPerShare">0.000017100448</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18yMQ_a943bbe1-e931-45f5-b1f4-80e018ecc2f6"
      unitRef="usdPerShare">0.000017100448</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM180Ng_8f0be365-deb1-47c7-82dd-62792fb470bc"
      unitRef="shares">2923900005</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM183Nw_35e201c9-d7a5-49ea-bba9-b26e53eb2e9b"
      unitRef="shares">108353831</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM183Nw_f2769e0d-98b3-4534-b7d6-a10dd9109d42"
      unitRef="shares">108353831</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18xMzk_ca59ca2f-ddee-4c48-954e-0fd2a0fcb7d5"
      unitRef="shares">2923900005</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18xNzQ_e6533453-0986-47c7-8d04-6dacddaa1ed7"
      unitRef="shares">107275458</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMC0xLTEtNDkwMzgvdGV4dHJlZ2lvbjo5YmQ0Yzc4Y2Q2OGI0MmZjOTRkZDQ1NzU5ZDMzMTJiM18xNzQ_f2e536fd-ea8c-4df5-9e74-a95d6e67d9f0"
      unitRef="shares">107275458</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMS0xLTEtNDkwMzg_1d490da1-5840-4eb6-aa16-e3ab0aca5849"
      unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjgtMy0xLTEtNDkwMzg_832bac7e-64f8-460b-98f0-1bf8824ae3f9"
      unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjktMS0xLTEtNDkwMzg_8092cbb2-f78f-474d-b49f-897cf49c021b"
      unitRef="usd">728915000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMjktMy0xLTEtNDkwMzg_5b2e2fe3-8b33-4b9d-845f-1a688726a625"
      unitRef="usd">713269000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzAtMS0xLTEtNDkwMzg_e12f4873-3365-42be-b498-1c88813436d9"
      unitRef="usd">-3844000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzAtMy0xLTEtNDkwMzg_7cbd61c2-874a-4a9d-8bb0-e98b7af2e477"
      unitRef="usd">526000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzEtMS0xLTEtNDkwMzg_18fc1018-52b6-42a3-bdd5-1741cbc126b0"
      unitRef="usd">-452249000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzEtMy0xLTEtNDkwMzg_e1cddaa4-2333-46b5-b6b8-779a677acc6d"
      unitRef="usd">-360235000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzItMS0xLTEtNDkwMzg_f4857326-ed04-4506-8934-0458265b80de"
      unitRef="usd">272824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzItMy0xLTEtNDkwMzg_f352b815-1f7d-47a2-9764-8ced7adc7272"
      unitRef="usd">353562000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzMtMS0xLTEtNDkwMzg_5660008f-e3b9-42a2-9537-aeffdc647c28"
      unitRef="usd">33774000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzMtMy0xLTEtNDkwMzg_9fee3ff9-520f-475b-8df0-f8855de1310f"
      unitRef="usd">33774000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzQtMS0xLTEtNDkwMzg_08bc1cf1-dda8-4626-8fd2-536cf2331e7b"
      unitRef="usd">306598000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzQtMy0xLTEtNDkwMzg_3b8ef9d3-e5a3-4ab0-98fd-7b7a36fad620"
      unitRef="usd">387336000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzUtMS0xLTEtNDkwMzg_7c28131b-22af-437d-b612-aaf596e08812"
      unitRef="usd">351842000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xNi9mcmFnOmQ1OTE0YWJiODQxMjRkMmRhZjc0MDE5OTllOTliYTM5L3RhYmxlOmI3YzkzMmE5NTU1ODQ5YzA5M2MwMGVkMmY0NjY0ZDNlL3RhYmxlcmFuZ2U6YjdjOTMyYTk1NTU4NDljMDkzYzAwZWQyZjQ2NjRkM2VfMzUtMy0xLTEtNDkwMzg_e5f8ef14-60d0-4047-adfc-f0ca4419004b"
      unitRef="usd">426343000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy0xLTEtMS00OTAzOA_2dbc3095-87bc-4409-909f-613655a3eff8"
      unitRef="usd">8258000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy0zLTEtMS00OTAzOA_ecc1384c-a6bd-462e-b0e6-1191d8ecbde5"
      unitRef="usd">4655000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy01LTEtMS00OTAzOA_bf376717-55ee-42e6-bd8f-b9693a21c8e8"
      unitRef="usd">49178000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfNy03LTEtMS00OTAzOA_eff00047-1f54-49d1-9630-1e8326d4f399"
      unitRef="usd">151038000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC0xLTEtMS00OTAzOA_5dc60cf5-a4cb-48f4-8b05-89adf4155199"
      unitRef="usd">16291000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC0zLTEtMS00OTAzOA_b979e658-9719-4dad-8f5b-7d7efd501b7d"
      unitRef="usd">8889000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC01LTEtMS00OTAzOA_c4a45be8-8dde-488f-8c76-a93b253ff52c"
      unitRef="usd">46930000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOC03LTEtMS00OTAzOA_d1772b02-c982-46b9-8a74-22be9b24aff9"
      unitRef="usd">22496000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS0xLTEtMS00OTAzOA_785849c2-a1f4-481c-9b63-64783e6f787a"
      unitRef="usd">24549000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS0zLTEtMS00OTAzOA_04e9d85b-5f0a-4bef-bb32-0c3be0405dd0"
      unitRef="usd">13544000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS01LTEtMS00OTAzOA_7e8f6997-73f4-4a4d-8dc6-b942eea124a7"
      unitRef="usd">96108000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfOS03LTEtMS00OTAzOA_abcbbe48-df2e-4e4f-b93f-1b95ea281177"
      unitRef="usd">173534000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtMS0xLTEtNDkwMzg_c0df36cb-9a8f-45c5-9545-4f53ad6792a8"
      unitRef="usd">-24549000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtMy0xLTEtNDkwMzg_63f63980-9883-4485-b93f-701776d5acdd"
      unitRef="usd">-13544000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtNS0xLTEtNDkwMzg_25e94142-8849-4ce2-a8ff-0c71e926400e"
      unitRef="usd">-96108000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTAtNy0xLTEtNDkwMzg_79eb4507-02b5-4e7a-bb55-716ec013ba10"
      unitRef="usd">-173534000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItMS0xLTEtNDkwMzg_b3ea4171-9f2c-46e6-9dd7-a38fabc46cf0"
      unitRef="usd">1405000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItMy0xLTEtNDkwMzg_063507b7-018f-4c70-9bb2-99deacfcdd8b"
      unitRef="usd">32000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItNS0xLTEtNDkwMzg_f13bc254-1f8a-4bb2-b832-5e6bb4b036a7"
      unitRef="usd">2238000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTItNy0xLTEtNDkwMzg_9dbe31b4-6b08-4037-880a-13005397f143"
      unitRef="usd">171000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtMS0xLTEtNDkwMzg_352e15fd-d53e-4346-af22-ba21a2b56bbe"
      unitRef="usd">1253000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtMy0xLTEtNDkwMzg_eddae970-a962-4b14-9494-80d39636f20e"
      unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtNS0xLTEtNDkwMzg_ee7031ab-88fd-4b2f-aba6-1478aece3f3c"
      unitRef="usd">1873000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTMtNy0xLTEtNDkwMzg_bc20399e-aa38-4e87-9ab3-656086185709"
      unitRef="usd">-189000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtMS0xLTEtNDkwMzg_08eb7f40-7abb-476b-b3cf-78ef4e6c63b6"
      unitRef="usd">-21891000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtMy0xLTEtNDkwMzg_2f84b74e-9c2b-459f-9928-4e0713753e1b"
      unitRef="usd">-13509000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtNS0xLTEtNDkwMzg_afea278b-cf40-4d9a-8181-968f73662923"
      unitRef="usd">-91997000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTQtNy0xLTEtNDkwMzg_3278ea9c-4114-4227-8ab5-6eff5329be58"
      unitRef="usd">-173552000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtMS0xLTEtNDkwMzg_3195ba1d-6c9b-4d23-8aa7-7819c06e45f4"
      unitRef="usd">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtMy0xLTEtNDkwMzg_8816490a-c7a8-4437-9e27-30055baaceac"
      unitRef="usd">-397000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtNS0xLTEtNDkwMzg_e1b3416e-231c-425d-bbc4-89e04b542050"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTUtNy0xLTEtNDkwMzg_3f5a658a-e78c-4d88-93b3-8f0e74d667ca"
      unitRef="usd">1553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtMS0xLTEtNDkwMzg_7c6a20f2-54d4-480c-b384-8c0d33cbe4f5"
      unitRef="usd">-21897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtMy0xLTEtNDkwMzg_e5f3456d-7dc6-4883-8de3-1cb703096da4"
      unitRef="usd">-13112000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtNS0xLTEtNDkwMzg_63bddc93-e01d-430a-b232-1f4c9c69dc2f"
      unitRef="usd">-92014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTYtNy0xLTEtNDkwMzg_2a80511d-6a79-4756-b07e-e7c10d2df4b4"
      unitRef="usd">-175105000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtMS0xLTEtNDkwMzg_acd538ce-ba7f-46ed-8fee-fe371196131d"
      unitRef="usd">-2282000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtMy0xLTEtNDkwMzg_bdd9e0cd-4e41-43e0-a0b1-95973c1bc622"
      unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtNS0xLTEtNDkwMzg_3f97b8c8-61a2-4d20-9ec7-dce14508d6da"
      unitRef="usd">-3096000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTgtNy0xLTEtNDkwMzg_f55a5f07-9def-40e8-a177-9713537e4a00"
      unitRef="usd">104000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktMS0xLTEtNDkwMzg_e4fa4867-b978-445f-a821-e3e4305ba0ad"
      unitRef="usd">-160000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktMy0xLTEtNDkwMzg_580b653f-e266-412f-b9d7-84269b30097b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktNS0xLTEtNDkwMzg_727bd0d8-8c84-4ad6-be13-ed43ec735c71"
      unitRef="usd">-1274000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMTktNy0xLTEtNDkwMzg_ad71f3da-082c-4f93-afa6-8e45e7d2c43f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtMS0xLTEtNDkwMzg_019cd7ee-28f3-4b37-9bf3-dd6331d76b72"
      unitRef="usd">-24339000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtMy0xLTEtNDkwMzg_02297240-60e0-40c8-b01c-e63b19a4201e"
      unitRef="usd">-13138000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtNS0xLTEtNDkwMzg_a2b0e882-3394-47ec-8f0b-089edbb4727c"
      unitRef="usd">-96384000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjAtNy0xLTEtNDkwMzg_d0699e55-947e-4203-894d-017853a68e3d"
      unitRef="usd">-175001000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMS0xLTEtNDkwMzg_62b47dfe-b1aa-4da6-b2fd-23fa75a95a49"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMS0xLTEtNDkwMzg_6b2e1c5a-5226-4417-b286-219e90bbf508"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMy0xLTEtNDkwMzg_5d6f486e-95a2-4664-b962-a0cea2211872"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtMy0xLTEtNDkwMzg_903e9d0d-bfac-4edc-8362-f0c145ccb836"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNS0xLTEtNDkwMzg_3f1f9d88-9612-40a9-9b94-d6c75e507233"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNS0xLTEtNDkwMzg_715f5ee5-e4fe-4734-b67c-2c7e1e211c5e"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNy0xLTEtNDkwMzg_4a3138dd-f6ef-4b66-8f0c-98b84d0ff7d1"
      unitRef="usdPerShare">-8.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjEtNy0xLTEtNDkwMzg_ad950d26-af2c-4462-a13a-0e299bbd1556"
      unitRef="usdPerShare">-8.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMS0xLTEtNDkwMzg_3729ced9-d8cb-4870-8436-8905095edff8"
      unitRef="shares">108353831</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMS0xLTEtNDkwMzg_91a58aaf-315f-402e-addf-89a181cda9e1"
      unitRef="shares">108353831</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMy0xLTEtNDkwMzg_46bb3e20-78de-486a-9b80-55f9a3e0776a"
      unitRef="shares">20690908</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItMy0xLTEtNDkwMzg_55040adc-90d5-4f67-8891-773b93990ec3"
      unitRef="shares">20690908</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNS0xLTEtNDkwMzg_2357993a-e893-4671-a2ee-cb8afb6f2d83"
      unitRef="shares">107854547</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNS0xLTEtNDkwMzg_821a9465-44ce-43a1-967c-e6cddf245fe6"
      unitRef="shares">107854547</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNy0xLTEtNDkwMzg_54318147-69af-49ca-b29e-24fa54192e73"
      unitRef="shares">20549310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8xOS9mcmFnOmM4MDA0NTU0NjMzNTRhNDlhZTZiMjc5YTA0ZWU0ZThkL3RhYmxlOmRiYjhjZDk5ODMyYTQ0Yzg4ODgyOWU4ODk1MDgwNWU2L3RhYmxlcmFuZ2U6ZGJiOGNkOTk4MzJhNDRjODg4ODI5ZTg4OTUwODA1ZTZfMjItNy0xLTEtNDkwMzg_7562811d-1319-4373-92ec-8d3a2e36cf26"
      unitRef="shares">20549310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xLTEtMS00OTAzOA_fb98e153-aa14-4b2f-be3e-a9a1fd898ac3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0zLTEtMS00OTAzOA_eb3ab32e-14da-4559-bb8d-bc125210efb4"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i96883e148f06434c841b1d92a4923249_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi02LTEtMS00OTAzOA_46ebb166-d371-49b8-a598-97b497cec207"
      unitRef="shares">107275458</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96883e148f06434c841b1d92a4923249_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi04LTEtMS00OTAzOA_88b76f21-5bff-42d0-ac30-c7d49e93e3ff"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f5d825b11064cda8a7136073c98c0d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xMC0xLTEtNDkwMzg_d256b9dc-f5d1-41a5-9f9c-f26ab0a1cc90"
      unitRef="usd">713269000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d073cf810c741b19b080eec0ae65138_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xMi0xLTEtNDkwMzg_0a2dca26-f3ad-417c-89ec-d5c72a986d1a"
      unitRef="usd">526000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ada05c0bc904557aaf7846916d75d12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xNC0xLTEtNDkwMzg_38b2f2d1-358c-4177-a19b-63d2add3a367"
      unitRef="usd">-360235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee8c4f4547c34b3e98e00215a606db47_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xNi0xLTEtNDkwMzg_af7b6493-91e2-4151-b574-a71628e5ee64"
      unitRef="usd">353562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ec729d6293a456680bf668222068517_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0xOC0xLTEtNDkwMzg_53e61ea4-60b0-4f85-b5b2-0a50c8fce7b4"
      unitRef="usd">33774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMi0yMC0xLTEtNDkwMzg_3184643e-7ced-48e1-9b5a-a13144d19085"
      unitRef="usd">387336000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i59e7137c17d549fd820917694b08fc47_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMy0xMC0xLTEtNDkwMzg_b92d3dad-9663-4a5d-a2f2-6f371758122d"
      unitRef="usd">4669000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMy0xNi0xLTEtNDkwMzg_606ad357-a9f6-4ab8-b77b-8cbbc0caa57b"
      unitRef="usd">4669000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMy0yMC0xLTEtNDkwMzg_bca5eeb2-0f2c-40d7-b44e-cbe8e0082ad8"
      unitRef="usd">4669000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <adr:APICDueFromRelatedPartiesIncreaseForCostRecognition
      contextRef="i59e7137c17d549fd820917694b08fc47_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNC0xMC0xLTEtNDkwMzg_ff3e061d-e6ba-46be-93e2-87829292855b"
      unitRef="usd">1710000</adr:APICDueFromRelatedPartiesIncreaseForCostRecognition>
    <adr:APICDueFromRelatedPartiesIncreaseForCostRecognition
      contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNC0xNi0xLTEtNDkwMzg_6c9df8ec-ee0e-4933-aa76-01ede832cbf6"
      unitRef="usd">1710000</adr:APICDueFromRelatedPartiesIncreaseForCostRecognition>
    <adr:APICDueFromRelatedPartiesIncreaseForCostRecognition
      contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNC0yMC0xLTEtNDkwMzg_94424d76-79b4-4966-9db0-30536c04435a"
      unitRef="usd">1710000</adr:APICDueFromRelatedPartiesIncreaseForCostRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="i5656796fbdd145b3849a36669cab8663_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNS0xNC0xLTEtNDkwMzg_879f36e3-a3da-4e12-894b-556b84517eac"
      unitRef="usd">-27726000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNS0xNi0xLTEtNDkwMzg_fdf9113a-9b6e-4088-9131-58017a12e9d8"
      unitRef="usd">-27726000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNS0yMC0xLTEtNDkwMzg_333a4d49-2aed-4acb-8035-82d0239002fa"
      unitRef="usd">-27726000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d7799072b4d422aab668bcd4244cab6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNi0xMi0xLTEtNDkwMzg_47b091a0-ea00-4ec6-8432-3ad54c70f7ef"
      unitRef="usd">-1216000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ied110c888d57481db184f6175b1e2860_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNi0xNi0xLTEtNDkwMzg_0451721e-8615-421a-93c4-b6b1785c166d"
      unitRef="usd">-1216000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i064a3b8cbec6421089d74007985ed2f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNi0yMC0xLTEtNDkwMzg_1b71f60d-73f8-4425-8673-68070d1646c6"
      unitRef="usd">-1216000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i25d221360f31476098a1fd21dbc69534_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xLTEtMS00OTAzOA_a1cc5044-479d-4516-a70d-682e001b3336"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i25d221360f31476098a1fd21dbc69534_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0zLTEtMS00OTAzOA_7e05a1e2-39d1-44d8-b00a-7649315c95ed"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ib9322e8463954303aeee1d8f5e12fc8a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy02LTEtMS00OTAzOA_cd73ea28-3b37-4742-8f3c-ba78817a4a6f"
      unitRef="shares">107275458</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9322e8463954303aeee1d8f5e12fc8a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy04LTEtMS00OTAzOA_77abb21f-4a64-4758-b883-4e9dbff4dd3a"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9466a2c38fce4a91b583d32e765dc4a2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xMC0xLTEtNDkwMzg_df63cd6e-a69b-4535-b7b8-0a1c3f52ddc4"
      unitRef="usd">719648000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d25dc71ceec4fb08e8991e050dccdbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xMi0xLTEtNDkwMzg_464b819c-98f5-49c6-8baf-67ac9674bd6b"
      unitRef="usd">-690000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63c9cc56d5dd4eccb90e6223bdf350c0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xNC0xLTEtNDkwMzg_cd81a4ec-5bfc-4346-8f57-14fd59bba0b9"
      unitRef="usd">-387961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd6572c181b34370ba0e953f6fa9f119_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xNi0xLTEtNDkwMzg_64806eb8-fc28-4ba3-a422-93202c29c34c"
      unitRef="usd">330999000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib22bfae9e2b24dca8b5d085801249b58_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0xOC0xLTEtNDkwMzg_52124ff4-2069-4158-8738-b2cd61aabd14"
      unitRef="usd">33774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25d221360f31476098a1fd21dbc69534_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfNy0yMC0xLTEtNDkwMzg_d9693ce9-fe25-4085-96d1-298fbd5513d8"
      unitRef="usd">364773000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i113de41b7dc04d4690e58ef90231b3a7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOC0xMC0xLTEtNDkwMzg_003ed68f-f06b-42a9-8207-7894cb7a38f8"
      unitRef="usd">4528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOC0xNi0xLTEtNDkwMzg_7778ff9e-8f22-482c-b740-a6c159e5ebaf"
      unitRef="usd">4528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOC0yMC0xLTEtNDkwMzg_39b06887-03d8-4cc2-8bc5-977d37886fec"
      unitRef="usd">4528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i922676779aab45b998d8c7c8042fb4b1_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfOS02LTEtMS00OTAzOA_3e6f1a93-c73d-4706-a48b-47c2f763b5e9"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <adr:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i922676779aab45b998d8c7c8042fb4b1_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTAtNi0xLTEtNDkwMzg_734d0b24-bd97-4358-9e83-4a59f2a26c49"
      unitRef="shares">78373</adr:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="iaf64ccfd7d8f40c18123b97e857d709b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTEtMTQtMS0xLTQ5MDM4_1d934628-3282-4dbe-a6cd-85b75d628775"
      unitRef="usd">-42391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTEtMTYtMS0xLTQ5MDM4_3bfbd65c-14bc-400f-ad8b-26b152c9be5a"
      unitRef="usd">-42391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTEtMjAtMS0xLTQ5MDM4_3e33e691-88bc-4889-9af6-aecbc68d38db"
      unitRef="usd">-42391000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a167087705d44768451e899dfad4ed5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTItMTItMS0xLTQ5MDM4_114cbbee-9908-4179-94ac-a6eba2f33a08"
      unitRef="usd">-712000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id5dc8773de5248b8a960cfef4bc2b2ec_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTItMTYtMS0xLTQ5MDM4_cd4caaf2-f055-4bdb-bdfd-4dac833b7ec0"
      unitRef="usd">-712000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie45044e7bac34acba96dffca46f242fc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTItMjAtMS0xLTQ5MDM4_43b39591-f054-4649-8c12-84b045a1d9aa"
      unitRef="usd">-712000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i475ba3da26c54ed1b8be00efe29feec9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMS0xLTEtNDkwMzg_f7e70a9c-fd73-4be3-8bbc-3c4d65fc4cce"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i475ba3da26c54ed1b8be00efe29feec9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMy0xLTEtNDkwMzg_11acd23c-fb01-4211-8a36-78b1f7b615fd"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i770c7a6615c24dab958345dedaeaca2a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtNi0xLTEtNDkwMzg_d9c30744-74b6-4b90-9a51-952cfdba8bb6"
      unitRef="shares">108353831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i770c7a6615c24dab958345dedaeaca2a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtOC0xLTEtNDkwMzg_5495d2ad-2125-4620-891f-e28d8ce6e655"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0afac83be094d4aa4542e69b5679207_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTAtMS0xLTQ5MDM4_a3121d3d-52fc-4b5a-8054-a6b25f9b2537"
      unitRef="usd">724176000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6ff887c265441c69507be611ce503ac_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTItMS0xLTQ5MDM4_0c41f09a-863c-4d9f-848a-86ce41506374"
      unitRef="usd">-1402000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie17b5e7664cc4df68c65d8b884872e95_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTQtMS0xLTQ5MDM4_410d9694-1ac8-4df0-b1d1-c51d45ff068c"
      unitRef="usd">-430352000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e238a55eb6949e3bfa3fc5e44d68d66_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTYtMS0xLTQ5MDM4_84f4336d-a320-40b6-b9ee-16b64cfc21e7"
      unitRef="usd">292424000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b044d6aec8a430b9c9d220877699973_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMTgtMS0xLTQ5MDM4_56ec02c4-e90f-4e2b-85d4-af3c0d6b081f"
      unitRef="usd">33774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i475ba3da26c54ed1b8be00efe29feec9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTMtMjAtMS0xLTQ5MDM4_1ba25e05-267f-43ac-bbd6-a7933902c8b8"
      unitRef="usd">326198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i53ad139f307f45f59574c837bac70329_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTQtMTAtMS0xLTQ5NzU2_6ea7c6a8-7740-4a34-b6c5-4058f7ed9f91"
      unitRef="usd">4739000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTQtMTYtMS0xLTQ5NzU2_13433d91-0d63-4d41-aaae-b2dd74fab8e9"
      unitRef="usd">4739000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTQtMjAtMS0xLTQ5NzU2_fa6863c2-d068-4562-9f3c-f0af1950e7e4"
      unitRef="usd">4739000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="iea7287c095dd4fb394874127ce8b32e2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTctMTQtMS0xLTQ5NzU2_2d3557cf-b583-4138-a31e-2a50c2599c56"
      unitRef="usd">-21897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTctMTYtMS0xLTQ5NzU2_bdd1730c-8e5d-403a-b77d-0837d7a39c87"
      unitRef="usd">-21897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTctMjAtMS0xLTQ5NzU2_ecbb04cd-5108-4b33-8e74-1277a69eb07b"
      unitRef="usd">-21897000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i48907c78fead48129720781ca8df4577_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTgtMTItMS0xLTQ5NzU2_a26842d4-f1ad-49c8-b98a-4bf97bfc4925"
      unitRef="usd">-2442000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaacd91cf42ae47f9b42b2cdd646a2781_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTgtMTYtMS0xLTQ5NzU2_cd5a1e3e-b16a-4ed4-a85a-5e6adf2babd5"
      unitRef="usd">-2442000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTgtMjAtMS0xLTQ5NzU2_b899fa62-94d5-44a4-ae9d-dd7d9b5e48c7"
      unitRef="usd">-2442000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMS0xLTEtNDk3NTY_6c963626-429e-45e4-a374-31544f07b137"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMy0xLTEtNDk3NTY_b5bce7a6-0c67-4f37-b2d4-84f89e70b860"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i664446c89c5d42d18ba427b660facc0a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktNi0xLTEtNDk3NTY_3a312ea0-2ccd-479e-99f7-76a3fc56fae4"
      unitRef="shares">108353831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i664446c89c5d42d18ba427b660facc0a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktOC0xLTEtNDk3NTY_9ecb9016-711d-4244-9aa8-7fafdb6f8c14"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iada45bd66c5c4ac1ad4b3ddabe552196_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTAtMS0xLTQ5NzU2_17f8c9ed-e132-4d35-bba8-5953e7680c65"
      unitRef="usd">728915000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff7da7e1062844c99aa94c7bbbe052e3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTItMS0xLTQ5NzU2_b89e13b7-b400-4e20-b163-abcd54756643"
      unitRef="usd">-3844000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i476a15e732a34295adea0c957a427196_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTQtMS0xLTQ5NzU2_79789b0b-6aa9-4a74-a414-96d97ab82453"
      unitRef="usd">-452249000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iefaabc71b2ab47ae804d1de9bee57351_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTYtMS0xLTQ5NzU2_7bafc4b3-062c-4932-b7e1-222fc730d8d3"
      unitRef="usd">272824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d6fbb393f9d410283f46ab5e21666d1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMTgtMS0xLTQ5NzU2_b2cfe8b5-9992-445d-be0f-0e2e0a292d9b"
      unitRef="usd">33774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOmI4NmYzMDA1OGFlYTQ2YWI4NjhmMTA5OTg1NTQzZGZmL3RhYmxlcmFuZ2U6Yjg2ZjMwMDU4YWVhNDZhYjg2OGYxMDk5ODU1NDNkZmZfMTktMjAtMS0xLTQ5NzU2_578cf015-f77d-43b1-b3e2-52bf21129968"
      unitRef="usd">306598000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xLTEtMS00OTAzOA_1e9a8a3b-90ba-479b-a40d-f7f85c04c281"
      unitRef="shares">10971231</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0zLTEtMS00OTAzOA_b27e96b3-5eb5-458b-853a-5e024de5e5ac"
      unitRef="usd">349789000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ib12f0d7ec46545459636f4595ce63971_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi02LTEtMS00OTAzOA_035e92cc-c585-4951-9666-45f88044df29"
      unitRef="shares">20477338</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib12f0d7ec46545459636f4595ce63971_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi04LTEtMS00OTAzOA_a19ef0f7-ab58-4b17-be7c-4f5c288ef4df"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i843b9dc93da54466be692b7fe0e517ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xMC0xLTEtNDkwMzg_f2d797cb-04b4-40d8-8b71-51fe27381d64"
      unitRef="usd">31132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf757ee092794a7b907ffc699c87df97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xMi0xLTEtNDkwMzg_eff42065-ea3b-4d98-aa1b-fbe5769548b1"
      unitRef="usd">-40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00ba9d6adbc545c784eb291a888dd93d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xNC0xLTEtNDkwMzg_8a70110a-5250-41b8-8cfe-c800891ff218"
      unitRef="usd">-163935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc809e33c664490faf057840bbfd54f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xNi0xLTEtNDkwMzg_8e8c55af-61f5-4766-9952-bc9ca7dd1db7"
      unitRef="usd">-132843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10c747e16a744468928214dcc9e51ae1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0xOC0xLTEtNDkwMzg_af245dbd-47c3-4ae4-8dad-82bab46b583c"
      unitRef="usd">34773000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMi0yMC0xLTEtNDkwMzg_5678659a-9c5b-469a-b327-707784b3505d"
      unitRef="usd">-98070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd068d3e42c34c279f69aaf1be33f5c3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMy0xMC0xLTEtNDkwMzg_f7366560-f8b9-49b0-af57-ca66282521fa"
      unitRef="usd">1674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e6744690158405abbd221d7a074c791_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMy0xNi0xLTEtNDkwMzg_b772f75f-98f8-447c-84f1-139bb2818cf1"
      unitRef="usd">1674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMy0yMC0xLTEtNDkwMzg_5774cdac-0ccc-4acb-ae0c-ddec971e5c13"
      unitRef="usd">1674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="if81a8e1bb8e14340b40f2c724b9842a9_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNC0wLTEtMS00OTAzOC90ZXh0cmVnaW9uOjliMjIyYTQyNDdiYTQyYTFhMTRmM2JhOGIzNjBmNWZhXzQ1_8b29f2aa-b9b3-470d-a29c-30e627df4853"
      unitRef="usdPerShare">56.66</us-gaap:SharesIssuedPricePerShare>
    <adr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNC0xLTEtMS00OTAzOA_1f26c6d2-cf5a-45dd-9e0e-be2ba01104e6"
      unitRef="shares">52947</adr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNC0zLTEtMS00OTAzOA_156cb42c-2587-4486-b8a9-cfc0206f99c7"
      unitRef="usd">2940000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i5aae9117d3e343aa9c8b422b360bbf8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNS0xOC0xLTEtNDkwMzg_b0b12b25-201c-448e-a012-c536443da6fc"
      unitRef="usd">9415000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNS0yMC0xLTEtNDkwMzg_fafab4e7-763a-4c7e-a087-dbb4e03e3fd0"
      unitRef="usd">9415000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLoss
      contextRef="ia555d7f1cdbb4263b3e681f74e9864c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNi0xNC0xLTEtNDkwMzg_421c6aee-f1a8-484c-8d02-58e18b596206"
      unitRef="usd">-61565000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e6744690158405abbd221d7a074c791_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNi0xNi0xLTEtNDkwMzg_39011f3c-0b00-4af2-a228-b3a290a1050f"
      unitRef="usd">-61565000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNi0yMC0xLTEtNDkwMzg_033a9106-5fa5-4278-813e-86d236a3ed05"
      unitRef="usd">-61565000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i094e8e47897d4872a7f705af07fdff66_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNy0xMi0xLTEtNDkwMzg_bca29a44-7b67-476f-90a9-86133d788bee"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5e6744690158405abbd221d7a074c791_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNy0xNi0xLTEtNDkwMzg_bf9a6a88-914c-4156-b71a-3d3a28aa15bb"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfNy0yMC0xLTEtNDkwMzg_24e644eb-7d12-4f70-bf32-9b8e69ed0faa"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xLTEtMS00OTAzOA_9e09150d-47b5-4234-9d54-109e81beed5f"
      unitRef="shares">11024178</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0zLTEtMS00OTAzOA_9c549e56-0cc5-40a0-8543-4e9a84e68a47"
      unitRef="usd">352729000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="id2cfe092feb045dbbc9f7ccb340f1d54_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC02LTEtMS00OTAzOA_38d8e220-9f35-45ec-b47d-d16396dd4549"
      unitRef="shares">20477338</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2cfe092feb045dbbc9f7ccb340f1d54_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC04LTEtMS00OTAzOA_e71264e9-c2d3-45f0-95fa-fd088625121b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87f9f534bbe64805a759a975c5e89677_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xMC0xLTEtNDkwMzg_24ad817c-1c9e-4530-b0f0-9915793e4e88"
      unitRef="usd">32806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a7631dd76cf40a4b4fcef577ab42fd2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xMi0xLTEtNDkwMzg_52ff6cc9-3421-4a55-898b-8167a3ea69ab"
      unitRef="usd">-32000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9065e3e77be445739a59ac03866a9ce3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xNC0xLTEtNDkwMzg_523ddd98-8e18-4097-82cf-975d7f1b38fc"
      unitRef="usd">-225500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b1e1b4992c34e169c7d86153c6eb2ce_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xNi0xLTEtNDkwMzg_33614e6d-7da3-454f-990d-3851dd9b3bf2"
      unitRef="usd">-192726000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i344b1e6c929d49dbb0309bbb28a88cbf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0xOC0xLTEtNDkwMzg_fdf841b6-bdd3-4a4a-bfa0-913078221525"
      unitRef="usd">44188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOC0yMC0xLTEtNDkwMzg_09551092-6bab-4a1e-93ae-01ed57d9f579"
      unitRef="usd">-148538000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5f6c3f36b5eb42d299c7131a79fec1a3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOS0xMC0xLTEtNDkwMzg_893fb9ce-3500-4a3f-9058-4c12be2fdd23"
      unitRef="usd">1443000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOS0xNi0xLTEtNDkwMzg_94262935-242b-4d09-a30c-67cf4ea3e709"
      unitRef="usd">1443000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfOS0yMC0xLTEtNDkwMzg_b1edc9a5-5570-4213-8c92-6227b1ffbb3c"
      unitRef="usd">1443000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i97b84f3425ae4c298fafa57dee035528_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTAtMTQtMS0xLTQ5MDM4_2be1972d-2897-4ad6-8762-96de1fe44be2"
      unitRef="usd">-100428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTAtMTYtMS0xLTQ5MDM4_922bf717-e344-449e-ae71-c6c715ee335a"
      unitRef="usd">-100428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTAtMjAtMS0xLTQ5MDM4_ad4d2ed4-e757-4e76-a00d-87c73c291bb6"
      unitRef="usd">-100428000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9cf331c6036a4355a4904f3f4bbb1cd2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTEtMTItMS0xLTQ5MDM4_13f52cb7-319b-4298-a4f3-3914c483c1e4"
      unitRef="usd">122000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e42afe1ad064bafa8f78d2e129acc5a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTEtMTYtMS0xLTQ5MDM4_27903f87-2bdd-4805-937b-4578febfdb12"
      unitRef="usd">122000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id228b9c3fbec4900baebd7063e20971d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTEtMjAtMS0xLTQ5MDM4_65624381-a2e6-4200-b560-9a880603f4b4"
      unitRef="usd">122000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ia7408c111d584b5ab590b62aac211dac_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMS0xLTEtNDkwMzg_9ec12628-3b4e-4093-b9be-abaa2d28ab2d"
      unitRef="shares">11024178</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ia7408c111d584b5ab590b62aac211dac_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMy0xLTEtNDkwMzg_7a868f10-4dd2-491a-8062-8469879f8cd5"
      unitRef="usd">352729000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i19cd0b34a996469990768d290687c7ee_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItNi0xLTEtNDkwMzg_10c60116-9b3a-43d0-b717-902122564d05"
      unitRef="shares">20477338</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19cd0b34a996469990768d290687c7ee_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItOC0xLTEtNDkwMzg_6edb0b76-4395-4a73-9dff-20b5416e8976"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib11048778c5e4d0687735a5893af9693_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTAtMS0xLTQ5MDM4_90451877-7d7a-4015-b3a8-2fcbe4c77adc"
      unitRef="usd">34249000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8db68d789694f5cb6106efce2a2b3ae_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTItMS0xLTQ5MDM4_cf75872c-ae8b-4697-aca5-9ca1e9531484"
      unitRef="usd">90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a99f5ddcd3340849368e824f80c8eb2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTQtMS0xLTQ5MDM4_9b21c1a6-13fd-44da-915a-e2171973f44b"
      unitRef="usd">-325928000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5f4de76939f4d41bae02354c1c148b7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTYtMS0xLTQ5MDM4_44249eb6-ddce-4fa2-a2ca-bb959547dcc2"
      unitRef="usd">-291589000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie78c90d28271496cbeedbefdec9b279f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMTgtMS0xLTQ5MDM4_f9e90abe-21ce-4b96-9778-29984b2ea82a"
      unitRef="usd">44188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7408c111d584b5ab590b62aac211dac_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTItMjAtMS0xLTQ5MDM4_90b53ea4-930f-4c08-a8da-cbe6111dc14d"
      unitRef="usd">-247401000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc84f64754e446c292da7857f70711f5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTMtMTAtMS0xLTQ5Nzcx_d8395c89-952d-40af-8770-af79d281a7f4"
      unitRef="usd">2168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTMtMTYtMS0xLTQ5Nzcx_d44166e7-f0b5-4413-81a0-964d3ea82174"
      unitRef="usd">2168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTMtMjAtMS0xLTQ5Nzcx_12fe6a1f-be05-478d-bdca-813d8e8ace84"
      unitRef="usd">2168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibde6fe20c7ce4abcb989cd5740f6517e_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtNi0xLTEtNDk3NzE_a1ddbeb7-ad93-48f8-adc3-106ca87497ad"
      unitRef="shares">1309907</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idc84f64754e446c292da7857f70711f5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtMTAtMS0xLTQ5Nzcx_c3d7a397-4bde-41db-8ce7-b72616a38642"
      unitRef="usd">5309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtMTYtMS0xLTQ5Nzcx_a0796496-79ce-4cfa-8f04-de71e964cbc7"
      unitRef="usd">5309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTQtMjAtMS0xLTQ5Nzcx_c12c3244-d442-4ed5-8c02-a0a6a9adace8"
      unitRef="usd">5309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="id926e92f71c541b1ae612d23291c8593_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTUtMTQtMS0xLTQ5Nzcx_2c8e78ee-d9e6-4674-b3d6-3e1c13398367"
      unitRef="usd">-13112000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTUtMTYtMS0xLTQ5Nzcx_d8f1a0cb-5d42-4e6e-95b3-96ea1c682704"
      unitRef="usd">-13112000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTUtMjAtMS0xLTQ5Nzcx_bba68486-6b5c-4338-af50-88f98d17bcf0"
      unitRef="usd">-13112000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0b839be2585f4f18bbac068fb248673d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTYtMTItMS0xLTQ5Nzcx_0f842a1b-6745-4985-9471-0b1b22a9b7d1"
      unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if50dc22d2d834a5392a711aa920a2205_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTYtMTYtMS0xLTQ5Nzcx_a4b13af8-54b8-4951-a966-da6e1b751e80"
      unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTYtMjAtMS0xLTQ5Nzcx_65ac3e03-7cd9-4e68-bbde-622e9c898d79"
      unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i0a135bc815214ea891762f3528c47479_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMS0xLTEtNDk3NzE_99c83ace-17df-43d0-8d42-2af866447e04"
      unitRef="shares">11024178</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i0a135bc815214ea891762f3528c47479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMy0xLTEtNDk3NzE_d03417c8-0141-4639-b706-8053a378d917"
      unitRef="usd">352729000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i54f1e96dce0d4efd8b146ffaad7ccb37_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctNi0xLTEtNDk3NzE_0d8cf5d6-af1a-4a22-97d5-027d200ed814"
      unitRef="shares">21787245</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54f1e96dce0d4efd8b146ffaad7ccb37_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctOC0xLTEtNDk3NzE_614b1e8e-1fd2-435c-a7ad-b9822dd782ea"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20f8c40cc106484c8030ad5495b23cfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTAtMS0xLTQ5Nzcx_4a02cdfc-8a1b-4eab-be2d-bec9f6356a1b"
      unitRef="usd">41726000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1be28631775249e1801ff1234f689d4e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTItMS0xLTQ5Nzcx_08772b83-a417-4a13-a822-442e367a1730"
      unitRef="usd">64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a3842c85d9f4a828a8135e64dcab877_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTQtMS0xLTQ5Nzcx_97c861a0-976b-4bb1-8e53-b223fd3fbfae"
      unitRef="usd">-339040000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5b0e96016484b7d974af94c79a8fb0d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTYtMS0xLTQ5Nzcx_20332fb2-7460-4c3b-8b58-f98e6aef13fb"
      unitRef="usd">-297250000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89dd2c9150114f349e9c78a6c5a2a70f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMTgtMS0xLTQ5Nzcx_3cfe1f2d-9aae-4149-95fd-68bf2c83e7cf"
      unitRef="usd">44188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a135bc815214ea891762f3528c47479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yMi9mcmFnOjQ3Y2E3N2NhMTY0ZDRjODZiNWFiMTliMjgzYTJjNDc1L3RhYmxlOjIzOGRlMmQ1YTFiYjRhZjRhNWQzZjAxMzgyMzcxOWE3L3RhYmxlcmFuZ2U6MjM4ZGUyZDVhMWJiNGFmNGE1ZDNmMDEzODIzNzE5YTdfMTctMjAtMS0xLTQ5Nzcx_c6b621da-435e-44c7-a95c-5668e1cc92d5"
      unitRef="usd">-253062000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMS0xLTEtMS00OTAzOA_f5aeb2db-0cc3-4d90-b8cb-f70aa03075f2"
      unitRef="usd">-92014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMS0zLTEtMS00OTAzOA_97f47f4d-df0c-4e3c-bcad-59093a5a7d8f"
      unitRef="usd">-175105000</us-gaap:NetIncomeLoss>
    <adr:NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMy0xLTEtMS00OTAzOA_de960930-946b-4e2a-9c14-4e27d08d061c"
      unitRef="usd">0</adr:NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD>
    <adr:NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMy0zLTEtMS00OTAzOA_b7061993-ebf4-4535-b5ef-68a37e558466"
      unitRef="usd">9415000</adr:NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD>
    <adr:NonCashOperatingLeaseExpenseBenefit
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNC0xLTEtMS00OTAzOA_8af3211f-0129-4ab9-b62d-67f47fafcbfe"
      unitRef="usd">354000</adr:NonCashOperatingLeaseExpenseBenefit>
    <adr:NonCashOperatingLeaseExpenseBenefit
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNC0zLTEtMS00OTAzOA_ea8b82e2-2126-400d-b065-1a1ffca21db0"
      unitRef="usd">-76000</adr:NonCashOperatingLeaseExpenseBenefit>
    <us-gaap:Depreciation
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNS0xLTEtMS00OTAzOA_d49718ba-85db-4180-8fc1-df0e81fd17c3"
      unitRef="usd">689000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNS0zLTEtMS00OTAzOA_f879fb43-2f72-475c-a87a-462525640c48"
      unitRef="usd">278000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNi0xLTEtMS00OTAzOA_23cc0f3d-24f2-4b54-9eaa-8f97b47deb34"
      unitRef="usd">13936000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNi0zLTEtMS00OTAzOA_9110b540-e725-4bee-8d78-852449a2e648"
      unitRef="usd">5285000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNy0xLTEtMS00OTAzOA_db0945f6-c0f9-45fc-aa89-465a47edc39f"
      unitRef="usd">481000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNy0zLTEtMS00OTAzOA_121d1a84-6800-48c8-987e-68c9754b4063"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfOC0xLTEtMS00OTAzOA_172452f7-d718-4c79-8319-cc36a429c78f"
      unitRef="usd">1375000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfOC0zLTEtMS00OTAzOA_5fcc7d48-9932-4376-b238-9bca8e1a3661"
      unitRef="usd">56000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTItMS0xLTEtNDkwMzg_3bdb3e97-d301-4be7-998a-ff6978a4781a"
      unitRef="usd">-4794000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTItMy0xLTEtNDkwMzg_5e4aa0bb-2cfd-473d-9a64-b226bddc101a"
      unitRef="usd">3801000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTMtMS0xLTEtNDkwMzg_81a46dd7-d603-44e2-8a18-38bdd98100eb"
      unitRef="usd">1244000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTMtMy0xLTEtNDkwMzg_5cc0e53c-b9ca-4c6a-91fc-34da777aa07f"
      unitRef="usd">-14216000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTUtMS0xLTEtNDkwMzg_2a42c9d7-d6d0-4254-9ba0-74ade7072096"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTUtMy0xLTEtNDkwMzg_305c258d-d89b-4a98-b364-e7ff315cb549"
      unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTYtMS0xLTEtNDkwMzg_bf7247ee-bdb0-442b-94ce-72d9945df0bf"
      unitRef="usd">-1091000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTYtMy0xLTEtNDkwMzg_ff8c5d04-07a4-408d-9174-dae686347594"
      unitRef="usd">-2690000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTctMS0xLTEtNDkwMzg_6e952d90-f00a-4c31-a9dd-2fd306cadf0c"
      unitRef="usd">8197000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTctMy0xLTEtNDkwMzg_59f8017a-2c09-4a22-a848-3544410aa03b"
      unitRef="usd">11568000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTgtMS0xLTEtNDkwMzg_bd1bc2ac-0907-4252-9fe6-1be950a35d7c"
      unitRef="usd">-248000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTgtMy0xLTEtNDkwMzg_dd60274e-ad10-4aba-a28f-c9159ba4daae"
      unitRef="usd">1434000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTktMS0xLTEtNTIyMTk_1585c9bb-0df0-4520-95e0-585a0b78fb94"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMTktMy0xLTEtNTIyMTk_a807d95a-da4d-40c1-9da0-226e619aa167"
      unitRef="usd">5957000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjAtMS0xLTEtNDkwMzg_47bea8b1-b92d-4956-979f-877a09ccf977"
      unitRef="usd">-68472000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjAtMy0xLTEtNDkwMzg_0f6bbc3c-e976-4767-bb92-0317626c2b0f"
      unitRef="usd">-133573000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjItMS0xLTEtNDkwMzg_7001f378-686a-4cf2-b942-5ce72b11e103"
      unitRef="usd">1610000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjItMy0xLTEtNDkwMzg_49069cd0-fef6-4720-8eb3-f2247dd5bb0b"
      unitRef="usd">159000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjMtMS0xLTEtNDkwMzg_1df54921-9796-42e5-a5ee-8fb9d0d1fe72"
      unitRef="usd">260367000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjMtMy0xLTEtNDkwMzg_ae796e05-cc40-4d7b-b6dd-28af36219722"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjQtMS0xLTEtNDkwMzg_0e1bd31b-cf32-453c-aba4-af2ef3fd0878"
      unitRef="usd">181780000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjQtMy0xLTEtNDkwMzg_ff5ba432-0112-4e95-bff3-9709e18579cf"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjUtMS0xLTEtNDkwMzg_b061a294-87da-46a5-a4a2-2d08a84ad528"
      unitRef="usd">-80197000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjUtMy0xLTEtNDkwMzg_34cb6b9b-95ee-4684-9ae0-690bd55ea083"
      unitRef="usd">-159000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjgtMS0xLTEtNDkwMzg_deacb168-1fc5-4967-bf0e-203823ae529a"
      unitRef="usd">1710000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjgtMy0xLTEtNDkwMzg_c1a34b8f-5b78-4068-8309-87a8b6784040"
      unitRef="usd">5309000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjktMS0xLTEtNDkwMzg_abff8737-0032-4d88-b612-bfeb9047e5a9"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMjktMy0xLTEtNDkwMzg_b9bf5152-f720-4796-8eca-17696a976112"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzAtMS0xLTEtNDkwMzg_5d9f899d-c410-45e8-81ef-e3c51eb14ce3"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzAtMy0xLTEtNDkwMzg_ed3020a0-0142-4166-980b-c3bba9fda3e3"
      unitRef="usd">60000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzEtMS0xLTEtNDkwMzg_419cbf1b-9cf1-4c19-be98-82b922f073bb"
      unitRef="usd">1710000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzEtMy0xLTEtNDkwMzg_9ca9e909-7bbc-48ba-ba9f-499ef185f703"
      unitRef="usd">8249000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzItMS0xLTEtNDkwMzg_a574df1c-a8a1-41f1-ba81-11e170dd81f4"
      unitRef="usd">-2291000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzItMy0xLTEtNDkwMzg_5591b865-9d8e-49b9-b9f0-89538ac72190"
      unitRef="usd">148000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzMtMS0xLTEtNDkwMzg_a6b6f2bc-23be-46fc-8e06-9f404f22b98b"
      unitRef="usd">-149250000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzMtMy0xLTEtNDkwMzg_ae51678d-b547-4246-ad12-a603f15af68e"
      unitRef="usd">-125335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzQtMS0xLTEtNDkwMzg_3f5c0edb-9591-4e1d-8d3c-b9c906ca8ac8"
      unitRef="usd">248182000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzQtMy0xLTEtNDkwMzg_19f319f5-7ecd-46ae-b546-d80cc6bc0b8f"
      unitRef="usd">254350000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzUtMS0xLTEtNDkwMzg_ee019a6e-ee9f-494e-a0a1-213429e3702d"
      unitRef="usd">98932000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a135bc815214ea891762f3528c47479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzUtMy0xLTEtNDkwMzg_b1ca6676-a2b1-40e2-b713-ae733183e587"
      unitRef="usd">129015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzYtMS0xLTEtNDkwMzg_dcd3c2fe-08be-49f2-b7f2-2501604fbe4f"
      unitRef="usd">78862000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0a135bc815214ea891762f3528c47479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzYtMy0xLTEtNDkwMzg_c0a78ada-bb46-40a4-9945-386e50e82d49"
      unitRef="usd">109015000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzctMS0xLTEtNDkwMzg_cca8bd4e-37d4-4e33-a06f-14adc6283185"
      unitRef="usd">20070000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0a135bc815214ea891762f3528c47479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzctMy0xLTEtNDkwMzg_ad2fa19f-b93e-4f62-bace-655b7c77a68c"
      unitRef="usd">20000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzgtMS0xLTEtNDkwMzg_725faa3e-1e29-4897-ac6d-432d1b17a67c"
      unitRef="usd">98932000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a135bc815214ea891762f3528c47479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfMzgtMy0xLTEtNDkwMzg_1a68f0f4-c0aa-460b-8f97-695e08439d3c"
      unitRef="usd">129015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDAtMS0xLTEtNDkwMzg_1f63f1f6-36bb-49c9-84d1-65f3356cbb07"
      unitRef="usd">523000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDAtMy0xLTEtNDkwMzg_84f877e8-99ad-45cd-95c9-0d11aff1d930"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDItMS0xLTEtNDkwMzg_d76f300d-a69c-4473-9d9c-1ed8635e4f39"
      unitRef="usd">1233000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDItMy0xLTEtNDkwMzg_62b52018-0e2e-484c-b6fb-9098ad9ee07e"
      unitRef="usd">247000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <adr:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDMtMS0xLTEtNDkwMzg_15c019ad-9c47-4a2d-bf7e-499faf8ae7f1"
      unitRef="usd">0</adr:DeferredOfferingCostsIncurredButNotYetPaid>
    <adr:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDMtMy0xLTEtNDkwMzg_45b2e56c-f316-4691-853c-8ad47f634ef3"
      unitRef="usd">3310000</adr:DeferredOfferingCostsIncurredButNotYetPaid>
    <adr:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDMtMy0xLTEtNDkwMzg_a6e1a6c5-b614-4834-81c0-80417cc2bf74"
      unitRef="usd">3310000</adr:DeferredOfferingCostsIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDQtMS0xLTEtNDkwMzg_0a39f92f-9b66-4919-9701-bcc47c9d499a"
      unitRef="usd">551000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8yNS9mcmFnOjMyNzYxZWVmMzc5NzRiYTBiMjZkYjg0M2Y2MmM3MmYxL3RhYmxlOjg1NDlmMjFhZjY5YzRlNDE4OTYyYzUxMmZiN2Y2ZGE2L3RhYmxlcmFuZ2U6ODU0OWYyMWFmNjljNGU0MTg5NjJjNTEyZmI3ZjZkYTZfNDQtMy0xLTEtNDkwMzg_be509217-8edd-43d4-8d47-a4eba2fe4775"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTQ3OA_2b42de17-d7de-4a3c-b678-276e3c0793cd">Nature of Business &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LianBio (&#x201c;LianBio&#x201d; or the &#x201c;Company&#x201d;) is a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was incorporated in the Cayman Islands in July 2019 and maintains its Chinese headquarters in Shanghai, China. The Company conducts its corporate activities at its United States headquarters located in Princeton, New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 3, 2021, the Company completed its initial public offering (&#x201c;IPO&#x201d;) through an underwritten sale of 20,312,500 American Depositary Shares (&#x201c;ADSs") representing 20,312,500 ordinary shares at a price of $16.00 per share. Following the close of the IPO, on December 1, 2021, the underwriters partially exercised their option to purchase additional shares and purchased an additional 593,616 ADSs at the IPO price of $16.00 per ADS. The Company received gross proceeds of $334.5 million in connection with the IPO and subsequent exercise of the underwriters&#x2019; option and aggregate net proceeds of $304.8 million after deducting underwriting discounts, commissions and other offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the IPO, all of the Company&#x2019;s convertible preferred shares then-outstanding were automatically converted into an aggregate of 64,467,176 ordinary shares and were reclassified into permanent equity. Following the IPO, there were no preferred shares outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if15bb3d88e144b8fb0462ca6bc65c410_D20211103-20211103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfNjYw_a22b29cb-6e94-46e3-a37e-6b5f6880729f"
      unitRef="shares">20312500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic9758d92ce7f4beb932f7cfa346c246c_D20211103-20211103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfNzEy_dbe8bebe-bb89-4f5a-9172-edf5a9907d2a"
      unitRef="shares">20312500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie6621d4b27834cd1a8fdbaa9dae39f18_I20211103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfNzQ1_fa3f9850-6535-424e-a573-babf31ea7a4a"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5d453bec4c3b4dceb7ea5525faa7b87e_D20211201-20211201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfOTIw_9b91fd67-6df8-42d6-bc5f-416f6647d74a"
      unitRef="shares">593616</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iff1946c96c304391bdd745ff4abb6f90_I20211201"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfOTQ4_2890e7b6-53e9-430c-bb7b-5139c0cbb646"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i13e6d021cd914175b381a66b8a7cbb8c_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfOTk5_765c750b-c6b2-4cb7-8767-106082726ce1"
      unitRef="usd">334500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i13e6d021cd914175b381a66b8a7cbb8c_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTExOQ_df00594b-b211-46f9-864a-2f3867a88114"
      unitRef="usd">304800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i378fd65bf5a34325aead1a87c2d54e68_I20211103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTM1Mw_f9106673-cc0a-4fbe-899f-442e0567c1cf"
      unitRef="shares">64467176</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i378fd65bf5a34325aead1a87c2d54e68_I20211103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMS9mcmFnOjk3MjQ2N2E5MmE2MzQ5MDlhY2M2YjRiYmZjOTY2MzEwL3RleHRyZWdpb246OTcyNDY3YTkyYTYzNDkwOWFjYzZiNGJiZmM5NjYzMTBfMTQ0Nw_7ef1a139-28d0-4ab9-bd75-5f0629f1d408"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc1OA_5b9ee03d-82b0-4759-946b-402ff9808a33">Significant Accounting Policies &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(A) Basis of presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, which include the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;) registered entities directly owned by the Company. All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim balance sheet as of September&#160;30, 2022, and the interim consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred shares and shareholders&#x2019; equity (deficit) for the three and nine months ended September&#160;30, 2022 and 2021, and the cash flows for the nine months ended September&#160;30, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial information. The financial data and other information disclosed in these notes related to the three and nine month periods are also unaudited. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(B) Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The only material estimates in the accompanying financial statements are the fair value of warrants, share-based compensation, and share options. Actual results could differ from those used in evaluating these accounting estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) outbreak a pandemic. The Company&#x2019;s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including planned clinical trials. The impact of the COVID-19 pandemic on the Company&#x2019;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy continue to be impacted for an extended period, the Company&#x2019;s results may be materially adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to material credit risk due to the financial position of the banking institutions. The Company has no off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations involve numerous risks and uncertainties. Factors that could affect the Company&#x2019;s operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials, uncertainty of regulatory approval of the Company&#x2019;s potential product candidates, uncertainty of market acceptance of its product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Company&#x2019;s product candidates require approvals from the National Medical Products Administration (&#x201c;NMPA&#x201d;) in China and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, such events could have a materially adverse impact on the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ii) Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred operating losses since inception and had an accumulated deficit of $452.2 million as of September&#160;30, 2022 and $360.2 million as of December&#160;31, 2021. The Company&#x2019;s cash and cash equivalents and marketable securities were $311.7 million and $383.2 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The Company has financed its operations to date primarily through equity capital raises. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that existing capital resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements, though it expects to continue to incur operating losses and negative operating cash flows. The Company will be required to raise additional capital to fund future operations, however, no assurance can be given as to whether additional needed financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail planned activities to preserve cash resources. These factors may adversely impact the Company&#x2019;s ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(C) Significant Accounting Policies Update&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are disclosed in Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Accounting Policies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Annual Report on Form 10-K for the year ended December&#160;31, 2021. There have been no material changes to the Company&#x2019;s significant accounting policies during the three and nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(D) Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/span&gt;&lt;/div&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, the Company has elected to &#x201c;opt out&#x201d; of such extended transition period for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards on the same timeline as other public companies. The Company has evaluated recent accounting pronouncements and believes that there are none that will have a material impact on its financial position or results of operations upon adoption.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc2Mw_bbca7a30-b3b1-46e8-be86-36d60a35c220">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(A) Basis of presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, which include the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;) registered entities directly owned by the Company. All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim balance sheet as of September&#160;30, 2022, and the interim consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred shares and shareholders&#x2019; equity (deficit) for the three and nine months ended September&#160;30, 2022 and 2021, and the cash flows for the nine months ended September&#160;30, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial information. The financial data and other information disclosed in these notes related to the three and nine month periods are also unaudited. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc1OQ_a00ed714-137d-4364-ae1c-0ae5d6d72bcc">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(B) Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The only material estimates in the accompanying financial statements are the fair value of warrants, share-based compensation, and share options. Actual results could differ from those used in evaluating these accounting estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc2NA_e3ef39de-807b-4a94-9891-29208a9f10e5">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) outbreak a pandemic. The Company&#x2019;s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including planned clinical trials. The impact of the COVID-19 pandemic on the Company&#x2019;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy continue to be impacted for an extended period, the Company&#x2019;s results may be materially adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to material credit risk due to the financial position of the banking institutions. The Company has no off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations involve numerous risks and uncertainties. Factors that could affect the Company&#x2019;s operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials, uncertainty of regulatory approval of the Company&#x2019;s potential product candidates, uncertainty of market acceptance of its product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Company&#x2019;s product candidates require approvals from the National Medical Products Administration (&#x201c;NMPA&#x201d;) in China and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, such events could have a materially adverse impact on the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTM2NQ_e4cfe938-7a8c-4cce-8806-16cf1e82f99e"
      unitRef="usd">-452200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTM4OQ_4ad586c5-b570-4abd-aad9-ed83c8f19da0"
      unitRef="usd">-360200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTQ4MQ_1d186a9b-0e51-4b38-b2c2-37282c210d16"
      unitRef="usd">311700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNTQ5Ng_1f0f45c8-69e2-4a3a-8fd7-dba0bc51e884"
      unitRef="usd">383200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNC9mcmFnOjY4ODQzNzExZjVhNzRiZmNiM2I5ZmRmNWM0OGFkZDExL3RleHRyZWdpb246Njg4NDM3MTFmNWE3NGJmY2IzYjlmZGY1YzQ4YWRkMTFfNzc2MQ_987e792a-9e58-4d65-8c6d-a810da0cbfd5">(D) Recently Issued Accounting Pronouncements Not Yet Adopted The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, the Company has elected to &#x201c;opt out&#x201d; of such extended transition period for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards on the same timeline as other public companies. The Company has evaluated recent accounting pronouncements and believes that there are none that will have a material impact on its financial position or results of operations upon adoption.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <adr:LicenseAndOtherRelatedAgreementsTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg4NTc_61334b7d-46c5-42e7-a8ba-c01740e871fc">Material Agreements &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with QED Therapeutics, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into a license agreement (as subsequently amended, the &#x201c;QED License Agreement&#x201d;) with QED Therapeutics, Inc. (&#x201c;QED&#x201d;), under which the Company obtained an exclusive license under certain patents and know-how (including patents and know-how that QED licensed from QED&#x2019;s upstream licensor) to develop, manufacture, use, sell, import, and commercialize QED&#x2019;s ATP-competitive, FGFR1-3 tyrosine kinase inhibitor, infigratinib, in pharmaceutical products in the licensed territory of Mainland China, Macau, Hong Kong, Taiwan, Thailand, Singapore and South Korea, in the licensed field of human prophylactic and therapeutic uses in cancer indications. In September 2020, the Company entered into an amendment with QED to reduce the licensed territories to include Mainland China, Macau and Hong Kong. In December 2021, the Company entered into a second amendment with QED to modify the Company&#x2019;s development obligations with respect to certain clinical trials, and change the development milestone payments the Company owes to QED and the royalty rates for the tiered royalties on net sales of licensed products the Company will pay to QED. Under the QED License Agreement, QED received a nonrefundable upfront payment of $10.0 million and was granted warrants to purchase 100,000 ordinary shares in Lian Oncology, a subsidiary of LianBio, valued at $1.0 million. Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model. The warrants were issued in three tranches with the aggregate number of shares across all tranches equaling 10% of the fully diluted equity of Lian Oncology as of the issue date. Vesting of the warrant shares are linked to regulatory milestones and the warrants expire 10 years from the issue date. The amended and restated option agreement also provides QED with the option to choose to either convert the warrant (&#x201c;Subsidiary Warrant&#x201d;) into ordinary shares of the Company (&#x201c;Parent Company Shares&#x201d;) or a warrant to purchase a certain number of Parent Company Shares (&#x201c;Parent Company Warrant&#x201d;) immediately prior to an IPO of the Company. In the event QED chose to convert the Subsidiary Warrant into Parent Company Shares, the number of Parent Company Shares QED is entitled to receive would be calculated as the aggregate fair market value of the ordinary shares of Lian Oncology that are under the Subsidiary Warrant, divided by the per share fair market value of the Parent Company Shares, on a fully diluted and as-converted basis and as of the date the Company sent QED the notice of the IPO. In the event QED chose to convert the Subsidiary Warrant into the Parent Company Warrant, the number of Parent Company Shares under the Parent Company Warrant QED was entitled to receive would have been calculated as the aggregate intrinsic value of the Subsidiary Warrant (the number of the ordinary shares of Lian Oncology under the Subsidiary Warrant multiplied by the difference between the strike price of the Subsidiary Warrant and the per share fair market value of Lian Oncology), divided by the per share intrinsic value of the Parent Company Warrant (the difference between the strike price of the Parent Company Warrant and the per share fair market value of Parent Company Shares), on a fully diluted and as-converted basis on the date of the warrant conversion. This conversion feature was not required to be bifurcated as it is clearly and closely related to the equity host instrument, pursuant to ASC 815. On October&#160;18, 2021, based on the conversion feature, LianBio issued to QED a warrant to purchase 347,569 of its ordinary shares at an exercise price of $0.000017100448 per share and, concurrently with such issuance, the Subsidiary Warrant was deemed to be performed and settled in full and was irrevocably terminated. The QED License Agreement also required the Company to refund QED for costs incurred on the study through the execution date which was determined to be $2.8 million. Additionally, QED is entitled to receive from the Company development milestone payments of up to $7.0 million upon achievement of specified development milestones, and sales milestone payments of up to $87.5 million based on cumulative net sales of infigratinib, in addition to tiered royalties on net sales of licensed products at the greater of (a) percentage rates in the mid- to high-teens on the net sales of the licensed products, or (b) the applicable rate payable under QED&#x2019;s agreement with its upstream licensor (capped in the mid-teens).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with MyoKardia &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an exclusive license agreement (the &#x201c;MyoKardia License Agreement&#x201d;) with MyoKardia Inc. (&#x201c;MyoKardia,&#x201d; now a wholly-owned subsidiary of Bristol-Myers Squibb (&#x201c;BMS&#x201d;)), under which the Company obtained an exclusive license under certain patents and know-how of MyoKardia to develop, manufacture, use, sell, import and commercialize MyoKardia&#x2019;s proprietary compound, mavacamten, in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand and Singapore, and in the licensed field of any indication in humans, which includes any prophylactic or therapeutic use in humans. Under the MyoKardia License Agreement, MyoKardia received a nonrefundable upfront payment of $40.0 million and was granted a warrant to purchase 170,000 ordinary shares in Lian Cardiovascular, a subsidiary of LianBio, valued at $33.8 million. Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model and the underlying assumptions are discussed in further detail in Note 10 in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021. The warrants, representing 17% of the fully diluted equity of Lian Cardiovascular, are exercisable by MyoKardia at any time after issuance. The amended and restated option agreement also provides MyoKardia with the option to choose to either convert the warrant (&#x201c;Subsidiary Warrant&#x201d;) into ordinary shares of the Company (&#x201c;Parent Company Shares&#x201d;) or a warrant to purchase a certain number of Parent Company Shares (&#x201c;Parent Company Warrant&#x201d;) immediately prior to an IPO of the Company. MyoKardia was entitled to choose to convert the Subsidiary Warrant into Parent Company Shares, and the number of Parent Company Shares MyoKardia was entitled to receive would have been calculated as the aggregate fair market value of the ordinary shares of Lian Cardiovascular that are under the Subsidiary Warrant, divided by the per share fair market value of the Parent Company Shares, on a fully diluted and as-converted basis on the date the Company sent MyoKardia the notice of the IPO. Alternatively, MyoKardia was entitled to choose to convert the Subsidiary Warrant into the Parent Company Warrant, the number of Parent Company Shares under the Parent Company Warrant MyoKardia was entitled to receive would be calculated as the aggregate intrinsic value of the Subsidiary Warrant (the number of the ordinary shares of Lian Cardiovascular under the Subsidiary Warrant multiplied by the difference between the strike price of the Subsidiary Warrant and the per share fair market value of Lian Cardiovascular), divided by the per share intrinsic value of the Parent Company Warrant (the difference between the strike price of the Parent Company Warrant and the per share fair market value of Parent Company Shares), on a fully diluted and as-converted basis on the date of the warrant conversion. This conversion feature was not required to be bifurcated as it was clearly and closely related to the equity host instrument, pursuant to ASC 815. As of October&#160;12, 2021, MyoKardia elected not to exercise this option and, therefore, continues to hold its warrant to purchase 170,000 ordinary shares in Lian Cardiovascular. MyoKardia&#x2019;s option to convert the warrant irrevocably terminated upon the completion of the Company&#x2019;s IPO. Additionally, MyoKardia was entitled to receive a nonrefundable financing milestone payment of $35.0 million upon a specified financing event, which occurred on October 29, 2020. The financing milestone was recorded at present value upon execution of the MyoKardia License Agreement, with total imputed interest of $2.3 million accreted under the effective interest method through the date the liability was settled. The financing milestone was paid to MyoKardia in December 2020 as a result of the Series A Preferred financing. Additionally, MyoKardia is entitled to receive from the Company development milestone payments of up to $60.0 million upon achievement of specified development milestones, and sales milestone payments of up to $87.5 million based on cumulative net sales of mavacamten, plus tiered royalties on net sales ranging from the low to upper-teens. As of September&#160;30, 2022, the Company has paid $5.0 million to MyoKardia upon the completion of the first development milestone under the MyoKardia License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Navire&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, pursuant to the BridgeBio exclusivity agreement, the Company entered into an exclusive license agreement with Navire Pharma, Inc. (&#x201c;Navire&#x201d;), a BridgeBio affiliate. Pursuant to the license agreement, Navire granted to the Company an exclusive, sublicensable license under certain patents and know-how of Navire to develop, manufacture, use, sell, import and commercialize Navire&#x2019;s proprietary SHP2 inhibitor, BBP-398 (formerly known as IACS-15509) in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand, Singapore, and South Korea. Under the license agreement, Navire received a nonrefundable upfront payment of $8.0 million. Additionally, Navire is entitled to receive from the Company development milestone payments of up to $24.5 million upon achievement of specified development milestones, and sales milestone payments of up to $357.6 million upon achievement of specified commercialization milestones, plus tiered royalties on net sales ranging from approximately 5-15% on the net sales of the licensed products. The Company paid the first development milestone of $8.5 million for IND acceptance in the PRC during the third quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Strategic Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a strategic collaboration agreement (the &#x201c;Pfizer Agreement&#x201d;) with Pfizer Inc. (&#x201c;Pfizer&#x201d;), pursuant to which Pfizer will contribute up to $70.0 million of restricted, non-dilutive capital (the &#x201c;Funds&#x201d;), including a $20.0 million upfront payment, toward the Company&#x2019;s in-licensing and co-development activities in Greater China. The Company has accounted for the Pfizer Agreement as a contract to perform research and development services for others under ASC 730-20 and the consideration received for performing these services will be recognized as contra-R&amp;amp;D in the consolidated statement of operations as the services are performed. Upon receipt of the $20.0 million  upfront payment in the first quarter of 2021, the upfront payment was recorded as restricted cash within consolidated balance sheet and will remain restricted until such time as the upfront payment is utilized for specified in-licensing and co-development activities or until the Pfizer Agreement terminates. Under the Pfizer Agreement, Pfizer and LianBio will form a joint collaboration committee to discuss potential third party in-license opportunities and development and commercialization of the Company&#x2019;s products in Greater China. In the event the Company seeks to engage a third-party commercialization partner with respect to the commercialization of the Company&#x2019;s future products in Greater China, Pfizer will have a right to opt into such product. Upon opting in, a portion of the Funds will be used to pay for development and commercialization costs of such product and Pfizer will thereafter have a right of first negotiation and right of last refusal to obtain the commercialization rights of such product in Greater China, in each instance for additional, separate financial consideration. During the collaboration, Pfizer may provide in-kind support to us for marketing, development and regulatory activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with ReViral &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive license agreement (the &#x201c;ReViral License Agreement&#x201d;) with ReViral Ltd. (&#x201c;ReViral,&#x201d;  now a wholly-owned subsidiary of Pfizer). Pursuant to the license agreement, ReViral granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize novel antiviral therapeutics that target respiratory syncytial virus in Mainland China, Macau, Hong Kong, and Singapore. Under the license agreement, ReViral received a nonrefundable upfront payment of $14.0 million. Additionally, ReViral is entitled to receive payments from the Company totaling an aggregate of up to $105.0 million upon the achievement of specified development and commercial milestones, up to $45.0 million and $60.0 million, respectively, plus tiered royalties on net sales ranging from ten to the low-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Tarsus&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive license agreement (the &#x201c;Tarsus License Agreement&#x201d;) with Tarsus Pharmaceuticals, Inc. (&#x201c;Tarsus&#x201d;). Pursuant to the license agreement, Tarsus granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize TP-03 for the treatment of patients with Demodex blepharitis and Meibomian Gland Disease in Mainland China, Macau, Hong Kong and Taiwan. Under the license agreement, Tarsus received a nonrefundable upfront payment of $15.0 million and was granted three warrants to purchase 125,000 ordinary shares in Lian Ophthalmology, a subsidiary of LianBio, valued at $9.4 million (the &#x201c;Tarsus Warrants&#x201d;). Pursuant to ASC 505-50, as the fair value of the warrants were more reliably determinable than the fair value of the benefits received from the licensing agreement, the Company valued the warrants using the Black-Scholes Model and the underlying assumptions are discussed in further detail in Note 10 in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021. The warrants were issued in three tranches with the aggregate number of shares across all tranches equaling 12.5% of the fully diluted equity of Lian Ophthalmology as of the issue date. Vesting of the warrant shares are linked to regulatory milestones and the warrants expire 10 years from the issue date. Pursuant to a related option agreement (the &#x201c;Tarsus Option Agreement&#x201d;), Tarsus also had the option to convert the warrants into ordinary shares of the Company or warrants to purchase a certain number of the Company&#x2019;s ordinary shares based on appreciation of the value in the Lian Ophthalmology since the inception of the Tarsus License Agreement. This conversion feature was not required to be bifurcated as it was clearly and closely related to the equity host instrument, pursuant to ASC 815.  On October&#160;18, 2021, Tarsus exercised its options to convert the Tarsus Warrants under the Tarsus Option Agreement and the Company subsequently issued to Tarsus 78,373 of its ordinary shares and two warrants to purchase an aggregate of 156,746 of its ordinary shares at an exercise price of $0.000017100448 per share. Following the issuances, the Tarsus Warrants were irrevocably terminated. On June 6, 2022, Tarsus exercised one warrant and the Company subsequently issued 78,373 of its ordinary shares at an exercise price of $0.000017100448 per share. Additionally, Tarsus is entitled to receive a nonrefundable second milestone payment of $10.0 million due and payable within forty-five days following the effective date. Furthermore, Tarsus is entitled to receive payments from the Company totaling an aggregate of up to $175.0 million upon the achievement of specified development and commercial milestones, up to $75.0 million and $100.0 million, respectively, plus tiered royalties at percentage rates ranging from the low- to high-teens on net sales.  In the second quarter of 2022, the Company was notified that Tarsus had achieved a certain development milestone and subsequently paid $15&#160;million in June 2022. As of September&#160;30, 2022, the Company has paid an aggregate of $45.0 million to Tarsus as a result of the achievement of various development milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Landos&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into an exclusive license agreement (the &#x201c;Landos License Agreement&#x201d;) with Landos BioPharma, Inc. (&#x201c;Landos&#x201d;). Pursuant to the license agreement, Landos granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize novel, gut-restricted small molecule omilancor (formerly known as BT-11) and NX-13 for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway in Mainland China, Hong Kong, Macau, Taiwan, Cambodia, Indonesia, Myanmar, Philippines, Singapore, South Korea, Thailand and Vietnam. Under the license agreement, Landos received a nonrefundable upfront payment of $18.0 million. Additionally, Landos is entitled to receive payments from the Company totaling an aggregate of up to $200.0 million upon the achievement of specified development and commercial milestones, up to $95.0 million and $105.0 million, respectively, plus tiered royalties at percentage rates ranging from the low- to the mid-teens on net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Nanobiotix&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into an exclusive license agreement (the &#x201c;Nanobiotix License Agreement&#x201d;) with Nanobiotix S.A. (&#x201c;Nanobiotix&#x201d;). Pursuant to the license agreement, Nanobiotix granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop and commercialize NBTXR3, a potential first-in-class radioenhancer in Mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore and Thailand. Under the license agreement, Nanobiotix received a nonrefundable upfront payment of $20.0 million. Additionally, Nanobiotix is entitled to receive payments from the Company totaling an aggregate of up to $220.0 million upon the achievement of specified development and commercial milestones, up to $65.0 million and $155.0 million, respectively, plus tiered royalties of 10-13% of net sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Lyra&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into an exclusive license agreement (the &#x201c;Lyra License Agreement&#x201d;) with Lyra Therapeutics, Inc. (&#x201c;Lyra&#x201d;). Pursuant to the license agreement, Lyra granted to the Company an exclusive, sublicensable license under the licensed patent rights and know-how to develop and commercialize LYR-210, an anti-inflammatory, intra-nasal drug matrix in late-stage development that is designed to treat chronic rhinosinusitis in Mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore and Thailand. Under the license agreement, Lyra received a nonrefundable upfront payment of $12.0 million. Additionally, Lyra is entitled to receive payments from the Company totaling an aggregate of up to $135.0 million upon the achievement of specified development and commercial milestones, up to $40.0 million and $95.0 million, respectively, plus tiered royalties from the low- to high-teens on net sales. As of September&#160;30, 2022, the Company has paid for the first development milestone of $5.0&#160;million.&lt;/span&gt;&lt;/div&gt;</adr:LicenseAndOtherRelatedAgreementsTextBlock>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="iaeeb6e6bbe6549bc95c5d66955d58c3e_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTMxNg_0214bbf1-d1c6-4d0c-b2a4-984a0d0ebd8b"
      unitRef="usd">10000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ib952974c6da148e98796252b1f567278_I20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM1Ng_af700e4d-51c5-43fe-97f3-09fe6ce4e454"
      unitRef="shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ib5eacd74781d44f289c25d5872d43093_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQyOA_5678effa-5450-4150-a20d-af1238108134"
      unitRef="usd">1000000</us-gaap:WarrantsAndRightsOutstanding>
    <adr:ClassOfWarrantOrRightNumberOfTranches
      contextRef="i3e2ea8c3730c405aaaa82862d9f64c8c_I20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY4OA_b138af0f-0825-465c-9e4f-0cb4c0c67523"
      unitRef="tranche">3</adr:ClassOfWarrantOrRightNumberOfTranches>
    <adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity
      contextRef="i696c50ecd8f14eb6b7b9e1bcbc34acce_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2NQ_31b73e7c-880d-4e4e-bbd7-a41f4c416387"
      unitRef="number">0.10</adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity>
    <adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity
      contextRef="iad897a5006884c3591079e3c6af4ff9b_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2NQ_95a3e155-8a44-4acc-a07d-67dcbd201ac3"
      unitRef="number">0.10</adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity>
    <adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity
      contextRef="ib6353efb7d3e492abdbd9b5ffce7d251_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2NQ_df698804-19e0-4423-a4c1-4fe48edbe928"
      unitRef="number">0.10</adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ib5eacd74781d44f289c25d5872d43093_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTkyNQ_2216f4f9-4353-47c6-b1bb-eff972b4112d">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i35b7d9bb22284b6badabc23d684178bd_I20211018"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMzc1Ng_000e6c9a-09ce-4bcc-b451-4bca4cc1b2ac"
      unitRef="shares">347569</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i35b7d9bb22284b6badabc23d684178bd_I20211018"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMzgwNg_42e3f169-9001-45a3-8b47-4ae6437a5841"
      unitRef="usdPerShare">0.000017100448</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adr:ReimbursementAmountDueTowardsCostsIncurredForTheStudy
      contextRef="i48477ba30acc44fda8e1ce1e3f7f5558_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNDExMQ_9142ab4c-45e1-4b9b-8134-16a3a5c8c6f4"
      unitRef="usd">2800000</adr:ReimbursementAmountDueTowardsCostsIncurredForTheStudy>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i89c392c6026c4ca9864f26feb3f567e3_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNDIxMw_59e4551a-f6c6-4618-a9cd-aa7f0972dcfd"
      unitRef="usd">7000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="id05b0fb48e914379a182a9bec0d03a93_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNDMwOA_ecb06d72-e29b-4a4b-824f-7315afc157a0"
      unitRef="usd">87500000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="i7a57dbf7904a433aa373a461fd34ad40_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTM4OA_643b3956-1505-4f1a-8480-6cb68fbb2034"
      unitRef="usd">40000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1c3b0a6c246849aa9cca5199dc89a774_I20200831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTQyOQ_285b0283-f68e-475f-8e6f-d468a813631f"
      unitRef="shares">170000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i1c3b0a6c246849aa9cca5199dc89a774_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTUwNw_79440f3d-9a35-4874-84b0-973e0557d140"
      unitRef="usd">33800000</us-gaap:WarrantsAndRightsOutstanding>
    <adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity
      contextRef="i1c3b0a6c246849aa9cca5199dc89a774_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNTkyMQ_64f70097-7e8c-4698-aa91-669dc9a4b454"
      unitRef="number">0.17</adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i43ad44c91d4b4706b2c2bdfbec79da2a_I20211012"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfNzk0NA_fcdc612d-76dc-4b05-9069-384f80be9907"
      unitRef="shares">170000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <adr:PaymentOfMilestoneAmount
      contextRef="i0f92dc83d35344a29383ddc78d8130f2_D20201029-20201029"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODE4OQ_31546f33-3b7a-4f8a-9473-30efa8218f0f"
      unitRef="usd">35000000</adr:PaymentOfMilestoneAmount>
    <adr:MilestonePaymentPayable
      contextRef="iacb5da7838574f67a606a8efb8a5436a_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODE4OQ_8d1d991a-7453-4188-8705-14d8ba38a1da"
      unitRef="usd">35000000</adr:MilestonePaymentPayable>
    <adr:ImputedInterestOnMilestonePayment
      contextRef="iacb5da7838574f67a606a8efb8a5436a_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODM5OA_e7050c22-2bf0-43f6-a341-3288725c6086"
      unitRef="usd">2300000</adr:ImputedInterestOnMilestonePayment>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="ie45cfe90a52b41838961759bc21b1b6f_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODY5NQ_3f0cad85-5aa9-4f10-934e-2f056e9f265d"
      unitRef="usd">60000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="i43f085f46e8c4f39a06df0cb33e0529d_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODc5MA_9ac779cb-b554-4e21-a341-c32b56d45fbe"
      unitRef="usd">87500000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:PaymentOfMilestoneAmount
      contextRef="i4327ccb2e1d04429bc1d974a2a6127be_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfODk4MA_9ee69e9a-4fab-4918-a070-3206031747a7"
      unitRef="usd">5000000.0</adr:PaymentOfMilestoneAmount>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="i10056a0bfe624fd0bdceedf504ed17c0_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTY1Mw_1a305945-69cf-4204-be12-cf042d8f58c7"
      unitRef="usd">8000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="ia198b999664b420daab0c08429b7466f_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTc1OA_e1a93f8a-ad15-4e9a-af5c-19eb2f853084"
      unitRef="usd">24500000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="ieeba3f0d0ce94801b53b3e5f40d513bd_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTg1Mw_62c7a201-193e-420f-8fac-0a63528a60fb"
      unitRef="usd">357600000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:TieredRoyaltyAsAPercentageOfNetSales
      contextRef="i0f3dfa4fc2174c5aa9f897019cc2c56d_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTk3OA_5fcda66a-72d3-49e0-a337-d24676793ade"
      unitRef="number">0.05</adr:TieredRoyaltyAsAPercentageOfNetSales>
    <adr:TieredRoyaltyAsAPercentageOfNetSales
      contextRef="if317a4c6058f43dc89f8e182c6ba342c_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfOTk4MQ_a03d7316-22c0-4d54-acbe-63fa892524af"
      unitRef="number">0.15</adr:TieredRoyaltyAsAPercentageOfNetSales>
    <adr:PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement
      contextRef="iaea5c2f5b96f411b9b2bb59234cd0005_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTAwNzk_c10c9d69-7938-4a3d-8f23-016ac4addcaf"
      unitRef="usd">8500000</adr:PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement>
    <adr:CommitmentToContributeCapital
      contextRef="ie9b66761f9ee4964817884acfbe7e816_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTAzNDg_847c4015-1406-40eb-ab26-b48c6006ffc9"
      unitRef="usd">70000000</adr:CommitmentToContributeCapital>
    <adr:UpfrontPaymentReceivable
      contextRef="ie9b66761f9ee4964817884acfbe7e816_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTA0MTQ_6f71fcdb-0a64-480c-ab92-c61224b892ff"
      unitRef="usd">20000000</adr:UpfrontPaymentReceivable>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="ibd6484953b02463e9394d252438606b9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTA4NDM_830848c6-b6fd-4649-8b16-e45f5a0ce5ba"
      unitRef="usd">20000000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ibd6484953b02463e9394d252438606b9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTA4NDM_aa6860a2-4621-46d5-abe2-b0b3f9b33fde"
      unitRef="usd">20000000</us-gaap:RestrictedCashNoncurrent>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="i63457cea5dad4e09a9dc7c0dc8901912_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI2NTI_22c9c60d-3950-43f2-a076-9cbf1172391a"
      unitRef="usd">14000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i1f5317e2a4b64ef4b0ab307c146b677b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI3NTg_b7baf87c-7d87-42b8-880e-9ed42b160c7d"
      unitRef="usd">105000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i1e97b24ff55f44ebbfc3c54fa67ea432_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI4NDA_e91e2396-d431-461c-b0d2-56ac76ffd43f"
      unitRef="usd">45000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="i77f8ab5e29f14552995e67ec5208c971_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTI4NDc_18fcce04-02c4-4b84-a880-2be5e915788a"
      unitRef="usd">60000000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="ieefd544ceaa8467c8b9da24c29b947d0_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM0OTk_410acca6-03f1-43c5-8cfb-e24bf2631c24"
      unitRef="usd">15000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <adr:ClassOfWarrantOrRightIssued
      contextRef="i52f7f825cc684f4eb4def6f2b5dec774_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM1MTg_b0280e5b-890e-488c-8c54-8245ae74c4cf"
      unitRef="shares">3</adr:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i0d52b39d0f33473c9075d48ee2705ecf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM1NDI_79c2adbf-e062-4f21-84fc-ae2670455c1e"
      unitRef="shares">125000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i0d52b39d0f33473c9075d48ee2705ecf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTM2MTk_642140db-2893-4520-aa74-b8e604d6f322"
      unitRef="usd">9400000</us-gaap:WarrantsAndRightsOutstanding>
    <adr:ClassOfWarrantOrRightNumberOfTranches
      contextRef="i1d15540792024becacd6f0a5ad4ad608_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQwNTg_5cae6b51-6fb4-4f6e-bb6c-45db57762a27"
      unitRef="tranche">3</adr:ClassOfWarrantOrRightNumberOfTranches>
    <adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity
      contextRef="i0796e693bdf44849a2a5a2478fe283e2_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQxMzU_1c599e68-11d5-4a59-95c8-390ada8b7cc4"
      unitRef="number">0.125</adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity>
    <adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity
      contextRef="i32b2cc0741f945b3921b5d42fb85ccf0_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQxMzU_7cd81636-fbd3-444d-9158-76f02cc54626"
      unitRef="number">0.125</adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity>
    <adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity
      contextRef="i39d96e7903c34602be47c9a10fe1600c_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQxMzU_baa8d2b2-5390-464e-b79a-6fdf89127d41"
      unitRef="number">0.125</adr:WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i0d52b39d0f33473c9075d48ee2705ecf_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQzMDA_bafaec8a-db96-4b03-b29b-a7b17b95c941">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i859df84b6220412c8216feaef8618ca5_D20211018-20211018"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQ5Njc_620e2322-f6e4-4e12-a79c-15ae988a31d0"
      unitRef="shares">78373</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <adr:ClassOfWarrantOrRightIssued
      contextRef="i859df84b6220412c8216feaef8618ca5_D20211018-20211018"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTQ5OTc_ec390222-fb7f-440a-aa93-a6a93855c694"
      unitRef="shares">2</adr:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="ife3c16d3aeff45b0a62a122f3ffc24be_I20211018"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUwMzc_7988805b-daab-437b-8440-5aaba992c89c"
      unitRef="shares">156746</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia1f77cc73d9d490ca49bf061664c20aa_I20211018"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUwODc_58a4cff1-4428-4c27-a3f0-a5d6aafdd014"
      unitRef="usdPerShare">0.000017100448</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adr:ClassOfWarrantOrRightIssued
      contextRef="ief6faf9500eb46d6b9d7bd6521997ed4_D20220606-20220606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUyMDk_9e264b71-f168-4624-ad74-584876cf2317"
      unitRef="shares">1</adr:ClassOfWarrantOrRightIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ief6faf9500eb46d6b9d7bd6521997ed4_D20220606-20220606"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUyNTY_b28e218e-2665-49ae-aca2-0b27186dc020"
      unitRef="shares">78373</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i500e758b45e84882b8dc0bafbe78d9c0_I20220606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTUzMDY_2c38ad97-2623-4310-99e3-f92b926a2d5b"
      unitRef="usdPerShare">0.000017100448</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adr:MilestonePaymentPayable
      contextRef="i5c7315d139a647a8916844403b35fcc1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU0MDg_819a29f5-8088-47d5-86c9-6cc4ebc35cf4"
      unitRef="usd">10000000</adr:MilestonePaymentPayable>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i4c0c055d4c454529972b2611f7bf8dde_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU1ODA_538a2f0d-eb58-40fc-aee8-1941a6a1cc4a"
      unitRef="usd">175000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i901497f9715b416b90b0380aaed8d696_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU2NjI_9fa7a856-582e-4367-aeec-efaa1b8b40b0"
      unitRef="usd">75000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="i439b9dc6a4324951a68387b66378f8af_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU2Njk_3ac9e470-3906-42f9-8724-8ff56bd8ac63"
      unitRef="usd">100000000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="iebb3f515f2af46d9a26d73623709d955_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU5MTU_53a89821-65cc-4403-bc65-cb64b2542081"
      unitRef="usd">15000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <adr:PaymentOfMilestoneAmount
      contextRef="i780e8a8772534c3abff5c2590cae6a48_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTU5Nzk_7188839b-c1a9-427f-800f-febba7242bbf"
      unitRef="usd">45000000</adr:PaymentOfMilestoneAmount>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="iaf9846b2679d481c9f25e70face7e95d_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY3Nzc_2279e777-a2c2-49ce-a0ab-bd26a69b89f2"
      unitRef="usd">18000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i4208c21f9651412684222291161e9b6b_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY4ODI_b23ccd63-dc04-4ca9-84d2-1020c44ec886"
      unitRef="usd">200000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="ie240169bdada412780e909f804cd7899_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY5NjQ_bc448a00-ee97-410f-be4a-3c916c620473"
      unitRef="usd">95000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="icfe5d9ec24324b71b0ae98324e5a1950_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTY5NzE_cd738642-0404-4a90-9e64-51ac4c5f40cb"
      unitRef="usd">105000000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="i91dd2f17d34d4482a133ebd0c73e8ac8_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc2MzY_8c159d90-ea64-458e-9a29-bd945f212607"
      unitRef="usd">20000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="idc8ffc33df4b44f6aac43fc889c6aab4_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc3NDU_db88ec7f-b9f4-4a13-b7d9-91ac2c51099e"
      unitRef="usd">220000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i8a8f8ab0d9c841ca90cb65c873df8e7a_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4Mjc_864c961c-6a95-495f-a164-9ba9e09e85e4"
      unitRef="usd">65000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="i82819a00611e420f849e1cfc3bd4f1b7_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4MzQ_c7d8311c-687f-49e2-80a2-97aaf8531fb2"
      unitRef="usd">155000000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:TieredRoyaltyAsAPercentageOfNetSales
      contextRef="ica33bd99f1a34aec981651e9aef22732_D20210501-20210531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4Nzc_66e082a7-8e2e-44d3-8f11-ba1b966e70b6"
      unitRef="number">0.10</adr:TieredRoyaltyAsAPercentageOfNetSales>
    <adr:TieredRoyaltyAsAPercentageOfNetSales
      contextRef="id161c6b8aad740d6bf1489f3fa9c21de_D20210501-20210531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTc4ODA_5458a537-64b8-4dc3-afe2-7ffa9ed8e420"
      unitRef="number">0.13</adr:TieredRoyaltyAsAPercentageOfNetSales>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="i25c130a8a3d84f3d9196a9765323af46_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg1MDk_84b6aeb9-235b-487a-8829-8fe1f78951f6"
      unitRef="usd">12000000</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i6eccd0754c4241649e346fd436f9f289_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg2MTI_d9cbd338-a565-4197-a55e-7c8b7ae34b05"
      unitRef="usd">135000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionMilestoneAmount
      contextRef="i2c15a8a30aac4770a88597df9720a6f1_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg2OTQ_254edd7c-7a38-4d2e-8b42-977b69dbd636"
      unitRef="usd">40000000</adr:AssetAcquisitionMilestoneAmount>
    <adr:AssetAcquisitionNetSalesMilestone
      contextRef="ib2977a88c5df432e8077c4dacb23d3e2_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg3MDE_df8e4527-9b06-4c3f-be23-348802e86afe"
      unitRef="usd">95000000</adr:AssetAcquisitionNetSalesMilestone>
    <adr:MilestonePaymentPayable
      contextRef="i7a53ee596d2c4c43965805d5c720ab94_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zNy9mcmFnOjMxYmI0YzgzZDgzMjQwYTVhNjhlMmJjZWFkOTAwYmVkL3RleHRyZWdpb246MzFiYjRjODNkODMyNDBhNWE2OGUyYmNlYWQ5MDBiZWRfMTg4NTM_3ca25328-a713-44cf-98b4-207c38d4ec9e"
      unitRef="usd">5000000</adr:MilestonePaymentPayable>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAxMQ_278939d8-a4b0-49fc-9f7d-d4de5cdf00d5">Marketable Securities and Fair Value Measurements&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at September&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2022 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2021 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September&#160;30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2022 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2021 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-indent:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities on the balance sheet at September&#160;30, 2022 and December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:0.6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its securities as current as they are all available for sale and are available for current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2022 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Level 2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Government obligations &amp;amp; &lt;br/&gt;&#160;&#160;&#160;agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2021 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%"&gt;Level 2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAxMg_113616ed-6be4-454a-9d62-9047bc7ea084">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at September&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2022 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2021 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-indent:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities on the balance sheet at September&#160;30, 2022 and December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:0.6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS0xLTEtMS00OTAzOA_1908fe2e-ee0e-4bbe-a5fc-25d11fb79739"
      unitRef="usd">155652000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS0zLTEtMS00OTAzOA_f98abd4d-873e-4b55-840f-f8d4807d7b90"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS01LTEtMS00OTAzOA_e26a46a3-ccd8-4285-adf5-9dc7faadaefa"
      unitRef="usd">574000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMS03LTEtMS00OTAzOA_cae62c7c-c9f7-467d-a31e-3b7fb0b784f1"
      unitRef="usd">155078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi0xLTEtMS00OTAzOA_f20a650a-bbca-41c1-a9df-4099be8a997c"
      unitRef="usd">14202000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi0zLTEtMS00OTAzOA_aa1f0a31-7eb1-4346-8bfe-0ef41f6d51b6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi01LTEtMS00OTAzOA_cef9e694-c496-4350-898f-046904bb1d06"
      unitRef="usd">136000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMi03LTEtMS00OTAzOA_54954bc3-5b7d-4fa1-9b42-7ae0f185cb6e"
      unitRef="usd">14066000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy0xLTEtMS00OTAzOA_f24623f0-a862-4731-a5fc-cee42701cdbc"
      unitRef="usd">64232000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy0zLTEtMS00OTAzOA_d1138b57-7980-46ae-9e08-a4b29a186f71"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy01LTEtMS00OTAzOA_86ed0430-f44a-4740-a220-d6fb84c6cc39"
      unitRef="usd">511000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfMy03LTEtMS00OTAzOA_18ea07c2-de3d-44fc-b715-527d94e18d47"
      unitRef="usd">63722000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC0xLTEtMS00OTAzOA_24677de3-6c66-4be9-9b59-bfee3da0a76c"
      unitRef="usd">234086000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC0zLTEtMS00OTAzOA_91f26ba0-0568-4a7f-aa7b-b075181ca219"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC01LTEtMS00OTAzOA_e4034143-f889-44ee-a2b6-6b9738b5ccfe"
      unitRef="usd">1221000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmNlMWMyMzEzYTRkYzQxOTliMTAyOTI3YTgyMjkzM2NiL3RhYmxlcmFuZ2U6Y2UxYzIzMTNhNGRjNDE5OWIxMDI5MjdhODIyOTMzY2JfNC03LTEtMS00OTAzOA_8836e9ff-8f7e-4be4-a856-3a0c929fdf56"
      unitRef="usd">232866000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS0xLTEtMS00OTAzOA_71b8d83c-0cbf-4c05-b32b-2ef578e0cf85"
      unitRef="usd">145894000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS0zLTEtMS00OTAzOA_5cd9e4b8-355c-4397-8a9a-b29b3be13030"
      unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS01LTEtMS00OTAzOA_2276608f-17db-4b3e-a510-65b648fe66fa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMS03LTEtMS00OTAzOA_bff3cf9a-3a79-4a79-ac25-0c9b3c483888"
      unitRef="usd">145949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi0xLTEtMS00OTAzOA_f1c0fe30-a4f4-4024-8739-0999c5a41b90"
      unitRef="usd">4138000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi0zLTEtMS00OTAzOA_15942552-ccae-4c47-b7bb-f6aeee3cb40c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi01LTEtMS00OTAzOA_a28ce445-4999-4556-a62c-d3eb0ac81cfe"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMi03LTEtMS00OTAzOA_fb3d99ff-a884-4a21-b40f-ff6020027a3d"
      unitRef="usd">4138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy0xLTEtMS00OTAzOA_fe5fadd4-c6c4-4663-9ae8-91e0801cd2f8"
      unitRef="usd">4986000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy0zLTEtMS00OTAzOA_36633e87-4d14-4450-b80d-53864fd6118b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy01LTEtMS00OTAzOA_3a38498a-916c-422d-82a6-dc508a97e4b1"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfMy03LTEtMS00OTAzOA_5bf6201d-03e0-4c75-b948-9b9ad45ebc95"
      unitRef="usd">4980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC0xLTEtMS00OTAzOA_28e69bb8-a876-4c66-98c0-7caa7b9588c5"
      unitRef="usd">155018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC0zLTEtMS00OTAzOA_9f4ca0c9-a5bf-4592-a270-d1d534a6c77b"
      unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC01LTEtMS00OTAzOA_563e35d3-1eba-4842-8337-a574ddf74a15"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjllYTkxZDRmNTk1MDQ5N2Q5NzEyMDAwMDk4MTJlZmUyL3RhYmxlcmFuZ2U6OWVhOTFkNGY1OTUwNDk3ZDk3MTIwMDAwOTgxMmVmZTJfNC03LTEtMS00OTAzOA_26bb96b9-f30a-4c64-8c4f-02aae30eaf93"
      unitRef="usd">155067000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAwOA_494e2f3c-452d-4572-8671-46a648c762e2">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September&#160;30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2022 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2021 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi0xLTEtMS00OTAzOA_93b6c76c-53d3-4fda-8155-4c92446836b6"
      unitRef="usd">574000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi0zLTEtMS00OTAzOA_d233a15a-d89f-448e-8cf0-c08f9bdd2f7e"
      unitRef="usd">147581000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi01LTEtMS00OTAzOA_3d80b885-a788-478c-af62-24a8c7300a43"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi03LTEtMS00OTAzOA_7941cd47-10d4-4e13-8ad9-4bdff69a4367"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi05LTEtMS00OTAzOA_742ce86d-7244-4a86-bb8d-9ea86944c1c3"
      unitRef="usd">574000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMi0xMS0xLTEtNDkwMzg_d8a996b5-0b85-4d08-86ef-d27f0ad0a50e"
      unitRef="usd">147581000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy0xLTEtMS00OTAzOA_613255ca-273e-41f5-8d52-3d8d8fba3fd6"
      unitRef="usd">136000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy0zLTEtMS00OTAzOA_ca715ead-e496-458a-bb0f-dbb8ed368a72"
      unitRef="usd">14065000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy01LTEtMS00OTAzOA_8c83466e-9d47-4a02-96af-5ab6a04195e0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy03LTEtMS00OTAzOA_70d92f82-7767-46f3-87d5-f44edc3b908e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy05LTEtMS00OTAzOA_ee567d07-a43c-409e-a984-1786c6b0c4d2"
      unitRef="usd">136000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfMy0xMS0xLTEtNDkwMzg_220fb255-e9f8-4771-9250-6e0f535e6d70"
      unitRef="usd">14065000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC0xLTEtMS00OTAzOA_642beb81-8427-4a54-9d32-eee2b8b05008"
      unitRef="usd">465000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC0zLTEtMS00OTAzOA_608767a3-6ac3-4596-b5df-b0c11123f112"
      unitRef="usd">46795000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC01LTEtMS00OTAzOA_004b386b-f583-45b1-b8e1-64a76c821d06"
      unitRef="usd">46000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC03LTEtMS00OTAzOA_a9615183-55ec-4180-b038-c999367f3372"
      unitRef="usd">14952000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC05LTEtMS00OTAzOA_eca55788-6935-4d46-a011-72909210e415"
      unitRef="usd">511000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNC0xMS0xLTEtNDkwMzg_b3785866-abe7-4dcc-8986-6f36d407904e"
      unitRef="usd">61747000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS0xLTEtMS00OTAzOA_b37908fa-4412-494e-ac95-661cc490b6db"
      unitRef="usd">1175000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS0zLTEtMS00OTAzOA_8e547cf4-8749-4978-a7c1-62df3ad6c84c"
      unitRef="usd">208441000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS01LTEtMS00OTAzOA_7abfa5e4-4aef-4ab0-8c40-add410e33407"
      unitRef="usd">46000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS03LTEtMS00OTAzOA_5d405b83-90bb-4918-977d-2deb02f37d36"
      unitRef="usd">14952000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS05LTEtMS00OTAzOA_7f81d9ed-f2db-4a01-9392-e0155bd0f93d"
      unitRef="usd">1221000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjNiY2Q4ZWMyYjk2OTRmZDhhZTg2ZDM2YjZkMzhlNGExL3RhYmxlcmFuZ2U6M2JjZDhlYzJiOTY5NGZkOGFlODZkMzZiNmQzOGU0YTFfNS0xMS0xLTEtNDkwMzg_5c7de075-ac43-4012-a76e-aa3220ad0854"
      unitRef="usd">223393000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi0xLTEtMS00OTAzOA_38cf32e4-d0e9-42f1-a8f7-901542d72518"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi0zLTEtMS00OTAzOA_e048245e-ea96-4c64-b72a-467bdbbd9e70"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi01LTEtMS00OTAzOA_fb251377-7107-4ec1-849d-71e9d5ce7f05"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi03LTEtMS00OTAzOA_2de15d59-b1f0-4f56-aeee-a030abc6335e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi05LTEtMS00OTAzOA_b13a0335-1f3c-4d6a-ab24-27b5c532390d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMi0xMS0xLTEtNDkwMzg_ffc18745-7633-4305-a3f8-119cc90e0b89"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy0xLTEtMS00OTAzOA_8a5eef18-bc92-4e0a-bda8-5a6fe343ef15"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy0zLTEtMS00OTAzOA_27fe2176-95f7-44c6-8e13-6f1520cd34d6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy01LTEtMS00OTAzOA_77ea22b7-1571-4704-940c-731612230914"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy03LTEtMS00OTAzOA_bc5ff037-d1cf-456d-aab6-0ecdebbbfdd0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy05LTEtMS00OTAzOA_30b7f95a-3e0d-4ae3-91c6-223087f227c1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfMy0xMS0xLTEtNDkwMzg_04fa4f63-f5ec-4337-965a-73a3e25ba434"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC0xLTEtMS00OTAzOA_83df4fb6-1cd7-4d50-accb-b6563143116b"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC0zLTEtMS00OTAzOA_35a17827-c0b3-42c4-8ccc-911d4e0045e2"
      unitRef="usd">4980000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC01LTEtMS00OTAzOA_734f7676-484c-487f-b5ff-0e1526634a4f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC03LTEtMS00OTAzOA_fe282954-05b2-4c61-93d1-b3fa19a837fc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC05LTEtMS00OTAzOA_8ec000c8-6cd4-461e-bbcf-5705bdbbffb7"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNC0xMS0xLTEtNDkwMzg_b0636903-e789-4dc7-85fa-a3243c4ea053"
      unitRef="usd">4980000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS0xLTEtMS00OTAzOA_b1a20826-ca5f-429b-9981-e7764e69287a"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS0zLTEtMS00OTAzOA_84aeb672-dfc7-4c35-8266-3ed06aa56e4e"
      unitRef="usd">4980000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS01LTEtMS00OTAzOA_ce143fad-a02a-47b6-afb3-74c43c7d7cda"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS03LTEtMS00OTAzOA_7d6a36f8-5c66-4e91-8c60-e70f9b060e4e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS05LTEtMS00OTAzOA_0b365eae-a414-4892-8944-30f37479b148"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjdjYTI4YzBmODNmNDQxMTY5MGNjZWYyODZhNzdmZjUxL3RhYmxlcmFuZ2U6N2NhMjhjMGY4M2Y0NDExNjkwY2NlZjI4NmE3N2ZmNTFfNS0xMS0xLTEtNDkwMzg_b55af496-ab1a-40ec-8f1b-97508fbe9eb5"
      unitRef="usd">4980000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMi0xLTEtMS00OTAzOA_f8746c07-cc80-4797-906c-e95d63db99c1"
      unitRef="usd">155078000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="i53ab1032d3924cd1b2dbf2289e458967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMi0zLTEtMS00OTAzOA_6f9cf3f6-627e-4678-bac4-4a133a22aa85"
      unitRef="usd">0</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMy0xLTEtMS00OTAzOA_a7860ec6-5cf8-45a3-981c-081b20a3e936"
      unitRef="usd">14066000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="i51c7d53772584519a9e4329929345cab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfMy0zLTEtMS00OTAzOA_638dae74-017c-41a9-a216-5572ded91893"
      unitRef="usd">0</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNC0xLTEtMS00OTAzOA_f2ff5531-8349-46aa-94ea-4ec22c7298ba"
      unitRef="usd">46795000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="i97d68f53f1f24fca8c2fdeb2502514ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNC0zLTEtMS00OTAzOA_5104a489-6cd7-41b1-8c7e-243438906bf2"
      unitRef="usd">16927000</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNS0xLTEtMS00OTAzOA_03a0f325-6b12-4537-831c-be3cac89a11e"
      unitRef="usd">215939000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmM1NGNhZTZkODQzMjRiODhhNTk5NzMzOTBlYTdiMzVlL3RhYmxlcmFuZ2U6YzU0Y2FlNmQ4NDMyNGI4OGE1OTk3MzM5MGVhN2IzNWVfNS0zLTEtMS00OTAzOA_89b87157-9b72-4c14-8127-6c1ab3c78373"
      unitRef="usd">16927000</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMi0xLTEtMS00OTAzOA_de708757-d0a6-4298-a042-67364c12ef4a"
      unitRef="usd">145949000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="ie515765f7aaa42f68cd4e053d2b602bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMi0zLTEtMS00OTAzOA_1cae4cf3-3223-414b-9470-fa47a2329b50"
      unitRef="usd">0</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMy0xLTEtMS00OTAzOA_de6ec666-3295-4e41-9c11-7f9c28c9cf45"
      unitRef="usd">4138000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="i85be39f95e554d6a8acaa6fff436b274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfMy0zLTEtMS00OTAzOA_4c2fff20-f60a-4143-96fd-31f51ba4869c"
      unitRef="usd">0</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNC0xLTEtMS00OTAzOA_d463ed64-d9d4-4453-9c0c-f0e19e3b1c60"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="i513f6fb095174b909385f721f0d3cf39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNC0zLTEtMS00OTAzOA_072f4d53-d39a-4dc1-9663-9b939a4bd8c5"
      unitRef="usd">4980000</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNS0xLTEtMS00OTAzOA_56a36519-1961-466c-ae8e-48c367ed5d74"
      unitRef="usd">150087000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmQ4NGQ0YTAwMzY3ZTRmZGE4ZWE0ODk2Y2M3MDEyYWZkL3RhYmxlcmFuZ2U6ZDg0ZDRhMDAzNjdlNGZkYThlYTQ4OTZjYzcwMTJhZmRfNS0zLTEtMS00OTAzOA_bd66567b-1c39-413f-a7ca-8feb9f7c6e80"
      unitRef="usd">4980000</adr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RleHRyZWdpb246YTI3YmRiN2NjMjlhNDU2N2E4MWRjMjg0MGQ1YjllNTRfMTAxMA_05c71d80-bb7f-4928-8b29-db3df2f9c0a1">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2022 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Level 2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Government obligations &amp;amp; &lt;br/&gt;&#160;&#160;&#160;agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2021 (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:7.05pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:67%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%"&gt;Level 2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:66%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:9%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i53c6ba62baae4983b42b842d1aeddb71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi0xLTEtMS00OTAzOA_41670769-5df7-4467-8cac-dfc4f9bab7aa"
      unitRef="usd">53472000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ica40e054da6d4740987c1dc1a6a68af4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi0zLTEtMS00OTAzOA_d82b830e-50b2-49b4-93b9-3bceab24769c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1827329195bd45ea9e34da5b92c6a744_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi01LTEtMS00OTAzOA_6de1cc57-1c4d-486c-bcc6-870d05778840"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b1fee8ff40e474fa97619a866abe5ac_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMi03LTEtMS00OTAzOA_c15ed407-b117-4723-b26b-5e8e62630149"
      unitRef="usd">53472000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i583601b6fd494097a9a15ee54c69d290_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy0xLTEtMS00OTAzOA_ef3c4850-f4cd-40eb-942e-d12d6c7d1029"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i97fca3542e3e4d248eba0ca3a2c0a2bd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy0zLTEtMS00OTAzOA_0a416ae6-a3c5-4ee9-8ab9-fefa51f69b46"
      unitRef="usd">4988000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i88787dac96ce45a1b690973dc5af39ba_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy01LTEtMS00OTAzOA_5b5c48fc-2c23-469a-9d0e-29123dd4c4e4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i92a84181a570474294e31e06040ab171_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfMy03LTEtMS00OTAzOA_213a11c3-fba4-4636-a49d-aa4336aae182"
      unitRef="usd">4988000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia40d9c3f368a452aa391f0d7c258b7d6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi0xLTEtMS00OTAzOA_264d1c84-190a-499c-ae7e-d009473d85ae"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d9e54db697947818a37b65b4445bf1a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi0zLTEtMS00OTAzOA_b20b2d2c-42b5-496e-899a-2afc30fec8e1"
      unitRef="usd">155078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id77f5c68e566442eaa1bc371b7f5c5e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi01LTEtMS00OTAzOA_95328970-88e8-4d9b-bc49-7547b714217a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79217e78f9c54cbe9bc25876957657bd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNi03LTEtMS00OTAzOA_9d45823c-8db4-4082-a47d-a07d72e52ed4"
      unitRef="usd">155078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8dacd15e2cb3482082951305e30bead4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy0xLTEtMS00OTAzOA_a56aea15-342f-42b2-8e7d-6c8bc197f8a4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81645e508a424863b1adaf26443dcfe7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy0zLTEtMS00OTAzOA_5368a25e-12b2-4b59-8c5e-ee17b286edab"
      unitRef="usd">14065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52e530e77a5746d1a9a908e7d98f902e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy01LTEtMS00OTAzOA_7e90271d-844f-4588-8f9b-32ed42053651"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1678e1fc3ee4b4c94d479a128462f4e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfNy03LTEtMS00OTAzOA_9c022004-3273-4192-8cbe-1a67400d450a"
      unitRef="usd">14065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19f2de6f0d02407e85017a1bd9af1bcd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC0xLTEtMS00OTAzOA_cba3a002-19b8-4192-aeb8-21bfddfe26ae"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i146df2fb452d4fe6b51355e29fee9c51_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC0zLTEtMS00OTAzOA_c5b5094c-6508-4f85-b4d3-8dd1dbce589f"
      unitRef="usd">63723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73431d4fcaa142f5bba2f3bcf88537aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC01LTEtMS00OTAzOA_ce3de697-2358-4bb6-8f67-5723b8258ce8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib86a2fcbc7d44e0db98ad39b9b8bdd1c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOC03LTEtMS00OTAzOA_f0280510-0d4a-4abe-9602-1fa4194c3b4e"
      unitRef="usd">63723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i089cc9baca7b42b3a27fc68ddcc75811_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS0xLTEtMS00OTAzOA_a79587a2-24a0-4bc9-84d2-a11ea16f9294"
      unitRef="usd">53472000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i02a7c6d6dd994b0e8d6e537613ef7302_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS0zLTEtMS00OTAzOA_4579d4bf-df04-4754-96c7-aaf363aef625"
      unitRef="usd">237854000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i599ef0489ae245fdad40419716223f6c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS01LTEtMS00OTAzOA_93001025-feb6-47fa-9212-e0cfe3bb770c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6992b347ac814ea5a287b5ea80729400_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOmY5YTVmZmIwMzQ0ZTRjNDU5MWJjMjVhZDFmMWUxMGRhL3RhYmxlcmFuZ2U6ZjlhNWZmYjAzNDRlNGM0NTkxYmMyNWFkMWYxZTEwZGFfOS03LTEtMS00OTAzOA_ab214370-ea30-4c65-92f2-f4346b746e80"
      unitRef="usd">291326000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i908a570e002147ee82ad8f4dcc47db40_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi0xLTEtMS00OTAzOA_8faccdc6-41aa-47ff-bc88-2aee3f7626b2"
      unitRef="usd">67289000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3b1ff5fc135e4f3c8cddc485f83622f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi0zLTEtMS00OTAzOA_9dcf47f8-0b82-4e25-a700-bc05b81d651b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i47023580772046b381bbc2733f87fab4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi01LTEtMS00OTAzOA_8f7b310c-6281-4e7d-8e5c-fe3f558e6512"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c847b99eb014c07aa341a9479de83f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMi03LTEtMS00OTAzOA_fb884812-e85f-4c07-b03c-f12fe1acb9e0"
      unitRef="usd">67289000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i052630a8432947fbab3f9d75efa151ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy0xLTEtMS00OTAzOA_5cc4f189-40b2-4ee7-85e5-d0ee5f058853"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4cb632483a8a4bb5ac50c44b07402ce5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy0zLTEtMS00OTAzOA_002eb15e-3f88-484f-899a-b720b21b630a"
      unitRef="usd">80541000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6e9201fc4c854336be93003ee6d57bf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy01LTEtMS00OTAzOA_8ee37c43-0b90-429c-81da-fc5d770df0d6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i04b9bb6127684414952f21a60b0d3628_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfMy03LTEtMS00OTAzOA_6818d877-9126-49d5-88e4-697a896134f9"
      unitRef="usd">80541000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9cfb1e63a5a148ea872a48d503461ff2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC0xLTEtMS00OTAzOA_4fd4a212-ceee-4a39-8f5e-8f555770c975"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib56571b3d91e404288ff07ea7e32d86b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC0zLTEtMS00OTAzOA_65cc5452-9d09-43d9-adcd-ed0321f5c07f"
      unitRef="usd">8165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7923c86f54e4a37aa181f8a66eb944f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC01LTEtMS00OTAzOA_96fe986b-6ac1-42c2-b88f-36acdf33d0fa"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i16a9d0cd183640358c221d658d05c903_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNC03LTEtMS00OTAzOA_a15aefd2-5f53-4c0f-96b2-e724a45d0111"
      unitRef="usd">8165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26445de729ae4d13b1780d0406629bb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi0xLTEtMS00OTAzOA_31b12e6c-6106-48e6-8778-2325bf6b8944"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1bd37354b8447fbbdf6d5058cd03cdb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi0zLTEtMS00OTAzOA_54bd8e4c-f0eb-4a16-b039-abcd5dfedda3"
      unitRef="usd">145949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92a707e5adbc4b99b70f59775be134fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi01LTEtMS00OTAzOA_45edf0b9-8fec-4cf8-be61-9d7873a249a7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idbaad0fc47e54c749c1bb25b94d34c50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNi03LTEtMS00OTAzOA_dfe381bf-c78e-4c5b-b76a-2c68580fb35c"
      unitRef="usd">145949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05ac8403115d4cd3b344dc73c9163e90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy0xLTEtMS00OTAzOA_f83b23db-f88f-4101-bfa7-048fe44f6b34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4b54ba31d4848fc98d64676da86fa94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy0zLTEtMS00OTAzOA_d7e792d8-ab16-48b1-824a-7cada9dd6048"
      unitRef="usd">4138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i006d54f5f1e04251898198b35f13f488_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy01LTEtMS00OTAzOA_6b2d21d3-54b9-4b96-abc1-74572b9a4f9b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia84c463023764fd7a23b168836df9331_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfNy03LTEtMS00OTAzOA_23df755f-cdb1-49f3-95a7-f869d700fafa"
      unitRef="usd">4138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67b91ef85a3c4df0a1c9a6cc175f3af4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC0xLTEtMS00OTAzOA_e7113f5e-5a95-4a2e-9ed2-ec0ce6422fad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f8f992a4500455285df2bab55116fb8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC0zLTEtMS00OTAzOA_6b8ce1d0-0eea-417b-930e-09fe8bdcd9dd"
      unitRef="usd">4980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8842f59d8ef141fcafb8b68fe12e360c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC01LTEtMS00OTAzOA_faa7d088-3594-4a7f-a098-883a3089f01a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76f313597efa43788e4abcc3748d1537_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOC03LTEtMS00OTAzOA_dc8700b4-65bf-4d1b-a173-1b59ebd246dc"
      unitRef="usd">4980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i52514ae79d6e4407beb955263f7b7dc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS0xLTEtMS00OTAzOA_69112a35-d99f-41bc-ba1e-b5f3dc10b0fe"
      unitRef="usd">67289000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i72c4d4eb4488417fbbe695608850e678_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS0zLTEtMS00OTAzOA_af9e6a93-ffe8-42b8-bd00-22725b2fcd3a"
      unitRef="usd">243773000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i36ea1b268ae24831a9bfec7be1c4c428_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS01LTEtMS00OTAzOA_85876baf-39ce-4833-87f1-23946aa6b7ab"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i949e844f555744609cfcfdbd4bd385ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80MC9mcmFnOmEyN2JkYjdjYzI5YTQ1NjdhODFkYzI4NDBkNWI5ZTU0L3RhYmxlOjZmYTY1YjczOWYwMjQxNGI5NGEzMzg1YTRkNDlkNjIyL3RhYmxlcmFuZ2U6NmZhNjViNzM5ZjAyNDE0Yjk0YTMzODVhNGQ0OWQ2MjJfOS03LTEtMS00OTAzOA_5de049bb-601f-4c5c-af16-b9a6d780cdd3"
      unitRef="usd">311062000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjg2_84e257aa-b708-4139-898b-69e7c2adc1b7">Property and Equipment, Net &lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total depreciation related to property and equipment was $0.3 million and  $0.7 million for the three and nine months ended September&#160;30, 2022, respectively, and $0.1 million and $0.3 million for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjg3_e3b99fee-ca6c-40a3-b1f5-9e3691bbfcf1">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id17263b03feb4bf599db6d71049821f1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMS0xLTEtMS00OTAzOA_dd2ece94-ae86-4bcc-ad87-7d674a7fff5e"
      unitRef="usd">2717000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4ad1474b304d494cb73a261a3a3b32c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMS0zLTEtMS00OTAzOA_1a4d5e1d-bbe1-497f-9574-4d115cc38cc0"
      unitRef="usd">807000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i94fe0cda96314d9780ce44c077411b21_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMi0xLTEtMS00OTAzOA_2c84f489-4c90-4417-85e9-3a23bc4dca5c"
      unitRef="usd">113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4aa405a5bd447b4a32e03e704b92251_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMi0zLTEtMS00OTAzOA_2afc8695-5c36-4af6-9ec1-550c74831ecf"
      unitRef="usd">65000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4396dac7b05e465b80f79cd6478b8a6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMy0xLTEtMS00OTAzOA_b6b6d83f-88a0-47c1-96d4-160865b8bb16"
      unitRef="usd">794000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib959c47e99054dfc80bccef6276320e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfMy0zLTEtMS00OTAzOA_0e24e9a6-a1a3-494a-ab08-da27d5ecb502"
      unitRef="usd">471000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iec0bf146cc074bbb926e252ce7e39da9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNC0xLTEtMS00OTAzOA_e6f077ea-b09a-48e2-9472-321fc2d3c05b"
      unitRef="usd">723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d076d62c9844f5cbc99d095571fcffa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNC0zLTEtMS00OTAzOA_4a59c1f6-507d-4ced-b59c-24c309af1be1"
      unitRef="usd">1145000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNS0xLTEtMS00OTAzOA_aa6bb3b2-9e40-4a30-9cb1-936a2bd20339"
      unitRef="usd">4347000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNS0zLTEtMS00OTAzOA_17eb2e19-0d4d-4b8b-98b9-b26a572df98f"
      unitRef="usd">2488000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNi0xLTEtMS00OTAzOA_eea7ecf1-2ce2-4f1f-bf97-cb1b76fa1247"
      unitRef="usd">1212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNi0zLTEtMS00OTAzOA_ed93f167-8e0c-42ca-b406-b1f738382088"
      unitRef="usd">606000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNy0xLTEtMS00OTAzOA_784167db-81ab-418e-8168-58d5dca18571"
      unitRef="usd">3135000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RhYmxlOmM3YTA3Yjk5OTg4ZjQ4YzliMzRjMjg2MmE0YWExOThiL3RhYmxlcmFuZ2U6YzdhMDdiOTk5ODhmNDhjOWIzNGMyODYyYTRhYTE5OGJfNy0zLTEtMS00OTAzOA_4fd2002d-d769-410b-b86e-ed55afeb1561"
      unitRef="usd">1882000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMTQ3_a04eceb4-a38a-42f6-bdcf-f1b342d8c115"
      unitRef="usd">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMTYz_45fef99c-b301-4f4e-a622-6de1194aebb2"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjIw_9cdf2014-7015-458e-a03b-38616300a131"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80My9mcmFnOjkxZTMzOGZlMTdiOTQ4MWE5NWVhZGY2ZGIzNzkwZGIwL3RleHRyZWdpb246OTFlMzM4ZmUxN2I5NDgxYTk1ZWFkZjZkYjM3OTBkYjBfMjM1_1db9a581-22eb-4845-beed-3cab2eb23da5"
      unitRef="usd">300000</us-gaap:Depreciation>
    <adr:PrepaidExpenseAndOtherCurrentAssetsTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RleHRyZWdpb246OGJmOTRkMGYwOTgxNDM4Y2E3ZTE3NWMwNGMzZjU3ZDlfMTE4_ab7411e4-7c4c-4d7f-8aa7-1cc525d8a8f3">Prepaid Expense and Other Current Assets &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Advance payments to suppliers and rent deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</adr:PrepaidExpenseAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RleHRyZWdpb246OGJmOTRkMGYwOTgxNDM4Y2E3ZTE3NWMwNGMzZjU3ZDlfMTE5_9daa2bca-cedd-4bef-a1d8-82d97598ee16">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Advance payments to suppliers and rent deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <adr:PrepaidRentAndSupplies
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMS0xLTEtMS00OTAzOA_8f33ff5d-1d2a-48fd-926f-6096e816d469"
      unitRef="usd">1592000</adr:PrepaidRentAndSupplies>
    <adr:PrepaidRentAndSupplies
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMS0zLTEtMS00OTAzOA_c649b949-3ecf-4c62-9698-fa78d075fe80"
      unitRef="usd">1499000</adr:PrepaidRentAndSupplies>
    <us-gaap:PrepaidInsurance
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMi0xLTEtMS00OTAzOA_c3db731e-6ae8-471f-8274-063ad85b6d8f"
      unitRef="usd">907000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMi0zLTEtMS00OTAzOA_13f9e1ae-508c-4b1e-b661-94cc6ca4e472"
      unitRef="usd">7378000</us-gaap:PrepaidInsurance>
    <us-gaap:DeferredCostsCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMy0xLTEtMS00OTAzOA_e84c348c-ff58-4270-b07b-61a835fe1f57"
      unitRef="usd">51000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfMy0zLTEtMS00OTAzOA_b49e2dc9-4d39-413a-83d1-4c405a940d1c"
      unitRef="usd">3000</us-gaap:DeferredCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNC0xLTEtMS00OTAzOA_f96e896c-d3fe-4aa1-883c-a150c17f111d"
      unitRef="usd">2093000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNC0zLTEtMS00OTAzOA_9863ccfc-d2c4-47ff-8ba4-5372283b06da"
      unitRef="usd">1176000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNS0xLTEtMS00OTAzOA_7db0fd31-27c5-41ec-8f6b-202d19c1cb05"
      unitRef="usd">474000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNS0zLTEtMS00OTAzOA_c9d13cc4-221b-4870-aeea-07ce7f31aeef"
      unitRef="usd">298000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNi0xLTEtMS00OTAzOA_e60dd1b7-2ce7-4aeb-bbff-441af84c6933"
      unitRef="usd">5117000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80Ni9mcmFnOjhiZjk0ZDBmMDk4MTQzOGNhN2UxNzVjMDRjM2Y1N2Q5L3RhYmxlOjI0NjBjNWQ2YmIwMjQ3NzViNmMyMTEwZDhhZTUyNDdlL3RhYmxlcmFuZ2U6MjQ2MGM1ZDZiYjAyNDc3NWI2YzIxMTBkOGFlNTI0N2VfNi0zLTEtMS00OTAzOA_d214d11f-99a4-437a-93b2-c09e653dfba8"
      unitRef="usd">10354000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RleHRyZWdpb246ODZjYzc5YzEzNGE3NDRmNWI0NGYyMGFmOGM1ZDNmYjBfNzA_014bc0de-a6ab-42e0-a411-2f89fddc6215">Accrued Expenses &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Consulting and contracted research&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RleHRyZWdpb246ODZjYzc5YzEzNGE3NDRmNWI0NGYyMGFmOGM1ZDNmYjBfNzE_32fd77ba-0bf8-46b1-8f3c-3ca1692ff46e">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Consulting and contracted research&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMS0xLTEtMS00OTAzOA_0843d7f6-277f-4714-84fc-1c8bccfb95fe"
      unitRef="usd">4801000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMS0zLTEtMS00OTAzOA_2f99cd04-6691-48a6-8e91-37c5e00afef3"
      unitRef="usd">2309000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMi0xLTEtMS00OTAzOA_a29c0456-aba1-41a6-a275-5a8005ea9931"
      unitRef="usd">4949000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMi0zLTEtMS00OTAzOA_4e629bb2-aafa-4ece-9ec2-834c1f2ae804"
      unitRef="usd">3625000</us-gaap:AccruedProfessionalFeesCurrent>
    <adr:AccruedConsultingAndContractedResearchCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMy0xLTEtMS00OTAzOA_6b59a25b-7399-4603-97c3-d2099d7cda2d"
      unitRef="usd">7968000</adr:AccruedConsultingAndContractedResearchCurrent>
    <adr:AccruedConsultingAndContractedResearchCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfMy0zLTEtMS00OTAzOA_e3c4a234-fb69-467d-8b6f-19d4d11bf9b6"
      unitRef="usd">3925000</adr:AccruedConsultingAndContractedResearchCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNC0xLTEtMS00OTAzOA_29c73450-ee1e-4cc4-9924-6bf78e9862eb"
      unitRef="usd">153000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNC0zLTEtMS00OTAzOA_5b1e6640-e8f3-4f9e-ba4b-1463f6c1d88e"
      unitRef="usd">117000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNS0xLTEtMS00OTAzOA_b7eb0fd2-30d7-42b9-99fc-ba6de892967b"
      unitRef="usd">17871000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF80OS9mcmFnOjg2Y2M3OWMxMzRhNzQ0ZjViNDRmMjBhZjhjNWQzZmIwL3RhYmxlOmMzYzg3YWM3ZTA1MDQ5OWZhODA5NTU5MGE3YzU2NzFmL3RhYmxlcmFuZ2U6YzNjODdhYzdlMDUwNDk5ZmE4MDk1NTkwYTdjNTY3MWZfNS0zLTEtMS00OTAzOA_dace3ac5-71a1-4388-95fe-7e3268119076"
      unitRef="usd">9976000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81Mi9mcmFnOmNlNzUzY2JlYWU4YjQ3MzE5M2Q3M2E4OGE4NzljNzIwL3RleHRyZWdpb246Y2U3NTNjYmVhZThiNDczMTkzZDczYTg4YTg3OWM3MjBfNjY0_e90fb73a-d428-4cca-a8a7-0257d9b8e4be">Commitments and Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. As of September&#160;30, 2022 and December&#160;31, 2021, there have been no such matters identified. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within the range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The Company is not currently party to any material legal proceedings.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitment
      contextRef="i6f18cb39c42c4b1c83be602d5ef25c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81Mi9mcmFnOmNlNzUzY2JlYWU4YjQ3MzE5M2Q3M2E4OGE4NzljNzIwL3RleHRyZWdpb246Y2U3NTNjYmVhZThiNDczMTkzZDczYTg4YTg3OWM3MjBfMzI3_b7dbcf19-99df-410e-aba7-b05617446e3d"
      unitRef="usd">0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="ief76923dc8d8411997af1d7252a67753_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81Mi9mcmFnOmNlNzUzY2JlYWU4YjQ3MzE5M2Q3M2E4OGE4NzljNzIwL3RleHRyZWdpb246Y2U3NTNjYmVhZThiNDczMTkzZDczYTg4YTg3OWM3MjBfMzI3_cd88f1f0-d213-4847-bdbe-03be1cbb9946"
      unitRef="usd">0</us-gaap:OtherCommitment>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4Mw_6ecd901e-9056-4e20-8726-fce19a8ac52f">Share-Based Compensation &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company adopted a shareholder-approved share-based compensation plan (the &#x201c;2019 Plan&#x201d;), which permits the granting of incentive share options, nonqualified share options, share awards and certain other awards to its employees, members of its Board of Directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, the Company adopted a shareholder-approved share-based compensation plan (the &#x201c;2021 Equity Plan&#x201d;), which permits the granting of incentive share options, nonqualified share options, share awards and certain other awards to its employees, members of its Board of Directors and consultants. The maximum number of shares that may be delivered in satisfaction of awards under the 2021 Equity Plan was initially approximately 14.2&#160;million shares, plus the number of shares that remained available for issuance under the 2019 Plan and that may again become available for issuance under such plan, not to exceed approximately 10.7&#160;million shares in the aggregate, and an annual increase, to be added as of January 1st of each year from January 1, 2022, to January 1, 2031, equal to the lesser of (i) four percent (4%) of the number of shares outstanding as of such date; and (ii) the number of shares determined by the Board of Directors on or prior to such date for such year. Subsequent to the effectiveness of the 2021 Equity Plan, no additional awards have been made pursuant to the 2019 Plan. However, any outstanding awards granted under the 2019 Plan will remain outstanding, subject to the terms of the 2019 Plan and award agreements. Through September&#160;30, 2022, there were awards outstanding for approximately 8.5 million ordinary shares under the 2019 Plan and approximately 5.5 million ordinary shares under the 2021 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Option Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022, the Company issued options to purchase a total of 464,734 ordinary shares to various employees, directors and board members with a weighted-average exercise price of $3.37 per share option and a weighted-average fair value of $2.31 per share option. The fair-value based method for valuing each share option grant on the grant date uses the Black-Scholes Model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 2.56% - 3.90%; expected dividend yield of 0.00%; expected share price volatility of 76.83% - 79.65%; and expected term of 5.50 - 6.08 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021 the Company issued options to purchase 3,820,173 ordinary shares with a weighted-average exercise price of $6.84 per share option and a weighted-average fair value of $3.47 per share option. The fair-value based method for valuing each share option grant on the grant date uses the Black-Scholes Model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 0.09% - 1.22%; expected dividend yield of 0.00%; expected share price volatility of 60.00%; and expected term of 0.50 - 6.25 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, $38.3 million of total unrecognized expense related to non-vested share options is expected to be recognized over a weighted average period of 2.86 years from the date of grant. As of September&#160;30, 2021, $18.1 million of total unrecognized expense related to non-vested share options is expected to be recognized over a weighted average period of 3.36 years from the date of grant. Options granted to senior management and employees generally vest in equal annual increments over four years and grants issued subsequent to the IPO generally vest over four years with 25% vesting over the first year and monthly thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Share Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no performance share awards granted during the nine months ended September&#160;30, 2022. During the nine months ended September&#160;30, 2021 the Company granted certain option awards with both market-vesting conditions and service-vesting conditions to a member of management. The market condition is based on the Company&#x2019;s enterprise value. Per the terms of the award, these options will vest in two equal tranches based on the following thresholds:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt"&gt;50% of the performance options will vest upon satisfaction of the Company achieving an enterprise value of not less than $2.0&#160;billion at any time after the grant date in accordance with the service condition described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2. 50% of the performance options will vest upon the satisfaction of the Company achieving an enterprise value of not less than $4.0&#160;billion at any time after the grant date in accordance with the service condition described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The enterprise value shall be equal to the number of outstanding ordinary shares of the Company multiplied by the volume weighted average price of a single ordinary share averaged over a period of thirty days ending one day prior to the date of the valuation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the market conditions described above, the option contains explicit service vesting conditions, with one-fourth vesting each year over four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The issued options are to purchase 1,938,615 ordinary shares with a weighted-average exercise price of $6.90 per share option and a weighted-average fair value of $4.72 per share option. The Company used a Monte-Carlo simulation to determine the grant date fair value for these awards, which takes into consideration the possible outcomes pertaining to the enterprise value market condition based on the following assumptions: risk-free interest rate of 0.81% - 1.63%; expected dividend yield of 0.0%; expected share price volatility of 47.07% - 80.64%; and expected term of 4.87 - 10.00 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, there was $6.0 million of total unrecognized compensation cost related to outstanding performance share awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No performance-based share units (&#x201c;PSUs&#x201d;) were granted during the nine months ended September&#160;30, 2022 or 2021. As of September&#160;30, 2022, there was $2.1 million of total unrecognized compensation cost related to outstanding PSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022, the Company granted 29,785 non-vested restricted share units (&#x201c;RSUs&#x201d;) to certain employees, with a weighted-average grant date fair value of $2.56 per RSU. As of September&#160;30, 2022, there was $2.4 million of total unrecognized compensation expense related to non-vested RSUs. There were no RSUs granted during the nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;During the nine months ended September&#160;30, 2022, the Company granted 217,985 performance-based RSUs to certain employees, with a weighted-average grant date fair value of $2.17 per RSU. 60% of the total number of RSUs will vest on the one-year anniversary of the date on which the mavacamten New Drug Application (&#x201c;NDA&#x201d;) acceptance in China is obtained. The remaining 40% of the RSUs will vest on the six-month anniversary of the date on which the mavacamten NMPA acceptance is obtained in China. Upon termination of an employee&#x2019;s service with the Company for any reason, any performance-based RSUs that are outstanding and not yet vested will be immediately forfeited. As of September&#160;30, 2022, there was $1.1 million of total unrecognized compensation expense related to non-vested performance-based RSUs. There were no performance-based RSUs granted in the nine months ended September&#160;30, 2021</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibef4c7d268f5402dae0e1b439efb68f4_I20211103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNzg0_fe74768d-ba64-4576-8a98-cab00c15fc9e"
      unitRef="shares">14200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie0f6b78d38b54b2b9954c7b5a6114f41_I20211103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfOTcy_eb4c6cd5-ffe0-4336-83ce-34505078a993"
      unitRef="shares">10700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <adr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares
      contextRef="ice923f6c800447bcb1d172a7ed1e741c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTE1MA_94d0cec9-f5b3-4312-93b8-747967d9a13b"
      unitRef="number">0.04</adr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i1a0efa3f6688449aa871fe22f08334a7_D20191201-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTYzOQ_ed412905-94e8-4900-905b-be768d7516cb"
      unitRef="shares">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="iadc7598a210a4dfeab2ec14ba7e4c6e4_D20211103-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTcwNA_d195f2bb-1e59-4530-bd22-eddc51cec99d"
      unitRef="shares">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTg2Mw_10f29128-3a82-4b63-9575-8872d1f28eb4"
      unitRef="shares">464734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ifc475a18a1634df89b155ffac5055809_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMTk3NA_91d4fe61-afc6-468d-a171-4fcc52f7ea55"
      unitRef="usdPerShare">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjAzMQ_1c18b29b-adf3-4125-99ec-8d92ecf053d9"
      unitRef="usdPerShare">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjMyNw_f0eb8256-2876-444f-9261-6ef17412c61a"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjMzMg_ec07c335-4b2a-4a66-b487-8662f5d350bc"
      unitRef="number">0.0390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjM2Mw_9bb2a44e-32eb-41e2-a945-fab3aed0b710"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQwMg_43aaca4c-a6da-4d79-9168-359b40273482"
      unitRef="number">0.7683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQwNw_99018ef3-335b-43b3-8c9a-8c16f25665a5"
      unitRef="number">0.7965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0e167d8302464f6d9c35491507ac8cb4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQzMg_eac00729-ad46-40f4-b75d-88e33f4e0021">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b3370e462484d7f8debdb37ce2ce8e3_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjQzNw_659a9609-5143-41c5-840b-2cd9902504eb">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjUyOQ_a9eedffc-d09e-4d53-884e-4f585df3af20"
      unitRef="shares">3820173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia858e3c7efff4cc39fbe4c012eb1ec90_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjU5MA_acb3e898-b22c-47b8-9f08-db6050d506bf"
      unitRef="usdPerShare">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjY0Nw_88d02256-ffb2-4c02-bd81-7274289bbc57"
      unitRef="usdPerShare">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i11c152c42e3146f894258b2b89a5e956_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjk0Mw_c0be9079-3abb-41dd-ac07-1c25d6994e56"
      unitRef="number">0.0009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia040378a6b2244fa861c27980e968a32_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjk0OA_595f3ff0-4469-49cf-b2e1-6bc9f4ba8016"
      unitRef="number">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjk3OQ_cf280276-9a3f-4f5e-8afd-2d9d30b74ef9"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzAxOA_d83a9515-0d38-407d-a850-68d9f1e032dc"
      unitRef="number">0.6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i11c152c42e3146f894258b2b89a5e956_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzA0Mw_00e96c5a-5db8-4285-8f50-624abfbf1bab">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia040378a6b2244fa861c27980e968a32_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzA0OA_d94fd297-3c25-4f33-a1ad-3c220bd6dbab">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ifc475a18a1634df89b155ffac5055809_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzA2OA_84b00f59-e681-4e06-9087-e881931805ab"
      unitRef="usd">38300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzIwOA_9d1655f1-8e5e-45be-ac5e-eaaee758116d">P2Y10M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ia858e3c7efff4cc39fbe4c012eb1ec90_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzI2Mg_a2620b8a-4786-4e2d-8425-84ac046a2ab0"
      unitRef="usd">18100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie3738be545f6478cb7087cd3dedf207d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzQwMg_dc5444be-0082-4409-8ec8-13c3c0c5ce45">P3Y4M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzUzMw_d401d2d3-e531-42ee-934e-89ad63d53858">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzU5Ng_8e83f689-7b90-4692-81d5-b4aa7822ce6b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1e109f290fac479bbc0fb50fd1e67ff8_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzYwNA_fcd4fe16-a12d-41c4-9ac2-bdad56ba33ff"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i1c27ecbad78a402aa40e15a813e287a6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzY5Nw_913303fe-e320-4df7-bf4f-ba0402417f0c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMzY5Nw_cf7e9a9c-1ffd-487a-b18f-61897fa18d03"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i163994ff7dd148e6a47533a384b804b8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDEwNQ_43118f67-7999-4a8e-9ac0-7bb433010181"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <adr:PerformanceConditionOnMarketValue
      contextRef="ia37aaf2e75dc4f9c8d8fedc3b1cb29f4_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDIyNQ_e0cee127-993e-4204-92c3-95cf37091124"
      unitRef="usd">2000000000</adr:PerformanceConditionOnMarketValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia37aaf2e75dc4f9c8d8fedc3b1cb29f4_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDMyMg_903f43ba-d7ef-49e2-a7f8-0800b4947180"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <adr:PerformanceConditionOnMarketValue
      contextRef="i163994ff7dd148e6a47533a384b804b8_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDQ0Nw_2b06dd1c-075b-4d50-b88c-963864b95ecd"
      unitRef="usd">4000000000</adr:PerformanceConditionOnMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1c27ecbad78a402aa40e15a813e287a6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4MQ_c4136b74-5d66-4473-a592-bab6287cf70e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNDk5Ng_e51ecaf4-90f8-43fd-8e13-4890e586f3f3"
      unitRef="shares">1938615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTA1Nw_171cba6f-7186-4bd5-b6cf-c310eae6feff"
      unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTExNA_36e1a65f-954d-4bc0-b830-5c3edd6c8730"
      unitRef="usdPerShare">4.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQwMg_d46fb36e-a268-4e40-98bc-4f6670f76cf3"
      unitRef="number">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQwNw_a73699a5-25f4-439b-be93-c1bd99363744"
      unitRef="number">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib1340243c4b74132babad381c7136bc2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQzOA_3822c4ee-5f46-4252-9135-bc6ebee2c266"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ3Nw_934a1af1-68db-445d-b908-5ecc1a90e7b4"
      unitRef="number">0.4707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ4Mg_8f2fe47e-7947-4576-9866-d610b186b4e4"
      unitRef="number">0.8064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4b5fec6761be478f87c1a94395d68e17_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTUwNw_33ae2ea6-1498-484d-9197-a5a439fee0c7">P4Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i30e049d5bd2d4457919e120ec9ab8b42_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTUxMg_443a63a4-00d8-4c3a-a109-f8840cd0c960">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i790b35dc63d348a8ad805f2a45e3e6a9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTU0Mg_1deb2da8-1f84-4c64-b6e1-d7dd8401dad6"
      unitRef="usd">6000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="iae18a04092e5496faf63315837e7fc8c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4Mg_28c05566-2991-4b32-a298-93d88b115139"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i385421b8aac749b6b3bb67d39e04d1d2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjU4Mg_87156e45-9134-49e3-9d46-53c624d3a0e1"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ic8b0e7ba818d4c4baf09cc8d2c41d451_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTc4MA_831642bd-a038-4649-89e1-e3ac2aa9feb3"
      unitRef="usd">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i34a4b2db597d4126ab138b1b321c7166_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTkzNQ_caf5f234-b30a-49cd-82f3-52ac049f7682"
      unitRef="shares">29785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34a4b2db597d4126ab138b1b321c7166_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjA1Mg_9f1e1423-9b56-4e75-92bf-c2bd9a5dfe24"
      unitRef="usdPerShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i42d2e669f7ca4fe89612a0a784bcd359_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjA5NQ_c6a9e14f-e8bc-435b-8a19-33883367a068"
      unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4875fecaf1f14bb5b5c2ceef28b17b17_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNjE4OA_ba2e8396-29d8-4be6-802d-d87cb248f73d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic09c463503db4ad7ae3248958a79fe4c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjE5OTAyMzI2MjM0NQ_28d7b96b-5d2f-4a9c-81f8-83f7488aefef"
      unitRef="shares">217985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic09c463503db4ad7ae3248958a79fe4c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjE5OTAyMzI2MjQ1NA_2ea95df8-c447-4d31-b2d6-0e828998b1ea"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i37e42e244697487da44b1a88c9ca695c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ5NzU1ODIzMTA4_e6a4df33-19b1-426e-9699-910facf95c36"
      unitRef="number">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id04ab5e91570453bafa51dfcaedd5a80_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfNTQ5NzU1ODIzMTEz_f0104825-aa25-4a13-8008-55984d8d4c05"
      unitRef="number">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ie7409e8003154a5392e873de4657fb1e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81NS9mcmFnOjE3OWE5OWE2ODJlODQ5MzViNTgwOGQzNjQ2NWNlMTFkL3RleHRyZWdpb246MTc5YTk5YTY4MmU4NDkzNWI1ODA4ZDM2NDY1Y2UxMWRfMjE5OTAyMzI2MzAyOA_ccfd4b54-4b07-4d45-b74e-0d9298524658"
      unitRef="usd">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RleHRyZWdpb246ZDkwNGJiNzRmYzJlNGZiNDg4OGU0NjNkYTRmNmM0ZmFfODQ0_6ffd3323-f5ae-40c9-94b6-08b9e6195904">Net Loss Per Share &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding, plus all additional ordinary shares that would have been outstanding, assuming dilutive potential ordinary shares had been issued for other dilutive securities. For the three and nine months ended September&#160;30, 2022 and 2021, diluted and basic net loss per ordinary share were identical since potential ordinary shares were excluded from the calculation, as their effect was anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,353,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,690,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,854,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,549,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per ordinary share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share, because including them would have been anti-dilutive during each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable Convertible Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,024,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Share Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,163,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,746,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;QED Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MyoKardia Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tarsus Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants in LianBio issued to QED and Tarsus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RleHRyZWdpb246ZDkwNGJiNzRmYzJlNGZiNDg4OGU0NjNkYTRmNmM0ZmFfODQ1_3341a1da-7e2c-4a10-aff3-cdd7fc6db482">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,353,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,690,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,854,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,549,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per ordinary share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi0xLTEtMS00OTAzOA_88245a1f-0189-4a9f-a03b-496e49e12a40"
      unitRef="usd">-21897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi0zLTEtMS00OTAzOA_53de6f84-a86f-4de0-8482-d74613f7ade4"
      unitRef="usd">-13112000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi01LTEtMS00OTAzOA_27eaa8d4-bfb8-4850-95d4-863ba506c2cc"
      unitRef="usd">-92014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi01LTEtMS00OTAzOA_b1fc7194-7175-4046-8cd6-b13cdb0c5272"
      unitRef="usd">-92014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi03LTEtMS00OTAzOA_754b036c-d29f-43d7-9905-978fb2535114"
      unitRef="usd">-175105000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfMi03LTEtMS00OTAzOA_ea4d70f2-2d01-4d69-8368-94091ef45b1d"
      unitRef="usd">-175105000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0xLTEtMS00OTAzOA_1b6ce997-82cb-4145-a36d-a22b603f221d"
      unitRef="shares">108353831</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0xLTEtMS00OTAzOA_d3ec30a7-5632-4103-afe5-38ebc470bd63"
      unitRef="shares">108353831</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0zLTEtMS00OTAzOA_222e2bb8-e015-49b1-b5c1-8e131b561ac4"
      unitRef="shares">20690908</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC0zLTEtMS00OTAzOA_6b107ddb-02bc-4075-bd23-290a70084298"
      unitRef="shares">20690908</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_00ef4bf9-699d-433c-8722-9985e428523e"
      unitRef="shares">107854547</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_8c38cba3-96df-4a6e-9676-84ba16b75792"
      unitRef="shares">107854547</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_c7192474-5f08-4cbc-9988-162b497230b5"
      unitRef="shares">107854547</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC01LTEtMS00OTAzOA_ef97f2a0-022c-4356-98a9-9626290c9150"
      unitRef="shares">107854547</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_14a58dd6-e592-49c3-89a2-7454e7445aaa"
      unitRef="shares">20549310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_4ac98de3-76b8-479d-8c7d-cba28e7752a8"
      unitRef="shares">20549310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_ab77e2b6-ca26-4a17-b6ff-a1b8648932a1"
      unitRef="shares">20549310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNC03LTEtMS00OTAzOA_e8556ac3-256a-4316-bcc6-8867acae44e1"
      unitRef="shares">20549310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0xLTEtMS00OTAzOA_3e6c536b-26bd-4fe6-9a1b-66c6a5ecaf30"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id77363498db642a188305f503a88fef2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0xLTEtMS00OTAzOA_583655f3-78a5-4962-b2c2-63a481469f06"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0zLTEtMS00OTAzOA_0a7104df-d567-474f-9287-74e06037c94b"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfbc2869e0ec457389bb9504562e55d9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS0zLTEtMS00OTAzOA_56150c59-ae4d-4982-bc62-b47e06e7adff"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_356af0b1-3cab-47d5-a557-cd5c0fccf086"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_6acb4257-6a89-4072-a06e-027ee42e50b9"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_f519dbe2-a7bb-40a2-a684-30729fc4fcee"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS01LTEtMS00OTAzOA_f8b4414e-cd68-4100-b851-54243a027bfd"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_0b7a39c7-c88c-47d9-a5d0-ee1926513a12"
      unitRef="usdPerShare">-8.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_11e9e699-83cc-4448-916a-7d380404be0f"
      unitRef="usdPerShare">-8.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_9d16d800-d909-49d1-825d-7fc3f2f54865"
      unitRef="usdPerShare">-8.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1164ff21af8f442e82273b5f67e43eb2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOjgyNjZjZmZiNzdiZjQ2ZWE4MzY3ZWFhMjNkZjliODU3L3RhYmxlcmFuZ2U6ODI2NmNmZmI3N2JmNDZlYTgzNjdlYWEyM2RmOWI4NTdfNS03LTEtMS00OTAzOA_d549467c-8a7a-424d-a998-48a721e00ff7"
      unitRef="usdPerShare">-8.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RleHRyZWdpb246ZDkwNGJiNzRmYzJlNGZiNDg4OGU0NjNkYTRmNmM0ZmFfODQ2_9d4779cd-70b3-4f1f-bdcf-576ee248c37a">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share, because including them would have been anti-dilutive during each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable Convertible Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,024,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Share Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,163,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,746,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;QED Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MyoKardia Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tarsus Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants in LianBio issued to QED and Tarsus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6a0e878a4e9940a8ba193c5c8a44bfe7_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMi0xLTEtMS00OTAzOA_6415900f-1046-42c3-915c-1c83e7f33566"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia34cd0bfaa564a92bd7ecdce2c826bc7_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMi0zLTEtMS00OTAzOA_4e5fccfe-31d4-469f-9698-7ff2289cce1b"
      unitRef="shares">11024178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i484a69d178e340c093a1bcad9d0db61c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMy0xLTEtMS00OTAzOA_745fdfe7-19ff-4eec-b200-195fd035679f"
      unitRef="shares">13163954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i862b94711dca4e4ba65e7ffa96c12b95_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfMy0zLTEtMS00OTAzOA_580b0d52-1d78-41a8-bca7-ccdb981235e2"
      unitRef="shares">9746977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i014e8a19793d40bcac2baddf7496bd9d_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNC0xLTEtMS00OTAzOA_f7e725af-7fdb-4064-b7ad-bbef038af2ca"
      unitRef="shares">864050</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide326c86d4704627b79b2a501c2b05bf_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNC0zLTEtMS00OTAzOA_ac93e4b2-71ef-4c3f-8fd8-c9262967b8a5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i05d0df6c0bc4407982ff2dcc72c8d5f7_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNS0xLTEtMS00OTAzOA_44aa893c-75b6-4d5f-a352-1909edff8527"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i42da493784984b80a81dd34f00fb97ed_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNS0zLTEtMS00OTAzOA_3983fc4a-ad1d-41c9-b351-5a86ddfad18b"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3dd61e8d2ee742ceacc281b00f2bf38e_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNi0xLTEtMS00OTAzOA_9477e203-316c-46af-b9fa-27bafa0e622c"
      unitRef="shares">170000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i961337664bec4684bab70b8f50eb6fb4_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNi0zLTEtMS00OTAzOA_408a9839-a043-41d4-bc98-8b99d0c49150"
      unitRef="shares">170000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib2547429e3324581bbf6156636e2a767_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNy0xLTEtMS00OTAzOA_29115ff6-503b-4405-8137-4d70fdb73039"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9a3a509b1bb04448b439c32f4c6b8a98_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfNy0zLTEtMS00OTAzOA_79f931fb-4862-46dc-871a-6245a5d911b7"
      unitRef="shares">125000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id423453fa6364ca8947d21bf8eeb83d4_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfOC0xLTEtMS00OTAzOA_b0c2bea2-9d13-42bf-bf88-e3090e729675"
      unitRef="shares">425942</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5dbf76887d084a01a1e484f9fc38af0a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF81OC9mcmFnOmQ5MDRiYjc0ZmMyZTRmYjQ4ODhlNDYzZGE0ZjZjNGZhL3RhYmxlOmFiZjUwN2Y2ZDJhZDQ5ZmM5OGI2YTU1MzMwZjNiNTY1L3RhYmxlcmFuZ2U6YWJmNTA3ZjZkMmFkNDlmYzk4YjZhNTUzMzBmM2I1NjVfOC0zLTEtMS00OTAzOA_e129a8fc-f544-49da-9cee-6d6bb05ffd33"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMDUvZnJhZzo3YWJmMmUyN2U3N2U0MTk0YjllY2Y3ODhiYzE4MDdjOC90ZXh0cmVnaW9uOjdhYmYyZTI3ZTc3ZTQxOTRiOWVjZjc4OGJjMTgwN2M4XzU0OTc1NTgxNDY5NA_6cb78492-9280-4dcf-b85b-9c0dcd9fb93a">Subsequent EventsIn October 2022, the Company was notified that Tarsus had achieved a certain development milestone, which, pursuant to the Tarsus License Agreement, triggered a $10.0 million milestone payment due in December 2022.</us-gaap:SubsequentEventsTextBlock>
    <adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement
      contextRef="i0378cbfd28884eb698663743fe75feda_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjczNzdiNjkxYmQ1ODQ1MTI5N2ZjMjZjYjk0MjFiMjAwL3NlYzo3Mzc3YjY5MWJkNTg0NTEyOTdmYzI2Y2I5NDIxYjIwMF8zMDUvZnJhZzo3YWJmMmUyN2U3N2U0MTk0YjllY2Y3ODhiYzE4MDdjOC90ZXh0cmVnaW9uOjdhYmYyZTI3ZTc3ZTQxOTRiOWVjZjc4OGJjMTgwN2M4XzIxOTkwMjMyNTYwMzg_979169bc-a3f0-4ced-9af6-c6cc09edd940"
      unitRef="usd">10000000.0</adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MO&;]#R D+G&1H+]!O48#QXMTY$;&R>V3+*&-KLNLT>&V!C*5KJ$OKJ067O5
M7/K:ES MW$-F^X!W.KF7$-VA"?6P6$AV9&N+T4.*"Q!M Q@[KB,'6C!9%,)8
M#;9I%U)9VNW*RQ3PHJ-/TG"4''N!_P>^0MX.]/\'VD^^XSPR'R7ZVS53?"WS
MC"O][DU"</R^T:0@3X\ROA*I,,?^#GR42U_=@O^B:/NST!$K&2?6SRH3)5-/
M2-OIT%/T-CBUVQ_'.(#^*0%%H! TYC4_162Z('0*&V\:!&'K@%AMUE*)?X"<
MF;:L=\LKPXL[J";/[U7>(QPD4QK2:4+QLY_0VA)ZTZ761ANXL)5R.,;+1K^&
M3M(Z;J;H^=6,11!/21Q.YV'R(@3^.-[MX.J)OE@=-=E?N$YOD'&]\2'+A!4:
M4&1LWW\B2FC_*@%%QPO2TT.39('[W93/#E,2#?%+IR_(N+X  5<7==Z\S6O?
M2L@"=O3:OGA]X.@HEUH?(U'"8Z_\)*Z<.*&)6RI=LY ,L4^G.LBXZMA%W]8&
M+T972)Q /2?SODKV&=(H('1 QY%.<Y!QS;&AG3\%*R^%W.QT;XWSPG>E!8%=
M0IPY]DB0D(;1P)ZFG0BAXR+DD^U=@8.4S'-[%$5I.)Q4[UQ35V90&L=]K ?-
M]J%V>H2.ZY'-/+]N?JFGZ0ZB<-%_3^2S2V)*![8Q[30)?:4F:8K?*Y,@SDM6
M;X/NL?,VZ+.=3P3V^\Q'INY%J4$RK\ Q.(UA&M3FD\?FQLBJ^6IP)XV117.Y
MY@S 6P/X?25!MK0W]D/$]L/3\E]02P,$%     @ +81J5;,X)5ZN @  ?@<
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M'WJHX(72Q,)71**JZ@=?J=O2K6X][4I)S'=E26+JE67-*G??O-, U;'+=D%
MBTH430^#\JREU^*[OF,O-]WW5@5*JTI;=IX2+-#"'$H34)I$T?2X*;-;NLWN
M$\9@1^+L)P:(=N0G!JAV9ASL)N0G!HAVU"<&J&;D)P:H724$R\7^MFV'JAF:
MRY=WS4W[<]/?K'?[8--^&+<+OYLF7/;KF]N'7X;N[M79>-%YWPU#MSW\>-LV
MXZAD:C#^^X>N&W[_Y6+D?^KZ7PXU+O\/4$L#!!0    ( "V$:E5K W-P- (
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M9K-<[([9B:-1"UO+#[-1QH/&FN/2T6<>6]=O0J^0[>+TK2WQ+$>QX9\'NN#
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MHTWYLF<VZ\^S.;$<<X@(/(]]A[.D5P@DK!"\CO4^O." +0!F63:U''!LVN.
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MP!VC9*MO2&P$2U,@4D6ZE$?'&,XB"37 M1M9'J$N+QLI@&)@Y,;LE=(9?,,
M4B\.Q>=>7\47))/P-9X0QN^;\E8*U]Z]YJ^@&&(Q^^R9^55/O!=^SQ=/9#V]
M2Q;SDZ?_>'"CJ"9 +;?8X6K:C)E[NM+?3\LOMFUTJ?;7;E'A]=>'L(GF*83Z
M+8I/[;V; FLQEAAA!##X3/P;2+>L+;^OFWHO>CQZAPT>LN$W]=QY38BOL\NO
MY3\#+.,[\&%Y_)\$[\ 2,9L ,-?8>G+T_;<'8/;\=CY^"7;+;\17-@3;\<<&
M([]RM #/UQ9!3E_H@/)?),[^#U!+ P04    "  MA&I5T=.&GIX3  !:4P
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M4=GLRA0P6\[5CDY,*5PE93BT)A=Z4 %F(R>H9&?'4B28:PW[Q2>IN'A"X'E
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M9G1.ZEQ]X@^_TB:>4.M+>2[-+WJP:T.PF-92\:(1AG[!2OLE/YH\= 02=T
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M/$"?LCACV3-X.D_GS^"#=EQZKA/IB4%1ZIY 'K-\1BN+E\ML1!Q1&ASL./T
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M+6KG0/>E4O9P< ]TTWOV&U!+ P04    "  MA&I5]3GFV30#  !S!P  &0
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MGR2Z6-AUGAZ5A!<K):V86I-O6@-/LX&M=UW\580P:B$G,N5<R.-K_09QEI9
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M[;:DZ8W:.=!]H93=&2Y _W\P_P=02P,$%     @ +81J59 OW_7< @  908
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M6U0V@-X74IK#PA[07^#)'U!+ P04    "  MA&I50(;#*1H$  !T"0  &0
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M-3K@YW4'_-S? ?\U7U?G._/=H#;/UE??!,O5\MOYMBR?>(N=GQN:/J@6HII
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M;#L_9LOL*!>RG& YR7(1R\4LE[!<RG**Y33+&9:S+.<PKI-DC<K[^(65=WK
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M0^DB07KL1R5-O(496-,W+;WLDZ(GE331?(">/E5ZV1^FC=NH<0^B!A_O5'V
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M@"H[CPM25GMR(C\$2@QQ2CPA;I1V^?CPRJ4&=&!H"!@:FI;%#TEQEDJ::#[
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M^Z$NUMT['*^+NBY6W8]W/%GRLFW0_/VF*.K'#^UK(??O ;WX'U!+ P04
M"  MA&I5^CL>):<#  !($0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6RU6-&.FS@4_16+K5:M-!TP$&!FDTAM9JM6ZE91T^X^K/;! S>)5<#4-LGT
M[]<&!D+PT,V*>4DPW'LX]_C8N<[\R/@WL0>0Z"%+<[&P]E(6M[8MXCUD1%RS
M G+U9,MX1J0:\ITM"@XDJ9*RU'8=)[ S0G-K.:_NK?ERSDJ9TAS6'(DRRPC_
M\192=EQ8V'J\\9GN]E+?L)?S@NQ@ _)KL>9J9+<H"<T@%Y3EB,-V8;W!MRL<
MZH0JXD\*1W%RC70I]XQ]TX,/R<)R-"-((98:@JBO ZP@3362XO&] ;7:=^K$
MT^M']'=5\:J8>R)@Q=*_:"+W"RNR4 );4J;R,SN^AZ:@F<:+62JJ3W1L8AT+
MQ:60+&N2%8.,YO4W>6B$.$G _A,);I/@_M<$KTGPJD)K9E59=T22Y9RS(^(Z
M6J'IBTJ;*EM50W,]C1O)U5.J\N1RS94CN/R!2)Z@W[^7M%!S)*_0)^6@UVA3
M3RYB6V0.1"_O0!*:OE+!7S=WZ.6+5^@%HCGZLF>E4*%B;DM%4[_,CAM*;VM*
M[A.4-E!<(\^Y0J[CNH;TU7CZ'<0J'5?IN)]N*W%:A=Q6(;?"\WZBT!5:IT15
MW*__[X\J''V0D(E_3*76V+X96Z_16U&0&!:66H0"^ &LY:^_X,#YS53X1& ]
M&;Q6!F\,O6\4Z(RRXTP8)[F&"RHXO9D<EK[GAW/[<%K1,,CUHZ@-ZC'U6Z;^
M*-,W<5QF94HD)&I!*REB2O2682)9(\U.WO\:N]@]8VF("IS S'+6LIR-LOS"
M)$E1\82J.4@3W=F B(>]V1G;81".(M?,-FC9!J-L/X+:*O<L31#-%.<#:)K&
M:1_%N=3P$X'U2@[;DL-G7/?AE#),!-:3(6IEB*9=]]' ?FZ(S]?],"AR0K-%
M;UJB-Z-$WY4\I[+D4#'=T@=];60XBG/IW$P$UBL9.]VOM_.,)FW )U)B*K2^
M%">-#)[6J U>;Z/$WIE1#4'!S&Q4W'44>/27>KEB65%*X!W-BK1@6WDD'(QD
M)VTDID+KU]^U$MA[3M>.-BH72S$16E^*KE?!X\W*Y:X=-B/AC7_NVF&0'^(G
M;-MU+'B\95FQ7$A>UN<OU>.K1F"G-#'3'(6Z>)(F0NL7WC4_.'A.OT[:$DV%
MUI>B:XKP:+/Q/_P:#EK\T!WLLL,@C/WS?=8^.>;J_QC^('Q'<X%2V*HTYSI4
M+N'UL;T>2%94)]][)M4YNKK< TF ZP#U?,N8?!SHPW3[Y\GR7U!+ P04
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MWQ&AHS&;;AAOC!JK886>Q:42^):A3D4+ 25E"?G\C.M" J%%0GZH% 29;82
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M3,>N'FDPP4XKMPUWNB3K^6_:&7];!?+#202J3F;K:E?'H]?F'+O2X "&6&E
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M8SQ*JBJ8JH&165E"K*3!@J3L)EAC@K(&N+Z6TNP&=H.F:@W^ %!+ P04
M"  MA&I5YD&F@$0#   X%   #0   'AL+W-T>6QE<RYX;6S=6-%NVC 4_94H
M7:=6FAH@:R K(&U(E29M4Z7V86^5(0Y8<NS,,1WTZ^=KAQ"H+^KZL)8%M;'O
M\3GWV+XA;H>57G-ZNZ!4!ZN"BVH4+K0N/T51-5O0@E07LJ3"(+E4!=&FJ^91
M52I*L@I(!8]ZG4X2%82)<#P4R^*ZT%4PDTNA1V&_"07N]C4;A=WD8Q@XN8G,
MZ"B\/WO_:RGUU;O W4\^G)QT[L^O]N-G%C@/(Z_HY3-$+SJM"\VP,PI+ESPO
MW:$DF'3_6=('E#'AP:ZP'7UJ=!SO%*.E'IJQOV5"!R'W.UYRBVJ)45TXXV$N
MQ;9^XM %C#(I:/! ^"B<$,ZFB@$K)P7C:Q?N06 FN52!-H5K4G4A4CTZN.MZ
M4-.U3L&$5#:WR^!^3^OA>\"F!P89YXW!7N@"XV%)M*9*7)N.'6R#3Z"@;M^M
M2^-PKLBZV[L,MP1[,TFF4F54-6FZX28T'G*:@QW%Y@NX:UE& &HM"]/(&)E+
M0:R'#:-N&-D9Y?P6'OB?^8[V*F_MF=TQT32-H;KI9%P']-MJ3KLM&[](-RC9
M@]1?EF8ZPO:AL.F-HCE;V?XJ;PQ@ZEU<G90E7W_F;"X*ZB;_[(3C(=GP@H54
M[-%D@U*9F0!58?! E6:S=N2W(N4=7>E-.:URW'/O"#W_VW6>4T$5X6W3IO;?
M\BJ_V''<?RW+]EMEW[#78_T6?^LF+X_!9'(,)H^B)@?'8#(] I/]5_O6/&@R
MJD\9K:/,SD&FB09P8!R%/^#HR;=)@^F2<<U$W5NP+*/BR7G&R&LR-7\6[>B;
M\1G-R9+KNP8<A=OV=YJQ99$VHVY@(>I1V_8WF%XW:4ZK)A<3&5W1;%)WU7QJ
MFX%IF*SU!81]Y-I>?@3C.,R/ (;EP1Q@',?"\OQ/\QF@\W$8YFW@108H9X!R
M',N'3.P'R^/GI.;RSS1-XSA)L!6=3+P.)MBZ)0G\^-4P;\# \D"FOUMK?+?Q
M"CE<!]B>'JH0;*9X)6(SQ=<:$/^Z 2--_;N-Y0$&M@M8[4!^?QZH*3\GCF%7
M,6_8$XPC:8HA4(O^&DT29'42^/CW!WM*XCA-_0A@?@=QC"'P-.((Y@ \8$@<
MV_?@WOLHVKRGHNW_"L=_ %!+ P04    "  MA&I5EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( "V$:E7ETS"<HP,
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M4$L! A0#%     @ +81J5;,X)5ZN @  ?@<  !@              ("!_Q0
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "V$:E5ZEZJV
M] 4   8;   8              " @>,7  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    "  MA&I5:+Q^;TL1  #%T@  &
M@($-'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ +81J
M56L#<W T @  F@0  !@              ("!CB\  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( "V$:E57$:L!'0@  +0D   8
M      " @?@Q  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M"  MA&I5:1E+)PH%  #A"@  &               @(%+.@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ +81J534HJEQ"#   +B$  !@
M             ("!BS\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( "V$:E71TX:>GA,  %I3   9              " @0-,  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ +81J53<A,FO^!0
M(Q4  !D              ("!V%\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    "  MA&I5 8V\00@#   7!P  &0              @($-
M9@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "V$:E68
M(0+:T (  'H&   9              " @4QI  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ +81J5<Q,_#F> @  R04  !D
M     ("!4VP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M"  MA&I5]3GFV30#  !S!P  &0              @($H;P  >&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "V$:E66(_O)70D  'X>   9
M              " @9-R  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M A0#%     @ +81J58'Y3<]]!   \PH  !D              ("!)WP  'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  MA&I5IC<R47$"
M  !S!0  &0              @(';@   >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+ 0(4 Q0    ( "V$:E6AUV]T:0L  #$?   9              "
M@8.#  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ +81J
M53F@QW<;!@  Y!4  !D              ("!(X\  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    "  MA&I5BEHY7<\"   ;!@  &0
M        @(%UE0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( "V$:E60+]_UW (  &4&   9              " @7N8  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ +81J517;S:RL @  S 4
M !D              ("!CIL  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    "  MA&I50(;#*1H$  !T"0  &0              @(%QG@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "V$:E69[O\C
M304  /$M   9              " @<*B  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ +81J5=?%F(]X @  [ 4  !D
M ("!1J@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  M
MA&I5V"]_!Z0G  "\%P, &0              @('UJ@  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "V$:E4[VH+9U@0  . :   9
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M970S,BYX;6Q02P$"% ,4    "  MA&I5< %?WJ4"  #E!P  &0
M    @($6\   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M "V$:E7)>O_-$P,  +T(   9              " @?+R  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ +81J5=8GT?W3 @  N0<  !D
M             ("!//8  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    "  MA&I5'=<T<"<"   =!0  &0              @(%&^0  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "V$:E5',S;" 0T
M *N2   9              " @:3[  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ +81J5>&(N@I"!   ^A0  !D              ("!
MW @! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  MA&I5
M/%=OHH $   0&@  &0              @(%5#0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "V$:E5RCD@EZ@(  ,$*   9
M      " @0P2 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ +81J5>9!IH!$ P  .!0   T              ( !+14! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  MA&I5EXJ[',     3 @  "P
M@ &<& $ 7W)E;',O+G)E;'-02P$"% ,4    "  MA&I5Y=,PG*,#   J&P
M#P              @ &%&0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M+81J53QA]1J- 0  3Q@  !H              ( !51T! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ +81J59C$(26B 0  IA@  !,
M             ( !&A\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #
,,  '#0  [2 !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>274</ContextCount>
  <ElementCount>216</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Material Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MaterialAgreements</Role>
      <ShortName>Material Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Prepaid Expense and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/PrepaidExpenseandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expense and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lian.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lian.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lian.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Prepaid Expense and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expense and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lian.com/role/PrepaidExpenseandOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lian.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lian.com/role/NetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/NatureofBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/SignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Material Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MaterialAgreementsAdditionalInformationDetail</Role>
      <ShortName>Material Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Marketable Securities and Fair Value Measurements - Available-for-sale Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Available-for-sale Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Marketable Securities and Fair Value Measurements - Marketable Securities on the Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Marketable Securities on the Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Marketable Securities and Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/PropertyandEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Prepaid Expense and Other Current Assets - Summary of Prepaid Expense and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expense and Other Current Assets - Summary of Prepaid Expense and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Net Loss Per Share - Summary of Diluted and Basic Net Loss Per Ordinary Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Diluted and Basic Net Loss Per Ordinary Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Were Excluded From Calculation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Potentially Dilutive Securities Were Excluded From Calculation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="adr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lian.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="adr-20220930.htm">adr-20220930.htm</File>
    <File>adr-20220930.xsd</File>
    <File>adr-20220930_cal.xml</File>
    <File>adr-20220930_def.xml</File>
    <File>adr-20220930_lab.xml</File>
    <File>adr-20220930_pre.xml</File>
    <File>exhibit101-amendmentno1tol.htm</File>
    <File>exhibit311-certificationof.htm</File>
    <File>exhibit312-certificationof.htm</File>
    <File>exhibit321-certificationof.htm</File>
    <File>exhibit322-certificationof.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>adr-20220930_g1.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="663">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adr-20220930.htm": {
   "axisCustom": 3,
   "axisStandard": 20,
   "contextCount": 274,
   "dts": {
    "calculationLink": {
     "local": [
      "adr-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adr-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "adr-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adr-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adr-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adr-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 374,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 28,
   "keyStandard": 188,
   "memberCustom": 30,
   "memberStandard": 32,
   "nsprefix": "adr",
   "nsuri": "http://lian.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://lian.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adr:LicenseAndOtherRelatedAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Material Agreements",
     "role": "http://lian.com/role/MaterialAgreements",
     "shortName": "Material Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adr:LicenseAndOtherRelatedAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Marketable Securities and Fair Value Measurements",
     "role": "http://lian.com/role/MarketableSecuritiesandFairValueMeasurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property and Equipment, Net",
     "role": "http://lian.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adr:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Prepaid Expense and Other Current Assets",
     "role": "http://lian.com/role/PrepaidExpenseandOtherCurrentAssets",
     "shortName": "Prepaid Expense and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adr:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Accrued Expenses",
     "role": "http://lian.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Commitments and Contingencies",
     "role": "http://lian.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Share-Based Compensation",
     "role": "http://lian.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Loss Per Share",
     "role": "http://lian.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Subsequent Events",
     "role": "http://lian.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://lian.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "role": "http://lian.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i6f18cb39c42c4b1c83be602d5ef25c91_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "role": "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://lian.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Prepaid Expense and Other Current Assets (Tables)",
     "role": "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expense and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://lian.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://lian.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i378fd65bf5a34325aead1a87c2d54e68_I20211103",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Nature of Business - Additional Information (Detail)",
     "role": "http://lian.com/role/NatureofBusinessAdditionalInformationDetail",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i378fd65bf5a34325aead1a87c2d54e68_I20211103",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://lian.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i1d15540792024becacd6f0a5ad4ad608_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adr:ClassOfWarrantOrRightNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Material Agreements - Additional Information (Detail)",
     "role": "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
     "shortName": "Material Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i1d15540792024becacd6f0a5ad4ad608_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adr:ClassOfWarrantOrRightNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)",
     "role": "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Marketable Securities and Fair Value Measurements - Available-for-sale Securities in an Unrealized Loss Position (Details)",
     "role": "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Available-for-sale Securities in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://lian.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Marketable Securities and Fair Value Measurements - Marketable Securities on the Balance Sheet (Details)",
     "role": "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Marketable Securities on the Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Marketable Securities and Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i6992b347ac814ea5a287b5ea80729400_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Detail)",
     "role": "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "id77363498db642a188305f503a88fef2_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "role": "http://lian.com/role/PropertyandEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "adr:PrepaidRentAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Prepaid Expense and Other Current Assets - Summary of Prepaid Expense and Other Current Assets (Detail)",
     "role": "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail",
     "shortName": "Prepaid Expense and Other Current Assets - Summary of Prepaid Expense and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "adr:PrepaidRentAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "role": "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCommitment",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://lian.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCommitment",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ief76923dc8d8411997af1d7252a67753_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ibef4c7d268f5402dae0e1b439efb68f4_I20211103",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "ibef4c7d268f5402dae0e1b439efb68f4_I20211103",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "id77363498db642a188305f503a88fef2_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Net Loss Per Share - Summary of Diluted and Basic Net Loss Per Ordinary Share (Detail)",
     "role": "http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail",
     "shortName": "Net Loss Per Share - Summary of Diluted and Basic Net Loss Per Ordinary Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i6a0e878a4e9940a8ba193c5c8a44bfe7_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Were Excluded From Calculation of Diluted Net Loss Per Share (Detail)",
     "role": "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail",
     "shortName": "Net Loss Per Share - Summary of Potentially Dilutive Securities Were Excluded From Calculation of Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i6a0e878a4e9940a8ba193c5c8a44bfe7_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "id77363498db642a188305f503a88fef2_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "id77363498db642a188305f503a88fef2_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "iebb3f515f2af46d9a26d73623709d955_D20220601-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://lian.com/role/SubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0378cbfd28884eb698663743fe75feda_D20221201-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "adr:PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0a0b0abea7af4c8cb2aae561fb94d45c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit)",
     "role": "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i4ef053472e8f4bb986eedfb17916fe7c_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "adr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "if81a8e1bb8e14340b40f2c724b9842a9_I20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) (Parenthetical)",
     "role": "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "if81a8e1bb8e14340b40f2c724b9842a9_I20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://lian.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "adr:NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Nature of Business",
     "role": "http://lian.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Significant Accounting Policies",
     "role": "http://lian.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adr-20220930.htm",
      "contextRef": "i0ad73b7d168f4347a98a2780e36148ee_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "adr_APICDueFromRelatedPartiesIncreaseForCostRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APIC, Due From Related Parties, Increase for Cost Recognition",
        "label": "APIC, Due From Related Parties, Increase for Cost Recognition",
        "terseLabel": "Receivable from related party"
       }
      }
     },
     "localname": "APICDueFromRelatedPartiesIncreaseForCostRecognition",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_AccruedConsultingAndContractedResearchCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Consulting And Contracted Research Current.",
        "label": "Accrued Consulting And Contracted Research Current",
        "terseLabel": "Consulting and contracted research"
       }
      }
     },
     "localname": "AccruedConsultingAndContractedResearchCurrent",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_AmendedLicensingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended licensing agreement.",
        "label": "Amended Licensing Agreement [Member]",
        "terseLabel": "Amended Licensing Agreement"
       }
      }
     },
     "localname": "AmendedLicensingAgreementMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_AssetAcquisitionMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Milestone, Amount.",
        "label": "Asset Acquisition, Milestone, Amount",
        "terseLabel": "Asset acquisition, milestone, amount"
       }
      }
     },
     "localname": "AssetAcquisitionMilestoneAmount",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_AssetAcquisitionNetSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Net Sales Milestone.",
        "label": "Asset Acquisition, Net Sales Milestone",
        "terseLabel": "Asset acquisition, net sales milestone"
       }
      }
     },
     "localname": "AssetAcquisitionNetSalesMilestone",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued",
        "label": "Class Of Warrant Or Right, Issued",
        "terseLabel": "Warrants issued during period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "adr_ClassOfWarrantOrRightNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Tranches",
        "label": "Class Of Warrant Or Right, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfTranches",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "adr_CommitmentToContributeCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment to contribute capital.",
        "label": "Commitment To Contribute Capital",
        "terseLabel": "Commitment to contribute capital"
       }
      }
     },
     "localname": "CommitmentToContributeCapital",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One",
        "terseLabel": "More Than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_DeferredOfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs incurred but not yet paid.",
        "label": "Deferred Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Issuance costs in accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_ImputedInterestOnMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imputed interest on milestone payment.",
        "label": "Imputed Interest On Milestone Payment",
        "terseLabel": "Imputed interest on milestone payment"
       }
      }
     },
     "localname": "ImputedInterestOnMilestonePayment",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_LandosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Landos.",
        "label": "Landos [Member]",
        "terseLabel": "Landos"
       }
      }
     },
     "localname": "LandosMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_LianOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lian oncology.",
        "label": "Lian Oncology [Member]",
        "terseLabel": "Lian Oncology"
       }
      }
     },
     "localname": "LianOncologyMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_LicenseAndOtherRelatedAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and other related agreements.",
        "label": "License And Other Related Agreements [Abstract]",
        "terseLabel": "License And Other Related Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndOtherRelatedAgreementsAbstract",
     "nsuri": "http://lian.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adr_LicenseAndOtherRelatedAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and other related agreements.",
        "label": "License And Other Related Agreements [Line Items]",
        "terseLabel": "License And Other Related Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndOtherRelatedAgreementsLineItems",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "adr_LicenseAndOtherRelatedAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and other related agreements.",
        "label": "License And Other Related Agreements [Table]",
        "terseLabel": "License And Other Related Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndOtherRelatedAgreementsTable",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "adr_LicenseAndOtherRelatedAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and other related agreements.",
        "label": "License And Other Related Agreements [Text Block]",
        "terseLabel": "Material Agreements"
       }
      }
     },
     "localname": "LicenseAndOtherRelatedAgreementsTextBlock",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adr_LyraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lyra.",
        "label": "Lyra [Member]",
        "terseLabel": "Lyra"
       }
      }
     },
     "localname": "LyraMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_MilestonePaymentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment payable.",
        "label": "Milestone Payment Payable",
        "terseLabel": "Milestone payment payable"
       }
      }
     },
     "localname": "MilestonePaymentPayable",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_MilestoneStageAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone stage.",
        "label": "Milestone Stage [Axis]",
        "terseLabel": "Milestone Stage [Axis]"
       }
      }
     },
     "localname": "MilestoneStageAxis",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "adr_MilestoneStageDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone stage.",
        "label": "Milestone Stage [Domain]",
        "terseLabel": "Milestone Stage [Domain]"
       }
      }
     },
     "localname": "MilestoneStageDomain",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_MilestoneStageTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone stage two.",
        "label": "Milestone Stage Two [Member]",
        "terseLabel": "Milestone Stage Two"
       }
      }
     },
     "localname": "MilestoneStageTwoMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_MyokardiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myokardia.",
        "label": "Myokardia [Member]",
        "terseLabel": "Myokardia"
       }
      }
     },
     "localname": "MyokardiaMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_NanobiotixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nanobiotix.",
        "label": "Nanobiotix [Member]",
        "terseLabel": "Nanobiotix"
       }
      }
     },
     "localname": "NanobiotixMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_NavireMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Navire.",
        "label": "Navire [Member]",
        "terseLabel": "Navire"
       }
      }
     },
     "localname": "NavireMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_NonCashOperatingLeaseExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash\u00a0operating lease expense (benefit).",
        "label": "Non Cash Operating Lease Expense (Benefit)",
        "terseLabel": "Non-cash operating lease expense (benefit)"
       }
      }
     },
     "localname": "NonCashOperatingLeaseExpenseBenefit",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Share Consideration Issued in Acquisition of IPR&amp;D.",
        "label": "Non Cash Share Consideration Issued In Acquisition Of I P R And D",
        "terseLabel": "Non-cash share consideration, issued in acquisition of IPR&amp;D"
       }
      }
     },
     "localname": "NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_NonRefundableFinancingMilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable financing milestone payment.",
        "label": "Non Refundable Financing Milestone Payment [Member]",
        "terseLabel": "Non Refundable Financing Milestone Payment"
       }
      }
     },
     "localname": "NonRefundableFinancingMilestonePaymentMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_NonrefundableResearchDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable research deposit.",
        "label": "Nonrefundable Research Deposit",
        "terseLabel": "Nonrefundable research deposit"
       }
      }
     },
     "localname": "NonrefundableResearchDeposit",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_PayableToRelatedPartyCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable to related party current.",
        "label": "Payable To Related Party Current [Member]",
        "terseLabel": "Payable To Related Party Current"
       }
      }
     },
     "localname": "PayableToRelatedPartyCurrentMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_PaymentOfMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of milestone amount.",
        "label": "Payment Of Milestone Amount",
        "terseLabel": "Payment of milestone amount"
       }
      }
     },
     "localname": "PaymentOfMilestoneAmount",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Towards Development Amount In Connection With License Agreement.",
        "label": "Payment Towards Development Amount In Connection With License Agreement",
        "verboseLabel": "Payment towards development amount in connection with license agreement"
       }
      }
     },
     "localname": "PaymentTowardsDevelopmentAmountInConnectionWithLicenseAgreement",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment towards upfront amount in connection with license agreement.",
        "label": "Payment Towards Upfront Amount In Connection With License Agreement",
        "terseLabel": "Payment towards upfront amount in connection with license agreement"
       }
      }
     },
     "localname": "PaymentTowardsUpfrontAmountInConnectionWithLicenseAgreement",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_PerformanceConditionOnMarketValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance condition on market value.",
        "label": "Performance Condition On Market Value",
        "terseLabel": "Performance condition on market value"
       }
      }
     },
     "localname": "PerformanceConditionOnMarketValue",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_PrepaidExpenseAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expense and other current assets.",
        "label": "Prepaid Expense And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expense and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adr_PrepaidRentAndSupplies": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid rent and supplies.",
        "label": "Prepaid Rent And Supplies",
        "terseLabel": "Advance payments to suppliers and rent deposit"
       }
      }
     },
     "localname": "PrepaidRentAndSupplies",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_QedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "QED.",
        "label": "QED [Member]",
        "terseLabel": "QED"
       }
      }
     },
     "localname": "QedMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_RedeemableConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Shares [Member]",
        "label": "Redeemable Convertible Preferred Shares [Member]",
        "verboseLabel": "Redeemable Convertible Preferred Shares"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredSharesMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_ReimbursementAmountDueTowardsCostsIncurredForTheStudy": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement amount due towards costs incurred for the study.",
        "label": "Reimbursement Amount Due Towards Costs Incurred For The Study",
        "terseLabel": "Reimbursement amount due towards costs incurred for the study"
       }
      }
     },
     "localname": "ReimbursementAmountDueTowardsCostsIncurredForTheStudy",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_ReviralMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reviral.",
        "label": "Reviral [Member]",
        "terseLabel": "Reviral"
       }
      }
     },
     "localname": "ReviralMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales based milestone.",
        "label": "Sales Based Milestone [Member]",
        "terseLabel": "Sales Based Milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Available for Issuance, Percentage of Outstanding Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Available for Issuance, Percentage of Outstanding Shares",
        "terseLabel": "Annual increase in shares available for issuance, percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAvailableForIssuancePercentageOfOutstandingShares",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "adr_SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified development regulatory and sales based milestone.",
        "label": "Specified Development Regulatory And Sales Based Milestone [Member]",
        "terseLabel": "Specified Development Regulatory And Sales Based Milestone"
       }
      }
     },
     "localname": "SpecifiedDevelopmentRegulatoryAndSalesBasedMilestoneMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_SpecifiedDevelopmentRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified development regulatory milestone.",
        "label": "Specified Development Regulatory Milestone [Member]",
        "terseLabel": "Specified Development Regulatory Milestone"
       }
      }
     },
     "localname": "SpecifiedDevelopmentRegulatoryMilestoneMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "adr_TarsusPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tarsus pharmaceuticals.",
        "label": "Tarsus Pharmaceuticals [Member]",
        "terseLabel": "Tarsus Pharmaceuticals"
       }
      }
     },
     "localname": "TarsusPharmaceuticalsMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TarsusWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tarsus Warrants [Member]",
        "label": "Tarsus Warrants [Member]",
        "terseLabel": "Tarsus Warrants"
       }
      }
     },
     "localname": "TarsusWarrantsMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series A Preferred Shares at $56.66, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "adr_TieredRoyaltyAsAPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered royalty as a percentage of net sales.",
        "label": "Tiered Royalty As A Percentage Of Net Sales",
        "terseLabel": "Tiered royalty as a percentage of net sales"
       }
      }
     },
     "localname": "TieredRoyaltyAsAPercentageOfNetSales",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "adr_TrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Axis]",
        "terseLabel": "Tranche [Axis]"
       }
      }
     },
     "localname": "TrancheAxis",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "adr_TrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Domain]",
        "terseLabel": "Tranche [Domain]"
       }
      }
     },
     "localname": "TrancheDomain",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one.",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three.",
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two.",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TwoThousandAndNineteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and Nineteen Plan [Member]",
        "label": "Two thousand and Nineteen Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineteenPlanMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TwoThousandAndTwentyOnePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and Twenty One Plan [Member]",
        "label": "Two thousand And Twenty One Plan [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePlanMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_TypeOfMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of milestone.",
        "label": "Type Of Milestone [Axis]",
        "terseLabel": "Type Of Milestone [Axis]"
       }
      }
     },
     "localname": "TypeOfMilestoneAxis",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "adr_TypeOfMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of milestone.",
        "label": "Type Of Milestone [Domain]",
        "terseLabel": "Type Of Milestone [Domain]"
       }
      }
     },
     "localname": "TypeOfMilestoneDomain",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_UpfrontPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment receivable.",
        "label": "Upfront Payment Receivable",
        "terseLabel": "Upfront payment receivable"
       }
      }
     },
     "localname": "UpfrontPaymentReceivable",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adr_WarrantsInLianCardiovascularIssuedToMyokardiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants in Lian Cardiovascular issued to MyoKardia [Member]",
        "label": "Warrants in Lian Cardiovascular issued to MyoKardia [Member]",
        "terseLabel": "MyoKardia Warrant"
       }
      }
     },
     "localname": "WarrantsInLianCardiovascularIssuedToMyokardiaMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_WarrantsInLianOncologyIssuedToQedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants in Lian Oncology issued to QED [Member]",
        "label": "Warrants in Lian Oncology issued to QED [Member]",
        "terseLabel": "QED Warrants"
       }
      }
     },
     "localname": "WarrantsInLianOncologyIssuedToQedMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_WarrantsInLianOphthalmologyIssuedToTarsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants in Lian Ophthalmology issued to Tarsus [Member]",
        "label": "Warrants in Lian Ophthalmology issued to Tarsus [Member]",
        "terseLabel": "Tarsus Warrants"
       }
      }
     },
     "localname": "WarrantsInLianOphthalmologyIssuedToTarsusMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "adr_WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants or rights issuable as a percentage of fully diluted equity.",
        "label": "Warrants Or Rights Issuable As A Percentage Of Fully Diluted Equity",
        "terseLabel": "Warrants or rights issuable as a percentage of fully diluted equity"
       }
      }
     },
     "localname": "WarrantsOrRightsIssuableAsAPercentageOfFullyDilutedEquity",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "adr_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase common stock.",
        "label": "Warrants To Purchase Common Stock [Member]",
        "terseLabel": "Warrants To Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://lian.com/20220930",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdrMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS).",
        "label": "ADR [Member]",
        "terseLabel": "ADR"
       }
      }
     },
     "localname": "AdrMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://lian.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r49",
      "r93",
      "r94",
      "r208",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r207",
      "r215",
      "r237",
      "r239",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r397",
      "r398",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r207",
      "r215",
      "r237",
      "r239",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r397",
      "r398",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r207",
      "r215",
      "r227",
      "r237",
      "r239",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r397",
      "r398",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r207",
      "r215",
      "r227",
      "r237",
      "r239",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r397",
      "r398",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r48",
      "r49",
      "r93",
      "r94",
      "r208",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail",
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r104",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r104",
      "r109",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r104",
      "r109",
      "r193",
      "r238",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "verboseLabel": "Accounts and other receivables, net, current"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r321"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of discounts on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r38"
     ],
     "calculation": {
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and related benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail",
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r38"
     ],
     "calculation": {
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r186"
     ],
     "calculation": {
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r54",
      "r55",
      "r56",
      "r386",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r63",
      "r64",
      "r65",
      "r96",
      "r97",
      "r98",
      "r282",
      "r399",
      "r400",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r261",
      "r262",
      "r263",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r241",
      "r244",
      "r266",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r140",
      "r142",
      "r146",
      "r167",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r279",
      "r283",
      "r300",
      "r319",
      "r321",
      "r371",
      "r385"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r46",
      "r91",
      "r167",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r279",
      "r283",
      "r300",
      "r319",
      "r321"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r174"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r155",
      "r156",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than 12 Months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r149",
      "r152",
      "r174",
      "r374"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Marketable securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r245",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r30",
      "r83"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents\u2014end of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets",
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r83",
      "r88"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, and restricted cash\u2014ending of period",
        "periodStartLabel": "Cash and cash equivalents, and restricted cash\u2014beginning of period",
        "totalLabel": "Cash and cash equivalents, and restricted cash\u2014ending of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r303"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash operating activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r112",
      "r113",
      "r114",
      "r116",
      "r118",
      "r126",
      "r127",
      "r128",
      "r167",
      "r196",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r213",
      "r214",
      "r217",
      "r218",
      "r300",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical",
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r226",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrants or rights exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of securities called by each warrant or right (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrants or rights number of securities covered by the warrants or rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r192",
      "r375",
      "r391"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r321"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares, $0.000017100448 par value. 2,923,900,005 shares authorized as of September 30, 2022; 108,353,831 shares issued and outstanding as of September 30, 2022; 2,923,900,005 shares authorized as of December\u00a031, 2021; 107,275,458 shares issued and outstanding as of December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r69",
      "r378",
      "r394"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r132",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r19",
      "r20",
      "r219",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r228",
      "r236",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r162",
      "r178",
      "r181"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Securities in an unrealized loss position greater than 12 months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r162",
      "r178"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "Securities in an unrealized loss position greater than 12 months, Unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r162",
      "r178",
      "r181"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Securities in an unrealized loss position less than 12 months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r162",
      "r178"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Securities in an unrealized loss position less than 12 months, Unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r160",
      "r175",
      "r181"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r161",
      "r176"
     ],
     "calculation": {
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total, Unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r159",
      "r177",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]",
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expense and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r184"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows",
      "http://lian.com/role/PropertyandEquipmentNetAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r110",
      "r112",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r290",
      "r291",
      "r379",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic (in dollars per share)",
        "verboseLabel": "Net loss per ordinary share\u00a0\u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r112",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r290",
      "r291",
      "r379",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted (in dollars per share)",
        "verboseLabel": "Net loss per ordinary share\u00a0\u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition for unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Share Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail",
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r96",
      "r97",
      "r98",
      "r100",
      "r106",
      "r108",
      "r125",
      "r168",
      "r221",
      "r224",
      "r261",
      "r262",
      "r263",
      "r271",
      "r272",
      "r289",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r399",
      "r400",
      "r401",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r293",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r209",
      "r228",
      "r229",
      "r234",
      "r236",
      "r293",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r228",
      "r229",
      "r234",
      "r236",
      "r293",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r293",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r177",
      "r179",
      "r180",
      "r181",
      "r210",
      "r220",
      "r288",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Marketable Securities and Fair Value Measurements"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r82",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign currency transaction gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r240",
      "r242",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r65",
      "r71"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r107",
      "r108",
      "r139",
      "r270",
      "r273",
      "r274",
      "r396"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income taxes (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r78",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Decrease in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Increase in withholding tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Increase in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "(Decrease) increase in other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Decrease in other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "(Increase) decrease in other receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease (increase) in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r91",
      "r143",
      "r167",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r280",
      "r283",
      "r284",
      "r300",
      "r319",
      "r320"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r91",
      "r167",
      "r300",
      "r321",
      "r373",
      "r389"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r91",
      "r167",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r280",
      "r283",
      "r284",
      "r300",
      "r319",
      "r320",
      "r321"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r37"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r44",
      "r91",
      "r167",
      "r196",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r300",
      "r372",
      "r388"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r129",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used for investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r57",
      "r60",
      "r65",
      "r67",
      "r82",
      "r91",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r115",
      "r140",
      "r141",
      "r144",
      "r145",
      "r147",
      "r167",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r291",
      "r300",
      "r376",
      "r392"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows",
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit",
      "http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r225",
      "r278",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Warrants issued in license agreement"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r224",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r140",
      "r141",
      "r144",
      "r145",
      "r147"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r38"
     ],
     "calculation": {
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/AccruedExpensesSummaryofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r51",
      "r52",
      "r54"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation (loss) income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r63",
      "r64",
      "r66",
      "r68",
      "r221",
      "r304",
      "r309",
      "r310",
      "r377",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r38",
      "r321"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r8",
      "r183"
     ],
     "calculation": {
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total LianBio Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Issuance costs related to redeemable convertible preferred shares"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r245",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets",
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r8",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance IPO"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r260"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r185"
     ],
     "calculation": {
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r187",
      "r321",
      "r383",
      "r390"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets",
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r235",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r235",
      "r316",
      "r318",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r269",
      "r357",
      "r413"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r17",
      "r88",
      "r406"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "periodEndLabel": "Restricted cash\u2014end of period",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets",
      "http://lian.com/role/ConsolidatedStatementsofCashFlows",
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Non-vested restricted share units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r224",
      "r264",
      "r321",
      "r387",
      "r402",
      "r404"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets",
      "http://lian.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r96",
      "r97",
      "r98",
      "r100",
      "r106",
      "r108",
      "r168",
      "r261",
      "r262",
      "r263",
      "r271",
      "r272",
      "r289",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Diluted and Basic Net Loss Per Ordinary Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r245",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum availability of ordinary shares under plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average grant date fair value per stock option (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued in period under plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r243",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r242",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r253",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r90",
      "r91",
      "r112",
      "r113",
      "r114",
      "r116",
      "r118",
      "r126",
      "r127",
      "r128",
      "r167",
      "r196",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r213",
      "r214",
      "r217",
      "r218",
      "r221",
      "r300",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical",
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r43",
      "r63",
      "r64",
      "r65",
      "r96",
      "r97",
      "r98",
      "r100",
      "r106",
      "r108",
      "r125",
      "r168",
      "r221",
      "r224",
      "r261",
      "r262",
      "r263",
      "r271",
      "r272",
      "r289",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r399",
      "r400",
      "r401",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit",
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical",
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r125",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit",
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficitParenthetical",
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r221",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares upon initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r221",
      "r224",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r221",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r91",
      "r148",
      "r167",
      "r300",
      "r321"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total LianBio shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r64",
      "r91",
      "r96",
      "r97",
      "r98",
      "r100",
      "r106",
      "r167",
      "r168",
      "r224",
      "r261",
      "r262",
      "r263",
      "r271",
      "r272",
      "r276",
      "r277",
      "r285",
      "r289",
      "r300",
      "r304",
      "r305",
      "r310",
      "r400",
      "r401",
      "r429"
     ],
     "calculation": {
      "http://lian.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets",
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r311",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r322",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r42",
      "r91",
      "r167",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Temporary equity, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit",
      "http://lian.com/role/NatureofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series A Preferred Shares at $56.66, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofRedeemableConvertiblePreferredSharesandShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r164",
      "r165",
      "r166",
      "r210",
      "r220",
      "r288",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government obligations &amp; agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "Government obligations"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsAvailableforsaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsMarketableSecuritiesontheBalanceSheetDetails",
      "http://lian.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/PrepaidExpenseandOtherCurrentAssetsSummaryofPrepaidExpenseandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants in LianBio issued to QED and Tarsus"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesWereExcludedFromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants and rights outstanding value"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Class of warrants or rights expiry period"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/MaterialAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, diluted (in shares)",
        "verboseLabel": "Weighted-average shares - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding used in computing net loss per share attributable to ordinary shareholders, basic (in shares)",
        "verboseLabel": "Weighted-average shares - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lian.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://lian.com/role/NetLossPerShareSummaryofDilutedandBasicNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r414": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r415": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r416": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r418": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r419": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r421": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r422": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r423": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r424": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r425": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r426": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r427": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r428": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001831283-22-000075-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001831283-22-000075-xbrl.zip
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M)_.WP1*9V(I71UDB04<OE!3XKU5<8=!BI8^*6TVGUP-+0FDG)QHCN+/!6QY
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M2JR()@IMK YY?BSHI)%N)*)32$FIY9/J[&<TS$30-% I!<EK"]"!1@\^J$1
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ML?OXL+LH'-,R,((:"E(3Y)C,BLAI)(H( H[6J:DYP>Z\P 5$7J; $U<&A&0
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MXXF1<(MX] QI81-!T5J9*"+%+"$6Q6VL<(/<IQ($:2C7*$;\ $8\1SL\:"9
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M^>M?IHC"4444'4E<@"<_P2FGD&61!8:5HT)?O[%>H41WBX$5)5I');*&,^>
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M10SBP0:DHW!(!04Q"$R25YP#SEHW:19;L>FF!T"*33^<3<^&0#RW7#C02(<
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M_.::*E.'06N*$K/CB"OPN=6*2UZ\@> <5U3YC4TCVTP_HWK% GX%_!ZN-K.
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M>8O2\^WJRA95MJ@UVJ+N>8A3MJ@5 ],,=^:6$:9#0%'F2GDG93Z=]LAHIWG
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MG:7;JJ*W]5+N\>KDDK_DO2E15KHH:>.4=.W?6F>UKKFI6%<_2*VNN>D\OR(
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M;WO]?$-;4WTA]GO)V?<7;O[$PQ\T??3KNL#CCQEX!,>L8Q00X<$B+H1!SNF
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M@N_Y9[A/GZDID;&T-J%WFF=IKVE"X+VJ#V^Y$FM4F%ADNZ:R;4I/JZ) :ZI
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M^=L>G4+Q!6KS!<X6I%LI)J60&$7M#.+&862C4,A;*:FF@I)H-S9)6]8VZ:2
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MH)S3?A=V;]ATS/@!O6L1%U/G:PSH6QSTB\9U,TCD2Y 8%:$2U"OD:0 ]2R0
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M2MH+E&PUE)1CHM"VT';W:'N3\$_DU*9(;,"2.YNL3DH'&@DUUGMABPKPH%6
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M8'>!2O=91U$ ]DX =BD&0)7!+&F%J L!Y1D*R# %4"N43M&EX @M +N#HEL
M=A>H=)\5" 5@[P)@EYW^4DC*F2;(TBA!@\48.2$Q,E9K#.8(6"!;I\$^VF*
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M2@HK0I)HBL_5I/C<E/%W#\< .ES(,3N":[X/FAGAM4%&T( XM@EII3"R29E
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M9]2)P]^N8>W<Z5SE.[O&)J?$;#L_'/5[J")UU90B0_6P$V+MP6VW.L/AN.8
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MI2T%C#C-V>W.8J2X#5%A!323 *FKEEWQXCP4(?[I^E(1XML*\9)>Q+#P5.B
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MG/;'<,TP;+>>?_41SJRWIW90QPW!:&_^>F9']M<=>, _>G8,RE8,OZZN]7K
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M:ZJH])'L[3/&GZPV[6J!L=:M_#2]3,Q>K*E<>00F4) /C^'8#>-_QCDC:G(
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MO:>=\_KJ]7E<!<=A(9]B[;O_W E L"9ZU>^"X/7'@RQ_>3Y:!TZ#G1.0YQ;
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M1DL.I-BMW1YPL>:Q8:DYQ7':2C\U@=!)FE=5$%QG%M097].SIY.[?I]->Q'
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M.H[QN?"'$:=85#Z7^P0$1VF>&1D4LIPD[CF13*MI'/^:!+5!&V4%QE)K[ID
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MWS6RON,H9#?WMQ5_E#H*Q=&A2@Z*2EYX\B.MT4JJFEK:XH_W:P5^%+5VM;;
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M[-MI17#)J<AX#(5!Y)H%)0.3N6CK,H_%54([T$O.3S=L6LSF):UK4P/ !PR
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M.0/%KITTLD")(8]<RQ^\DC?C98XJ/WG,8+BSQJ)B!J.JW :&!9T*(W]$U$;
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M=BL#B(:Y+!0SI.Z2QZ1(!)K:-[6_([5OQX%W@@)3/4QM1BF#9>3 "@:6 _/
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M0O9S/H+M<8[/^,GCR\^[2Q,Z.+HF]7-MS+F7^7-Q[K6+;JOT<VG4#]WVXFO
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M#R'5C)SN!$;E9( E7^DZ01-211Y9X5GXK(*(9NX^UP(%GIJ:STO-6WK)0X&
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M72: D@V@&D MQ+M=IV8Z.K#!^QRX@,@MHB(7P8/U*3L2[>;F+3)*3=58!N?
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MLW48^R!ZR$"&2XT4.Q7-S3RE3D4YG67V!SOBV_/7X#__P5W._F$E@JN%[G@
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M#889 X3V9U\>13\9PF@B(*TW@YJRN(UMZSFFN';)''ZZ.L<KU#.,?W'+R[Q
MQI5Q'39XCCN QI&QRU_V1OGC\;OO3G PLW-WX*N^I@_ &<*_=8:MF!+R6V$4
M ^BP0Z8O?9-JJA]K@?_R[1@FW;B7%FUQ5I"M?JCE-?O@)VR?V6<A)+,L6%)&
M[C$W0 $Y)D%\".#R57!2\T5[^]]CG+8S)#X$^$# Q'7MT2@^G_[P(G1&1UU[
M\KS3SX8J?^G%>4R)Z!.T/0MI#<VS):TNU\#4E)N,,\2FXR'\+TP?7,/6S0Q;
M_SD.R]<DVU2RN/ RW6077KOLMHQO4BIO==O+KTE^N[M>,5A9\L<R6+%)C7H\
M@Y7L>@/Z9Y;<2GI!/]!,_O^?B6=G85MF!'Y.6RQ;Q^G]+ODH/_J.'WZQ%-0N
MZE.E2O>-1_158)M65&[H\78J1_?ZO*-K37W<S&M<_=)/<7[8$YZ?7<1)\]/S
MWV[XSY>-"-U\BLY+T17FR%G_]7 XF/0#J=_"8_E5>G')S""9^</,R]6!?C4Q
MB"WM>#"\AG!<^,(UMLG ]6C<&@VZG=#"L;^X@3Q=.9UWN4<SP@<?X8VU)^7_
M6U/M64HD5-HSC2WM>#SLN$F%^+&%YESDB.?DQ.%H4<5N,A.T]1CFXV]W>L7Y
M5QOB7=?JW?Y^@ZW(4)9""6ET<$IRR[06M$@%%5;K%!.O@_/R@JU_@FH"+PP_
M+<;L('%O^\@=^,>U^7#%XPS8VP>][]V]+X<GN_"W3ST(T&&,G[Z\XY\^OI8[
MIP?BT\<W[1T(UC]]Z7;VMC^(Z7?@69-/_(/:VW[+=R&,_]1[*W;YOWN[VY^Z
M!_N'I[M?0O?@X^N3'?Z^M_?QK=S=#VFG0[__L?]ZO/,7I7O[6\AVI367A66)
M4*;QP!Z3L O/$6E4E,@/8B7%7:H-;99+H?YQ%T5 ZWI#A;B1/5]XY*)/:,S2
MKVJ6?'*>:V4BC5X6I=#&.5-062@>BR*8NF.@O.@(D,8L/;Q9.ETP2X4(42$/
MB-4J$1DB)5IJ3D(I%1.IM $)LIC88&R9&;<Q2^NDNHU9NL-61F.6?JI98@MF
MB9?16ATD<<DA-UM!B2G@5ZV$LP55GOO+3@ANA.)7% K'DB^9D:1D94$DE8IH
M'Q1Q3/C@J"]XR9^]-'R#LN4^R\9Y-<[K$3@OQI1,B3.;P$Y)'C7G8+>*I,HH
M1717T4,U=NHGV"FQ8*?*0CHJE">!0Y0O1<#C4VE!3*F3XX4H&),W<EZ-4#Q^
MH8A6AI(F3GB 99)!&:*%TL1(:EA,LG L0*!5%AN,+K=OKH?W>@H[6-NQ/\BM
M+W?;PUJ779;F'M>XQU/86YIV+<\*/>LBQ-S/Q5[4U8U8YUC7/%XH_?QF$[,2
M?ZX?2+L9V\(==V26:B<7>LIW<Q'N7JH+)BNBSKVSRMG'09KP&#SU[JNEG1KF
ME(_&E$1S[XADLB!6*% <SIVB(G&.GGHMY65)4'+E;2,M/U!:@HA>4%N20@D.
MTD(%L2D61.CHO"RI"PK/R:1Z0Q1B0XOEKL,+3N5^Q.F)QE7<WRY9H_IKH_J+
M>V><\\B=TR125A")[!6N\"R?D\M<H9CUE\7Y/U-:&F#Q$^1%.5BX$!RA'$D"
M:5D0%[@@W(#_H%1+;I DD&XH0S<,U8VG>%J>XHY[5(VG6!O-7]RYHC0FZ9(A
MRIA I!">Z))S8HPNHN2ZX"(VTM)(2UTJZ(7VS@IB5$"FOTR(52JBI;-,N;(H
M#5]3:6EPQ4^0%]P4Y[*4I$@4SS #< &&11.FN).FY(*ZHI&71EYF6U')E(E;
M"CB49[)J/!33&C R7 $6]885^<R[<D,7<J.0R_7(M_A# U5_):AZQQWI!GRL
MC7%8W*=FTA8Z!$5B83B>["&(-I:34A8REE(6UMI&6AIIJ:1%6F]TB(*4"NLT
M2XANM"_!'#K+=2S+@EN]IM+20(^?("_6E67D3A%ON4+BDY(XE1*QS&DEM1'<
MLD9>&GF9055=%,J"#^+P'X"J3!'G/83"6I76VR@E'K[(*:!4LR'8,IGNHT*J
M3Z&^:O<2_JQKUZ+<9$)^M?KG5:^XWJ'%I?7/%QP.<<>""7YAQ>M*;K+&3-_$
M3/^U5 0AHO*%4(YPY0*1*2IBP*43I;RR!1XJ)>CE%<\_6PQJ[]X(PMT$H=!"
M%46">$!;W!)7G#CN.5'"2LVD,HFJ9R_I)K^&I[Y^B?-J-_A#DT57E*0V#NI7
M=U!W+-1H'-0/M4N+I1?4EHS*D$@H5$ED*1,Q7)>DE)$J*DIOI+N5@WHP,6@<
MU+T(0J%807UA",2.@%2,!@?ET4O)$B0AEC:DA Y*B<9!-0YJ7=[M-@[JCCNX
M^3S7QC;]2-NTN"\K"F43=8P(;QTXJ5 06Q0E\:'P-'F?J%:W<E)W%(7&23VP
M("CKG>2P\LHB5Q@M.;'@G CE9<2S#0OJS'H+0@-:[T$,4L%,<!$6OW1@#ZB%
MGY261(! F.1E C_6B,&O+P;:2<ED!#^@-'884>)TP4@AN106;()+ 2'KBE-_
M;_&'!M2N$_!K0.V][O4V2.8'VZ[%_5OJ2BN,!PRKM4=("X%W$2B)D1FN"B8L
MNZR4N1&$7T40&(LFXJG.6G@0!"DU,4Q94@:AJ:3219K66Q :+',/8F  <P8-
M""88"I$-_$HT+P(IDQ>)IT)J=5FI>B,&OX88A$(:J4I/M"TM 1P;B#4&B1YM
MR5G$@SC+9R_U9K',.?M8(&VNY?EG9O!_N7PNXO1 Q <YCFVK/^Y,CXO[:W9$
MWNOZX+DWPT'O53XJ,!\YMWQZVQ,^J8V#P9)E:3Q8*.H$D8DEXH)/I"A5C%QJ
M+TJ[=%+;Q8?PK<N1E?OMV$J#;G=PC*<OSI^^/CNNL'NRZF#%:QQ:B&='A@M/
MIMQHN>CM9!1;G3[>!)\)-^@M'11Y[I3#5H#GPR>C]6V\5V<0-ELW./GP8<_.
M*]6F9OHV9^<5>I.6MSMN[=)#T\PF9[<[DN_R:X76]S]8O:GX]8ZCN^L);^9Q
M'C^U-0(=N]>SI>Z#4NU13-VMCC%KIN_"Z;OC$6>/D$CO?0PQ]K(_>37HYY'A
MSW\.8XK#(1XFF#L$[D*?=_716+]L8Z&R-.I26QF-D=1J9YD1OO#P%^E2+&_:
M=WQ'[+O5@^49GV_Q2)WO,9#3.!S\&F%@[PV$?A^.=^&NG[;_W?ZT_:Z [Q9[
MO\-S]C^PG=.=8_A&9W?_@"V&@0<?(?3;WQ)PSZ\[O3=?=[>[,+ZO\N#+I_;N
M_H?3G=/?>CO\+=O]\I]59R(IR0H#P1YAR.4NN1?$L,(3YK6(91*B4.K9R]P5
MP%_<4Y_&]73K$?4:/V%C887T@;ID;:&D-=R%,OK@(_>:*^?+FW9^_0!C\4OV
M@SV<Q5@LWY.QP$*82 0+DF ].3'*:%*FQ+DV *F8>_:2L0W*Y08KERFTUM%H
M_%IM7ZL5^W7OJ#LXB;%"1ZV](UR-VX&DZV[F/G;K)K6TR@20XB@D]6"]+'/>
M!A-H<(KY-8!"C76[@W4[6<)#I2Q2 )!+F$F)R!@]<9Q2^!7^3@$-E295A[$I
ML6&*Y4-N;FC=UJ^"HS$ <P9 *^Z,+!D+'N(AZ:PJ !4G:Y1G<*5HX,UC-P!+
MW0F:.AH*3E@HL=3+:@(6OR3>!V<TXZ*(>,+51BG5ABF7>9E^GOX_A<S/[J!/
MOL41[FN LHZ''8\_5JWKJ,EWROG\\M:,,AFU9:8T(D@*8NVY@W=.I33* :AI
MX,RCMF8KJ/%3&4M>V 316<#Z926)*VT@SL5$A;:)>_OLI59R@Q;+_< -8=RO
MI/TA"JZ\5D&65"I>NM(X;@O*P K0PJ4UP#)-7O>VBK\(8ZPW O J)R6+$,=X
MD8A.01-OD&!2E4[;XK[SNDTBYGIJ^^[U=NNC'0YM_Y9XY:E$7[0(-"3E :I(
M24NC>4H\>%]RKT.1FIVHQVNQEGE+I+16&^%)63A%)*POL0+C,$--#"GI@I?W
M9K&:M,M:*[[DP4HC2BV-EDY3JUD(0B9*DS-E#&L 59I Y4[:OXA7A-$B>6F)
M#2P0R;PA3F"'G07 &A+\5>.N$J4;(*=KI/U/(>FR<S+X'SL,'3M%+4V2Y1+;
M)4)0+.K 8RPE]]%ZSS5S8+JX2T+?F+:_L5WK9;N6:VB,1$9=*HA@RA.I;"+.
M)$L@Q+;)TJ@X]WBN]+W8KB;)LM;:;Q03HE1*NNBEPN-B7$F=3@6-3B4G&^3R
MV+5_J1Z&:@O@Q1!+I0#D$B1QWFBBG3&!>ED?Y;%VVO\4,BW[=CB:C)IDRW4L
ME^.%!,!BHA!<%H!87%*L4$JHR&VIFF3+XS5:RV4NW#!6I*1(084C4M*":"9*
M(D-)4W"EH,(TR9:GH?C&"EM0XT#C*;("."F,%SQ)KQRZM@:R/';M7X0LI4E&
ML 2*KQ6'@"7@69C,$@6&WQ8!;(,K ;+PXG$E6QX3,IE"DE:GW_JC8_N_=0:M
MSF@TB:$U'K1PAPC/7JCPRS5@RR]OI(+D0A8B6< CTEL-,7?@S"4=H],BR#5
M)XV1NKV1VELN77'4<Q<M)R8PB*NX2P266Y,HJ*&QQ$WLXME+"4;*R&6.BDN-
MU(]#(C< '+^\RA;!I5)I70:JI:7,LBBU3"9Y+#RB=@UP11-0W%9;%R%%9-Q8
MG3Q)A93(*F2) <=/5%  *R'4"$+<,J"X?RJ83%:Q1 @#OZ/\=OH36Y'8()U%
MEH52E*53AKE0:%G FY;)<^4=&!Z&W0&?!47*I$M),/0#$(TL-8QGHA'&-EL_
MFNAFXD;Q_R:Q/W[]#?X9K0E?S>G.]H=OG_J@"/ ]%/"=WH>37?Y!P/_HSOY7
M>O"EVSW@!P*4JG-P^EKN;(<OH(#TT_^VJ>_]IV\_FLG>EP"*<@ *^%9\VO?P
MOW??]_;?=_8^_@=&Z.7>[__^LK-_"$JW(__W] ,HA&<PKN^@I,7NUF<0$]S&
MYGC8 87XVB>D#G6@'33X8)(SPE:&$P0OABVT3(*)0HF"%K:DTC%CRA"+I*A+
M4=O"\T6VF[/I;U7SORS<5].TJ/6AQOGO!56LA.C*67GYMM_:\^,!<B.@I&YD
M6AQT"K9_TCJVHU9_,.ZD#F+LMAW7Z+K5MJ%E?;L3O\$%V_)@1RR@\@"_=P='
M/9Q5>,<X&@_Z<:-UW.[X]D;K: +?!0"/:!V?4M_KCXZ/_5%L;1T.8\2OPAC
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M;*4#BCB"".4TPTL#?DJ.;CZI*IY+:LE<>/TE?3Z\TUG.UEMEV2CN^U/V@1"
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MNDBW>4Z\8B#7$)/6#/XX50B05EEZ74O@C1'8CO.H<"X<JVE(.T^$K$_IIS9
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ME,P4G75K!WETIM_,"@FUA'P(XP6TE'$/2XT%C&E(KQ8@G;X%BF-%U;2T5CZ
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MF:JT(Z,T#JBW=!SDBZA)SG'TT612S!3')=RAGL"#EP1VE0-(]E7?[4KKIE@
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M24C>ZL7@&;I42.UI,HBPN"<JHP>5E08Z-!*-,\ $Z3@BE:,G0($1 R1&W'1
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MWKLP<<;<A!A2 9=90 -$2,J"?5:*N>*-59%K+K"/P?\6M#W-0W>S^TWUT<-
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MU&F_?VAJ/!)K/S0S=I%[WT=#EJU8WS<WL].KSBKKDT>Q[&P9%T:E$9V1DOC
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M]"UA[M6/RU_EZO1__Y?_#U!+ P04    "  MA&I5( T1#@AX  #[>   $P
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M48ZWO(T#V$:G/<%GFB.OK>,_!<9;TR9\EDD@0D]@I(O?"4L@&$N0/$RP^)2
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MM&6\ZZC(@MEF]40PA/C@D?%D#1ME__#)'GW.;%E+RZA(2T,_RW*>RP@:RUY
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ML[_7YQ1?$D:R,#L(X4;P24;MZR_/U5,,-'W7_1 P#C2_4RMX,8Q_%#E8J%U
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M,YT0UU%&<G:V,TSX0[MMP9/[8=3""T8,&@\Y_GLH"^45@4TT@XQD\Y(XTN/
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M$:T^*\29Q/PSE,LU*%5ME%%P*RJ1'VD0)4V]UH%_F?EDU,EIC^AO[82?KT4
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M)Z&T//++EGF2I\#$<7%6&7=#<8$%+K(8@3T9MJG?B[C"6(_[O$Q25VKZGRD
M5%\0EVTKTE&.7 7>N*JH,DAH/:U-+!U83=L EMV2SV@69N5;1E52T'.AV5^W
M.T)XE-XRP5^A2JBVD%4%5&\(9O=MJ):7]YD.>\ <DX!R25E_IYI$2:%0#!A*
M[V<WD[>(IA"7@'O^(^1?9WP7@^B6=[9CL*G9=\Z5*CD K&HLL91#_(QCXW"U
M:Y>)=5UOPL/(CPCTBQC6_8B%<(BR(]SU]L)7C\E'6@":DW0C!>$XUR-]7@70
MBNT&7GVH#]:B@=PH*E=C!P#%)^_SP/3'%9'J8U@WG5OROUKP[HU"]#)5YG\_
M$<+:5 YU@/6?Y*U#N^Q'Y"-XL@L@"2+0F%=Y7\#-P"DAJ!S@/4CWS76TYV&W
M_:2@V)A"![ ,_:+X! 2X26%2:*L2PP)/.0#)C>;WZHTM,?E0:P IV2L66N?J
ME3HL$5\=_!DMD6\+"B8FG$7!JP_$B]X53T[61!.#PH$^^4CN+,LHHKNR5BH0
M)=9Y4D5KCQJ PSY=HMH.P7\E]"E *)@"#L?U+(LW/=91098I^>KM*@87*57M
M040NO;@J_2B1Q'1QF&>\YCD:Q8QT1HH]W$55X FR#W .?K<*1750D8 X[*)3
M-3-ZB&FKG(4DY5 V'S'6V,JXN<9GLVY"Z<3*P83NA4@4#LPB*?T#>+L%N?.L
M+$(U*BHX4L "0,TTIJ/>^']BX'0,EI5D(3I)27^U(I2U_C:,^1:9L]G(_R(6
M54$TBE4><2: C4\MPX;\+*H/D4ESAJJ?C]"3'<$9E.^/NP/F%6+/6=6R5M$H
MXBI:\E;C41"=*VK?_ALV]+F FSP; (J% 1U6 E6EG0;%F8KOHRR;(P$TE4H7
M@TE3M_B C3L]F;"*#_%.PV&45[;8MX(=LAZ+&.[8,$2G;XD!=,U9U1=DDGH^
MKQ"L?>728$4L@,0\I>24GT1_&>+>W %3WP\DN!*01PUN ^(\\>=3D,K9EK@%
M>X\O9+;*PZ3E?()Q0@#98:M0F2X+([=MH=!WNS1.4:C3.)L []9LIEN^=!4?
MZWHD34. C8(*G>[==#*Q#U7W>$H#+4YE2MW=&0\ZJ%\FA=US75;FYP<#KNAO
M*S7+ODN'WK M8'-B:2^'LLF?S@;V5GR'#ET8T>=2H2#3BRXQ^E%>W,T6UIXJ
M SEM.^6ZH^"W92_7@$*J;QH*XHQ.?\S\'9:'ZKM8KC 2D+9Z\NI@=]SF=Y@6
M*&1KX1>#J(3T-)A$N;H=Q(CL%MR5P'ZCIG62N(C/0.ZELM)")WX_VXI1/L?&
MA89+%.C& +9A 9+<*@";[6R*Q0N&5"P(OOW0KG'N8 D6'KU$DZ!8A_0O0XH?
M ;>R%\")S'PD,O 7M("J$(K7UM8KABMFY)>0[YX0X$)V,:>,WY<+^8=>@I:O
M\J5@,3G0$:9W%N7YJ#ZD\>BKJIG-UTF6$>[HDC:M_4S3ZGK#-!5QSM3GI70+
M)!KN^A;5)>3;(IES-';C]<RT=/N&WH?0%M,18_,@1[TH.68!<9!%5>F+2BT(
M,$!,AIXN636AQ=$#55]!YIOT]%P?QC0@=(-^-MM2)HFMV5EIJ>-:>!O6@BI=
M(!A=<7"OWNBK<7AVZ:NXQ^(TB),BCJW.#%.;F;1/4?B>-1Q=G[,^,7&B;7<#
M9PK=D*K,F$5L82?G-FX=^-\;T<19S=9_^R#5/S9Q[G0;L0?_SEH0?4@O$A\/
MD(XIQ.[P.N>[/'O]Q E[4;BI/4&#Y8K_"(CJ-*MS@C7D84L"U@.BVP>LK;[H
M4O0E%5!0A6TY^!C%F**,,1(P+K&X,#IOF.":O1J"+JLC?GW)E?K;M%"C/F>[
M6OK:XFSV:]3PYU[W%['O9#/AJX[_;6Q=L*!<3V1RDE1_*Y"4&_9=N(5M 3:G
M U/_;JQ?3?4A8_2<:]QY:=!6C29C2;13Q[>+$6P'AMJ?^#R:_G9%=5+;F//<
MW5V(^,+$WPX:5U4:;T'^,L+./KBSK7_8UV*1H_1T8L?V.K$8V,&I('7/BS+=
M*5!,V7VH\,<\1>/4.'QE!Z6E+Q"+8IG%>9>0=[E3^(4C:L93>NG/VV,6_KEJ
M0.+CJUV.0K4,$^8W!@M ,I75$S8N"VGU;$Q><[K%$39H.?1W!@9U>\S,)&ZO
M3T23X\=]7@IX#-%O= B*Y[OG__+;/AFNMZB.=J<O[)DTGU&50#"6#PT!6 .'
M.I''5C$[S9'+MU'PGH0_H^\>/>2QC]"U:<$\"F#.#O!!MKR>AHHE$4*I7V;2
MJH<@V6R!D35;5B8M>XY:-($8]=^V>TCJA6,_*"25!1N(JD)" B))]L!'W4HE
M^[5]"7QW%1-/I&HD+I,GCKQS1T,FXYQ,J!/R3G58W4/^623T40>\_#H,><#:
M&B7W<MP@(0L!O8*M3(UQG.2W*?&5#M_AHM#TRE#(P#0*5DTK28?U'4-PFS>J
M1\E7_F%OD<G3+6/K(ILQ54XK/JA2^%A6#T1/>\=P-%@N(/?WI2=0CF7BSN)P
M"]*]5N=;B6AR_*"AG]XG-5W? (;.BF1IC)#*[$96"(QW('_NL)AB)58E7QJY
M6DS )CSHA=%-FXWUWF[@<LFK(I/BW6D)XR.&V1F'<<@_*4\IO=+*0U04>U;I
M5;LC9_;F3C-"KEGBXI)-XSGZW3742)]76<2&B=$Q9$"'5C!CQ>Q\!?7BBMDB
MO'][M+WA5_DQLPP4Q:QJ!_[;'R\_JV9/H206RE"FQ&ELR!!^VMX[@!Q;*8J!
ME4-37%X/9$3P9&&$HF]6RG#,<QHK62Y\.?PH.7RU(A=%F2>(0G.:CMBPOC6R
M?J>)S&PB9P21#GX(O01(1AMD#((9EQX9MS*:U/['\ "./HI%F3]4!YE*S"N(
M#@X;O.2K,8%Y/D5/?-!+G=7@"EW4<02#2(.:'PDCSY92;I9:6?J7H_>K-NE.
MO#=P\(:)'S'P71 ZIPU6"C>Z?V!J5*\AV!8K;"^11#RJ6CDZD]UZB@KC#'<Z
M!BWS9CXIQA[)1$2659)'2AQ6'XB_P#XPVJK&CG?KI60SM<'5*D>P.]V/7\="
M=O]+)NI9,M#YHM>"S]TQV4J#UUVR)-,];_;&:,1F)"L"8I( ,7Z0]>O]XC]8
MYC=?YK_,[,A0\+F&H5) 7TXD77D@\K,W>I4Z^E4SZ='MX?>YZ9;FV.)/%+V.
MI 8E%D&LQT]+H7G^@]"GA GUG*'R$ZX2JM%A#=V@Z9;L_.^?*#"<#Q@*^^.-
MIEJJ8S$RQZ%W2SL6T>I\2<Z68!?RLCA/5%>A82N6LEDSM9_^DT0I!I2.B-)S
MY1F\]9QV07/E/1FYM9$G9WE!_>(F410MRHKN2?E5L_\ FXD5FPE]R9;.JF _
M?1"@VC;+$I3569$]>.9X6G:*;%WQQ"S'HK>#9K/?H=%5\S'(M7#E;'WSDO2J
MFZKFO^U\TB!U7S.,=:@&H1EQ]T'X&X5\?3JSF'4/$-I%M$'Q&)5FHSZ3'4/1
M0W3!L+T1066XO%$5PEKZRT;AX31N^?P!+^(0?,3L&O*ZN+L*V*8<*ZXIF+**
MGZJTIM<-/%I3IRMQL-V_Q:2&JVN%549NXM4>_5<M%D)/.-R:R=@64-6V;&NT
MK/QTRCC%&%)ZRX"AG-]@F9<_G\\^/L$T&[N:C/@<9$?U@^>\S1]'E:XJ\H,:
MIS$CG"FDSF=_)EN#?$ZC=G:K.X?!,X7MM\?42TXQ.&!'9?N_4:RJV/'S:A1T
M6Y4T+W@_A@VJ+:.6YRNQJ!'^];-RO#E;PLM.7$G.BLCL"[))_7CL'IZ]:<]D
MP['#UMCAZ"J5\%T4GM[A_\I/]L%>QH&H>EP[4RA<6U]A44C>8# D9UT^EDU^
M66Q8@7&^/PBLQ#9\#)5_$V$TEZ*0F9V"BB@6U:OF^^ZKX)]OS\;FCM(4NE+\
M,*7#$*A\6]Q(>;*4@4VUHSNT"H4T/5::9FO\_?"9_3?FE01'Q/$^P?!T.5.N
ML:!9\][L*.E5NRN'["R"S9LC38YX$>TJUSW=B=ELS=V0]FK-W/-AP;&AUK->
M/Y,FZC!Y -039]J>4%=I\99MM7Q,4A;Z@40BD(+5L?XHYG,^K(DIOX42A(,'
M3H>S$FPQ(ES4'W,=E6[.=M'/H,[7LA9%*^;G:C=GRW3#1X)7,J8FB)LR%5)&
M=R'Y\/%$N63'OW;<K;;6(859 8[3#48QE4!=@.;V 5/NTB7=R:$:[5$=BB7V
M*[KMR3K5-9/3LH2-I=#LC@C';QF.4\"IXX\K!B%5>L]MLTJ6-]]:65@MXW.*
M'--'^\!EM(P"#)5P G> -;HRT];-I:7IE68468/N6W7"9.-':[OCDB6=![8]
M:K;.Z+QHK!*&XZT[=M[U'%,CM>H24JN0?:WF^<0?A7.I5L\XM?*C6G*':6OX
M3J1^+/*'1;+U=4N__E.&<RN,-BQ[;O_KY.8UXC)K-IQB.Y(U=?Q^,X5>=',"
M4I%.2")[VR9<-[(+3"+01KT0VT&SFB?SW$-Y("M8(J;PS!"O(,!MXG@W'K[&
MV@^8U7B4<-P+ I-=%^-:Z#BHFF0,&A[=U7&*[7^1OR'UBQMGZ<==.;9^P5XD
MXN6K.$:Z1J4,#KD!7;3.PBP$;R=>;\0"#!6IEHPV>=G4P,)O(XFZ]FR?+[X5
M(]BI"1KERIV]E#=O_]L31-Y)KW$BE=UT_@8@J=Q&3<XF"J@^'^.W_78';[Y\
M]WZ4Z/O4HGE344E#9/PN :E%-4/Y*Q9&@Y'+K"0M35[(LQ/%:WLY3]AYB1'V
M\O#X3'TD4MRU36[(4RS)V^,X=!7*;DLNQ/6UJ64^XT6#N.^V0Q.+JVF40 A+
MU"U<5)QD0"^)7C3QG(Z<H<WM4D.7\9\^?3>U9%<NE>OLUX+WYV2:+.):(E6N
MN$PL0A@YI;Q9%$N,U=V%9";\X)]@,H33H:7FV^0&D4D435>#]+ZM\N'*V6'<
MYV3Y>[9M+6 H:.3!Y-U]NKS[]\A[A<,'S\MFNK_-R J(%NVFIHF.>\:":MT9
M<ZJP O=J_JN@._6V8F@6^$] EIF-!PIU>5TTY]Z>($=HL\H3-I\9.>K!M,S7
M#2"2WF:G(/Y+BQ+#O4"09[7(!H\HWL)S>D1FCN%*<QC ,Q>C50'2Z@G98?RY
M1X>YX^A(^5DM_/,[#YUPW;$6RBN%-O</:Y##IHP;_DRI=>MP,&S93%_+SN8@
MZ]\J]R^L@<"<W]"R89\LC[+"EMDMBT,R^>W]'3*"/W+1 O6U-<QWB:6\5")5
ML0UK#>H;K2JC+$O$3;*PKX[?:_2JOL(LO25=G4+I_\BS_+E<3I4S7@:EUTH@
MEK&^0K%Q/W@("XLJ&(Q1[43E(9+$-1JEHN#>PI]5:0":8B%$ D<JK]X?OU;+
M(XUH6@MJ.1>AG!-%HV._0C#DD=KE3'GM?VJ@HEJ\G:H7 .X3)XR)E=M5DME5
MH0VX/+QF<9B4/1-%A^,FV/+TY$'8X,MX7#X%0Q-\9O#6F96L]I.V\9.".^>L
MK4A/2KWLKFFP7WL]>,PU,-QSXQQVV"Z\XZER2AY.(D\,Z%!YF,O^*YI(^B=1
M]"GQE%7U5%2>]"7DY^[W. _UV5;%TQS9^$Y>^DYYF+>G?[97=/^HV$N15DL$
M5F3DATZ33YTJJS#R>S%;70]A\8AT5$_K[_([G$^M[@..^%6UDB;23IBOA'[I
M:AUR]8BZ>(]%2D>U:LH%QQ=5R[<H ))XY.A+]?\)T3<NR!OG#.CZKC?[13P!
MI?BZ$ $=+']-KK1FJ_P-!]07'KC/3T#0(53+6LEF* J[L:LZLJ,V3</UI\L[
M$'9@ZO0*Z$SB$[2;LZ&2 @QD\69-(*4Z^;Z$M[.$@;X1Z#!;KY2$!A[ LO$$
MLX$-JQTZNS<$K<,[0T*ZYYEW)5J&M73! &I+4^)!E[[+ 0Q JPR D:UFL]T.
M#T 0T",87Z\'G1>)IS\3J'?ZPG?$L^>B_=#=I25CUN@:Y;28:HM\/]M$R6>\
M#6:PO)S]H#[Y1BA]XIEZA]>\S>.\WFN'S@.F>9^%O9L*>@%%WAQ KG1$E?)B
M6!?DBM#\\->WQ!4C736O>U4_?+*'>M9;_=9GQ(,*D/RH6OYL//9EK7ZO/-J/
M-\F/CM\,P8.V6,\ J ;&;=JJ*L7_TSS>IW"0H+C>QZ%42WQ%T %D<-0OR84A
M<*Z0C[:WH1<*^$#4=\$UIAHR$3U" /_=<[L59 ]:X,G50\3UTP4*\%#FZWA'
M;((8S04'+);O'WM*=+W\@/VV.9M,NO'#BG&?7WY&K/UDYF*_O+VOQ"U ' B
M D!!  %\ !"(QV!#AP\A1G080&)%BQ<Q9M2XD6-'CQDVA!0YDF1)DR)!= C9
M843(3AV<G)1IDD,'0QMJWIPY,^5.GS,S>(1(4:C%+@D!H"!ZD&$7&PX/=#E(
M<,"!@CX,2;5Q@ > HTD## $P0"P 'DL-'F!8U"+:CFZ+;MA4T,I: #2DL@6
MQTK!0W8[_YH!K/?@6\))%="UBY=PW8(*\GK,$EDO7,.$QU@%L.F)P8&$-XE5
M2E#H)M*$+7M,?=C@DP"OP]IX2B?LV*=*LXPE.B# ;=B?L[RFC8!UV\O%)=J
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MFD)XD\U"\X3/)C-_ A"U\@[I:LR*4$BLO"XG8LV*O*HL:("\:'CM$,5>ZPN
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M;L%1<A/7OL+V<I,N_OSD"9 'IF0"#SJ@"V3"3U;&=?NM=!D6<J_1<S?"-<R
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M.L,&+(6<GS,XZ$:C 0"/ P!XB50YH*,SKAEX?>"#L>R>86-67K@S)%BF/S@
M1J6/N3FSYCF:.3:0=?@D(OE0.L:&-B!]TV!UXV,$;L $5K<F$" ^Z$!B.N"J
M%R5]&R90BF<E"-F)G[B([R-AN/HFZA<!;*DFLOICQD"5'4P^R!=E/@8!_.0&
M:@(/_Y"(=1O9EH)G QH9 0*E=1KY"0(E!&[ 3?"@B.<CMXR'B?2Z ]* 8J+X
MZ*:X<*OXHE[#4ERC5:H#!=3SFY5#M%?Z(,AE$W)#(*1B$\2FGKL -\#9(+X@
M +X@*0J"!A*#M3<#M']#*K+XFPEZN-U&7EQ#*KX9#YX@M.^"(JIC"![JS.YI
M.R@X[;ZYII.Y _<&JB#HM$FCIK>C+VH:#Y["U?KKT'B/-+"7-S;NC:KG-I+L
MGEQC5)C[-[CI*8(C7.9+ =J8-(370#0D+ "\.A# -:1[N1_G(/KBNRDB"RSG
MN-'*-FXE(=B;- Q<FNO+<HWZ F6BB-^$IG(K/O*$ U:GMO^&IP-0II<B.U 2
M!:S?=ZRWFHF.&:;0)+<6P$T>9@@^1G;,6JY51CZH6F$X8)BV>J?R1(=T*"20
MR ,"!0]N *Q=G)84K)(5.985Y3X 6(H!61IMUR(J! 4>JBEXCYQS0Z1O)3>Z
M9BM$CRHLY3?&0+9W9"FV0[$@4""HXBF8.X//HK$US 8RRG'L(LP/8E240KDU
M;"S8ZYY,X)Z8N]!=C8+%(K]M@(0_$ <?L,R')C=<;;%<3;%0@+P!H+;[*W"Z
MAF=:Y8\9R[VEXZN>0-!!6L%OI56DPP:0@KF7Q+I8?80]Q5KZ^+D;/0#HH- A
M?-/EQ4$(PM81/=;+ABC<?-"'8L/W!X[?=MP)=BBWF#IX2KQC\F0%%B"64L:8
MOKIC.)F0&_D#K$ EC(G&E1BRB<B)>>? 7H)-<B*PWS<$F'JV"CG)?2E04 ;*
M.T;*6X>I7UR&LARSMWP:E]D@'*<+G$-"$*"^,?W,EUWC[%S"#T&BF ;./26<
MF0;"?> I*GX \/PS'HKA@;WDER3'E.)%YOP@6J70HQN:?B\L?/TS"IU93.6A
M>#N[*_WCW_O,"UWT),33\8HA9+OD7]T&Z@<M&KZ@U5E"AD"->2\ -,/G9_V#
MD#U>Z,:U'1[.17[CL>IQ?MV=M@+4&"*_OX4#D/WK#X+"*>+B*1BYK;>HH?\=
MSURI$V[(=9V8AYBZ4$@<36J+F$:"QD-@"!:EEYI\X MY"!JFE\_Z3VK\/?0^
MAVH+A_QWE3]\E=6#ISA&)Q9?=6M9)0K[80C[WR&_=0J%K<?]RA?@KUF&YQ%^
MLY,FP%O=;5R-!T+;-:Q".@XB"QYJ?T+^*;Z^.CA X]%*SCN^:S[/I"4\S^])
MT(7[T)<]0P*@S0T(#W2]"X: N7U@G\+"<<@EM!W\(?9F>??/*];B07Z^]X/>
MI5'%TPVTGZB>@CE@.X9 *4X=+03=Z95>] #BR9  > !P"# $0( L !0. &##
M!H # 1K:\-&P(8^%#;.@L/$P2X G* (<:(@G (+_DA53(A@X!D!*%#(#!+ "
MH&1!&Q4Q*L33)4 7  Q% @CZT$?% 1)3#@W@,V/#BE*K6KV*-:O6K5R[>OT*
M-JS8L63+FCV+-JU:K!DVN'WK-D2'N1\VR*TK8L0&#W-'=.#PH4.(#1PZ>"@\
MMX.A#2/T;A!LMV^'O8;A)E9\-W!?0S<:NX4LXG+=NQL,)?8 5W/?MWQ74Y[L
MUO1<$9%')^9 .71EOJCE?J;-.#&>Q[0#+T8\'.[;#&.I7@W@R2STM5P#T*!.
MEL:AKQO35'5^%OS7H#:'#BP8](E"FPI.1IQZTJ9-C!1I^I X, #/+B499AP@
MWR%!#:64?A+5!\!] - A_Y]0 "! $ #YF605@/-E!%5.$9*W78+RT922>BF5
M=U2#0]7D7W-EB:> 31)!]"*%(NE745 <U(3"B#:1Q-% 0[48@ (/ 2C5$PT.
M\1YY/ TQ$!TEJM?@B^]!))]51MJ$GHL(]9<13P15Q" "-9&H80 \-&2%E@^R
MAR:692K@PY 504CC4P]9)1YV>N[)9Y]^_@EHH()ZU99RAAZ*Z*%YQ05;HHX^
M"FFDDDXZ*6^47HHH<V(YET8 WDV%4U<;R1>=0J%F94:#9DC78:!Z3"=522?*
MIUY#-,@7Z@"M3J56GH/.5**8@PY;UD4-^:! 0T$)JR)9OJ+%$411$4MMM<U:
MB_]MMMINRVVW9Q6*J:2(S85;N.:>BRZFEJ9[J:9A.7?0B6&5U$A-M7(5(@!&
MGKKIM'^6Q"\ G=+T2;( 7+=>1H>(F=)WO6;;8$'>=DN>330!H,"+SJZXIX[/
M3@PRH!^'3'+))I^,LE7@LLMRRRZ_#'.Z[H+E7%"?*K1=(_*M:J0G-N&D$XXX
MVRK?F1GE2U0 -/ELD\ CZ>OIP39],I5/GU0)P"&'W!J 'EG[</5(-B$\:@#U
M=LITO0UZW1%5-AB,TM-5I2?5R#2GC'?>O&ZL=]\FV^UWX((/3CA;,1^.>.**
MLSSS5YPZ6'5.<:-@)$8SL72A0TDWM(G&-27T9,, ?#+_ ,  I$E4C QER-14
MUP'XU'8 \L"2O3\!,,9(03&$NNE2*3BF3TI!O>.:\BKT<.'*5PMX5LTO#_U:
MST=/??76"[KRXMIOS_WBC7M5,^2:7VDQA%GR6!"7 3QDK-!QUQK4$ 6ZF*!$
MQGIITT/K*^0?ZL-["$!3E:@+Y"O/@'#$):FT#D--^]_GH!83#"7O>A2<X*8J
MB$%H97"#'.P@6;+7O1"RBS0B1-SWN@*O -PH<AR9B9'.%S2(Z \C()G<T1#2
M)A0 +R-!<8H,OX,1"FV.2  @$A%O8A"A&.EX\4)@M#*R0V6IQ"5Q$Y./ZF9!
MDAUDA1GTG9^FAR>4(2V#+Q29_P?/B,8T2@6$)6178@9S*3Q4QBTK:-1;2-A&
MF)VP.AGY0@"^@"'],40I*#A/$M&GH=4]A"(6F5:^!L*0,,4*:P@*9!%C=!+8
M:>Y_'/%C[*1R0& ),2.,A$C;:**?]ST)BVD!(U@VT:"+C<6/@!34%JVB(UE^
M10%P*^,D4]0G5[)23PT2IE3&"*@TZ;(AAV#3IEJ5.RXVQ)!_,J8:KXG-O+$Q
MC^;JP KB4JY*S7$#H3$4'KG9LCUNQ3E^_%"&1L03R@7 2<O"W/XT1Z6F'3-B
M4)2/Q)1RDH8 R4'WE,^+E%*@AAR1(0<L(.Y4*+09@5)I8\*A11H4-X>UDD]3
M2M.]PC<2E%H&BI95R1<*=N65C&7$EQE)X!<YMJ< =*B9R_Q*2D 7*)$L\W]=
MD!C-[E0BD3:$I<',IE&/_[J\;:*34J;I@G+D0JY'K0NJ'0#!!NJ8F+HL-9W7
MPB 1_Q6AK[1/@AO=TY04XA,@801U0L/50X>"N0Y]*0"; )5--G&0L.;U:3Y
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M1?F(J"F50UF(YMB4CA@IZ)@I[F<M79D?0T%:#*%<]O042#0B/K1_VH*04J$
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M[_F?#_JA+_JC3_JE;_JGC_JIK_JKS_JM[_JO#_NQ+_NS3_NU;_NWC_NYK_M
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MB5;VF2D/W^GH#  @M(20!$$$3@G:<2#_W W$PWPHLE$K=+2ON^4^?\J^C7*
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MQ.A'M-\&\XK3R%2C906;1EB@I06UN$#+6R$'?JU%=K#2^B&T-]J\0CF1#7<
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MA-P%KK<#XLY.1EH4RDO"5'^8"[\FPZ.>129];[/CQBA6$5<9I+C.5!9!ID@
MDR@1.&9A'(1N=W1'$')N2T0E*3"B#DWP/<9(>EH.1AZ?D5<%EZ'Q3^=78#<M
MJP\1=%[D?@74SAQ_35_NM=/>KTU%IJ_KE6R+\"+$*$H2*%1*(0JS"-(T05"*
M"*6A)%(BZR*\QXW/C5HK^4 EH'.EW1/@NAGQ6CA&9C('))QJH%U2>7#ILY,&
M)ZMX=DF5_4)G%Y\9Y()_R*M=_OWZU7JU*7+VM)&OZ&.^H<N%HEB&(5<0QY1
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M+DS$!=5(?93Z^UZ9M#AWZNYI4VZTT9NOOM0O+ CCYG!>0A9E*42*$,BP4#!
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M5WRO?Y[7$2ZE--%\6ES'D$@;T"W]+7ZA')E$!Z/H[F2QQ\6OB\6BWVD=+/9
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M/^B5O:S*H?_)\2[P".-H1U$O/#HC\UPE.JS3L.SK!_84!.P9[#_7* DJ+6]
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MTY F.(0J,&L BP+(XBB&,B54(HHYDE;U@\\U/C?Z;N0#6D"'$Z9CQ"P.Y*[
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MO#=Y4=NK,Y$?MCI9!O*SRNQG'C__@/N)SNLFAK:>WF]60N\*Y8(& 8I,Z;M
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MJ4,V6ZV5/G0L9?V/;;';'9,.;<+:*Z6+K;(9?BI&R-"+B2ES(0&&.@$LRV.
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M;*RJIHRR0]>'1- 7RM7.)GV3]+G\_!72>_T-D^R3^C\ZI4*JE *1:*MT2&/
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MC"?*J@N&M5?VG#]D'8ER'HU-EA/G[V [_6W W8'EY\IZN\LT552DB:T;F7*
M!<X!PY@ H@G),Y0QP>,@@G-E=W,+AJ^I"G^SQ@82F:MP=@MXPZ$W,G_W:-[^
MHQ._<+IQ)[!,HQ17=3D/;;@3]YW5X$[ONK'\65DO9_?>IN\FS6LUR1F-(0$B
MIV8"3K4 3$(,1"HS3C.6Q0P/*F=VWM?<^*1=SZJR=A&5]D;)P )C%_!UHY)
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M_#NK0U_:5Q[#;W]N,Z$_%/M_5_O/2A3?-G8:6QUR^Z78UK^RU\5+#G.DE>!
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MP:.*B*]@2P?4[AOC 0"<8(^\C=V)G6%WR7O "+YA?JV_R??.>QR_M(W>=\M
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M/PLW7.X91B3E!-TN\YM)FYFSKWZH*@_YO9GN?5#[C_HK^W.I68((%!3PC'*
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ME%,&D$Z0C#.9:^W%*$Z]SHU9RN(P-CPOWZ+J:+?G1H\KXG%*$ 0ZXRG B6"
M91B"G*E8YXK*/-;+AW++_NW&438[..JG_;\ \G_]"T$Q^KLR'Q4ZJLP98S0<
M=^)"XSOVYEP#:_E#R^2%3<IJK.ZI]^N_8^>#4MA-/*>>I]W7\P'C;*O/Z^:A
MNH]'L>HECA.4TMQ0D3+H8LH)8+F" '(E,IY(+ECBI^%X;'QN;-^V;=AT\P0Z
M-P89"LC82]DNE0@&"!B>.QM8C+#5P<3"@N>NG8L$7KAFH*I[L5%/E<KS+X\;
MN6N*(XL49:F&0-B3(%CDB97W@P8FG) <*ISKS$O._6(W<WMP2RNC^]+,2%L[
M/77;+X/I]@#?#M'(CW*%3F5A5)HXPA2O&X6PVNR7NYI6E+W3W3,U]NZK_?>D
MZTR^XQZ8"<C?L+U:4L%5DFL"H"0*8$8E()120%2*::H3F4KMNBE]K9.Y/?V-
M*DU[T]68&EE;W?>EKT+:S0*A@!H[[A^"D=?>=!\(@S>GKS8\V>YTGVOM[>G>
M:T-EY-T)L7U4LI7>N]0"\CA.,T 3;2N/9AE@6B"00JJ(,+_4N5>L[M+IW,C@
MD .VVD2LLK8)Y3V# B?(W4*$T$".3!97\NAJFZ/W#N<9 N3-78=HY&2Y"QV_
M<(;<=2CZT^(Z[AU&1;^L-FQC)C'K=YO=?EOFXERL'4"5D#!#.8"&=P F,@44
M"0T@C"E&,,\Q])+*<^QW;H1TN4Z278)KZ5C\:L;*.''OO[3L.AIN1#4"QB-S
MU<'BJ&7R:3V&,2HQ> (5E+%<^YZ4M#P!><Y;OK</W$,_YD;L[C;R0[%AQ]]\
M-3_MF"C5.^H% (F18HIF .99#'"L4\!C(H&AKAABSE.8>F7@>/8_-RI[7:R-
M-X651?RA3@1[RKJ8K7]7Q5'VW]DF.KUIV$$IWW%S([L11V/LV=P$ ^&_R3\,
MSK#;_IXV3)L(, R@L]2 @<WX:P]]>5!BI5>V?.D/M2[*E,?/ZIM5UBNV3P<%
MCOJAPS3-TQPQH'2BS.Q3(D"4+?XEJ" 242[<1.N\>YX;31Z,CUK61T?SCPHQ
M[AH[?D/1S7^C CPR\[ECV[_&?2/([K)&HX$]D<C1$739 GU[!/T@NQ5(ZF@0
M8!W"1W[M32:#-,C-MBC2L 8&KT 6]U8V5>UL2MI2Q41)DFE $JL^%Y<:I:D
MB4YBS0B"C.2>BXWM]N=&ZF6^3%FB41?;:%75-=U;:[U7%4]@=%Y ' K.^&N%
M%HG2M#*3-.B2X"6G0Z_^G?0Q]4+?)0<OK.E=O.PF^8Y_ED'C_N/V\^K;]_V'
M1\L0'_5QA>HU6Z^5?/547[>K+]PMXSC/:(HE2&C"39A'N7GN50;B),]EFLDT
M55[+>C?:,SN>:-0O_J@--8,3;4M3HTWIE?UP=UP)%,4/9:71^).9IJE+M_VT
MVD2[4CCM>@GE48;:C9LF',"QI]7-V-4VVC$HC5Q$'PY#UUK$K5RR(_?/UJA5
M;@67.[D5WS&T40;;]!)"*K<">$5UY>9F!^9_';85CET=5_MCG"J=I2F0-(X!
MA@DV85K"0()EGJ4F,L.Q5^7MSM[F1L$7=UP\$\(ZT77CQ6"8C<QZES>HQBQC
M[81,V)2QSAZGS1QS<?XL@<SIIH$5S^P2\8=B<ZCD5<6;]9'1948I3!-&@4JD
MF>?E9IY'((\!)3"&,L,BI]"KXEEG=W/CDFK]O)[N_50GDOQ<RM9ZEC?K1MF-
M4L)A-S*G5+"U+8WJB>)/M;'70UG_\F9.J(0M;];=Y;3ES9S</RMOYG;70$&#
M/=NK8[WS+":I)#0#N4438X( H2H&,B:<,X81YU[1R&GS<Z.,@W4#J\B?8N=&
M#,,1&7N]WAD,?PF"BSZ'E1XX[6):R8&+[IU)#5R^RG^O[[!8;%K\IK[^4=2[
M'"*AL9*8 F&/D6"48L $%2"CG,0ZETH*IV7>CC[F]@ ?MY!*.R-CJ/L>TC4<
M^[?D J S]DSA')@!NVS7$'+?3PN U$0[9T?$=B5B^S^*0%MD/1AT;(9=NW.R
M;:\>T]L;7'V7#@M//J@_[H2P94.L!O[6!$&/QN@RH>)3L5Z)I^K/XX1?,:OH
MF', $V9(4!!L I@< JBX4!#"-%9>6@B^!LR-(3\K86Q=/S6%)([.1*?>F"G
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MVKUH;?R+]L;!*$;1?>GB(OKM]&K?3-!QOR9N]/CRHSX-TSY3Q%I$!U>!+K;
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M?[)^+QQA\_6O=S=MRGZOVV=9^_UW#% BW;*-^*Z^&HQ5D^QC9EU0I +0.$D
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MS'-%_<M96*UV0MJTF3+%.!8S Y^Q7K^JPXJ%MA"92 :3++RT.O][A*1.D'2
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MRNH4A13L;8*ZM^%B4UR$UCI;NRZCJ@74EKY$CQE2=#[DDBV*-K7F7R6MM]Y
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MV2NQ3<%&ITB0Q$%4@I/OTJ;H]_FTCILW/W7D,Y32.K"5MS:#!UO\2QX#4S$
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M-^4![E:UQ\+JX5]=]H=A7 9;!'C%:S->8\!Y:\#GJ&22PDEL@\ AN1@7MH/
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M8&01M#UR"QZ1W$1O2] 87>)MJD &('Z<R82]H7QX/1]MW0>KE#^$\TDPPJK
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M%E4BM:"8&23Y"A[(YZXC7:.5!82KR7TDCQL;=3C:E\1.3/,80-KKMLRQ6NT
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MTNO+J]GTRV9(S.:BI.-H@RT0E/5 "X($1P8)LF"2(2:4N<W\E1\0-5" '0N
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M9G4\K24'G+Q+%"9*3=SD ,XJ \8F9V@U#U8_<3UP1== X_8C47 HR!ZOD@$
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M%IR)")(2)JN$2X$_Z<7'SCD\S,3^WK1_0AS]%]G7PP?Q@N8N,I7!2*=!*5[
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M!$4C+@F/R32:)MTI'P--H1^#ON]JC?TI>@ U_Q-Y_N7;_B]8]?7-/B0F/ D
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M,?Y"+=+B5M:>BP=G3=A8(1FZU(U.1322^"ZL*"%-H.)LB[_0>V_DN3E'8JU
MG@U"7=PJL>Y%F/W +GZ!CI]=<BN0>'X?ZP*H.<8ZUVR#+R;BE *I1F^ZBH+N
MXI3IT)>]-QX"'0?>]&W*M @';'6%Y)^(9!OC!$D*%/M#QH$/'>N=:0&8_4#(
MOV'\(4X;%-*3.(!@PPA-,5>D"H92YUFFPJ2I[+,>*)8I1^E^C!F62U_-?-G(
M8&O:IQ^8LY^B,U2 A9$,M$[&A!>KV5[O1X\5J@,+]I1\=GB_>E1>9[!VZ^S.
M4[H%T(5G:?A?>FJ$34GO+B[Q.!2X @ 4>'B!\EQI8=LU9S&%I'&Q(,7"*\G
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M .(.$:&>;"I"U4.)Q< \%/M0YQ #7L1$!OT4)^'@-"V3<N81'RX+M =Q[!,
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M3KW)6-^P:GLKBI"J@E- )E4]4NMJ'B6 (WG*=E?UGA!\HW(P(F8TQ=3/]:=
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M>D\)OM4Y&)%SFF+KY^95H/DF_$^A4U:@MEN$&S@+]J&C) O*LA7)1I119;H
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M<BTR,#(R,#DS,"YX<V102P$"% ,4    "  MA&I5GV."T/$7  "1Y0  %
M            @ &2TP$ 861R+3(P,C(P.3,P7V-A;"YX;6Q02P$"% ,4
M"  MA&I5:[))S $Z   8> ( %               @ &UZP$ 861R+3(P,C(P
M.3,P7V1E9BYX;6Q02P$"% ,4    "  MA&I5( T1#@AX  #[>   $P
M        @ 'H)0( 861R+3(P,C(P.3,P7V<Q+F=I9E!+ 0(4 Q0    ( "V$
M:E4258IBIJP  ,PI!P 4              "  2&> @!A9'(M,C R,C Y,S!?
M;&%B+GAM;%!+ 0(4 Q0    ( "V$:E7;]I 8IF,  'M=!  4
M  "  ?E* P!A9'(M,C R,C Y,S!?<')E+GAM;%!+ 0(4 Q0    ( "V$:E7]
MI&2U!A8  'V:   >              "  =&N P!E>&AI8FET,3 Q+6%M96YD
M;65N=&YO,71O;"YH=&U02P$"% ,4    "  MA&I56PA= \@(  !V0   '@
M            @ $3Q0, 97AH:6)I=#,Q,2UC97)T:69I8V%T:6]N;V8N:'1M
M4$L! A0#%     @ +81J5;G:;-[4"   GD   !X              ( !%\X#
M &5X:&EB:70S,3(M8V5R=&EF:6-A=&EO;F]F+FAT;5!+ 0(4 Q0    ( "V$
M:E6\^C1F_ 0  (T4   >              "  2?7 P!E>&AI8FET,S(Q+6-E
M<G1I9FEC871I;VYO9BYH=&U02P$"% ,4    "  MA&I56+U0"@(%  ":%
M'@              @ %?W , 97AH:6)I=#,R,BUC97)T:69I8V%T:6]N;V8N
9:'1M4$L%!@     ,  P 00,  )WA P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
